CN114533863A - 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 - Google Patents
用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 Download PDFInfo
- Publication number
- CN114533863A CN114533863A CN202210008931.0A CN202210008931A CN114533863A CN 114533863 A CN114533863 A CN 114533863A CN 202210008931 A CN202210008931 A CN 202210008931A CN 114533863 A CN114533863 A CN 114533863A
- Authority
- CN
- China
- Prior art keywords
- seq
- cells
- patient
- car
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 204
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 62
- 239000012472 biological sample Substances 0.000 title description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 220
- 210000004027 cell Anatomy 0.000 claims abstract description 110
- 238000004519 manufacturing process Methods 0.000 claims abstract description 51
- 238000001802 infusion Methods 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 267
- 239000000427 antigen Substances 0.000 claims description 175
- 102000036639 antigens Human genes 0.000 claims description 174
- 108091007433 antigens Proteins 0.000 claims description 174
- 230000027455 binding Effects 0.000 claims description 97
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 95
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 95
- 108091008874 T cell receptors Proteins 0.000 claims description 89
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 108091033319 polynucleotide Proteins 0.000 claims description 49
- 102000040430 polynucleotide Human genes 0.000 claims description 49
- 239000002157 polynucleotide Substances 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 38
- 230000003834 intracellular effect Effects 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 25
- 125000006850 spacer group Chemical group 0.000 claims description 21
- 206010034016 Paronychia Diseases 0.000 claims description 18
- 208000036142 Viral infection Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 230000009385 viral infection Effects 0.000 claims description 18
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 108090001126 Furin Proteins 0.000 claims description 6
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims description 4
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 101800001494 Protease 2A Proteins 0.000 claims description 2
- 101800001066 Protein 2A Proteins 0.000 claims description 2
- 229940045207 immuno-oncology agent Drugs 0.000 claims 8
- 239000002584 immunological anticancer agent Substances 0.000 claims 8
- 102000004961 Furin Human genes 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 36
- 238000012986 modification Methods 0.000 abstract description 21
- 230000004048 modification Effects 0.000 abstract description 21
- 238000002372 labelling Methods 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 152
- 230000015572 biosynthetic process Effects 0.000 description 77
- 238000003786 synthesis reaction Methods 0.000 description 77
- 108090000765 processed proteins & peptides Proteins 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 58
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 48
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 48
- -1 OX-40 Proteins 0.000 description 44
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 39
- 229920001184 polypeptide Polymers 0.000 description 39
- 125000003275 alpha amino acid group Chemical group 0.000 description 38
- 241000282414 Homo sapiens Species 0.000 description 37
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 31
- 108010015792 glycyllysine Proteins 0.000 description 31
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 29
- 108010068380 arginylarginine Proteins 0.000 description 27
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 27
- 108010087924 alanylproline Proteins 0.000 description 26
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 24
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 23
- 102100025390 Integrin beta-2 Human genes 0.000 description 23
- 108010073969 valyllysine Proteins 0.000 description 23
- 241000880493 Leptailurus serval Species 0.000 description 22
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 22
- 239000012620 biological material Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 20
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000012737 microarray-based gene expression Methods 0.000 description 20
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 20
- 102100022339 Integrin alpha-L Human genes 0.000 description 19
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 19
- 108010051242 phenylalanylserine Proteins 0.000 description 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 18
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 18
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 18
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 18
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 18
- 108010051330 Arg-Pro-Gly-Pro Proteins 0.000 description 17
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 17
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 17
- 108010016616 cysteinylglycine Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 17
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 16
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 16
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 16
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 16
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 16
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 16
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 15
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 108010077245 asparaginyl-proline Proteins 0.000 description 15
- 238000004891 communication Methods 0.000 description 15
- 108010089804 glycyl-threonine Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical group 0.000 description 15
- 108010031719 prolyl-serine Proteins 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 14
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 14
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 14
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 14
- 102100025323 Integrin alpha-1 Human genes 0.000 description 14
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 14
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 208000007452 Plasmacytoma Diseases 0.000 description 14
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 14
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 14
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 14
- 108010078144 glutaminyl-glycine Proteins 0.000 description 14
- 108010050848 glycylleucine Proteins 0.000 description 14
- 108010081551 glycylphenylalanine Proteins 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 108010000998 wheylin-2 peptide Proteins 0.000 description 14
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 13
- VRJZMZGGAKVSIQ-SRVKXCTJSA-N Cys-Tyr-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VRJZMZGGAKVSIQ-SRVKXCTJSA-N 0.000 description 13
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 13
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 13
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 13
- CFIBZQOLUDURST-IHRRRGAJSA-N Val-Tyr-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N CFIBZQOLUDURST-IHRRRGAJSA-N 0.000 description 13
- 108010018006 histidylserine Proteins 0.000 description 13
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 13
- 108010003700 lysyl aspartic acid Proteins 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 12
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 12
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 12
- DBOMZJOESVYERT-GUBZILKMSA-N Met-Asn-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N DBOMZJOESVYERT-GUBZILKMSA-N 0.000 description 12
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 12
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 12
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 12
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 12
- 108010081404 acein-2 Proteins 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 12
- CEHZCZCQHUNAJF-AVGNSLFASA-N (2s)-1-[2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(O)=O)CCC1 CEHZCZCQHUNAJF-AVGNSLFASA-N 0.000 description 11
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 11
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 11
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 11
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102100032818 Integrin alpha-4 Human genes 0.000 description 11
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 11
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 11
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 11
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 11
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 11
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 11
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 11
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 11
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 11
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 11
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 11
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 11
- 108010069495 cysteinyltyrosine Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 11
- 108010044292 tryptophyltyrosine Proteins 0.000 description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 10
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 10
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 10
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 10
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 10
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 10
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 10
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 10
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 10
- 102100038078 CD276 antigen Human genes 0.000 description 10
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 10
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 10
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 10
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 10
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 10
- WSWAUVHXQREQQG-JYJNAYRXSA-N His-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O WSWAUVHXQREQQG-JYJNAYRXSA-N 0.000 description 10
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 10
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 10
- 102100032816 Integrin alpha-6 Human genes 0.000 description 10
- 102100022341 Integrin alpha-E Human genes 0.000 description 10
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 10
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 10
- 206010049258 Lymphoblastosis Diseases 0.000 description 10
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 10
- YLLWCSDBVGZLOW-CIUDSAMLSA-N Met-Gln-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O YLLWCSDBVGZLOW-CIUDSAMLSA-N 0.000 description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 10
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 10
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 10
- NAXBBCLCEOTAIG-RHYQMDGZSA-N Thr-Arg-Lys Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O NAXBBCLCEOTAIG-RHYQMDGZSA-N 0.000 description 10
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 10
- KIMOCKLJBXHFIN-YLVFBTJISA-N Trp-Ile-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O)=CNC2=C1 KIMOCKLJBXHFIN-YLVFBTJISA-N 0.000 description 10
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 description 10
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 10
- RYSNTWVRSLCAJZ-RYUDHWBXSA-N Tyr-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RYSNTWVRSLCAJZ-RYUDHWBXSA-N 0.000 description 10
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 10
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 10
- 108010079547 glutamylmethionine Proteins 0.000 description 10
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 10
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 10
- 108010087823 glycyltyrosine Proteins 0.000 description 10
- 108010034529 leucyl-lysine Proteins 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- 108010003137 tyrosyltyrosine Proteins 0.000 description 10
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 9
- DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 description 9
- HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 9
- CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 9
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 9
- FQHBAQLBIXLWAG-DCAQKATOSA-N Asp-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N FQHBAQLBIXLWAG-DCAQKATOSA-N 0.000 description 9
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 9
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 9
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 9
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 9
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 9
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 9
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 9
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 9
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 9
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 9
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 9
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 9
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 9
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 9
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 9
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 9
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 9
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 9
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 9
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 9
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 9
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 9
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 9
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 9
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 9
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 9
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 9
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 9
- 108010062796 arginyllysine Proteins 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 8
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 8
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 8
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 8
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 8
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 8
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 8
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 8
- SUDUYJOBLHQAMI-WHFBIAKZSA-N Gly-Asp-Cys Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O SUDUYJOBLHQAMI-WHFBIAKZSA-N 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 8
- DMSVBUWGDLYNLC-IAVJCBSLSA-N Ile-Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DMSVBUWGDLYNLC-IAVJCBSLSA-N 0.000 description 8
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 8
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 8
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 8
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 8
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 8
- 102000014128 RANK Ligand Human genes 0.000 description 8
- 108010025832 RANK Ligand Proteins 0.000 description 8
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 8
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 8
- OOEUVMFKKZYSRX-LEWSCRJBSA-N Tyr-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OOEUVMFKKZYSRX-LEWSCRJBSA-N 0.000 description 8
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 8
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 8
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 8
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 8
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 8
- 108010008355 arginyl-glutamine Proteins 0.000 description 8
- 108010068265 aspartyltyrosine Proteins 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 8
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 7
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 7
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 7
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 7
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 7
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 7
- XMHFCUKJRCQXGI-CIUDSAMLSA-N Asn-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O XMHFCUKJRCQXGI-CIUDSAMLSA-N 0.000 description 7
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 7
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 7
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 7
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 7
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 7
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 7
- KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 7
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 7
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 7
- QMOSCLNJVKSHHU-YUMQZZPRSA-N Glu-Met-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QMOSCLNJVKSHHU-YUMQZZPRSA-N 0.000 description 7
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 7
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 7
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 7
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 7
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 description 7
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 7
- 108010065920 Insulin Lispro Proteins 0.000 description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 7
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 7
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 7
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 7
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 7
- UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 7
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 7
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 7
- BTAIJUBAGLVFKQ-BVSLBCMMSA-N Phe-Trp-Val Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=CC=C1 BTAIJUBAGLVFKQ-BVSLBCMMSA-N 0.000 description 7
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 7
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 7
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 7
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 7
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 7
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 7
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 7
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 7
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 7
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 7
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 7
- QOEZFICGUZTRFX-IHRRRGAJSA-N Tyr-Cys-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O QOEZFICGUZTRFX-IHRRRGAJSA-N 0.000 description 7
- QRCBQDPRKMYTMB-IHPCNDPISA-N Tyr-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N QRCBQDPRKMYTMB-IHPCNDPISA-N 0.000 description 7
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 7
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 108010047857 aspartylglycine Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 108010079317 prolyl-tyrosine Proteins 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 6
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 6
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 6
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 6
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 6
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 6
- QPTAGIPWARILES-AVGNSLFASA-N Asn-Gln-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QPTAGIPWARILES-AVGNSLFASA-N 0.000 description 6
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 6
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 6
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 6
- WOKXEQLPBLLWHC-IHRRRGAJSA-N Asp-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 WOKXEQLPBLLWHC-IHRRRGAJSA-N 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 101710185679 CD276 antigen Proteins 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 6
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 6
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 6
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 6
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 6
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 6
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 6
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 6
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 6
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 6
- LJUIEESLIAZSFR-SRVKXCTJSA-N His-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N LJUIEESLIAZSFR-SRVKXCTJSA-N 0.000 description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 6
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 6
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 description 6
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 6
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 6
- 206010053869 POEMS syndrome Diseases 0.000 description 6
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 6
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 6
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 6
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 6
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 6
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 6
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 6
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 6
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 6
- UTCFSBBXPWKLTG-XKBZYTNZSA-N Thr-Cys-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O UTCFSBBXPWKLTG-XKBZYTNZSA-N 0.000 description 6
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 6
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 6
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 6
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 6
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 6
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 6
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 6
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 6
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 6
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 108010060199 cysteinylproline Proteins 0.000 description 6
- 201000003444 follicular lymphoma Diseases 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 108010004914 prolylarginine Proteins 0.000 description 6
- 108010026333 seryl-proline Proteins 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 108010061238 threonyl-glycine Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 5
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 5
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 5
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 5
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 5
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 5
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 5
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 5
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 5
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 5
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 5
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 5
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 5
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 5
- POOCJCRBHHMAOS-FXQIFTODSA-N Asn-Arg-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O POOCJCRBHHMAOS-FXQIFTODSA-N 0.000 description 5
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 5
- WPOLSNAQGVHROR-GUBZILKMSA-N Asn-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N WPOLSNAQGVHROR-GUBZILKMSA-N 0.000 description 5
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 5
- ZKDGORKGHPCZOV-DCAQKATOSA-N Asn-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZKDGORKGHPCZOV-DCAQKATOSA-N 0.000 description 5
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 5
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 5
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 5
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 5
- 102100035233 Furin Human genes 0.000 description 5
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 5
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 5
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 5
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 5
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 5
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 5
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 5
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 5
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 5
- VDHOMPFVSABJKU-ULQDDVLXSA-N His-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N VDHOMPFVSABJKU-ULQDDVLXSA-N 0.000 description 5
- PUFNQIPSRXVLQJ-IHRRRGAJSA-N His-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N PUFNQIPSRXVLQJ-IHRRRGAJSA-N 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 5
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 5
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 5
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 5
- APDIECQNNDGFPD-PYJNHQTQSA-N Ile-His-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N APDIECQNNDGFPD-PYJNHQTQSA-N 0.000 description 5
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 5
- 102100039904 Integrin alpha-D Human genes 0.000 description 5
- 102100022297 Integrin alpha-X Human genes 0.000 description 5
- 108010041100 Integrin alpha6 Proteins 0.000 description 5
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 5
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 5
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 5
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 5
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 5
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 5
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 5
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 5
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 5
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 5
- URGPVYGVWLIRGT-DCAQKATOSA-N Lys-Met-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O URGPVYGVWLIRGT-DCAQKATOSA-N 0.000 description 5
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 5
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 description 5
- UZWMJZSOXGOVIN-LURJTMIESA-N Met-Gly-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(=O)NCC(O)=O UZWMJZSOXGOVIN-LURJTMIESA-N 0.000 description 5
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 5
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 5
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 5
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 5
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 5
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 5
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 5
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 5
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 5
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 5
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 5
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 5
- CDHQEOXPWBDFPL-QWRGUYRKSA-N Tyr-Gly-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDHQEOXPWBDFPL-QWRGUYRKSA-N 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 5
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 5
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 5
- 108010005233 alanylglutamic acid Proteins 0.000 description 5
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000002617 apheresis Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 5
- 108010020688 glycylhistidine Proteins 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- ISJKIHHTPAQLLW-TUFLPTIASA-N (2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ISJKIHHTPAQLLW-TUFLPTIASA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 4
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 4
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 4
- 101710145634 Antigen 1 Proteins 0.000 description 4
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 4
- TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 4
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 4
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 4
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 4
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 108010017009 CD11b Antigen Proteins 0.000 description 4
- 102100038077 CD226 antigen Human genes 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- PRXCTTWKGJAPMT-ZLUOBGJFSA-N Cys-Ala-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O PRXCTTWKGJAPMT-ZLUOBGJFSA-N 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 4
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 4
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 4
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 4
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 4
- HHSKZJZWQFPSKN-AVGNSLFASA-N Glu-Tyr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O HHSKZJZWQFPSKN-AVGNSLFASA-N 0.000 description 4
- JVWPPCWUDRJGAE-YUMQZZPRSA-N Gly-Asn-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JVWPPCWUDRJGAE-YUMQZZPRSA-N 0.000 description 4
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 4
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 4
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 4
- ZKJZBRHRWKLVSJ-ZDLURKLDSA-N Gly-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O ZKJZBRHRWKLVSJ-ZDLURKLDSA-N 0.000 description 4
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- NKRWVZQTPXPNRZ-SRVKXCTJSA-N His-Met-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CN=CN1 NKRWVZQTPXPNRZ-SRVKXCTJSA-N 0.000 description 4
- QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 description 4
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 4
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 4
- 101000979596 Homo sapiens NF-kappa-B-repressing factor Proteins 0.000 description 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- 108010073807 IgG Receptors Proteins 0.000 description 4
- 102000009490 IgG Receptors Human genes 0.000 description 4
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 4
- JTBFQNHKNRZJDS-SYWGBEHUSA-N Ile-Trp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)O)N JTBFQNHKNRZJDS-SYWGBEHUSA-N 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 4
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 4
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 4
- CQGSYZCULZMEDE-SRVKXCTJSA-N Leu-Gln-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CQGSYZCULZMEDE-SRVKXCTJSA-N 0.000 description 4
- MPSBSKHOWJQHBS-IHRRRGAJSA-N Leu-His-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N MPSBSKHOWJQHBS-IHRRRGAJSA-N 0.000 description 4
- SXOFUVGLPHCPRQ-KKUMJFAQSA-N Leu-Tyr-Cys Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(O)=O SXOFUVGLPHCPRQ-KKUMJFAQSA-N 0.000 description 4
- VHTIZYYHIUHMCA-JYJNAYRXSA-N Leu-Tyr-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VHTIZYYHIUHMCA-JYJNAYRXSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 4
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 4
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 4
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 description 4
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 4
- 102100023379 NF-kappa-B-repressing factor Human genes 0.000 description 4
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 4
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 4
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 4
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 4
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 4
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 4
- QNBVFKZSSRYNFX-CUJWVEQBSA-N Ser-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N)O QNBVFKZSSRYNFX-CUJWVEQBSA-N 0.000 description 4
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 4
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 4
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 4
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 4
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 4
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 4
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 4
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 4
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 4
- DZKFGCNKEVMXFA-JUKXBJQTSA-N Tyr-Ile-His Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O DZKFGCNKEVMXFA-JUKXBJQTSA-N 0.000 description 4
- NVZVJIUDICCMHZ-BZSNNMDCSA-N Tyr-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O NVZVJIUDICCMHZ-BZSNNMDCSA-N 0.000 description 4
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 4
- 108010047495 alanylglycine Proteins 0.000 description 4
- 238000011130 autologous cell therapy Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 108010028295 histidylhistidine Proteins 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 108010070643 prolylglutamic acid Proteins 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108010009962 valyltyrosine Proteins 0.000 description 4
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 3
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 3
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 description 3
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- RYRQZJVFDVWURI-SRVKXCTJSA-N Arg-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N RYRQZJVFDVWURI-SRVKXCTJSA-N 0.000 description 3
- ZEAYJGRKRUBDOB-GARJFASQSA-N Arg-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZEAYJGRKRUBDOB-GARJFASQSA-N 0.000 description 3
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 3
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 3
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 3
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 102100027217 CD82 antigen Human genes 0.000 description 3
- 101710139831 CD82 antigen Proteins 0.000 description 3
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 description 3
- KFYPRIGJTICABD-XGEHTFHBSA-N Cys-Thr-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N)O KFYPRIGJTICABD-XGEHTFHBSA-N 0.000 description 3
- LPBUBIHAVKXUOT-FXQIFTODSA-N Cys-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N LPBUBIHAVKXUOT-FXQIFTODSA-N 0.000 description 3
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 3
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 3
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 3
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 3
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 3
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 3
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 3
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 3
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 3
- SWBUZLFWGJETAO-KKUMJFAQSA-N His-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O SWBUZLFWGJETAO-KKUMJFAQSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 description 3
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
- CYHYBSGMHMHKOA-CIQUZCHMSA-N Ile-Ala-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CYHYBSGMHMHKOA-CIQUZCHMSA-N 0.000 description 3
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 3
- AMSYMDIIIRJRKZ-HJPIBITLSA-N Ile-His-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AMSYMDIIIRJRKZ-HJPIBITLSA-N 0.000 description 3
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- KVRKAGGMEWNURO-CIUDSAMLSA-N Leu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N KVRKAGGMEWNURO-CIUDSAMLSA-N 0.000 description 3
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 3
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 3
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 3
- 108091036060 Linker DNA Proteins 0.000 description 3
- WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 3
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 description 3
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 3
- ATBJCCFCJXCNGZ-UFYCRDLUSA-N Met-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 ATBJCCFCJXCNGZ-UFYCRDLUSA-N 0.000 description 3
- VYXIKLFLGRTANT-HRCADAONSA-N Met-Tyr-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N VYXIKLFLGRTANT-HRCADAONSA-N 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- 102100023384 NK-tumor recognition protein Human genes 0.000 description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 3
- GXDPQJUBLBZKDY-IAVJCBSLSA-N Phe-Ile-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GXDPQJUBLBZKDY-IAVJCBSLSA-N 0.000 description 3
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 3
- YDUGVDGFKNXFPL-IXOXFDKPSA-N Phe-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YDUGVDGFKNXFPL-IXOXFDKPSA-N 0.000 description 3
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 3
- LCRSGSIRKLXZMZ-BPNCWPANSA-N Pro-Ala-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LCRSGSIRKLXZMZ-BPNCWPANSA-N 0.000 description 3
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 3
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 3
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 3
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 3
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 3
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 3
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 3
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 3
- YMDNFPNTIPQMJP-NAKRPEOUSA-N Ser-Ile-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(O)=O YMDNFPNTIPQMJP-NAKRPEOUSA-N 0.000 description 3
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 3
- ATEQEHCGZKBEMU-GQGQLFGLSA-N Ser-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N ATEQEHCGZKBEMU-GQGQLFGLSA-N 0.000 description 3
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 3
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 3
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 3
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 3
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 3
- ILMVQSHENUZYIZ-JYJNAYRXSA-N Val-Met-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N ILMVQSHENUZYIZ-JYJNAYRXSA-N 0.000 description 3
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 3
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 3
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 3
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 3
- 108010041407 alanylaspartic acid Proteins 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 201000003115 germ cell cancer Diseases 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 3
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 3
- 108010077515 glycylproline Proteins 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 108010085325 histidylproline Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010020532 tyrosyl-proline Proteins 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000023761 AL amyloidosis Diseases 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 2
- RUXQNKVQSKOOBS-JURCDPSOSA-N Ala-Phe-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RUXQNKVQSKOOBS-JURCDPSOSA-N 0.000 description 2
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 2
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 2
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 2
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000037398 BCR-ABL1 negative atypical chronic myeloid leukemia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 206010008583 Chloroma Diseases 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102100039554 Galectin-8 Human genes 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
- DCWNCMRZIZSZBL-KKUMJFAQSA-N Gln-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O DCWNCMRZIZSZBL-KKUMJFAQSA-N 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 2
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 2
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 241000192019 Human endogenous retrovirus K Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 2
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 2
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 2
- KLJKJVXDHVUMMZ-KKPKCPPISA-N Ile-Phe-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N KLJKJVXDHVUMMZ-KKPKCPPISA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- 206010062038 Lip neoplasm Diseases 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- CLBGMWIYPYAZPR-AVGNSLFASA-N Lys-Arg-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O CLBGMWIYPYAZPR-AVGNSLFASA-N 0.000 description 2
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000037379 Myeloid Chronic Atypical BCR-ABL Negative Leukemia Diseases 0.000 description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
- 102000027581 NK cell receptors Human genes 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 2
- 102100033118 Phosphatidate cytidylyltransferase 1 Human genes 0.000 description 2
- 101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 2
- PTLOFJZJADCNCD-DCAQKATOSA-N Pro-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 PTLOFJZJADCNCD-DCAQKATOSA-N 0.000 description 2
- DRKAXLDECUGLFE-ULQDDVLXSA-N Pro-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O DRKAXLDECUGLFE-ULQDDVLXSA-N 0.000 description 2
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 2
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 description 2
- 102100023884 Probable ribonuclease ZC3H12D Human genes 0.000 description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- MOQDPPUMFSMYOM-KKUMJFAQSA-N Ser-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N MOQDPPUMFSMYOM-KKUMJFAQSA-N 0.000 description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 102000007000 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- NMOIRIIIUVELLY-WDSOQIARSA-N Trp-Val-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)=CNC2=C1 NMOIRIIIUVELLY-WDSOQIARSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- LQGDFDYGDQEMGA-PXDAIIFMSA-N Tyr-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N LQGDFDYGDQEMGA-PXDAIIFMSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 102100026497 Zinc finger protein 654 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
- 201000002454 adrenal cortex cancer Diseases 0.000 description 2
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 201000004892 atypical chronic myeloid leukemia Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000011061 large intestine cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 201000004962 larynx cancer Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000006721 lip cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000005987 myeloid sarcoma Diseases 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 201000002511 pituitary cancer Diseases 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 108010079891 prostein Proteins 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000012429 release testing Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- WJRXVTCKASUIFF-FXQIFTODSA-N Ala-Cys-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WJRXVTCKASUIFF-FXQIFTODSA-N 0.000 description 1
- DAEFQZCYZKRTLR-ZLUOBGJFSA-N Ala-Cys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O DAEFQZCYZKRTLR-ZLUOBGJFSA-N 0.000 description 1
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 1
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- RTXQQDVBACBSCW-CFMVVWHZSA-N Asp-Ile-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RTXQQDVBACBSCW-CFMVVWHZSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100022443 CXADR-like membrane protein Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- QLCPDGRAEJSYQM-LPEHRKFASA-N Cys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)C(=O)O QLCPDGRAEJSYQM-LPEHRKFASA-N 0.000 description 1
- YRJICXCOIBUCRP-CIUDSAMLSA-N Cys-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N YRJICXCOIBUCRP-CIUDSAMLSA-N 0.000 description 1
- PFAQXUDMZVMADG-AVGNSLFASA-N Cys-Gln-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PFAQXUDMZVMADG-AVGNSLFASA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 101100272587 Gallus gallus ITA gene Proteins 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- WIKMTDVSCUJIPJ-CIUDSAMLSA-N Glu-Ser-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WIKMTDVSCUJIPJ-CIUDSAMLSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- NTNUEBVGKMVANB-NHCYSSNCSA-N Glu-Val-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O NTNUEBVGKMVANB-NHCYSSNCSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 1
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000901723 Homo sapiens CXADR-like membrane protein Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- RWYCOSAAAJBJQL-KCTSRDHCSA-N Ile-Gly-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N RWYCOSAAAJBJQL-KCTSRDHCSA-N 0.000 description 1
- REXAUQBGSGDEJY-IGISWZIWSA-N Ile-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N REXAUQBGSGDEJY-IGISWZIWSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 description 1
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 description 1
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 1
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241001637516 Polygonia c-album Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- YYARMJSFDLIDFS-FKBYEOEOSA-N Pro-Phe-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YYARMJSFDLIDFS-FKBYEOEOSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
- DYJTXTCEXMCPBF-UFYCRDLUSA-N Pro-Tyr-Phe Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O DYJTXTCEXMCPBF-UFYCRDLUSA-N 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- FOOZNBRFRWGBNU-DCAQKATOSA-N Ser-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N FOOZNBRFRWGBNU-DCAQKATOSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
- VZBWRZGNEPBRDE-HZUKXOBISA-N Trp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N VZBWRZGNEPBRDE-HZUKXOBISA-N 0.000 description 1
- LORJKYIPJIRIRT-BVSLBCMMSA-N Trp-Pro-Tyr Chemical compound C([C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 LORJKYIPJIRIRT-BVSLBCMMSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 1
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 1
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 208000016035 malignant germ cell tumor of ovary Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
- 201000000360 urethra cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
- G06Q10/083—Shipping
- G06Q10/0833—Tracking
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Business, Economics & Management (AREA)
- Economics (AREA)
- General Business, Economics & Management (AREA)
- Oncology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Development Economics (AREA)
- Physics & Mathematics (AREA)
- Operations Research (AREA)
- Marketing (AREA)
- Human Resources & Organizations (AREA)
- Entrepreneurship & Innovation (AREA)
- Theoretical Computer Science (AREA)
- Strategic Management (AREA)
- Tourism & Hospitality (AREA)
- Quality & Reliability (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
描述了用于进行患者特异性免疫疗法规程的方法和装置。计算装置接收为患者创建经转染的T细胞的请求。计算装置生成与细胞订购请求相关联的患者特异性标识符。计算装置启动创建用于输注到患者的血流中的经转染的T细胞的过程,包括:对患者的血液样品进行白细胞单采术规程以从样品中收集T细胞,将收集的T细胞转移到容器,用患者特异性标识符标记容器,将收集的T细胞传输到制造设施,使用细胞修饰技术从收集的T细胞创建经转染的T细胞,从制造设施接收经转染的T细胞,并且将经转染的T细胞输注到患者的血流中。计算装置记录每个步骤的跟踪事件,包括患者特异性标识符,以生成患者T细胞的监管链。
Description
本申请是申请日为2018年9月17日,申请号为201880060078.9,发明名称为“用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统”的中国发明专利申请的分案申请。
相关申请
本申请要求2017年9月15日提交的美国临时专利申请No.62/559,330和2017年10月2日提交的美国临时专利申请No.62/566,912的优先权,每篇通过引用完整并入本文。
技术领域
一般地,本申请涉及用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和装置,包括计算机程序产品
背景技术
近年来,医疗技术的进步导致了免疫疗法治疗不同类型的病和疾病,包括各种形式的癌症的新兴使用。通常,免疫疗法是通过刺激或抑制免疫应答来治疗疾病。通常,将患者自身生物材料(例如免疫细胞)的修饰形式重新引入患者中,以启动和/或补充免疫应答。
例如,已显示了工程化的免疫细胞在治疗性处理中,特别是在肿瘤学中拥有期望的质量。工程化免疫细胞的两种主要类型是含嵌合抗原受体(称为“CAR”或“CAR-T”)和T细胞受体(“TCR”)的细胞。这些工程化的细胞经过工程化改造,使其具有抗原特异性,同时保留或增强它们识别和杀死靶细胞的能力。嵌合抗原受体可包含例如(i)抗原特异性成分(“抗原结合分子”),(ii)胞外域,(iii)一个或多个共刺激域,和(iv)一个或多个活化域。每个域可以是异质的,即由源自(或对应于)不同蛋白质链的序列构成。
由于许多经历免疫疗法的患者是重病的,此类免疫疗法规程的功效中的关键因素是尽快向患者提供经修饰的生物材料的能力,从而可以使治疗益处最大化。另外,由于针对特定患者定制多种类型的免疫疗法(即使用患者自身的细胞),重要的是确保在整个免疫疗法过程中准确跟踪患者的生物材料——从提取到修饰,再到输注回患者中——以避免制造中的延迟、材料的错误标记和患者的错误鉴定。但是,现有的免疫疗法规程通常缺乏自动跟踪患者生物材料并确保在整个制造过程中将生物材料与特定患者身份联系在一起的技术机制。
发明内容
因此,需要用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统。与现有系统相比,本文所述的技术提供特定的技术优势,即为免疫疗法规程中的患者特异性生物样品提供连续且自动的监管链和身份链,以创建计算机化的信息门户,使感兴趣的各方——例如患者、内科医生、制造商和其他医务人员——可以用来快速了解和跟踪免疫疗法规程的当前阶段以及该规程过程中患者生物样品的状态。此种先进的跟踪是对现有系统的改进,所述现有系统没有用于维持监管链和身份链的技术解决方案——导致制造过程中的延误,对于处理危及生命的疾病的患者而言,这可能是极其严重的。
在一方面,本发明的特征在于一种进行患者特异性免疫疗法规程的方法。计算装置接收细胞创建用于患者的经转染的T细胞的订购请求。计算装置生成与细胞订购请求相关的患者特异性标识符,所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号。计算装置启动创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:对所述患者的血液样品进行白细胞单采术规程以从所述样品中收集T细胞,将收集的T细胞转移到容器,用所述患者特异性标识符标记所述容器,将收集的T细胞传输到制造设施,使用细胞修饰技术从收集的T细胞创建经转染的T细胞,从所述制造设施接收所述经转染的T细胞,以及将所述经转染的T细胞输注到所述患者的血流中。计算装置为所述过程中的每个步骤记录跟踪事件,每个跟踪事件包括所述患者特异性标识符。跟踪事件包括在所述过程期间所述患者的T细胞的监管链。
在另一方面,本发明的特征在于一种在免疫疗法规程期间跟踪细胞订购的方法。计算装置接收创建用于患者的经转染的T细胞的细胞订购请求。计算装置生成与所述细胞订购请求相关的患者特异性标识符,所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号。计算装置监视创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:接收已经对所述患者的血液样品进行白细胞单采术规程以从所述样品收集T细胞的记号(indicia),接收已经将收集的T细胞转移到容器的记号,接收所述容器已经用所述患者特异性标识符标记的记号,接收已经将收集的T细胞传输到制造设施的记号,接收已经使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞的记号,接收已经从所述制造设施接收所述经转染的T细胞的记号,以及接收已经将所述转染的T细胞输注到所述患者的血流中的记号。当接收记号时通过所述计算装置记录跟踪事件,每个跟踪事件包括所述患者特异性标识符。通过存储所述过程期间的所述跟踪事件,计算装置维护所述患者的T细胞的监管链。
在另一方面,本发明的特征在于一种进行患者特异性免疫疗法规程的方法。接收创建用于患者的经转染的T细胞的细胞订购请求。在处理器上执行的事件跟踪模块生成与所述细胞订购请求相关的患者特异性标识符。启动创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:对所述患者的血液样品进行白细胞单采术规程以从所述样品中收集T细胞,将收集的T细胞转移到容器,用所述患者特异性标识符标记所述容器,将收集的T细胞传输到制造设施,使用细胞修饰技术从收集的T细胞创建经转染的T细胞,从所述制造设施接收所述经转染的T细胞,以及将所述经转染的T细胞输注到所述患者的血流中。事件跟踪模块从位于所述白细胞单采术规程点处的第一客户端装置接收第一跟踪事件,其确认所述白细胞单采术规程并含有所述患者特异性标识符。事件跟踪模块将所述第一跟踪事件集成在与所述患者特异性标识符有关的数据结构中,其中在数据库中存储所述数据结构,并且集成步骤记录具有所述第一跟踪事件的第一时间戳。事件跟踪模块从位于所述制造设施处的第二客户端装置接收第二跟踪事件,其确认在所述制造设施处收到收集的T细胞并含有所述患者特异性标识符。事件跟踪模块将所述第二跟踪事件集成在所述与所述患者特异性标识符有关的数据结构中,其中集成步骤记录具有所述第二跟踪事件的第二时间戳。
在另一方面,本发明的特征在于一种进行患者特异性免疫疗法规程的方法,处理器上执行的跟踪模块接收创建用于患者的经转染的T细胞的细胞订购请求。跟踪模块生成与所述细胞订购请求相关的患者特异性标识符和细胞订购批次,所述患者特异性标识符识别患者。数据库生成用于跟踪所述细胞订购的数据记录,所述数据记录根据所述患者特异性标识符在所述数据库中识别。跟踪模块接收第一跟踪事件,所述第一跟踪事件指示收集的T细胞已准备好运输到制造设施。根据所述第一跟踪事件,更新与所述患者特异性标识符对应的数据记录。基于容器已经由所述制造设施接收,跟踪模块接收第二跟踪事件,所述第二跟踪事件指示所述收集的T细胞已经由制造设施接收。根据所述第二跟踪事件,更新与所述患者特异性标识符对应的数据记录。基于所述制造设施已经使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞,跟踪模块接收第三跟踪事件,所述第三跟踪事件指示已经创建所述经转染的T细胞。根据所述第三跟踪事件更新与所述患者特异性标识符对应的数据记录。基于所述经转染的T细胞已经从所述制造设施接收,跟踪模块接收第四跟踪事件,所述第四跟踪事件指示已经接收所述经转染的T细胞。根据所述第四跟踪事件,更新与所述患者特异性标识符对应的数据记录。基于所述经转染的T细胞已经输注到所述患者的血流中,跟踪模块接收第五跟踪事件,所述第五跟踪事件指示已经将经转染的T细胞输注到所述患者的血流中。根据所述第五跟踪事件,更新与所述患者特异性标识符对应的数据记录,其中,所述第一、第二、第三、第四和第五跟踪事件中的每个含有所述患者特异性标识符、时间戳和事件标识符,以及其中当根据相应事件更新所述数据记录时,与所述患者特异性标识符对应的数据记录以有序顺序存储所述第一、第二、第三、第四和第五跟踪事件。
上述任何方面可以包括以下一个或多个特征:
在一些实施方案中,通过用编码嵌合抗原受体(CAR)的多核苷酸转染收集的T细胞来创建经转染的T细胞,所述CAR包含特异性结合靶分子的抗原结合分子。优选地,抗原结合分子是单链可变片段(scFv)。
设想在一些实施方案中,靶分子是血源性癌症相关抗原。本发明的血源性癌症相关抗原与一种或多种选自下组的癌症相关:急性髓样白血病(AML)、慢性髓性白血病(CML)、慢性骨髓单核细胞性白血病(CMML)、青少年骨髓单核细胞性白血病、非典型慢性髓样白血病、急性早幼粒细胞性白血病(APL)、急性单核母细胞性白血病、急性红系白血病、急性巨核细胞性白血病、淋巴母细胞性白血病、B谱系急性淋巴母细胞性白血病、B细胞慢性淋巴细胞性白血病、B细胞非何杰金氏淋巴瘤、脊髓发育不良综合征(MDS)、骨髓增生病症、髓样新生物、髓样肉瘤)和母细胞性浆细胞样树突细胞新生物(BPDCN)。
在一些实施方案中,靶分子是病毒感染相关抗原。本发明的病毒感染可以由任何病毒,包括例如HIV引起。
本发明的嵌合抗原受体(CAR)可以进一步包含至少一个共刺激域。本发明的共刺激域包括但不限于以下各项的信号传导区或其它合适的部分:CD28、OX-40、4-1BB/CD137、CD2、CD7、CD27、CD30、CD40、程序性死亡-1(PD-1)、诱导性T细胞共刺激物(ICOS)、淋巴细胞功能相关抗原-1(LFA-1(CDl la/CD18)、CD3 gamma、CD3 delta、CD3 epsilon、CD247、CD276(B7-H3)、LIGHT、(TNFSF14)、NKG2C、Ig alpha(CD79a)、DAP-10、Fc gamma受体、MHC I类分子、TNF受体蛋白、免疫球蛋白蛋白、细胞因子受体、整联蛋白、信号传导淋巴细胞活化分子(SLAM蛋白)、活化NK细胞受体、BTLA、Toll配体受体、ICAM-1、B7-H3、CDS、ICAM-1、GITR、BAFFR、LIGHT、HVEM(LIGHTR)、KIRDS2、SLAMF7、NKp80(KLRF1)、NKp44、NKp30、NKp46、CD19、CD4、CD8alpha、CD8beta、IL-2R beta、IL-2R gamma、IL-7Ralpha、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CDl ld、ITGAE、CD103、ITGAL、CDl la、LFA-1、ITGAM、CDl lb、ITGAX、CDl lc、ITGBl、CD29、ITGB2、CD18、LFA-1、ITGB7、NKG2D、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRTAM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Lyl08)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、CD19a、与CD83特异性结合的配体或其任何组合。
优选地,共刺激域包含CD28。本发明的CD28共刺激域包括例如选自下组的序列:SEQ ID NO.2、SEQ ID NO.4、SEQ ID NO.6和SEQ ID NO.8。
在其他实施方案中,共刺激域包括CD8。本发明的CD8共刺激域包括例如SEQ IDNO.14。
本发明的嵌合抗原受体(CARs)可以进一步包含至少一个活化域。本发明的活化域包括例如CD3。优选地,CD3活化域包含CD3 zeta。本发明的CD3 zeta活化域包括例如SEQ IDNO.10。
在一个优选的实施方案中,嵌合抗原受体(CAR)包含抗CD19 scFv,CD28和CD3zeta的全部或部分。
在另外的优选实施方式中,嵌合抗原受体(CAR)包括:
-以下全部或部分:抗CD19 scFv、CD8和4-1BB;
-以下全部或部分:抗BCMA scFv和CD8;
-以下全部或部分:抗CD19 scFv、CD28和4-1BB;
-以下全部或部分:抗CD22 scFv和CD8;
-以下全部或部分:抗CD19 scFv、CD28和EGFRt/19-28z/4-1BBL;
-以下全部或部分:抗MUC16 scFv和CD28;
-以下全部或部分内容:抗CD171;
-以下全部或部分:抗CD123和CD28;
-以下全部或部分:抗BCMA、CD8和4-1BB;
-以下全部或部分:抗CD19和CD28;
-以下全部或部分:抗CD19和CD8;或者
-以下全部或部分内容:CD28。
在另一个优选的实施方案中,CAR包含前导序列(CSF2RA)、抗CD19scFv、Whitlow接头、CD28间隔物、CD28共刺激域和CD3 zeta。此类CAR的一个实例是由SEQ ID NO.146的核苷酸序列编码和SEQ ID NO.147的氨基酸序列。
在另一个优选的实施方案中,CAR包含前导序列(CD8)、抗CD19 scFv、Whitlow接头、CD28T间隔物、CD28共刺激域和CD3 zeta。此类CAR的一个实例是由SEQ ID NO.148的核苷酸序列编码和SEQ ID NO.149的氨基酸序列。
在另一个优选的实施方案中,CAR包含前导序列(CD8a)、CD19 scFv、Whitlow接头,CD8a间隔区和跨膜域、CD28共刺激域和CD3 zeta。此类CAR的一个实例是由SEQ ID NO.150的核苷酸序列编码和SEQ ID NO.151的氨基酸序列。
在另一个优选的实施方案中,CAR包含前导序列(CD8)、抗CLL-1scFv、G4S接头、微型间隔物(Minispacer)、CD28T(CD28的细胞外/跨膜区)、CD28(CD28的细胞内共刺激)和CD3zeta。此类CAR的一个实例是由SEQ ID NO.154的核苷酸序列编码和SEQ ID NO.155的氨基酸序列。
在另一个优选的实施方案中,CAR包含前导序列(CD8a)、抗BCMA scFv、Whitlow接头、CD28T间隔物、CD28共刺激域和CD3 zeta。此类CAR的一个实例是由SEQ ID NO.156的核苷酸序列编码和SEQ ID NO.157的氨基酸序列。
在一些实施方案中,通过用编码T细胞受体(TCR)的多核苷酸转染收集的T细胞来创建经转染的T细胞。本发明的TCR可以结合肿瘤相关抗原。肿瘤相关抗原与一种或多种选自下组的癌症相关:肾上腺皮质癌、肛门癌、膀胱癌、骨癌、脑癌、乳腺癌、类癌癌、宫颈癌、结肠癌、子宫内膜癌、食道癌、肝外胆管癌、颅外生殖细胞癌、眼癌、胆囊癌、胃癌、生殖细胞瘤、妊娠滋养细胞肿瘤、头颈癌、下咽癌、胰岛细胞癌、肾癌、大肠癌、喉癌、白血病、唇和口腔癌、肝癌、肺癌、淋巴瘤、恶性间皮瘤、默克尔细胞癌、蕈样肉芽肿病、脊髓发育不良综合征、骨髓增生病症、鼻咽癌、神经母细胞瘤、口腔癌、口咽癌、骨肉瘤、卵巢上皮癌、卵巢生殖细胞癌、胰腺癌、鼻旁窦和鼻腔癌、甲状旁腺癌、阴茎癌、垂体癌、浆细胞瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、肾盂和输尿管的移行细胞癌、唾液腺癌、Sezary综合征、皮肤癌、小肠癌、软组织肉瘤、胃癌、睾丸癌、胸腺瘤、甲状腺癌、尿道癌、子宫癌、阴道癌、外阴癌和Wilms肿瘤。
在某些方面,本申请可以适用于血液学癌症的靶分子。在一些实施方案中,癌症是白细胞的癌症。在其他实施方案中,癌症是浆细胞的癌症。在一些实施方案中,癌症是白血病、淋巴瘤或骨髓瘤。在某些实施方案中,癌症是急性淋巴母细胞性白血病(ALL)(包括非T细胞ALL)、急性淋巴样白血病(ALL)和嗜血细胞性淋巴组织细胞增多症(HLH))、B细胞幼淋巴细胞白血病、B细胞急性淋巴细胞样白血病(“BALL”)、母细胞性浆细胞样树突细胞新生物、伯基特氏淋巴瘤、慢性淋巴细胞性白血病(CLL)、慢性髓性白血病(CML)、慢性髓样白血病(CML)、慢性或急性肉芽肿性疾病、慢性或急性白血病、弥漫性大B细胞淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤、滤泡性淋巴瘤(FL)、毛细胞白血病、噬血细胞性综合征(巨噬细胞活化综合征(MAS)、何杰金氏病、大细胞肉芽肿、白细胞粘附缺乏、恶性淋巴增生性病况、MALT淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤、意义不明的单克隆gamma病变(gammapathy)(MGUS)、多发性骨髓瘤、骨髓增生异常和骨髓增生异常综合症(MDS)、髓样疾病,包括但不限于急性髓样白血病(AML)、非何杰金氏淋巴瘤(NHL)、浆细胞增生性疾病(例如无症状骨髓瘤(隐袭性多发性骨髓瘤或无痛性骨髓瘤)、浆母细胞性淋巴瘤、浆细胞样树突细胞新生物、浆细胞瘤(例如浆细胞体液不调;孤立性骨髓瘤;孤立性浆细胞瘤;髓外浆细胞瘤和多发性浆细胞瘤),POEMS综合征(Crow-Fukase综合征;Takatsuki病;PEP综合征)、原发性纵隔大B细胞淋巴瘤(PMBCL)、小细胞或大细胞滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、系统性淀粉样蛋白轻链淀粉样变性、T细胞急性淋巴样白血病(TALL)、T细胞淋巴瘤、转化的滤泡性淋巴瘤、Waldenstrom巨球蛋白血症或其组合。
在另外的优选实施方案中,TCR包含AV38-2可变alpha链、BV7-2可变beta链、鼠恒定alpha域、鼠恒定beta域、TRAJ40、弗林蛋白酶-SG SG-P2A和TRBJ1-3。此类TCR的一个实例是由SEQ ID NO.152的核苷酸序列编码和SEQ ID NO.153的氨基酸序列。
在进一步的优选实施方案中,TCR包含TCR beta链可变区、TCR beta链恒定区、P2A肽(具有弗林蛋白酶切割位点和接头)、TCR alpha链可变区和TCR alpha链恒定区。此类TCR的一个实例是由SEQ ID NO.158的核苷酸序列编码和SEQ ID NO.159的氨基酸序列。此类TCR的另一个实例由SEQ ID NO.160的核苷酸序列编码和SEQ ID NO.161的氨基酸序列。
在其他实施方案中,本发明的TCR结合病毒感染相关抗原。本发明的病毒感染可以由任何病毒,包括例如HIV引起。
本发明的多核苷酸可以是载体的组分。合适的载体包括但不限于逆转录病毒载体、DNA载体、质粒、RNA载体、腺病毒载体、腺病毒相关载体、慢病毒载体或其任何组合。优选地,载体是慢病毒载体。本发明的慢病毒载体包括但不限于pGAR及其衍生物。
在一些实施方案中,启动用于创建经转染的T细胞的过程进一步包括从远程计算装置请求用于进行白细胞单采术规程的时隙,响应于时隙的请求接受时隙可用于进行白细胞单采术规程的记号,并用远程计算装置确认可用时隙的接受。
在一些实施方案中,启动创建经转染的T细胞的过程进一步包括接收创建后已经从第一位点运输经转染的T细胞的记号,以及接收输注前已经在第二地点处接收经转染的T细胞的记号,其中计算装置在接收已经运输经转染的T细胞的记号时记录跟踪事件,并且计算装置在接收已经在第二地点处接收经转染的T细胞时记录跟踪事件。
在一些实施方案中,患者身份要素包括与免疫疗法规程相关的第一患者ID和与实施以下一种或多种方法的设施相关的第二患者ID:白细胞单采术规程或经转染的T细胞的输注。在一些实施方案中,计算装置以有序顺序存储跟踪事件。在一些实施方案中,该有序顺序按时间顺序排列。
通过以下结合附图的详细描述,本发明的其他方面和优点将变得明显,所述附图仅通过示例的方式示出了本发明的原理。
附图说明
通过参考以下结合附图的描述,可以更好地理解上述本发明的优点以及其他优点。附图不一定按比例绘制,而是通常将重点放在说明本发明的原理上。
图1A是用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的系统的框图。
图1B是用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的系统的详细框图。
图2是进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的计算机化方法的流程图。
图3A和3B是由用户界面模块生成的示例性屏幕截图,以在患者特异性的免疫疗法规程期间接收患者特异性的信息。
图4A至图4D是由用户界面模块生成的示例性屏幕截图,以在患者特异性免疫疗法规程期间接收提取和输注部位的确认并安排预约。
图5A和图5B是由用户界面模块生成的示例性屏幕截图,以显示患者特异性免疫疗法规程期间生物材料的监管链。
发明详细
图1A是用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的系统100的框图。图1A的系统包括多个客户端计算装置102a-102d、通信网络104、具有用户接口模块108a、事件跟踪模块108b和监管链模块108c的服务器计算装置106以及数据库110。
客户端计算装置102a-102d连接到通信网络104,以便与服务器计算装置106进行通信,以提供输入和接收与具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的过程有关的输出,如本文所述。在一些实施方案中,每个客户端计算装置102a-102d可以偶联到相应的显示装置,以例如提供详细的图形用户界面(GUI),该图形用户界面接收本文描述的方法和系统的输入并呈现源自本文描述的方法和系统的输出。例如,客户端计算装置102a-102d可以连接到服务器计算装置106的用户界面模块108a,例如,其向客户端计算装置102a-102c的用户提供基于网络的门户,以访问与本文描述的方法相关的功能性。
示例性客户端装置102a-102d包括但不限于台式计算机、膝上型计算机、平板电脑、移动装置、智能电话和互联网装置。应当理解,在不脱离本发明范围的情况下。也可以使用能够连接到图1A的系统的组件的其他类型的计算装置。还应当理解,客户端计算装置102a-102d中的每个可以与不同的用户类型相关联——例如,客户端计算装置102a可以与访问图1A的系统的患者相关联,以生成用户简档并接收有关患者特异性免疫疗法规程的更新;客户端计算装置102b可以与正在治疗患者并且访问图1A的系统的内科内科医生联系,以为患者启动免疫疗法规程;客户端计算装置102c可以与正在对患者施用免疫疗法规程的医院或其他设施联系;并且客户端计算装置102d可以与制造设施联系,该制造设施正在创建患者特异性免疫疗法产品(如会在本文中进行描述)以用于免疫疗法规程。
通信网络104使系统100的其他组件能够相互通信,以进行实施具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的过程,如本文所述。网络104可以是诸如LAN的局域网,或者诸如因特网和/或蜂窝网络的广域网。在一些实施方案中,网络104由使得图1A的系统的组件能够彼此通信的几个离散网络和/或子网络(例如,蜂窝到因特网)构成。
服务器计算装置106是硬件和软件模块的组合,该组合包括专化硬件和/或软件模块,它们在处理器上执行并且与服务器计算装置106的存储模块进行交互以进行用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的功能,如本文描述。服务器计算装置106包括在服务器计算装置106的处理器上进行和/或与之交互的用户界面模块108a、事件跟踪模块108b和监管链模块108c(如上文提及)。
在一些实施方案中,用户界面模块108a、事件跟踪模块108b和监管链模块108c是被编程到服务器计算装置106中的一个或多个专用处理器上的计算机软件指令的专化集合,并且可以包括专门指定的存储器位置和/或寄存器,用于执行专化计算机软件指令。尽管在图1A中显示了模块108a-108c,如在同一服务器计算装置106内执行,在一些实施方案中,模块108a-108c的功能性可以分布在多个服务器计算装置之间。如图1A所示,服务器计算装置106使模块108a-108c能够彼此通信,以便交换数据以进行所描述的功能。应当理解,可以在不脱离本发明的范围的情况下使用以多种架构、资源和配置(例如,集群计算、虚拟计算、云计算)布置的任何数量的计算装置。下面详细描述了模块108a-108c的示例性功能性。
数据库110是偶联到服务器计算装置106的计算装置(或者在一些实施方案中,一组计算装置),并且配置为接收、生成和存储与进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的过程有关的数据的特定段,如本文描述。在一些实施方案中,数据库110的全部或部分可以与服务器计算装置106集成或位于分开的一个或多个计算装置上。数据库110可以包括一个或多个数据库,其配置为存储由图1A的系统的其他组件使用的数据的部分,如将在下面更详细地描述。在一些实施方案中,数据库110包括企业业务套件,例如Oracle E-Business Suite(EBS),该企业业务套件包括使一批功能性能够支持本文描述的方法和系统的各种模块,包括后勤、供应链、运输、CRM和其他类型的模块。
图1B是用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的图1A的系统的详细框图。在图1B中所示,服务器计算装置106是总体硬件架构中的中心组件,其与客户端计算装置102a-102e和数据库110接口,并且还与调度模块114和内科医生主数据馈送116接口。在一些实施方案中,服务器计算装置106和相应的模块108a-108c利用可从加利福尼亚州旧金山的Salesforce.com,Inc.获得的Salesforce平台来集成本文描述的某些功能。客户端计算装置102a-102e与服务器计算装置106通信,以进行免疫疗法规程中的患者登记并监视监管链和身份链跟踪(例如,经由基于浏览器的用户界面),如本文中描述。
例如,客户端计算装置102a可以与正在进行免疫疗法规程的患者联系,并且可以包括浏览器软件和电子邮件软件,以使患者既能够监视跟踪又能够对参与免疫疗法规程所需要的文件进行电子签名(例如,经由DocuSign或其他类似技术)。类似地,客户端计算装置102b-102d可以位于不同的医院,在那里内科医生可以在免疫疗法规程中登记患者,向系统下达细胞订购,并使用浏览器软件监视监管链和身份链跟踪。客户端计算装置102b-102d还包括单点登录(SSO)模块,该模块使装置能够向服务器计算装置106认证(例如,使用支持SAML 2.0的SSO或服务器的特定用户名/密码)。客户端计算装置102e可以位于管理或制造地点,以使服务器计算装置106的管理员能够与服务器进行通信,从系统中的其他参与者接收诸如电子邮件的通信并使用浏览器软件监视监管链和身份链跟踪。
如上所述,数据库110可以包括企业商务套件,该企业商务套件管理用于服务器计算装置106的数据,并且包括模块以实现生物样品的监管链和身份链的跟踪以及后勤。例如,数据库110可以在请求时将批准的客户地点发送到服务器106,从服务器106接收单元订购条目数据,并且向服务器106提供细胞订购预订和单采血液成分术批次更新信息。
调度模块114可以集成到服务器计算装置106中或驻留在分开的计算装置上。调度模块114可以向服务器计算装置106认证并与服务器计算装置106通信,以接收关于细胞订购和免疫疗法规程的某些信息(例如,患者ID、单采血液成分术地点、输注地点和产品代码),并且向服务器106提供日历确定和调度功能性(例如,使治疗内科医生能够选择单采血液成分术日期/时间,并在生物样品经过制造过程后为其提供估计的递送日期/时间)。此外,服务器计算装置106可以与内科医生主数据馈送116通信(例如,使用与HerokuTM应用规程集成的VeevaTM CRM平台提供)以接收关于治疗内科医生的某些信息。
图2是使用图1A的系统和/或图1B的系统进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的计算机化方法200的流程图。如应当理解,在进行患者特异性免疫疗法规程的背景下提出本文描述的方法和系统。如本文所用,“患者特异性免疫疗法规程”是指使用免疫系统的分子或细胞成分靶向和/或破坏癌症、病原性或其他致病细胞的任何规程。若免疫疗法利用患者免疫系统的成分来治疗该患者自身的癌症、病理学或其他疾病,则该免疫疗法是“患者特异性的”。
如本文所用,术语“患者”和“受试者”可互换使用,并且包括人和非人动物,以及具有正式诊断的病症的、没有正式识别的病症的、接收医疗关注的、有风险形成病毒的,等等。除人以外,本发明范围内的动物类别还包括例如农用动物、家畜、实验动物等。农用动物的一些实例包括牛、猪、马、山羊等。家畜的一些实例包括狗、猫等。实验动物的一些实例包括大鼠、小鼠、兔、豚鼠等。
术语“白细胞单采术”是指涉及从血液样品中选择性分离和去除白细胞的单采血液成分术的特定形式。在白细胞单采术期间,取出的血液通过细胞分离装置,该装置将有核的白细胞(包括T细胞)与红细胞和血浆分离。然后可以收集分离的T细胞以用于本发明的细胞修饰技术。在某些实施方案中,红细胞和血浆作为分离过程的一部分返回给个体。在另外的实施方案中,弃去或存储红细胞和血浆以用于进一步分析。
如本文所用,术语“T细胞”和“T淋巴细胞”是可互换的。T细胞是由它们在胸腺中的发育以及与CD3复合物蛋白质缔合的异二聚体受体定义的淋巴细胞子集。本发明的T细胞包括但不限于幼稚T细胞、细胞毒性T细胞、辅助T细胞、抑制性T细胞、调节性T细胞、记忆性T细胞、NKT细胞、γδ细胞、CD8αα细胞、淋巴因子活化的细胞、表达TCR的细胞、其亚型以及可以表达嵌合受体链的任何其他细胞类型。
可以将T细胞工程化改造成对一种或多种期望靶标具有特异性。例如,可以用编码抗原结合分子,诸如抗体的一个或多个单链可变片段(“scFv”),连同一种或多种信号传导分子和/或一个或多个活化域,例如CD3 zeta的DNA或其它遗传材料转导T细胞。除了CAR-T细胞识别和破坏靶细胞的能力外,成功的T细胞疗法受益于CAR-T细胞持续存在和维持响应抗原而增殖能力。
如本文所用,术语“细胞修饰技术”包括但不限于转染和转导。术语“转染”及其语法变化是指将外来或外源DNA导入细胞。许多转染技术是本领域中公知的,并在本文中公开。参见例如Graham等人,1973,Virology 52:456;Sambrook等人,2001,MolecularCloning:A Laboratory Manual,上文;Davis等人,1986,Basic Methods in MolecularBiology,Elsevier;Chu等人,1981,Gene13:197。转染技术包括但不限于磷酸钙-DNA共沉淀、DEAE-右旋糖酐介导的转染、阳离子脂质介导的递送、聚凝胺介导的转染、电穿孔、声穿孔、显微注射、脂质体融合、脂转染(脂质转染)、聚合物转染、纳米颗粒、多聚复合物(Polyplex)、受体介导的基因传递、由聚赖氨酸、组蛋白、壳聚糖和肽介导的递送、原生质体融合、逆转录病毒感染和生物射弹(例如基因枪)。术语“转导”及其语法变体是指经由病毒载体将外来DNA导入细胞中的过程。参见Jones等人,(1998).Genetics:principles andanalysis.Boston:Jones&Bartlett Publ。
如本文所用,术语“输注”及其语法变化是指通过血管将溶液引入体内。本发明的输注包括但不限于将除全血以外的流体治疗性引入血管。例如,可以将本发明的经转染的T细胞例如在肌肉内、静脉内、动脉内、腹膜内或皮下输注到患者的血流中。
应当理解,嵌合抗原受体(CAR或CAR-T)是遗传工程化受体,并且T细胞受体(TCR)可以是遗传工程化受体。根据本领域已知的技术,这些工程化的受体可以容易地插入包括T细胞在内的免疫细胞中并由其表达。使用CAR,可以对单个受体进行编程以既识别特定抗原,又与该抗原结合时活化免疫细胞以攻击并破坏带有该抗原的细胞。当这些抗原存在于肿瘤细胞上时,表达CAR的免疫细胞可以靶向并杀死肿瘤细胞。
可以将CAR工程化改造成结合抗原(例如细胞表面抗原),其通过掺入与该靶定抗原相互作用的抗原结合分子进行。如本文所用,“抗原结合分子”是指结合规定靶分子的任何蛋白质。抗原结合分子包括但不限于抗体及其结合部分,例如免疫功能片段。肽体(peptibody)(即包含肽结合域的Fc融合分子)是合适的抗原结合分子的另一个实例。
抗原结合分子的术语“免疫功能片段”(或“片段”)是包含抗体部分(无论如何获得或合成该部分)的抗原结合分子种类,该抗体部分缺乏全长抗体中存在的至少一些氨基酸但仍能与抗原特异性结合。此类片段具有生物活性,因为它们与靶抗原结合并且可以与包括完整抗体在内的其他抗原结合分子竞争与给定表位的结合。在一些实施方案中,片段是中和片段。一方面,此类片段将保留存在于全长轻链或重链中的至少一个CDR,并且在一些实施方案中,将包含单个重链和/或轻链或其部分。这些片段可以通过重组DNA技术产生,或者可以通过包括完整抗体在内的抗原结合分子的酶促或化学裂解来产生。
免疫学功能性免疫球蛋白片段包括但不限于scFv片段、Fab片段(Fab’、F(ab’)2等)、一个或多个CDR、双抗体(通过短肽接头连接的与轻链可变域在相同多肽上的重链可变域,该接头太短而无法在同一条链上的两个域之间配对)、域抗体和单链抗体。这些片段可以源自任何哺乳动物来源,包括但不限于人、小鼠、大鼠、骆驼科动物(camelid)或兔。如本领域技术人员将理解的,抗原结合分子可包括非蛋白质组分。
在一些实施方案中,抗原结合分子与肿瘤细胞上的抗原结合。在一些实施方案中,抗原结合分子与参与过度增殖性疾病的细胞上的抗原或与病毒或细菌抗原结合。在另外的实施方案中,抗原结合分子是抗体或其片段,包括其一个或多个互补决定区(CDR)。在进一步的实施方案中,抗原结合分子是单链可变片段(scFv)。
优选地,抗原结合分子是其抗体片段。更优选地,抗原结合分子包含一个或多个单链可变片段(“scFv”)。scFv是单链抗体片段,其具有连接在一起的抗体的重链和轻链的可变区。参见美国专利No.7,741,465,6,319,494,PCT申请WO88/01649和美国专利No.4,946,778和5,260,203,其公开内容通过引用完整并入本文,以及Eshhar等人,Cancer ImmunolImmunotherapy(1997)45:131-136。scFv保留了亲本抗体与靶抗原特异性相互作用的能力。scFv优选用于嵌合抗原受体,因为它们可以工程化改造成与其他CAR成分一起表达为单链的一部分。同上。还参见Krause等人,J.Exp.Med.,Volume 188,No.4,1998(619–626);Finney等人,Journal of Immunology,1998,161:2791–2797。
应当理解,抗原结合分子通常包含在CAR的胞外部分内,使得它能够识别和结合感兴趣的抗原。在本发明的范围内考虑了双特异性和多特异性CAR,其对超过一种感兴趣的靶标具有特异性。
在某些实施方案中,抗原结合分子的多肽结构基于抗体,包括但不限于单克隆抗体、双特异性抗体、微型抗体、域抗体、合成抗体(有时在本文中称为“抗体模拟物”)、嵌合抗体、人源化抗体、人抗体、抗体融合物(有时在本文中称为“抗体缀合物”)及其片段。在一些实施方案中,抗原结合分子包含avimer或由avimer组成。
当解离常数(Kd)为约1x10-7M时,抗原结合分子称为“特异性结合”其靶抗原。当Kd为1-5x10-9M时,抗原结合分子以“高亲和力”特异性结合抗原,并且当Kd为l-5x10-10M时以“非常高的亲和力”特异性结合抗原。在一个实施方案中,抗原结合分子具有10-9M的Kd。在一个实施方案中,解离速率为<1x10-5。
本领域普通技术人员将理解,本发明的靶分子可以是期望针对其的特异性转移至经转染的T细胞的任何分子。术语“靶分子”或“抗原”是指能够被抗原结合分子结合的分子或分子的一部分。在某些实施方案中,靶物可以具有一个或多个表位。
优选地,本发明的靶分子包括但不限于血源性癌症相关抗原。血源性癌症相关抗原的非限制性实例包括与一种或多种癌症相关的抗原,所述癌症选自下组:急性髓样白血病(AML)、慢性髓性白血病(CML)、慢性骨髓单核细胞性白血病(CMML)、青少年骨髓单核细胞性白血病、非典型慢性髓样白血病、急性早幼粒细胞性白血病(APL)、急性单核母细胞性白血病、急性红系白血病、急性巨核细胞性白血病、淋巴母细胞性白血病、B谱系急性淋巴母细胞性白血病、B细胞慢性淋巴细胞性白血病、B细胞非何杰金氏淋巴瘤、脊髓发育不良综合征(MDS)、骨髓增生病症、髓样新生物、髓样肉瘤)和母细胞性浆细胞样树突细胞新生物(BPDCN)。
在一些实施方案中,抗原选自肿瘤相关表面抗原,例如5T4、甲胎蛋白(AFP)、B7-1(CD80)、B7-2(CD86)、BCMA、B-人绒毛膜促性腺激素、CA-125、癌胚抗原(CEA)、癌胚抗原(CEA)、CD123、CD133、CD138、CD19、CD20、CD22、CD23、CD24、CD25、CD30、CD33、CD34、CD4、CD40、CD44、CD56、CD8、CLL-1、c-Met、CMV特异性抗原、CSPG4、CTLA-4、二唾液酸神经节苷脂GD2、导管上皮粘蛋白(mucine)、EBV特异性抗原、EGFR变体III(EGFRvIII)、ELF2M、内皮糖蛋白(endoglin)、ephrin B2、上皮生长因子受体(EGFR)、上皮细胞粘附分子(EpCAM)、上皮肿瘤抗原、ErbB2(HER2/neu)、成纤维细胞相关蛋白(fap)、FLT3、叶酸结合蛋白、GD2、GD3、胶质瘤相关抗原、鞘糖脂、gp36、HBV特异性抗原、HCV特异性抗原、HER1-HER2、HER2-HER3组合、HERV-K、高分子量黑素瘤相关抗原(HMW-MAA)、HIV-1包膜糖蛋白gp41、HPV特异性抗原、人端粒酶逆转录酶、IGFI受体、IGF-II、IL-11Ralpha、IL-13R-a2、流感病毒特异性抗原;CD38、胰岛素生长因子(IGF1)-1、肠羧基酯酶、kappa链、LAGA-la、lambda链,拉沙病毒特异性抗原、凝集素反应性AFP、谱系特异性或组织特异性抗原,例如CD3、MAGE、MAGE-A1、主要组织相容性复合物(MHC)分子、呈递肿瘤特异性肽表位的主要肿瘤相容性复合物(MHC)分子、M-CSF、黑素瘤相关抗原、间皮素、间皮素、MN-CA IX、MUC-1,mut hsp72、突变的p53、突变的p53、突变的ras、嗜中性粒细胞弹性蛋白酶、NKG2D、Nkp30、NY-ESO-1、p53、PAP、蛋白酶、蛋白酶特异性抗原(PSA)、前列腺癌肿瘤抗原1(PCTA-1)、前列腺素特异性抗原、prostein、PSMA、RAGE-1、ROR1、RU1、RU2(AS)、表面粘附分子、存活和端粒酶、TAG-72、纤连蛋白的额外域A(EDA)和额外域B(EDB)以及腱糖蛋白-C的Al域(TnC A1)、甲状腺球蛋白、肿瘤基质抗原、血管内皮生长因子受体2(VEGFR2)、病毒特异性表面抗原,例如HIV特异性抗原(例如HIV gp120),以及这些表面标志物的任何衍生物或变体。
在一些实施方案中,本发明的靶分子包括病毒感染相关抗原。本发明的病毒感染可以由任何病毒引起,包括例如HIV。
可能的靶分子的此列表并不意图是排他的,并且本领域普通技术人员将知道许多可用于用本发明的嵌合抗原受体靶向的其他分子。
嵌合抗原受体可以掺入共刺激(信号传导)域以增加其效力。参见美国专利Nos.7,741,465和6,319,494以及Krause等人和Finney等人(上文),Song等人,Blood 119:696-706(2012);Kalos等人,Sci Transl.Med.3:95(2011);Porter等人,N.Engl.J.Med.365:725-33(2011),和Gross等人,Annu.Rev.Pharmacol.Toxicol.56:59–83(2016)。例如,CD28是在T细胞上自然发现的共刺激蛋白。本文阐述了多种共刺激分子,但应理解,其他共刺激分子也包括在本发明的范围内。
CD28的完整天然氨基酸序列在NCBI参考序列:NP_006130.1中描述。完整的天然CD28核酸序列在NCBI参考序列:NM_006139.1中描述。
某些CD28域已用于嵌合抗原受体。根据本发明,现已发现,称为“CD28T”的新型CD28胞外(铰链)构建体在用于CAR构建体时出乎意料地提供了某些益处。尽管从细胞外CD28序列中截短(去除)了多个氨基酸,该构建体证明保留(并且有时超过)含CD28的CAR的特性的能力。这些益处包括等同或优异的细胞因子产生、等同或优异的细胞溶解活性和/或等同或优异的CAR表达水平。
包括胞外域以及CD28跨膜和细胞内域的CD28T分子的核苷酸序列在SEQ ID NO.1中列出:
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC
相应的氨基酸序列在SEQ ID NO.2中列出:
LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYM NMTPRRPGPT RKHYQPYAPP RDFAAYRS
CD28T的胞外部分的核苷酸序列在SEQ ID NO.3中列出:
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCA
CD28T胞外域的相应氨基酸序列在SEQ ID NO.4中列出:
LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP
CD28跨膜域的核苷酸序列在SEQ ID NO.5中列出:
TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTT
CD28跨膜域的氨基酸序列在SEQ ID NO.6中列出:
FWVLVVVGGV LACYSLLVTV AFIIFWV
CD28胞外信号传导域的核苷酸序列在SEQ ID NO.7中列出:AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC
CD28胞内信号传导域的氨基酸序列在SEQ ID NO.8中列出:
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
适合用于本发明的另外的CD28序列包括SEQ ID NO.11中列出的CD28核苷酸序列:
ATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGAAAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCC
相应的氨基酸序列在SEQ ID NO.12中列出:
IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP
应当理解,本发明涉及包含SEQ ID NO.1或SEQ ID NO.3的至少一个分离的核酸序列的抗原结合分子、CAR、TCR等。还应理解,本发明涉及抗原结合分子、CAR、TCR等,其中胞外部分由SEQ ID NO.1或SEQ ID NO.3的至少一个分离的核酸序列组成。另外,应当理解,本发明涉及抗原结合分子、CAR、TCR等,其中胞外部分基本上由SEQ ID NO.1或SEQ ID NO.3的至少一个分离的核酸序列组成。
应当理解,本发明涉及包含SEQ ID NO.2或SEQ ID NO.4的至少一个氨基酸序列的抗原结合分子、CAR、TCR等。还应理解,本发明涉及抗原结合分子、CAR、TCR等,其中胞外部分由SEQ ID NO.2或SEQ ID NO.4的至少一个氨基酸序列组成。另外,应当理解,本发明涉及抗原结合分子、CAR、TCR等,其中胞外部分基本上由SEQ ID NO.2或SEQ ID NO.4的至少一个氨基酸序列组成。
胞外和/或跨膜域的另一个合适的来源可以源自(或对应于)部分或整个CD8。
合适的CD8胞外和跨膜域的核苷酸序列在SEQ ID NO.13中列出:
GCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAAC
相应的氨基酸序列在SEQ ID NO.14中列出:
AAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN
在结构上,应理解,本文所述的域对应于相对于免疫细胞或其他细胞的位置。因此,这些域可以是(i)“铰链”或胞外(EC)域、(ii)跨膜(TM)域和/或(iii)胞内/胞质域(IC)的部分。胞内组分经常部分包含活化域,例如CD3家族成员,优选CD3 zeta的部分。当抗原结合分子与其靶标结合时,该域能够活化T细胞。应当理解,胞内域通常还包含一种或多种如本文所述的共刺激分子。
如本文所用,“共刺激分子”是指提供介导T细胞应答的信号的分子,包括但不限于增殖、活化、分化等。如本文所述,共刺激分子还可提供除由活化分子提供的主要信号外的信号。
应当理解,在本发明范围内的合适的共刺激域可以源自(或对应于)共刺激分子,例如,CD28、CD28T、OX40、4-1BB/CD137、CD2、CD3(alpha、beta、delta、epsilon、gamma、zeta)、CD4、CD5、CD7、CD9、CD16、CD22、CD27、CD30、CD 33、CD37、CD40、CD 45、CD64、CD80、CD86、CD134、CD137、CD154、PD-1、ICOS、淋巴细胞功能相关抗原-1(LFA-1(CDl la/CD18)、CD247、CD276(B7-H3)、LIGHT(肿瘤坏死因子超家族成员14;TNFSF14)、NKG2C、Ig alpha(CD79a)、DAP-10、Fc gamma受体、MHC I类分子、TNF、TNFr、整联蛋白、信号传导淋巴细胞活化分子、BTLA、Toll配体受体、ICAM-1、B7-H3、CDS、ICAM-1、GITR、BAFFR、LIGHT、HVEM(LIGHTR)、KIRDS2、SLAMF7、NKp80(KLRF1)、NKp44、NKp30、NKp46、CD19、CD4、CD8alpha、CD8beta、IL-2R beta、IL-2R gamma、IL-7R alpha、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CDl-ld、ITGAE、CD103、ITGAL、CDl-la、LFA-1、ITGAM、CDl-lb、ITGAX、CDl-lc、ITGBl、CD29、ITGB2、CD18、LFA-1、ITGB7、NKG2D、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRT AM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Lyl08)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、CD19a、CD83配体或其片段或组合。应当理解,以上未列出的其他共刺激分子或其片段在本发明的范围内。
在一些实施方案中,共刺激域可以包含整个或部分的SEQ ID NO.140中列出的4-1BB核酸序列和如SEQ ID NO.141中列出的相应氨基酸序列。在其他实施方案中,共刺激域可以包含整个或部分如SEQ ID NO.141列出的OX40的氨基酸序列。还参见Hombach等人,Oncoimmunology.2012Jul.1;1(4):458–466。在其他实施方案中,共刺激域可包含整个或部分的ICOS分子,如Guedan等人,August 14,2014;Blood:124(7)和Shen等人,Journal ofHematology&Oncology(2013)6:33。在其他实施方案中,如Song等人,Oncoimmunology.2012Jul.1;1(4):547–549中所述,共刺激域可以包含整个或部分CD27。
本发明的工程化的T细胞包含抗原结合分子(例如scFv)、胞外域(其可以包含“铰链”域)、跨膜域和胞内域。胞内域可以至少部分包含活化域,优选由CD3家族成员,例如CD3zeta、CD3 epsilon、CD3 gamma或其部分构成。
将进一步理解,对抗原结合分子(例如,一个或多个scFv)工程化改造,使得其位于分子/构建体的胞外部分中,从而其能够识别并结合其一个或多个靶标。
应当理解,铰链区可以含有免疫球蛋白家族的一些或全部成员,例如IgG1、IgG2、IgG3、IgG4、IgA、IgD、IgE、IgM或其片段。
在一些实施方案中,胞外域位于抗原结合分子和跨膜域之间。
在本发明中特别使用的胞外域可以源自(即包括)以下一些或全部:CD28、OX-40、4-1BB/CD137、CD2、CD7、CD27、CD30、CD40、程序性死亡-1(PD-1)、诱导性T细胞共刺激物(ICOS)、淋巴细胞功能相关抗原-1(LFA-1、CDl-la/CD18)、CD3 gamma、CD3 delta、CD3epsilon、CD247、CD276(B7-H3)、LIGHT、(TNFSF14)、NKG2C、Ig alpha(CD79a)、DAP-10、Fcgamma受体、MHC 1类分子、TNF配体受体、免疫球蛋白蛋白、细胞因子受体、整联蛋白、信号传导淋巴细胞活化分子(SLAM蛋白)、活化NK细胞受体、BTLA、Toll配体受体、ICAM-1、B7-H3、CDS、ICAM-1、GITR、BAFFR、LIGHT、HVEM(LIGHTR)、KIRDS2、SLAMF7、NKp80(KLRF1)、NKp44、NKp30、NKp46、CD19、CD4、CD8alpha、CD8beta、IL-2R beta、IL-2R gamma、IL-7Ralpha、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CDl ld、ITGAE、CD103、ITGAL、CDl la、LFA-1、ITGAM、CDl lb、ITGAX、CDl lc、ITGBl、CD29、ITGB2、CD18、LFA-1、ITGB7、NKG2D、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRT AM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Lyl08)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、CD19a、与CD83特异性结合的配体或其任何组合。胞外域可源自天然或合成来源。
胞外域通常包含铰链部分,有时称为“间隔物”区域。根据本发明,可以使用多种铰链,包括本文所述分子的部分或衍生物。
可以设计具有与CAR的胞外域融合的跨膜域的CAR。它可以类似地融合至CAR的胞内域。在一些情况下,可以通过氨基酸取代来选择或修饰跨膜域,以避免此类域与相同或不同表面膜蛋白的跨膜域结合,以最小化与受体复合物的其他成员的相互作用。跨膜域可以源自天然或合成来源。若来源是天然的,则该域可以源自任何膜结合蛋白或跨膜蛋白。在本发明中特别使用的跨膜区可以源自(包括或对应于)CD28、CD28T、OX-40、4-1BB/CD137、CD2、CD7、CD27、CD30、CD40、程序性死亡-1(PD-1)、诱导性T细胞共刺激物(ICOS)、淋巴细胞功能相关抗原-1(LFA-1、CDl-la/CD18)、CD3 gamma、CD3delta、CD3 epsilon、CD247、CD276(B7-H3)、LIGHT、(TNFSF14)、NKG2C、Ig alpha(CD79a)、DAP-10、Fc gamma受体、MHC 1类分子、TNF受体蛋白、免疫球蛋白、细胞因子受体、整联蛋白、信号转导淋巴细胞活化分子(SLAM蛋白)、活化NK细胞受体、BTLA、Toll配体受体、ICAM-1、B7-H3、CDS、ICAM-1、GITR、BAFFR、LIGHT、HVEM(LIGHTR)、KIRDS2、SLAMF7、NKp80(KLRF1)、NKp44、NKp30、NKp46、CD19、CD4、CD8alpha、CD8beta、IL-2R beta、IL-2R gamma、IL-7R alpha、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CDl ld、ITGAE、CD103、ITGAL、CDl la、LFA-1、ITGAM、CDl lb、ITGAX、CDl lc、ITGBl、CD29、ITGB2、CD18、LFA-1、ITGB7、NKG2D、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRTAM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Lyl08)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、CD19a、与CD83特异性结合的配体或其任何组合。
任选地,短接头可以在CAR的细胞外、跨膜和胞内域的任何或一些之间形成连接。
在其他实施方案中,本发明的CAR中的跨膜域是CD8跨膜域。在一个实施方案中,CD8跨膜域包含SEQ ID NO:13的核酸序列的跨膜部分。在另一个实施方案中,CD8跨膜域包含编码SEQ ID NO:14中包含的跨膜氨基酸序列的核酸序列。
在某些实施方案中,本发明的CAR中的跨膜域是CD28跨膜域。在一个实施方案中,CD28跨膜域包含SEQ ID NO:5的核酸序列。在一个实施方案中,CD28跨膜域包含编码SEQ IDNO:6的氨基酸序列的核酸序列。CD28跨膜域包含SEQ ID NO:6的氨基酸序列。
本发明的工程化T细胞的胞内(胞质)域可以提供免疫细胞的正常效应器功能中的至少一种的活化。例如,T细胞的效应期功能可以指细胞溶解活性或辅助活性,包括细胞因子的分泌。
应当理解,合适的胞内分子包括但不限于源自或对应于以下项的信号传导域:CD28、CD28T、OX-40、4-1BB/CD137、CD2、CD7、CD27、CD30、CD40、程序性死亡-1(PD-1)、诱导性T细胞共刺激物(ICOS)、淋巴细胞功能相关抗原-1(LFA-1、CDl-la/CD18)、CD3 gamma、CD3delta、CD3 epsilon、CD247、CD276(B7-H3)、LIGHT、(TNFSF14)、NKG2C、Ig alpha(CD79a)、DAP-10、Fc gamma受体、MHC 1类分子、TNF受体蛋白、免疫球蛋白、细胞因子受体、整联蛋白、信号转导淋巴细胞活化分子(SLAM蛋白)、活化NK细胞受体、BTLA、Toll配体受体、、ICAM-1、B7-H3、CDS、ICAM-1、GITR、BAFFR、LIGHT、HVEM(LIGHTR)、KIRDS2、SLAMF7、NKp80(KLRF1)、NKp44、NKp30、NKp46、CD19、CD4、CD8alpha、CD8beta、IL-2R beta、IL-2R gamma、IL-7Ralpha、ITGA4、VLA1、CD49a、ITGA4、IA4、CD49D、ITGA6、VLA-6、CD49f、ITGAD、CDl ld、ITGAE、CD103、ITGAL、CDl la、LFA-1、ITGAM、CDl lb、ITGAX、CDl lc、ITGBl、CD29、ITGB2、CD18、LFA-1、ITGB7、NKG2D、TNFR2、TRANCE/RANKL、DNAM1(CD226)、SLAMF4(CD244、2B4)、CD84、CD96(Tactile)、CEACAM1、CRT AM、Ly9(CD229)、CD160(BY55)、PSGL1、CD100(SEMA4D)、CD69、SLAMF6(NTB-A、Lyl08)、SLAM(SLAMF1、CD150、IPO-3)、BLAME(SLAMF8)、SELPLG(CD162)、LTBR、LAT、GADS、SLP-76、PAG/Cbp、CD19a、与CD83特异性结合的配体或其任何组合。
在优选的实施方案中,可以将CAR的胞内/胞质域设计成包含单独或与本发明的CAR的背景下有用的任何其他期望的胞内域组合的CD3 zeta域。例如,CAR的胞内域可以包含CD3 zeta链部分和共刺激信号传导分子的部分。本发明的CAR的胞内信号传导部分内的胞内信号传导序列可以以随机或规定顺序彼此连接。
在另一个优选的实施方案中,将胞内域设计为包含CD3 zeta的活化域和CD28的信号传导域。在另一个实施方案中,将胞内域设计为包含CD3 zeta的活化域和4-1BB的信号传导域。在另一个实施方案中,将CAR中的细胞内域设计为包含CD28和CD3 zeta的部分,其中胞内CD28包含SEQ ID NO:7中列出的核酸序列和SEQ ID NO:8所示的氨基酸序列。CD3 zeta核酸序列在SEQ ID NO:9中列出,并且氨基酸序列在SEQ ID NO:8中列出。
如本文所用,“活化”或“刺激”指通过活化分子与其关联配体的结合而诱导的主要反应,其中所述结合介导信号转导事件。
“活化分子”或“刺激分子”是指与抗原呈递细胞上存在的关联刺激配体特异性结合的T细胞上的分子,例如TCR/CD3复合物。本文描述了合适的活化分子。
应当理解,在本发明范围内的合适的活化域可以源自(或对应于)活化/刺激分子,诸如例如CD3或CD3 zeta。CD3是天然T细胞上T细胞受体的元件,并且已显示是CAR中重要的胞内活化元件。
在优选的实施方案中,CD3是CD3 zeta,其核苷酸序列在SEQ ID NO.9中列出:
AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG
胞内CD3 zeta的相应氨基酸在SEQ ID NO.10中列出:
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
应当理解,根据本发明的CAR的一种优选的取向包括与胞外和/或铰链域、共刺激域和活化域串联的抗原结合分子(例如scFv)。应当进一步理解,可以串联使用多个域。
表1列出了根据本发明的示例性CAR构建体:
表1
构建体名称 | scFv | 铰链域 | 活化域 |
24C1 CD28T | 24C1 | CD28T | CD3 zeta |
24C1 CD28 | 24C1 | CD28 | CD3 zeta |
24C1 CD8 | 24C1 | CD8 | CD3 zeta |
24C8 CD28T | 24C8 | CD28T | CD3 zeta |
24C8 CD28 | 24C8 | CD28 | CD3 zeta |
24C8 CD8 | 24C8 | CD8 | CD3 zeta |
20C5.1 CD28T | 20C5.1 | CD28T | CD3 zeta |
20C5.1 CD28 | 20C5.1 | CD28 | CD3 zeta |
20C5.1 CD8 | 20C5.1 | CD8 | CD3 zeta |
20C5.2 CD28T | 20C5.2 | CD28T | CD3 zeta |
20C5.2 CD28 | 20C5.2 | CD28 | CD3 zeta |
20C5.2 CD8 | 20C5.2 | CD8 | CD3 zeta |
术语“载体”是指用于将蛋白质编码信息转移到宿主细胞中的任何分子或实体(例如,核酸、质粒、噬菌体或病毒)。术语“表达载体”或“表达构建体”是指适于转化宿主细胞并包含指导和/或控制(与宿主细胞结合)与其可操作连接的一种或多种异源编码区域表达的核酸序列的载体。表达构建体可包括但不限于影响或控制转录、翻译和(若存在内含子)影响与其可操作连接的编码区的RNA剪接的序列。
术语“宿主细胞”是指已经被核酸序列转化或能够被转化并由此表达感兴趣的基因的细胞。该术语包括亲代细胞的后代,无论该后代在形态或遗传组成上是否与原始亲代细胞相同,只要存在感兴趣的基因即可。
术语“转化”是指细胞遗传特性的改变,并且当细胞被修饰以包含新的DNA或RNA时,细胞已经得到转化。例如,通过经由转染、转导或其他技术导入新的遗传物质转化细胞,其中其从天然状态进行遗传修饰。转染或转导后,转化的DNA可以通过物理整合到细胞的染色体中而与细胞的DNA重组,或者可以作为附加体元件瞬时维持而不被复制,或者可以作为质粒独立复制。当转化的DNA随细胞分裂而复制时,认为细胞已经“稳定转化”。
本发明进一步涉及编码本发明的嵌合抗原受体(CAR)和T细胞受体(TCR)的分离的多核苷酸,以及包含该多核苷酸的载体。本领域已知的任何载体可适用于本发明。在一些实施方案中,载体是病毒载体。在一些实施方案中,载体是逆转录病毒载体(例如pMSVG1)、DNA载体、鼠白血病病毒载体、SFG载体、质粒、RNA载体、腺病毒载体、杆状病毒载体、埃巴病毒载体、乳头瘤病毒载体、牛痘病毒载体、单纯疱疹病毒载体、腺病毒相关载体(AAV)、慢病毒载体(例如pGAR)或其任何衍生物或组合。
pGAR序列如下:
CTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGACCCGGGGATGGCGCGCCAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGCTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCCGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAATTCAAAATTTTATCGCGATCGCGGAATGAAAGACCCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCCGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGCGCGCCAGTCCTTCGAAGTAGATCTTTGTCGATCCTACCATCCACTCGACACACCCGCCAGCGGCCGCTGCCAAGCTTCCGAGCTCTCGAATTAATTCACGGTACCCACCATGGCCTAGGGAGACTAGTCGAATCGATATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTTCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGGTTAATTAAAGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCGAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGGCATGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTGGCGCGCCATCGTCGAGGTTCCCTTTAGTGAGGGTTAATTGCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC
合适的另外的示例性载体包括例如pBABE-puro、pBABE-neo largeTcDNA、pBABE-hygro-hTERT、pMKO.1GFP、MSCV-IRES-GFP、pMSCV PIG(Puro IRES GFP空质粒)、pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE、MSCV IRES萤光素酶、pMIG、MDH1-PGK-GFP_2.0、TtRMPVIR、pMSCV-IRES-mCherry FP、pRetroX GFP T2A Cre、pRXTN、pLncEXP、和pLXIN-Luc。
在另一个实施方案中,不同表达载体的混合物可以用于遗传修饰免疫效应细胞的供体群体,其中每个载体编码如本文公开的不同CAR。所得的转导的免疫效应细胞形成工程化细胞的混合群体,其中一定比例的工程化细胞表达超过一种不同的CAR。
在本发明的优选实施方案中,CAR包含抗-CD19 scFv、CD28和CD3 zeta的全部或部分。
还可以通过用编码T细胞受体(TCR)的多核苷酸转染收集的T细胞来创建本发明的转染的T细胞。T细胞受体(TCR)是在T细胞表面上发现的分子,其负责以与主要组织相容性复合物(MHC)分子结合的肽识别抗原片段。TCR由两条不同的蛋白质链组成-在约95%的人TCR中,TCR由一条alpha(α)和beta(β)链组成。在约5%的人T细胞中,TCR由gamma和delta(γ/δ)链组成。每条链由都为免疫球蛋白超家族的两个胞外域组成:可变(V)区和恒定(C)区。与其他免疫球蛋白中一样,TCRα链和β链(或gamma和delta(γ/δ)链)的可变域各具有三个高变或互补决定区(CDR)。当TCR与抗原肽和MHC(肽/MHC)结合时,T细胞被活化,使其能够攻击并破坏靶细胞。
本发明的TCR可以结合例如肿瘤相关抗原。如本文所用,“肿瘤相关抗原”是指与一种或多种选自下组的癌症相关的抗原:肾上腺皮质癌、肛门癌、膀胱癌、骨癌、脑癌、乳腺癌、类癌癌、癌瘤、宫颈癌、结肠癌、子宫内膜癌、食道癌、肝外胆管癌、颅外生殖细胞癌、眼癌、胆囊癌、胃癌、生殖细胞瘤、妊娠滋养细胞肿瘤、头颈癌、下咽癌、胰岛细胞癌、肾癌、大肠癌、喉癌、白血病、唇和口腔癌、肝癌、肺癌、淋巴瘤、恶性间皮瘤、默克尔细胞癌、蕈样肉芽肿病、脊髓发育不良综合征、骨髓增生病症、鼻咽癌、神经母细胞瘤、口腔癌、口咽癌、骨肉瘤、卵巢上皮癌、卵巢生殖细胞癌、胰腺癌、鼻旁窦和鼻腔癌、甲状旁腺癌、阴茎癌、垂体癌、浆细胞瘤、前列腺癌、横纹肌肉瘤、直肠癌、肾细胞癌、肾盂和输尿管的移行细胞癌、唾液腺癌、Sezary综合征、皮肤癌、小肠癌、软组织肉瘤、胃癌、睾丸癌、胸腺瘤、甲状腺癌、尿道癌、子宫癌、阴道癌、外阴癌和Wilms肿瘤。
在某些方面,本申请可以适用于血液学癌症的靶分子。在一些实施方案中,癌症是白细胞的癌症。在其他实施方案中,癌症是浆细胞的癌症。在一些实施方案中,癌症是白血病、淋巴瘤或骨髓瘤。在某些实施方案中,癌症是急性淋巴母细胞性白血病(ALL)(包括非T细胞ALL)、急性淋巴样白血病(ALL)和嗜血细胞性淋巴组织细胞增多症(HLH))、B细胞幼淋巴细胞白血病、B细胞急性淋巴细胞样白血病(“BALL”)、母细胞性浆细胞样树突细胞新生物、伯基特氏淋巴瘤、慢性淋巴细胞性白血病(CLL)、慢性髓性白血病(CML)、慢性髓样白血病(CML)、慢性或急性肉芽肿性疾病、慢性或急性白血病、弥漫性大B细胞淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤、滤泡性淋巴瘤(FL)、毛细胞白血病、噬血细胞性综合征(巨噬细胞活化综合征(MAS)、何杰金氏病、大细胞肉芽肿、白细胞粘附缺乏、恶性淋巴增生性病况、MALT淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤、意义不明的单克隆gamma病变(gammapathy)(MGUS)、多发性骨髓瘤、骨髓增生异常和骨髓增生异常综合症(MDS)、髓样疾病,包括但不限于急性髓样白血病(AML)、非何杰金氏淋巴瘤(NHL)、浆细胞增生性疾病(例如无症状骨髓瘤(隐袭性多发性骨髓瘤或无痛性骨髓瘤)、浆母细胞性淋巴瘤、浆细胞样树突细胞新生物、浆细胞瘤(例如浆细胞体液不调;孤立性骨髓瘤;孤立性浆细胞瘤;髓外浆细胞瘤和多发性浆细胞瘤),POEMS综合征(Crow-Fukase综合征;Takatsuki病;PEP综合征)、原发性纵隔大B细胞淋巴瘤(PMBCL)、小细胞或大细胞滤泡性淋巴瘤、脾边缘区淋巴瘤(SMZL)、系统性淀粉样蛋白轻链淀粉样变性、T细胞急性淋巴样白血病(TALL)、T细胞淋巴瘤、转化的滤泡性淋巴瘤、Waldenstrom巨球蛋白血症或其组合。
在一些实施方式中,抗原选自肿瘤相关表面抗原,例如例如5T4、甲胎蛋白(AFP)、B7-1(CD80)、B7-2(CD86)、BCMA、B-人绒毛膜促性腺激素、CA-125、癌胚抗原(CEA)、癌胚抗原(CEA)、CD123、CD133、CD138、CD19、CD20、CD22、CD23、CD24、CD25、CD30、CD33、CD34、CD4、CD40、CD44、CD56、CD8、CLL-1、c-Met、CMV特异性抗原、CSPG4、CTLA-4、二唾液酸神经节苷脂GD2、导管上皮粘蛋白(mucine)、EBV特异性抗原、EGFR变体III(EGFRvIII)、ELF2M、内皮糖蛋白(endoglin)、ephrin B2、上皮生长因子受体(EGFR)、上皮细胞粘附分子(EpCAM)、上皮肿瘤抗原、ErbB2(HER2/neu)、成纤维细胞相关蛋白(fap)、FLT3、叶酸结合蛋白、GD2、GD3、胶质瘤相关抗原、鞘糖脂、gp36、HBV特异性抗原、HCV特异性抗原、HER1-HER2、HER2-HER3组合、HERV-K、高分子量黑素瘤相关抗原(HMW-MAA)、HIV-1包膜糖蛋白gp41、HPV特异性抗原、人端粒酶逆转录酶、IGFI受体、IGF-II、IL-11Ralpha、IL-13R-a2、流感病毒特异性抗原;CD38、胰岛素生长因子(IGF1)-1、肠羧基酯酶、kappa链、LAGA-la、lambda链,拉沙病毒特异性抗原、凝集素反应性AFP、谱系特异性或组织特异性抗原,例如CD3、MAGE、MAGE-A1、主要组织相容性复合物(MHC)分子、呈递肿瘤特异性肽表位的主要肿瘤相容性复合物(MHC)分子、M-CSF、黑素瘤相关抗原、间皮素、间皮素、MN-CA IX、MUC-1,mut hsp72、突变的p53、突变的p53、突变的ras、嗜中性粒细胞弹性蛋白酶、NKG2D、Nkp30、NY-ESO-1、p53、PAP、蛋白酶、蛋白酶特异性抗原(PSA)、前列腺癌肿瘤抗原1(PCTA-1)、前列腺素特异性抗原、prostein、PSMA、RAGE-1、ROR1、RU1、RU2(AS)、表面粘附分子、存活和端粒酶、TAG-72、纤连蛋白的额外域A(EDA)和额外域B(EDB)以及腱糖蛋白-C的Al域(TnC A1)、甲状腺球蛋白、肿瘤基质抗原、血管内皮生长因子受体2(VEGFR2)、病毒特异性表面抗原,例如HIV特异性抗原(例如HIV gp120),以及这些表面标志物的任何衍生物或变体。
本发明的TCR也可以结合病毒感染相关抗原。病毒感染相关抗原包括与任何病毒感染相关的抗原,包括例如由HIV引起的病毒感染。
为了启动本文所述的患者特异性免疫疗法规程,客户端计算装置102a处的内科医生或其他医务人员访问服务器计算装置106的用户界面模块108a(例如,经由门户网站、网站或其他类似平台)。用户界面模块108a生成用于在客户端计算装置102a上呈现给内科医生的用户界面屏幕和/或元件,以便内科医生登记患者并启动患者特异性免疫疗法规程。用户界面模块108a可以生成UI屏幕,以使内科医生能够输入患者的识别信息(例如,全名,出生日期)、人口统计学(例如,性别)和医疗保健提供者信息(例如,内科医生名称,医院名称)。用户界面模块108a还可以提供用于输入医疗保健提供者特异性或医院特异性用户标识符(例如,病历号,医院患者ID)的UI元件。图3A和3B是由用户界面模块108a生成的示例性屏幕截图,其使新患者能够登记到系统中;图3A描述了患者登记数据输入屏幕,而图3B描绘了患者信息回顾和确认屏幕。
返回图2,客户端计算装置102a生成请求以创建用于患者的经转染的T细胞,并且服务器计算装置106接收(202)该请求。如上所述,客户端计算装置102a处的内科医生与用户界面模块108a交互以通过提供必要的患者信息来登记患者。一旦用户界面模块108a从客户端计算装置102a接收患者信息已经被完全输入并且是准确的确认,则用户界面模块108a将数据存储在数据库110中。用户界面模块108a还生成(204)患者特异性标识符,其将用作以下所述的样品跟踪和监管链/身份链过程的一部分。在一个实施方案中,患者特异性标识符包括患者身份元件(例如,患者ID号)、销售订购标识符和细胞订购批次号。例如,用户界面模块108a可以通过将患者身份元件、销售订购号和细胞订购批次号映射到以标识符(例如,九位数字代码)作为索引的数据库表中来生成患者特异性标识符。所述标识符独特识别患者、销售订购和细胞批次组合。
接下来,客户端计算装置102a处的内科医生与用户界面模块108a交互以安排预约以从患者获得生物材料,并且由于将改变的生物材料快速提供给患者的时间敏感性,确认制造设施具有在获得材料后不久处理生物材料的利用度。用户界面模块108a请求确认材料提取地点(例如,站点名称、地址、联系信息)以用于提取试剂盒(例如,白细胞单采术试剂盒)的寄件以及改变的材料递送和处理地点(例如,站点名称、地址、联系信息)的确认,用于从制造设施递送材料(例如,经转染的T细胞)。图4A-4D是由用户界面模块108a生成的示例性屏幕截图,其使得能够确认这些地点并安排预约;图4A描绘了寄件地点确认屏幕。图4B描绘了材料递送地点确认屏幕。图4C描绘了打开预定调度程序的屏幕;并且图4D描绘了预约调度程序。在一些实施方案中,用户界面模块108a与制造设施的远程计算装置以及数据库110通信,以协调生物材料修改的调度,以确保最有效的处理日程表,从而使经修饰的材料快速返回到患者。
返回图2,如上所述,一旦完成细胞订购过程,启动过程206以在提取地点处进行生物材料提取规程,将提取的材料运输到制造设施以进行修饰,然后将经修饰的材料发送回递送地点,以输注回患者血液中。首先,患者到达材料提取地点,并对患者的血液样品进行规程(例如白细胞分离规程)(206a),以从样品中收集T细胞。当进行该规程时,提取地点处的客户端计算装置(例如,装置102b)与服务器计算装置106的事件跟踪模块108b通信,以将与该规程的进行相对应的跟踪事件发送给模块108b。例如,客户端计算装置102b处的临床医生可以通过将信息输入用户界面来提交跟踪事件。在另一个实例中,当客户端计算装置102b捕获关于规程的信息(例如,扫描条形码)时,客户端计算装置102b可以自动将跟踪事件传输给模块108b(例如,经由API)。
跟踪事件可以包括患者特异性标识符、时间戳、事件ID(例如,其指示进行材料提取规程)以及与该过程有关的其他信息(例如,细胞订购批次号、销售订购号、地点位置等)。事件跟踪模块108b基于从客户端计算装置102b接收的信息将跟踪事件存储在数据库110中。因为这是生物材料提取和修饰过程中的第一步,所以事件跟踪模块108b对监管链模块108c通知跟踪事件的收据。监管链模块108c生成监管链数据结构(例如,数据库110中),该结构以使患者、内科医生、制造商和其它各方了解生物材料的确切状态,并确保始终对生物材料进行说明以避免丢失或处理不当的有序顺序掺入跟踪事件(以及本文描述的每个后续跟踪事件)。在一个实例中,监管链数据结构可以是链接列表,该链接列表根据例如跟踪事件的时间戳以顺序的方式将每个跟踪事件连接在一起。
接下来,将收集的T细胞转移(206b)到容器(例如管、小瓶或其他类型的生物材料载体)中,并捕获另一个跟踪事件,并将其传输到事件跟踪模块108b中以整合到上文描述的监管链数据结构链中。然后,用患者特异性标识符对容器进行标记(206c),并捕获另一个跟踪事件,并将其传输到事件跟踪模块108b,以与监管链模块108c通信,以集成到监管链数据结构中。例如,容纳收集的T细胞的容器用包含患者特异性标识符的条形码标记,然后在提取地点扫描所述条形码——指示收集的T细胞已准备好运输到制造设施。在扫描条形码时,客户端计算装置102b生成跟踪事件,并将该事件传输到事件跟踪模块108b。
然后,提取地点将收集的T细胞传输(206d)到制造装置,该制造装置进行生成经转染的T细胞的规程。既在将收集的T细胞运输到制造设施时又在制造设施处接收收集的T细胞时,用于记录T细胞的运输和收据的一个或多个装置与事件跟踪模块108b进行通信,以传输与特定活动相关的跟踪事件,以与监管链模块108c通信,以集成到监管链中。以此方式,监管链模块108c利用最新信息自动且连续地更新监管链数据结构,并且在由用户界面模块108a生成的一个或多个屏幕中反映该信息。
然后,制造设施使用细胞修饰技术从收集的T细胞创建(206e)经转染的T细胞,并且客户端计算装置(例如,装置102c)基于使用的特定的细胞修饰技术生成一个或多个跟踪事件。例如,细胞修饰技术可以包括几个阶段——例如(i)修饰之前收集的T细胞的质量保证,(ii)T细胞的修饰;(ii)经转染的T细胞的释放测试,和(iv)终止经转染的T细胞以运输回到输注地点。对于这些阶段中的每个阶段,客户端计算装置102c捕获跟踪事件,并将跟踪事件传输到事件跟踪模块108b,以通过监管链模块108c集成到监管链数据结构中。
一旦运输经转染的T细胞,输注地点接收(206f)经转染的T细胞,并且客户端计算装置(例如,装置102d)生成跟踪事件,以传输到事件跟踪模块108b,以通过监管链模块108c集成到监管链数据结构中。例如,客户端计算装置102d可以扫描与运输和/或经转染的T细胞相关的条形码以自动生成跟踪事件并将该事件传输到服务器计算装置106。
接收后,将经转染的T细胞输注(206g)到患者的血流中,从而完成该过程。同时,客户端计算装置102d生成跟踪事件,并将该事件传输到事件跟踪模块108b,以通过监管链模块108c集成到监管链数据结构中。
图5A和5B是由用户界面模块108a生成的示例性屏幕截图,以使客户端计算装置102a-102d能够查看与特定患者、生物材料和细胞修饰过程相关的监管链。如图5A所示,在白细胞单采术过程期间生物材料的监管链(包括安排规程、完成规程以及将提取的T细胞准备好运输的步骤)在屏幕顶部的时间线中捕获,其中白细胞单采术过程的每个步骤都与时间线上的点相关联,并且在屏幕底部的时间线上捕获在递送过程期间生物材料的监管链(例如,从提取地点运输的T细胞、递送到制造设施的T细胞)。当事件跟踪模块108b和监管链模块108c如上所述记录跟踪事件时,用户界面模块108a遍历监管链数据结构以在屏幕上以图形方式表示监管链的当前状态。
如在图5B中所示,在屏幕顶部的时间线中显示了制造过程(包括QA、制造、释放测试和终止以运输)期间生物材料的监管链,并且在屏幕中间显示了在最终产品递送过程(包括运输和递送到输注站点)期间生物材料的监管链。另外,在屏幕底部显示了治疗细节,包括治疗日期。此外,监管链始终与特定患者相关联——从而确保在制造的所有阶段期间患者与生物材料之间的完整身份链。
可以以数字和/或模拟电子电路,或以计算机硬件、固件、软件或它们的组合来实现上述技术。该实现可以作为计算机程序产品,即有形地体现在机器可读存储装置中的计算机程序,以由数据处理装置(例如,可编程处理器、计算机和/或多台计算机)执行或控制数据处理装置(例如,可编程处理器、计算机和/或多台计算机)。可以以任何形式的计算机或编程语言(包括源代码、编译代码、解释性代码和/或机器代码)编写计算机程序,并且可以以任何形式(包括以独立程序或以适用于计算环境的子例程、元件或其他单元)部署计算机程序。可以将计算机规程部署为在一台计算机上或在一个或多个地点的多台计算机上执行。计算机程序可以部署在云计算环境(例如, AWS, Azure,)中。
方法步骤可以由一个或多个处理器进行,所述处理器执行计算机程序以通过对输入数据进行操作和/或生成输出数据来进行本发明的功能。方法步骤也可以由专用逻辑电路进行,并且装置可以作为专用逻辑电路实现,例如FPGA(现场可编程门阵列)、FPAA(现场可编程模拟阵列)、CPLD(复杂可编程逻辑器件)、PSoC(可编程片上系统)、ASIP(专用指令集处理器)或ASIC(专用集成电路)等。子例程可以指所存储的计算机程序和/或处理器和/或实现一个或多个功能的专用电路的部分。
例如,适合于执行计算机程序的处理器包括专用微处理器,该专用微处理器特别编程有可执行以进行本文描述的方法的指令。通常,处理器从只读存储器或随机存取存储器或两者接收指令和数据。计算机的基本元件是用于执行指令的处理器和用于存储指令和/或数据的一个或多个存储装置。诸如高速缓存的存储装置可以用于临时存储数据。存储装置也可以用于长期数据存储。通常,计算机还包括一个或多个用于存储数据的大容量存储装置,例如,磁盘、磁光盘或光盘,或可操作地偶联以从该大容量存储装置接收数据和/或将数据转移到该大容量存储装置。计算机还可以可操作地偶联到通信网络,以便从网络接收指令和/或数据和/或将指令和/或数据转移到网络。适合于体现计算机程序指令和数据的计算机可读存储介质包括所有形式的易失性和非易失性存储器,包括例如半导体存储装置,例如DRAM、SRAM、EPROM、EEPROM和闪存装置;磁盘,例如内部硬盘或可移动磁盘;磁光盘;和光盘,例如CD、DVD、HD-DVD和蓝光盘。处理器和存储器可以由专用逻辑电路补充和/或并入专用逻辑电路。
为了提供与用户的交互,可以在计算装置上实现上述技术,所述计算装置与以下项通信:显示装置,例如CRT(阴极射线管)、等离子体或LCD(液晶显示器)监视器、移动装置显示器或屏幕、全息装置和/或投影仪,用于向用户显示信息,以及用户可以对计算机提供输入(例如,与用户界面元件交互)的键盘和指向装置,例如鼠标、轨迹球、触摸板或运动传感器。也可以使用其他种类的装置来提供与用户的交互;例如,提供给用户的反馈可以是任何形式的感觉反馈,例如视觉反馈、听觉反馈或触觉反馈;并且可以以任何形式接收来自用户的输入,包括声音、语音和/或触觉输入。
可以在包括后端组件的分布式计算系统中实现上述技术。后端组件可以例如是数据服务器、中间件组件和/或应用服务器。可以在包括前端组件的分布式计算系统中实现上述技术。前端组件可以例如是具有图形用户界面的客户端计算机、用户可以与示例性实现进行交互的网络浏览器和/或用于传输装置的其他图形用户界面。可以在包括此类后端、中间件或前端组件的任何组合的分布式计算系统中实现上述技术。
计算系统的组件可以通过传输介质互连,该传输介质可以包括数字或模拟数据通信(例如,通信网络)的任何形式或介质。传输介质可以以任何配置包括一个或多个基于分组的网络和/或一个或多个基于电路的网络。基于分组的网络可以包括例如因特网、运营商因特网协议(IP)网络(例如,局域网(LAN)、广域网(WAN)、校园网(CAN)、城域网(MAN)、家域网(HAN)、专用IP网络、IP专用小交换机(IPBX)、无线网络(例如,无线电访问网络(RAN)、蓝牙、近场通信(NFC)网络、Wi-Fi、WiMAX、通用分组无线服务(GPRS)网络、HiperLAN)和/或其他基于分组的网络。基于电路的网络可以包括例如公共交换电话网络(PSTN)、遗产专用分组交换(PBX)、无线网络(例如,RAN,码分多址(CDMA)网络、时分多址(TDMA)网络、全球移动通信系统(GSM)网络和/或其他基于电路的网络。
通过传输介质的信息传输可以基于一种或多种通信协议。通信协议可以包括例如以太网协议、互联网协议(IP)、IP语音(VOIP)、点对点(P2P)协议、超文本传输协议(HTTP)、会话发起协议(SIP)、H.323、媒体网关控制协议(MGCP)、7号信令系统(SS7)、全球移动通信系统(GSM)协议、按键通话(PTT)协议、蜂窝PTT(PTT over Cellular,POC)、通用移动电信系统(UMTS)、3GPP长期演进(LTE)和/或其他通信协议。
计算系统的装置可以包括例如计算机、具有浏览器装置的计算机、电话、IP电话、移动装置(例如,蜂窝电话、个人数字助理(PDA)装置、智能电话、平板电脑、膝上计算机、电子邮件装置)和/或其他通信装置。浏览器装置包括,例如,具有万维网浏览器的计算机(例如,台式计算机和/或膝上计算机)(例如,来自Google,Inc.的ChromeTM,可从MicrosoftCorporation获得的 Internet 和/或可从Mozilla Corporation获得的 Firefox)。移动计算装置包括,例如来自Research in Motion的来自Apple Corporation的和/或基于AndroidTM的装置。IP电话包括例如可从Cisco Systems,Inc.获得的 Unified IP电话7985G和/或Unified无线电话7920。
另外的定义
术语“多肽”或“蛋白质”是指具有蛋白质的氨基酸序列的大分子,包括天然序列的一个或多个氨基酸的缺失、添加和/或取代,并且优选地其中不超过8个氨基酸取代。优选地,多肽或蛋白质是分离的,如本文定义的。术语“多肽片段”是指与全长天然蛋白相比具有氨基端缺失、羧基端缺失和/或内部缺失的分离的多肽。与天然蛋白质相比,此类片段还可含有经修饰的氨基酸。有用的多肽片段包括抗原结合分子的免疫功能片段。有用的片段包括但不限于一个或多个CDR区、重链和/或轻链的可变域、抗体链的其他部分的部分等。
术语“抗体”是指可以与完整抗体竞争对靶抗原/分子的特异性结合的任何同种型的完整免疫球蛋白或其片段,并且包括例如嵌合的、人源化的、完全人的和双特异性的抗体。“抗体”是如本文定义的抗原结合分子的种类。完整的抗体通常将包含至少两条全长重链和两条全长轻链,但在某些情况下可包含较少的链,例如天然存在于骆驼科动物中的抗体,其仅可包含重链。抗体可以仅源自单一来源,或者可以是嵌合的,即,抗体的不同部分可以源自两种不同的抗体,如下文进一步所述。抗原结合分子、抗体或结合片段可以在杂交瘤中,通过重组DNA技术或通过完整抗体的酶促或化学切割而产生。除非另有说明,除包含两条全长重链和两条全长轻链的抗体外,术语“抗体”还包括其衍生物、变体、片段和突变蛋白,其实例在下文描述。此外,除非明确排除,否则抗体包括单克隆抗体、双特异性抗体、微型抗体、域抗体、合成抗体(在本文中有时称为“抗体模拟物”)、嵌合抗体、人源化抗体、人抗体、抗体融合物(在本文中有时称为“抗体缀合物”)及其片段。
可变区通常表现出由3个高变区(即“CDR”)连接的相对保守的框架区(FR)的相同总体结构。来自每对的两条链的CDR通常通过框架区对齐,这可以使得能够结合特定的表位。从N端到C端,轻链和重链可变区两者通常包含域FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。按照惯例,重链中的CDR区通常称为HC CDR1、CDR2和CDR3。轻链中的CDR区通常称为LCCDR1、CDR2和CDR3。对每个域的氨基酸分配通常根据Kabat、Chothia或AbM的定义。
术语“Kabat编号”和类似术语在本领域中是公认的,并且是指对抗体或其抗原结合部分的重链和轻链可变区中的氨基酸残基进行编号的系统。在某些方面,可以根据Kabat编号系统确定抗体的CDR(参见,例如Kabat EA &Wu TT(1971)Ann NY Acad Sci 190:382-391and Kabat EA et al.,(1991)Sequences of Proteins of Immunological Interest,Fifth Edition,U.S.Department of Health and Human Services,NIH PublicationNo.91-3242)。使用Kabat编号系统,抗体重链分子内的CDR通常存在于第31至35位氨基酸(它们任选地可包含35位之后的一个或两个额外的氨基酸(在Kabat编号方案中称为35A和35B))(CDR1)、第50至65位氨基酸(CDR2)和第95至102位氨基酸(CDR3)。使用Kabat编号系统,抗体轻链分子内的CDR通常存在于氨基酸位置24至34(CDR1)、氨基酸位置50至56(CDR2)和氨基酸位置89至97(CDR3)。在一个具体的实施方案中,已经根据Kabat编号方案确定了本文描述的抗体的CDR。
在某些方面,可以根据Chothia编号方案确定抗体的CDR,所述Chothia编号方案指免疫球蛋白结构环的位置(参见例如Chothia C&Lesk AM,(1987),J Mol Biol 196:901-917;Al-Lazikani B et al.,(1997)J Mol Biol 273:927-948;Chothia C et al.,(1992)J Mol Biol 227:799-817;Tramontano A et al.,(1990)JMol Biol 215(1):175-82;和美国专利No.7,709,226)。通常,当使用Kabat编号约定时,Chothia CDR-H1环存在于重链氨基酸26至32、33或34处,Chothia CDR-H2环存在于重链氨基酸52至56处,并且Chothia CDR-H3环存在于重链氨基酸95至102,而Chothia CDR-L1环存在于轻链氨基酸24至34,ChothiaCDR-L2环存在于轻链氨基酸50至56,并且Chothia CDR-L3环存在于轻链氨基酸89至97。使用Kabat编号约定编号时Chothia CDR-HI环的末端在H32和H34之间随环长度而变化(这是因为Kabat编号方案将插入置于H35A和H35B处;若不存在35A和35B,则环在32处结束;若仅存在35A,则环在33处结束;若存在35A和35B两者,则环在34处结束)。
在一个具体的实施方案中,已经根据Chothia编号方案确定了本文描述的抗体的CDR。
通常使用多个CDR的定义:Kabat编号、Chothia编号、AbM编号或接触编号。AbM定义是Oxford Molecular的AbM抗体建模软件使用的两者之间的折衷方案。接触定义基于对可用复杂晶体结构的分析。
表2:CDR编号
如本文所用,术语“重链”在提及抗体使用时可以指基于恒定域的氨基酸序列的任何不同类型,例如,alpha(α)、delta(δ)、epsilon(ε)、gamma(γ)和mu(μ),它们分别产生IgA、IgD、IgE、IgG和IgM类抗体,包括IgG的亚类,例如IgG1、IgG2、IgG3和IgG4。
如本文所用,术语“轻链”在提及抗体使用时可以指基于恒定域的氨基酸序列的任何不同的类型,例如kappa(κ)或lambda(λ)。轻链氨基酸序列是本领域公知的。在具体的实施方案中,轻链是人轻链。
术语“可变区”或“可变域”是指抗体的轻链和/或重链的一部分,通常包含重链中的氨基端的约120-130个氨基酸和轻链中约100-110个氨基端氨基酸。抗体的可变区通常确定特定抗体对其靶标的特异性。
可变性未在抗体或抗原结合分子的可变域中均匀分布;它集中在重链和轻链可变区中每个的亚域中。如本文进一步描述的,这些亚域称为“高变区”或“互补决定区”(CDR)。可变域的更保守的(即,非高变的)部分称为“框架”区(FRM或FR),并在三维空间中为六个CDR提供了支架以形成抗原结合表面。天然存在的重链和轻链的可变域各自包含四个FRM区域(FR1、FR2、FR3和FR4),主要采用β-片层结构,它们由三个高变区连接,所述高变区形成连接β-片层,在某些情况下形成β-片层的一部分的环。每条链中的高变区通过FRM紧密结合在一起,并且与另一条链中的高变区一起促成形成抗原结合位点(参见Kabat等人,在本文中进一步描述)。
通常,CDR形成可以分类为规范结构的环结构。术语“规范结构”是指抗原结合(CDR)环所采用的主链构象。从比较的结构研究中,已经发现六个抗原结合环中的五个仅具有有限的可用构象库。每个规范结构可以通过多肽主链的扭转角来表征。因此,尽管在环的大部分部分中氨基酸序列变异性高,但抗体之间的对应环可以具有非常相似的三维结构(Chothia and Lesk,J.MoI.Biol.,1987,196:901;Chothia et al.,Nature,1989,342:877;Martin and Thornton,J.MoI.Biol,1996,263:800)。此外,所采用的环结构与其周围的氨基酸序列之间存在关系。特定规范类别的构象由环的长度和位于环内以及保守框架内(即环外)关键位置的氨基酸残基决定。因此,可以基于这些关键氨基酸残基的存在来进行特定规范类别的分配。
术语“规范结构”还可以包括关于抗体的线性序列的考虑因素,例如,如Kabat(Kabat等人,本文)所分类的。Kabat编号方案(系统)是用于以一致的方式对抗体可变域的氨基酸残基进行编号的广泛采用的标准,并且是在本发明中应用的优选方案,如本文其他地方所述。还可以使用其他结构考虑因素来确定抗体的规范结构。例如,可以通过Chothia等人的编号系统描述那些未完全由Kabat编号反映的差异和/或通过其他技术(例如,晶体学和二维或三维计算模型)揭示。因此,可以将给定的抗体序列置于规范类别中,该规范类别特别允许鉴定合适的底架序列(例如,基于在文库中包括多种规范结构的需求)。文献中描述了抗体氨基酸序列的Kabat编号和如Chothia等人(本文)所述的结构考虑及其对解释抗体结构的规范方面的意义。不同类别的免疫球蛋白的亚基结构和三维构型是本领域公知的。有关抗体结构的综述,参见Antibodies:A Laboratory Manual,Cold Spring HarborLaboratory,Harlow等人编,1988。
轻链的CDR3,以及特别是重链的CDR3可以构成轻链和重链可变区内的抗原结合中最重要的决定因素。在一些抗体构建体中,重链CDR3似乎构成抗原和抗体之间的主要接触区域。单独改变CDR3的体外选择方案可用于改变抗体的结合特性或确定哪些残基有助于抗原的结合。因此,CDR3通常是抗体结合位点内分子多样性的最大来源。例如,H3可以短至两个氨基酸残基或大于26个氨基酸。
如本文所用,术语“恒定区”和“恒定域”是可互换的,并且具有本领域中共同的含义。恒定区是抗体部分,例如轻链和/或重链的羧基端部分,其不直接参与抗体与抗原的结合,但是可以表现出各种效应器功能,例如与Fc受体的相互作用。相对于免疫球蛋白可变域,免疫球蛋白分子的恒定区通常具有更保守的氨基酸序列。
“Fc”区包含两个包含抗体的CH1和CH2域的重链片段。两个重链片段通过两个或多个二硫键以及通过CH3域的疏水相互作用保持在一起。
“Fab片段”包含一条轻链和一条重链的CH1和可变区。Fab分子的重链不能与另一个重链分子形成二硫键。“Fab'”片段”包含一条轻链和一条重链中含有VH域和CH1域及还有CH1和CH2域之间的区域的部分,因此可以在两个Fab’片段的两个重链之间形成链间二硫键以形成F(ab’)2分子。“F(ab’)2片段”含有两条轻链和两条含有CH1和CH2域之间恒定区的部分的重链,因此在两条重链之间形成链间二硫键。因此,F(ab’)2片段由通过两条重链之间的二硫键保持在一起的两个Fab’片段构成。
“Fv区”包括来自重链和轻链两者的可变区,但是缺乏恒定区。
“二价抗原结合分子”包含两个抗原结合位点。在某些情况下,两个结合位点具有相同的抗原特异性。二价抗原结合分子可以是双特异性的。“多特异性抗原结合分子”是靶向超过一个抗原或表位的分子。“双特异性”、“双重特异性”或“双功能性”抗原结合分子是分别具有两个不同抗原结合位点的杂合抗原结合分子或抗体。双特异性抗原结合分子的两个结合位点将结合两个不同的表位,它们可以位于相同或不同的蛋白质靶标上。
“结合亲和力”通常是指分子(例如,抗体)的单个结合位点与其结合配偶体(例如,抗原)之间的非共价相互作用的总和的强度。除非另有说明,否则如本文所用,“结合亲和力”是指内在结合亲和力,其反映结合对的成员(例如抗体和抗原)之间的1:1相互作用。分子X对其配偶体Y的亲和力通常可以用解离常数(KD)表示。亲和力可以以本领域中已知的多种方式来测量和/或表示,包括但不限于平衡解离常数(KD)和平衡缔合常数(KA)。KD从k解离/k缔合的商计算,而KA从k缔合/k解离的商计算。K缔合是指例如抗体与抗原的缔合速率常数,而k解离是指例如抗体与抗原的解离。K缔合和k解离可以通过本领域普通技术人员已知的技术,例如或KinExA来确定。
术语“中和”分别是指与配体结合并防止或降低该配体的生物学效应的抗原结合分子、scFv或抗体。这可以例如通过直接封闭配体上的结合位点或通过与配体结合并通过间接手段(例如配体中的结构或能量改变)改变配体的结合能力来完成。在一些实施方案中,该术语还可以表示防止与其结合的蛋白质进行生物学功能的抗原结合分子。
当在竞争相同表位的抗原结合分子的上下文中使用时,术语“竞争”是指抗原结合分子之间的竞争,如通过如下的测定法测定,在所述测定法中,测试的抗原结合分子(例如抗体或其免疫功能片段)防止或抑制(例如减少)参照抗原结合分子与抗原的特异性结合。多种类型的竞争性结合测定法可用于确定一个抗原结合分子是否与另一种竞争,例如:固相直接或间接放射免疫测定法(RIA)、固相直接或间接酶免疫测定法(EIA)、三明治式竞争测定法(Stahli et al.,1983,Methods in Enzymology 9:242-253);固相直接生物素-亲合素EIA(Kirkland et al.,1986,J.Immunol.137:3614-3619)、固相直接标记测定法、固相直接标记三明治式测定法(Harlow and Lane,1988,Antibodies,A Laboratory Manual,Cold Spring Harbor Press);使用1-125标记物的固相直接标记RIA(Morel et al.,1988,Molec.Immunol.25:7-15);固相直接生物素-亲合素EIA(Cheung,et al.,1990,Virology176:546-552);直接标记的RIA(Moldenhauer et al.,1990,Scand.J.Immunol.32:77-82)。
如本文所用,术语“表位”是指抗体可以特异性结合的抗原的局部区域。表位可以是例如多肽的连续氨基酸(线性或连续表位),或者表位可以例如一起来自一个或多个多肽的两个或多个非连续区域(构象性、非线性、不连续或非连续的表位)。在某些实施方案中,可以通过例如NMR光谱法、X射线衍射晶体学研究、ELISA测定法、氢/氘交换偶联质谱法(例如液相层析电喷雾质谱法)、基于阵列的寡肽扫描测定法和/或诱变作图(例如,定点诱变作图)来确定抗体结合的表位。对于X射线晶体学,可以使用本领域任何已知方法来完成结晶(例如GiegéR.et al.,(1994)Acta Crystallogr D Biol Crystallogr50(Pt 4):339-350;McPherson A(1990)Eur J Biochem 189:1-23;Chayen NE(1997)Structure 5:1269-1274;McPherson A(1976)J Biol Chem 251:6300-6303)。抗体:抗原晶体可以使用公知的X射线衍射技术来研究,并且可以使用计算机软件改进,所述计算机软件诸如X-PLOR(YaleUniversity,1992,Molecular Simulations,Inc.分配;参见例如Meth Enzymol(1985)volumes114&115,Wyckoff HW等人.编;U.S.2004/0014194),和BUSTER(Bricogne G(1993)Acta Crystallogr D Biol Crystallogr 49(Pt 1):37-60;Bricogne G(1997)MethEnzymol 276A:361-423,Carter CW编;Roversi P等人,(2000)Acta Crystallogr D BiolCrystallogr 56(Pt 10):1316-1323)。诱变作图研究可以使用本领域技术人员已知的任何方法来完成。关于诱变技术的描述,包括丙氨酸扫描诱变技术,参见例如Champe M et al.,(1995)J Biol Chem 270:1388-1394和Cunningham BC&Wells JA (1989)Science 244:1081-1085。
术语“遗传工程化”或“工程化”是指修饰细胞基因组的方法,包括但不限于删除编码或非编码区或其一部分或插入编码区或其一部分。在一些实施方案中,修饰的细胞是可以自患者或供体获得的淋巴细胞,例如T细胞。可以修饰细胞以表达掺入细胞基因组中的外源构建体,例如嵌合抗原受体(CAR)或T细胞受体(TCR)。
“免疫应答”是指免疫系统的细胞(例如,T淋巴细胞、B淋巴细胞、自然杀伤(NK)细胞、巨噬细胞、嗜酸性粒细胞、肥大细胞、树突细胞和嗜中性粒细胞)和由这些细胞或肝中的任一种产生的可溶性大分子(包括抗体、细胞因子和补体)的作用,其导致选择性靶向、结合、损害、破坏和/或从脊椎动物身体消除侵入病原体、被病原体感染的细胞或组织、癌性或其它异常细胞、或者在自身免疫或病理学炎症的情况下正常人细胞或组织。
术语“免疫疗法”是指通过包括诱导、增强、抑制或以其他方式修改免疫应答的方法来治疗罹患、或有风险染上疾病或者遭受疾病复发的受试者。免疫疗法的实例包括但不限于T细胞疗法。T细胞疗法可以包括过继性T细胞疗法、肿瘤浸润性淋巴细胞(TIL)免疫疗法、自体细胞疗法、工程化自体细胞疗法(eACT)和同种异体T细胞移植。然而,本领域技术人员将理解,本文公开的调理方法将增强任何移植的T细胞疗法的有效性。T细胞疗法的实例记载于美国专利公开号2014/0154228和2002/0006409、美国专利号5,728,388和国际公开号WO 2008/081035。
免疫疗法的T细胞可以来自本领域已知的任何来源。例如,可以在体外从造血干细胞群体中分化T细胞,或者可以从受试者获得T细胞。T细胞可以获自例如外周血单个核细胞(PBMC)、骨髓、淋巴结组织、脐带血、胸腺组织、来自感染部位的组织、腹水、胸腔积液、脾组织和肿瘤。另外,T细胞可以源自本领域可用的一种或多种T细胞系。T细胞也可以使用熟练技术人员已知的许多技术,例如FICOLLTM分离和/或单采血液成分术,从受试者收集的血液单元中获得。在美国专利公开号2013/0287748(其通过引用整体并入本文)中公开分离用于T细胞疗法的T细胞的其他方法。
术语“工程化自体细胞疗法”,可以缩写为“eACTTM”,也称为过继性细胞转移,是收集患者自身的T细胞并随后进行遗传改变以识别和靶向一种或多种特定肿瘤细胞或恶性的细胞表面上表达的一种或多种抗原的过程。可以工程化改造T细胞以表达例如嵌合抗原受体(CAR)或T细胞受体(TCR)。将CAR阳性(+)T细胞工程化改造为表达与胞内信号传导部分连接的对特定肿瘤抗原具有特异性的胞外单链可变片段(scFv),所述胞内信号传导部分包含至少一个共刺激域和至少一个活化域。共刺激域可以源自(或对应于)例如CD28,而活化域可以源自(或对应于)例如CD3-zeta。在某些实施方案中,CAR设计为具有两个、三个、四个或更多个共刺激域。
术语“自体的”是指随后接受其再导入的源自同一个体的任何材料。例如,本文所述的工程化自体细胞疗法(eACTTM)方法涉及从患者收集淋巴细胞,然后将所述淋巴细胞工程化改造以表达例如CAR构建体,然后施用回到同一患者。
术语“同种异体的”是指随后导入相同物种的另一个个体的源自一个个体的任何材料,例如同种异体T细胞移植。
标准技术可以用于重组DNA、寡核苷酸合成和组织培养和转化(例如,电穿孔,脂转染)。酶促反应和纯化技术可以根据制造商的说明书或如本领域通常完成或如本文所述进行。前述技术和规程通常可以根据本领域公知的常规方法并且如本说明书通篇所引用和讨论的各种一般性和更具体的参考文献中所述进行。参见例如Sambrook等人,MolecularCloning:A Laboratory Manual(第2版,Cold Spring Harbor Laboratory Press,ColdSpring Harbor,N.Y.(1989)),其通过引用并入本文用于任何目的。
包含、包括和/或复数形式各自是开放式的,并且包括列出的部分,并且可以包括未列出的其他部分。和/或是开放式的,并且包括一个或多个列出的部分以及列出的部分的组合。
应当理解,本文的描述仅是示例性和说明性的,并且不限制要求保护的本发明。在本申请中,单数的使用包括复数,除非另有明确说明。
本申请中引用的所有文件或文件的一部分,包括但不限于专利、专利申请、文章、书籍和专着在此明确通过引用完整并入用于任何目的。如根据本公开所使用的,除非另外指出,否则以下术语应理解为具有以下含义:
在本申请中,除非另有说明,否则“或”的使用表示“和/或”。此外,术语“包括”以及其他形式的使用不是限制性的。另外,除非另外特别说明,否则诸如“元件”或“组件”的术语涵盖包含一个单元的元件和组件以及包含超过一个亚单元的元件和组件。
本文中对参考文献的引用不应解释为承认此类参考文献是本发明的现有技术。就通过引用并入的参考文献中提供的任何定义或术语与本文提供的术语和讨论不同而言,以本术语和定义为准。
本领域技术人员将意识到,在不脱离本发明的精神或基本特征的情况下,主题可以以其他特定形式来体现。因此,前述实施方案在所有方面都应认为是说明性的,而不是限制本文所述的主题。
以下序列将进一步举例说明本发明:
CD28T DNA胞外、跨膜、胞内
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC(SEQ ID NO.1)
CD28T胞外、跨膜、胞内AA
LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS(SEQ ID NO.2)
CD28T DNA-胞外
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCA(SEQ ID NO.3)
CD28T AA-胞外
LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP(SEQ ID NO.4)
CD28 DNA跨膜域
TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTT(SEQ ID NO.5)
CD28 AA跨膜域
FWVLVVVGGV LACYSLLVTV AFIIFWV(SEQ ID NO.6)
CD28 DNA胞内域
AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC(SEQ ID NO.7)
CD28 AA胞内域
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS(SEQ ID NO.8)
CD3 zeta DNA
AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.9)
CD3 zeta AA
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.10)
CD28 DNA
ATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGAAAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCC(SEQ ID NO.11)
CD28 AA
IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP(SEQ ID NO.12)
CD8 DNA胞外和跨膜域
GCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAAC(SEQ IDNO.13)
CD8 AA胞外和跨膜域
AAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN(SEQ ID NO.14)
克隆24C1 HC DNA
CAGGTGCAGCTGCAGGAATCCGGACCGGGGCTGGTGAAGCCCAGCGAGACTCTGAGTCTCACGTGTACAGTTTCTGGAGGTAGCATTAGCTCCTACTATTGGTCATGGATAAGGCAGCCCCCCGGGAAGGGATTGGAATGGATCGGCTATATTTACTACAGTGGGAGCACCAATTACAACCCCTCACTGAAGTCTAGAGTTACAATCAGCGTTGACACCTCAAAGAATCAGTTCAGTTTGAAATTGTCTAGCGTCACAGCAGCTGATACAGCCGTCTATTATTGTGTTTCTCTGGTCTATTGCGGTGGGGATTGTTACAGTGGCTTTGACTATTGGGGGCAGGGTACTCTGGTTACAGTTTCTTCC(SEQ IDNO.15)
克隆24C1 HC AA(CDR加下划线)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSS(SEQ ID NO.16)
克隆24C1 HC AA CDR1:GGSISSY(SEQ ID NO.17)
克隆24C1 HC AA CDR2:YYSGS(SEQ ID NO.18)
克隆24C1 HC AA CDR3:LVYCGGDCYS GFDY(SEQ ID NO.19)
克隆24C1 LC DNA
GACATCCAGTTGACACAGAGCCCGAGTTCCTTGTCCGCCTCCGTCGGGGATAGAGTGTCATTTACCTGTCAGGCCTCTCAGGATATTAATAACTTTCTGAATTGGTATCAGCAAAAGCCCGGAAAGGCACCCAAGCTGTTGATTTACGACGCCAGTAACCTGGAGACAGGCGTGCCCTCCCGGTTTAGTGGTAGCGGAAGCGGTACGGATTTTACCTTTACTATCAGCTCTCTCCAACCCGAAGACATTGCAACCTACTATTGTCAACAATATGGAAACCTGCCTTTTACATTTGGCGGCGGCACCAAGGTGGAGATTAAGCGG(SEQ IDNO.20)
克隆24C1 LC AA(CDR加下划线)
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKR(SEQ ID NO.21)
克隆24C1 LC CDR1 AA:QASQDINNFLN(SEQ ID NO.22)
克隆24C1 LC CDR2 AA:DASNLET(SEQ ID NO.23)
克隆24C1 LC CDR3 AA:QQYGNLPFT(SEQ ID NO.24)
克隆24C1 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTCCAACTGCAAGAAAGCGGACCCGGACTGGTGAAGCCTTCTGAGACACTTAGTCTGACGTGCACGGTCAGTGGCGGCTCCATCTCCTCCTATTATTGGTCATGGATACGACAACCCCCAGGTAAGGGCCTGGAATGGATTGGCTATATCTACTATTCAGGAAGCACGAACTACAATCCCAGCCTGAAGTCCCGAGTGACAATTTCAGTAGATACCAGTAAAAACCAGTTCAGTCTTAAACTGTCAAGCGTGACAGCTGCCGACACCGCTGTGTATTACTGCGTCTCACTGGTGTATTGTGGAGGGGATTGTTATAGCGGGTTCGATTATTGGGGACAGGGAACCCTGGTGACTGTATCTTCCGGCGGCGGCGGCTCAGGGGGTGGCGGTAGTGGCGGTGGGGGTTCCGATATTCAACTGACACAATCCCCCAGCTCACTCAGCGCCAGCGTGGGGGACAGGGTTAGCTTTACCTGTCAAGCCTCTCAGGATATAAATAACTTTCTGAACTGGTATCAACAGAAGCCTGGGAAGGCGCCCAAACTCCTGATCTATGATGCGTCCAACCTGGAAACTGGCGTGCCTTCACGCTTTAGCGGCTCTGGCAGTGGTACAGACTTCACTTTTACCATCTCTTCACTTCAGCCGGAGGACATCGCCACATATTACTGTCAACAGTACGGAAACTTGCCCTTTACTTTTGGAGGCGGCACCAAAGTTGAAATCAAAAGGGCCGCTGCCCTGGATAACGAAAAGAGCAATGGGACTATAATACATGTTAAAGGAAAACACCTGTGTCCATCTCCCCTGTTCCCTGGACCGTCAAAGCCATTTTGGGTGCTCGTGGTTGTCGGTGGCGTTCTCGCCTGTTATAGCTTGCTGGTGACAGTAGCCTTCATTATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.25)
克隆24C1 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD28T CD3 zeta CAR DNA重链和轻链
CAGGTCCAACTGCAAGAAAGCGGACCCGGACTGGTGAAGCCTTCTGAGACACTTAGTCTGACGTGCACGGTCAGTGGCGGCTCCATCTCCTCCTATTATTGGTCATGGATACGACAACCCCCAGGTAAGGGCCTGGAATGGATTGGCTATATCTACTATTCAGGAAGCACGAACTACAATCCCAGCCTGAAGTCCCGAGTGACAATTTCAGTAGATACCAGTAAAAACCAGTTCAGTCTTAAACTGTCAAGCGTGACAGCTGCCGACACCGCTGTGTATTACTGCGTCTCACTGGTGTATTGTGGAGGGGATTGTTATAGCGGGTTCGATTATTGGGGACAGGGAACCCTGGTGACTGTATCTTCCGGCGGCGGCGGCTCAGGGGGTGGCGGTAGTGGCGGTGGGGGTTCCGATATTCAACTGACACAATCCCCCAGCTCACTCAGCGCCAGCGTGGGGGACAGGGTTAGCTTTACCTGTCAAGCCTCTCAGGATATAAATAACTTTCTGAACTGGTATCAACAGAAGCCTGGGAAGGCGCCCAAACTCCTGATCTATGATGCGTCCAACCTGGAAACTGGCGTGCCTTCACGCTTTAGCGGCTCTGGCAGTGGTACAGACTTCACTTTTACCATCTCTTCACTTCAGCCGGAGGACATCGCCACATATTACTGTCAACAGTACGGAAACTTGCCCTTTACTTTTGGAGGCGGCACCAAAGTTGAAATCAAAAGGGCCGCTGCCCTGGATAACGAAAAGAGCAATGGGACTATAATACATGTTAAAGGAAAACACCTGTGTCCATCTCCCCTGTTCCCTGGACCGTCAAAGCCATTTTGGGTGCTCGTGGTTGTCGGTGGCGTTCTCGCCTGTTATAGCTTGCTGGTGACAGTAGCCTTCATTATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.27)
克隆24C1 CD28T CD3 zeta CAR AA重链和轻链
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.28)
克隆24C1 CD28 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGCTGCAGGAATCCGGACCGGGGCTGGTGAAGCCCAGCGAGACTCTGAGTCTCACGTGTACAGTTTCTGGAGGTAGCATTAGCTCCTACTATTGGTCATGGATAAGGCAGCCCCCCGGGAAGGGATTGGAATGGATCGGCTATATTTACTACAGTGGGAGCACCAATTACAACCCCTCACTGAAGTCTAGAGTTACAATCAGCGTTGACACCTCAAAGAATCAGTTCAGTTTGAAATTGTCTAGCGTCACAGCAGCTGATACAGCCGTCTATTATTGTGTTTCTCTGGTCTATTGCGGTGGGGATTGTTACAGTGGCTTTGACTATTGGGGGCAGGGTACTCTGGTTACAGTTTCTTCCGGGGGGGGAGGCTCTGGGGGCGGAGGCTCAGGTGGTGGAGGCAGCGACATCCAGTTGACACAGAGCCCGAGTTCCTTGTCCGCCTCCGTCGGGGATAGAGTGTCATTTACCTGTCAGGCCTCTCAGGATATTAATAACTTTCTGAATTGGTATCAGCAAAAGCCCGGAAAGGCACCCAAGCTGTTGATTTACGACGCCAGTAACCTGGAGACAGGCGTGCCCTCCCGGTTTAGTGGTAGCGGAAGCGGTACGGATTTTACCTTTACTATCAGCTCTCTCCAACCCGAAGACATTGCAACCTACTATTGTCAACAATATGGAAACCTGCCTTTTACATTTGGCGGCGGCACCAAGGTGGAGATTAAGCGGGCGGCAGCTATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGAAAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCCTTCTGGGTTCTTGTGGTCGTGGGAGGCGTGCTTGCTTGTTATTCTCTGCTCGTTACCGTGGCGTTTATCATTTTTTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.29)
克隆24C1 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD28 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGCTGCAGGAATCCGGACCGGGGCTGGTGAAGCCCAGCGAGACTCTGAGTCTCACGTGTACAGTTTCTGGAGGTAGCATTAGCTCCTACTATTGGTCATGGATAAGGCAGCCCCCCGGGAAGGGATTGGAATGGATCGGCTATATTTACTACAGTGGGAGCACCAATTACAACCCCTCACTGAAGTCTAGAGTTACAATCAGCGTTGACACCTCAAAGAATCAGTTCAGTTTGAAATTGTCTAGCGTCACAGCAGCTGATACAGCCGTCTATTATTGTGTTTCTCTGGTCTATTGCGGTGGGGATTGTTACAGTGGCTTTGACTATTGGGGGCAGGGTACTCTGGTTACAGTTTCTTCCGGGGGGGGAGGCTCTGGGGGCGGAGGCTCAGGTGGTGGAGGCAGCGACATCCAGTTGACACAGAGCCCGAGTTCCTTGTCCGCCTCCGTCGGGGATAGAGTGTCATTTACCTGTCAGGCCTCTCAGGATATTAATAACTTTCTGAATTGGTATCAGCAAAAGCCCGGAAAGGCACCCAAGCTGTTGATTTACGACGCCAGTAACCTGGAGACAGGCGTGCCCTCCCGGTTTAGTGGTAGCGGAAGCGGTACGGATTTTACCTTTACTATCAGCTCTCTCCAACCCGAAGACATTGCAACCTACTATTGTCAACAATATGGAAACCTGCCTTTTACATTTGGCGGCGGCACCAAGGTGGAGATTAAGCGGGCGGCAGCTATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGAAAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCCTTCTGGGTTCTTGTGGTCGTGGGAGGCGTGCTTGCTTGTTATTCTCTGCTCGTTACCGTGGCGTTTATCATTTTTTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.31)
克隆24C1 CD28 CD3 zeta CAR AA重链和轻链
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.32)
克隆24C1 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAATTGCAAGAGTCCGGCCCCGGACTCGTTAAACCCAGTGAGACGCTTAGCCTGACCTGTACCGTCTCAGGGGGCAGCATCTCCTCTTATTACTGGAGCTGGATCAGGCAGCCTCCAGGAAAAGGCCTTGAATGGATTGGGTACATCTACTACTCTGGCTCAACAAATTATAATCCATCCCTGAAGTCCCGCGTGACTATCTCTGTGGACACCAGCAAGAATCAGTTTTCACTGAAGTTGTCTAGTGTTACCGCGGCCGACACCGCCGTATACTACTGTGTGTCTCTTGTGTACTGTGGCGGCGACTGCTATTCCGGGTTCGACTACTGGGGCCAAGGGACTCTGGTAACCGTGTCCTCAGGCGGCGGCGGGTCAGGAGGAGGCGGCAGTGGAGGTGGCGGCTCCGACATCCAGCTGACACAATCACCATCTTCCCTTTCAGCTTCAGTCGGGGACAGAGTGTCCTTCACATGCCAGGCCAGCCAGGATATCAATAACTTCCTGAACTGGTACCAACAGAAACCCGGAAAGGCTCCAAAGCTCCTGATCTATGATGCTTCCAACCTGGAGACCGGCGTGCCCTCCAGGTTCAGTGGTTCAGGATCAGGCACTGACTTTACGTTCACCATATCCAGTCTTCAGCCCGAAGACATTGCAACCTATTACTGCCAACAATACGGGAACCTTCCCTTTACATTCGGAGGCGGCACCAAGGTGGAAATCAAAAGGGCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.33)
克隆24C1 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD8 CD3 zeta CAR DNA重链和轻链
CAGGTGCAATTGCAAGAGTCCGGCCCCGGACTCGTTAAACCCAGTGAGACGCTTAGCCTGACCTGTACCGTCTCAGGGGGCAGCATCTCCTCTTATTACTGGAGCTGGATCAGGCAGCCTCCAGGAAAAGGCCTTGAATGGATTGGGTACATCTACTACTCTGGCTCAACAAATTATAATCCATCCCTGAAGTCCCGCGTGACTATCTCTGTGGACACCAGCAAGAATCAGTTTTCACTGAAGTTGTCTAGTGTTACCGCGGCCGACACCGCCGTATACTACTGTGTGTCTCTTGTGTACTGTGGCGGCGACTGCTATTCCGGGTTCGACTACTGGGGCCAAGGGACTCTGGTAACCGTGTCCTCAGGCGGCGGCGGGTCAGGAGGAGGCGGCAGTGGAGGTGGCGGCTCCGACATCCAGCTGACACAATCACCATCTTCCCTTTCAGCTTCAGTCGGGGACAGAGTGTCCTTCACATGCCAGGCCAGCCAGGATATCAATAACTTCCTGAACTGGTACCAACAGAAACCCGGAAAGGCTCCAAAGCTCCTGATCTATGATGCTTCCAACCTGGAGACCGGCGTGCCCTCCAGGTTCAGTGGTTCAGGATCAGGCACTGACTTTACGTTCACCATATCCAGTCTTCAGCCCGAAGACATTGCAACCTATTACTGCCAACAATACGGGAACCTTCCCTTTACATTCGGAGGCGGCACCAAGGTGGAAATCAAAAGGGCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.35)克隆24C1 CD8 CD3zeta CAR AA重链和轻链
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK DTYDALHMQALPPR(SEQ ID NO.36)
克隆24C1 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGATATCCAGCTCACGCAATCCCCCTCAAGCTTGAGTGCCTCCGTGGGCGACCGGGTGTCCTTCACATGTCAGGCAAGCCAAGACATAAATAATTTCCTGAATTGGTACCAACAAAAACCCGGCAAGGCTCCCAAACTCCTGATTTATGATGCCTCCAATCTGGAGACCGGGGTCCCTTCTAGATTCAGCGGAAGTGGCAGCGGCACAGACTTTACATTTACTATCTCTTCTCTGCAACCAGAGGACATCGCCACATACTATTGCCAGCAATACGGCAATCTGCCCTTCACCTTCGGAGGCGGAACCAAGGTAGAAATTAAAAGGGGCGGTGGAGGCTCCGGAGGGGGGGGCTCTGGCGGAGGGGGCTCCCAAGTACAATTGCAGGAGTCAGGGCCTGGACTCGTGAAGCCTTCAGAAACTTTGTCACTGACATGTACAGTGTCCGGCGGAAGCATTTCCAGTTACTATTGGTCCTGGATTAGACAGCCACCCGGCAAAGGACTGGAATGGATTGGATATATCTACTACTCTGGATCTACAAACTATAATCCCAGCCTCAAATCCAGGGTCACTATTAGTGTGGATACATCAAAGAATCAGTTCTCCTTGAAGCTGAGCTCAGTCACTGCTGCCGACACCGCAGTGTACTATTGTGTGAGCCTGGTCTACTGCGGCGGAGATTGCTACAGCGGTTTCGATTACTGGGGCCAGGGCACCCTGGTTACCGTTAGTTCCGCGGCTGCTCTTGATAACGAGAAGTCCAACGGTACGATTATCCACGTTAAGGGTAAGCACCTTTGCCCTAGCCCGCTGTTCCCAGGCCCCAGTAAGCCCTTTTGGGTCCTCGTTGTGGTAGGTGGGGTACTCGCCTGCTACTCCCTGCTCGTCACTGTCGCATTCATCATCTTCTGGGTCAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.37)
克隆24C1 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD28T CD3 zeta CAR DNA重链和轻链
GATATCCAGCTCACGCAATCCCCCTCAAGCTTGAGTGCCTCCGTGGGCGACCGGGTGTCCTTCACATGTCAGGCAAGCCAAGACATAAATAATTTCCTGAATTGGTACCAACAAAAACCCGGCAAGGCTCCCAAACTCCTGATTTATGATGCCTCCAATCTGGAGACCGGGGTCCCTTCTAGATTCAGCGGAAGTGGCAGCGGCACAGACTTTACATTTACTATCTCTTCTCTGCAACCAGAGGACATCGCCACATACTATTGCCAGCAATACGGCAATCTGCCCTTCACCTTCGGAGGCGGAACCAAGGTAGAAATTAAAAGGGGCGGTGGAGGCTCCGGAGGGGGGGGCTCTGGCGGAGGGGGCTCCCAAGTACAATTGCAGGAGTCAGGGCCTGGACTCGTGAAGCCTTCAGAAACTTTGTCACTGACATGTACAGTGTCCGGCGGAAGCATTTCCAGTTACTATTGGTCCTGGATTAGACAGCCACCCGGCAAAGGACTGGAATGGATTGGATATATCTACTACTCTGGATCTACAAACTATAATCCCAGCCTCAAATCCAGGGTCACTATTAGTGTGGATACATCAAAGAATCAGTTCTCCTTGAAGCTGAGCTCAGTCACTGCTGCCGACACCGCAGTGTACTATTGTGTGAGCCTGGTCTACTGCGGCGGAGATTGCTACAGCGGTTTCGATTACTGGGGCCAGGGCACCCTGGTTACCGTTAGTTCCGCGGCTGCTCTTGATAACGAGAAGTCCAACGGTACGATTATCCACGTTAAGGGTAAGCACCTTTGCCCTAGCCCGCTGTTCCCAGGCCCCAGTAAGCCCTTTTGGGTCCTCGTTGTGGTAGGTGGGGTACTCGCCTGCTACTCCCTGCTCGTCACTGTCGCATTCATCATCTTCTGGGTCAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.39)
克隆24C1 CD28T CD3 zeta CAR AA重链和轻链
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.40)
克隆24C1 CD28 CD3 zeta CAR DNA AA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGATATCCAGCTGACCCAGTCTCCATCCTCTTTGAGTGCCTCCGTGGGTGACCGCGTCTCTTTCACTTGCCAAGCCAGCCAAGACATCAACAACTTTCTGAATTGGTACCAGCAGAAACCAGGCAAAGCACCAAAGCTCCTCATCTACGACGCCTCCAACCTGGAAACCGGGGTGCCCAGCAGGTTTAGCGGGAGCGGTTCTGGCACGGATTTTACGTTCACCATCTCCTCTCTGCAGCCCGAGGATATAGCTACTTATTACTGTCAGCAGTACGGGAATCTGCCATTTACTTTTGGGGGTGGAACTAAGGTGGAAATCAAAAGGGGCGGCGGGGGAAGCGGGGGCGGGGGCTCAGGTGGCGGAGGGAGCCAGGTGCAACTCCAGGAAAGTGGCCCAGGATTGGTGAAGCCCAGCGAGACCCTTTCCCTTACTTGTACTGTTAGCGGAGGCAGCATAAGCAGCTACTATTGGTCCTGGATCAGACAGCCACCAGGGAAAGGGCTTGAATGGATTGGCTACATTTACTATTCCGGGTCCACCAACTACAACCCATCCCTCAAGTCCCGCGTGACAATTTCCGTCGACACAAGCAAGAACCAGTTCTCCCTGAAACTTAGTAGCGTCACTGCTGCAGATACAGCAGTGTACTATTGTGTCAGCCTTGTCTACTGTGGCGGCGACTGCTACAGTGGCTTTGATTACTGGGGACAGGGCACGCTCGTGACAGTGTCCAGCGCTGCGGCTATCGAGGTAATGTATCCGCCACCGTATCTGGACAACGAGAAGTCTAATGGGACAATCATTCACGTGAAGGGGAAGCACCTGTGTCCATCCCCCCTGTTTCCGGGTCCCAGTAAACCCTTCTGGGTGCTTGTTGTCGTTGGCGGGGTGCTGGCCTGCTATTCCCTGCTGGTGACCGTCGCGTTTATTATTTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.41)
克隆24C1 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD28 CD3 zeta CAR DNA重链和轻链
GATATCCAGCTGACCCAGTCTCCATCCTCTTTGAGTGCCTCCGTGGGTGACCGCGTCTCTTTCACTTGCCAAGCCAGCCAAGACATCAACAACTTTCTGAATTGGTACCAGCAGAAACCAGGCAAAGCACCAAAGCTCCTCATCTACGACGCCTCCAACCTGGAAACCGGGGTGCCCAGCAGGTTTAGCGGGAGCGGTTCTGGCACGGATTTTACGTTCACCATCTCCTCTCTGCAGCCCGAGGATATAGCTACTTATTACTGTCAGCAGTACGGGAATCTGCCATTTACTTTTGGGGGTGGAACTAAGGTGGAAATCAAAAGGGGCGGCGGGGGAAGCGGGGGCGGGGGCTCAGGTGGCGGAGGGAGCCAGGTGCAACTCCAGGAAAGTGGCCCAGGATTGGTGAAGCCCAGCGAGACCCTTTCCCTTACTTGTACTGTTAGCGGAGGCAGCATAAGCAGCTACTATTGGTCCTGGATCAGACAGCCACCAGGGAAAGGGCTTGAATGGATTGGCTACATTTACTATTCCGGGTCCACCAACTACAACCCATCCCTCAAGTCCCGCGTGACAATTTCCGTCGACACAAGCAAGAACCAGTTCTCCCTGAAACTTAGTAGCGTCACTGCTGCAGATACAGCAGTGTACTATTGTGTCAGCCTTGTCTACTGTGGCGGCGACTGCTACAGTGGCTTTGATTACTGGGGACAGGGCACGCTCGTGACAGTGTCCAGCGCTGCGGCTATCGAGGTAATGTATCCGCCACCGTATCTGGACAACGAGAAGTCTAATGGGACAATCATTCACGTGAAGGGGAAGCACCTGTGTCCATCCCCCCTGTTTCCGGGTCCCAGTAAACCCTTCTGGGTGCTTGTTGTCGTTGGCGGGGTGCTGGCCTGCTATTCCCTGCTGGTGACCGTCGCGTTTATTATTTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.43)
克隆24C1 CD28 CD3 zeta CAR AA重链和轻链
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.44)
克隆24C1 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGACATTCAATTGACCCAGTCCCCTAGCAGTCTCTCAGCAAGTGTGGGAGATAGGGTGTCATTCACCTGTCAGGCTTCACAGGACATCAACAACTTCCTCAATTGGTATCAGCAGAAGCCAGGGAAGGCACCAAAGCTGCTCATATATGACGCTTCAAACCTTGAAACCGGAGTACCTAGCCGCTTCAGCGGAAGCGGATCAGGGACTGACTTCACTTTTACCATCTCTTCACTGCAGCCCGAAGACATCGCCACATACTACTGCCAGCAGTACGGAAACTTGCCTTTTACATTTGGGGGCGGCACCAAAGTGGAGATTAAGCGAGGGGGAGGCGGCTCAGGAGGCGGTGGCTCCGGAGGCGGGGGTTCCCAGGTCCAGCTCCAGGAATCCGGCCCAGGTCTGGTTAAGCCCAGTGAAACTTTGTCCCTCACGTGTACTGTGAGCGGTGGTTCAATCTCCTCATACTATTGGTCTTGGATACGGCAACCTCCTGGAAAGGGCCTCGAGTGGATCGGCTATATCTACTATAGTGGCTCCACTAATTACAACCCTTCCCTCAAGTCCAGAGTCACCATTTCCGTGGACACATCTAAGAACCAGTTCAGTCTGAAGTTGTCCAGCGTTACAGCCGCAGACACAGCCGTTTATTACTGTGTGTCTCTTGTTTACTGCGGGGGAGACTGTTATAGCGGCTTCGATTACTGGGGCCAGGGCACCTTGGTCACAGTCTCTTCCGCGGCCGCCCTCTCTAACAGTATTATGTACTTTTCTCATTTTGTACCCGTGTTCCTTCCCGCTAAGCCAACTACTACCCCGGCCCCACGGCCGCCTACCCCTGCACCCACAATAGCCAGTCAGCCTTTGAGCCTGAGACCTGAGGCTTGTCGGCCGGCTGCTGGGGGTGCAGTGCACACACGAGGTCTTGATTTTGCTTGCGACATATACATCTGGGCCCCTCTGGCCGGGACCTGTGGGGTGCTGCTTCTGAGCTTGGTCATCACGCTCTATTGCAACCATCGCAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.45)
克隆24C1 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C1 CD8 CD3 zeta CAR DNA重链和轻链
GACATTCAATTGACCCAGTCCCCTAGCAGTCTCTCAGCAAGTGTGGGAGATAGGGTGTCATTCACCTGTCAGGCTTCACAGGACATCAACAACTTCCTCAATTGGTATCAGCAGAAGCCAGGGAAGGCACCAAAGCTGCTCATATATGACGCTTCAAACCTTGAAACCGGAGTACCTAGCCGCTTCAGCGGAAGCGGATCAGGGACTGACTTCACTTTTACCATCTCTTCACTGCAGCCCGAAGACATCGCCACATACTACTGCCAGCAGTACGGAAACTTGCCTTTTACATTTGGGGGCGGCACCAAAGTGGAGATTAAGCGAGGGGGAGGCGGCTCAGGAGGCGGTGGCTCCGGAGGCGGGGGTTCCCAGGTCCAGCTCCAGGAATCCGGCCCAGGTCTGGTTAAGCCCAGTGAAACTTTGTCCCTCACGTGTACTGTGAGCGGTGGTTCAATCTCCTCATACTATTGGTCTTGGATACGGCAACCTCCTGGAAAGGGCCTCGAGTGGATCGGCTATATCTACTATAGTGGCTCCACTAATTACAACCCTTCCCTCAAGTCCAGAGTCACCATTTCCGTGGACACATCTAAGAACCAGTTCAGTCTGAAGTTGTCCAGCGTTACAGCCGCAGACACAGCCGTTTATTACTGTGTGTCTCTTGTTTACTGCGGGGGAGACTGTTATAGCGGCTTCGATTACTGGGGCCAGGGCACCTTGGTCACAGTCTCTTCCGCGGCCGCCCTCTCTAACAGTATTATGTACTTTTCTCATTTTGTACCCGTGTTCCTTCCCGCTAAGCCAACTACTACCCCGGCCCCACGGCCGCCTACCCCTGCACCCACAATAGCCAGTCAGCCTTTGAGCCTGAGACCTGAGGCTTGTCGGCCGGCTGCTGGGGGTGCAGTGCACACACGAGGTCTTGATTTTGCTTGCGACATATACATCTGGGCCCCTCTGGCCGGGACCTGTGGGGTGCTGCTTCTGAGCTTGGTCATCACGCTCTATTGCAACCATCGCAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.47)
克隆24C1 CD8 CD3 zeta CAR AA重链和轻链
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK DTYDALHMQA LPPR(SEQ ID NO.48)
克隆24C8重链(HC)DNA
CAGGTACAGCTGCAGGAATCTGGGCCCGGACTTGTCAAGCCAAGTCAGACACTTTCTCTTACATGTACCGTGAGCGGCGGAAGTATAAGCAGTGGAGGCTTTTACTGGTCTTGGATACGGCAGCACCCAGGCAAAGGCTTGGAGTGGATTGGATACATTCATCATTCAGGATCTACACACTATAATCCATCCCTTAAGTCCCGGGTCACCATTAGCATTGATACGTCTAAGAATCTGTTCAGTCTCAGGCTGTCCTCCGTCACTGCTGCCGACACAGCCGTGTACTACTGCGCCTCCTTGGTTTACTGCGGAGGCGACTGTTATAGCGGCTTTGATTATTGGGGGCAGGGGACCCTCGTAACCGTGAGCTCT(SEQ ID NO.49)
克隆24C8 AA HC(CDR加下划线)
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGFYWSWIRQHPGKGLEWIGYIHHSGSTHYNPSLKSRVTISIDTSKNLFSLRLSSVTAADTAVYYCASLVYCGGDCYSGFDYWGQGTLVTVSS(SEQ ID NO.50)
克隆24C8 HC CDR1 AA:GGSISSGGF(SEQ ID NO.51)
克隆24C8 HC CDR2 AA:HHSGS(SEQ ID NO.52)
克隆24C8 HC CDR3 AA:LVYCGGDCYS GFDY(SEQ ID NO.53)
克隆24C8轻链(LC)DNA
GATATCCAGCTCACTCAAAGCCCCTCTAGTCTCTCTGCCTCAGTGGGGGATCGGGTCAGTTTTACTTGTCAAGCTTCACAGGATATCAACAACTTCCTTAATTGGTATCAGCAGAAGCCAGGAAAAGCACCCAAGCTGCTCATCTATGATGCCTCAAATTTGGAGACGGGTGTTCCCAGTCGATTCTCTGGGTCAGGGTCCGGGACCGACTTTACGTTTACGATCTCCTCTCTGCAGCCCGAAGACATCGCCACATACTATTGTCAACAGTACGGCAACTTGCCTTTCACATTTGGGGGCGGGACTAAGGTTGAAATCAAGAGG(SEQ ID NO.54)
克隆24C8 LC AA(CDR加下划线)
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLET GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKR(SEQ ID NO.55)
克隆24C8 LC CDR1 AA:QASQDINNFLN(SEQ ID NO.56)
克隆24C8 LC CDR2 AA:DASNLET(SEQ ID NO.57)
克隆24C8 LC CDR3 AA:QQYGNLPFT(SEQ ID NO.58)
克隆24C8 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTACAGCTGCAGGAATCTGGGCCCGGACTTGTCAAGCCAAGTCAGACACTTTCTCTTACATGTACCGTGAGCGGCGGAAGTATAAGCAGTGGAGGCTTTTACTGGTCTTGGATACGGCAGCACCCAGGCAAAGGCTTGGAGTGGATTGGATACATTCATCATTCAGGATCTACACACTATAATCCATCCCTTAAGTCCCGGGTCACCATTAGCATTGATACGTCTAAGAATCTGTTCAGTCTCAGGCTGTCCTCCGTCACTGCTGCCGACACAGCCGTGTACTACTGCGCCTCCTTGGTTTACTGCGGAGGCGACTGTTATAGCGGCTTTGATTATTGGGGGCAGGGGACCCTCGTAACCGTGAGCTCTGGAGGGGGTGGGAGCGGGGGAGGAGGTTCAGGGGGGGGCGGCTCCGATATCCAGCTCACTCAAAGCCCCTCTAGTCTCTCTGCCTCAGTGGGGGATCGGGTCAGTTTTACTTGTCAAGCTTCACAGGATATCAACAACTTCCTTAATTGGTATCAGCAGAAGCCAGGAAAAGCACCCAAGCTGCTCATCTATGATGCCTCAAATTTGGAGACGGGTGTTCCCAGTCGATTCTCTGGGTCAGGGTCCGGGACCGACTTTACGTTTACGATCTCCTCTCTGCAGCCCGAAGACATCGCCACATACTATTGTCAACAGTACGGCAACTTGCCTTTCACATTTGGGGGCGGGACTAAGGTTGAAATCAAGAGGGCCGCTGCACTGGACAATGAGAAGTCCAACGGCACCATCATCCACGTGAAGGGCAAGCACCTGTGCCCTAGTCCTCTGTTCCCAGGCCCATCCAAACCTTTTTGGGTTCTTGTTGTGGTCGGGGGGGTGCTGGCCTGCTATTCTCTGCTGGTCACGGTGGCCTTCATAATTTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.59)
克隆24C8 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C8 CD28T CD3 zeta CAR DNA重链和轻链
CAGGTACAGCTGCAGGAATCTGGGCCCGGACTTGTCAAGCCAAGTCAGACACTTTCTCTTACATGTACCGTGAGCGGCGGAAGTATAAGCAGTGGAGGCTTTTACTGGTCTTGGATACGGCAGCACCCAGGCAAAGGCTTGGAGTGGATTGGATACATTCATCATTCAGGATCTACACACTATAATCCATCCCTTAAGTCCCGGGTCACCATTAGCATTGATACGTCTAAGAATCTGTTCAGTCTCAGGCTGTCCTCCGTCACTGCTGCCGACACAGCCGTGTACTACTGCGCCTCCTTGGTTTACTGCGGAGGCGACTGTTATAGCGGCTTTGATTATTGGGGGCAGGGGACCCTCGTAACCGTGAGCTCTGGAGGGGGTGGGAGCGGGGGAGGAGGTTCAGGGGGGGGCGGCTCCGATATCCAGCTCACTCAAAGCCCCTCTAGTCTCTCTGCCTCAGTGGGGGATCGGGTCAGTTTTACTTGTCAAGCTTCACAGGATATCAACAACTTCCTTAATTGGTATCAGCAGAAGCCAGGAAAAGCACCCAAGCTGCTCATCTATGATGCCTCAAATTTGGAGACGGGTGTTCCCAGTCGATTCTCTGGGTCAGGGTCCGGGACCGACTTTACGTTTACGATCTCCTCTCTGCAGCCCGAAGACATCGCCACATACTATTGTCAACAGTACGGCAACTTGCCTTTCACATTTGGGGGCGGGACTAAGGTTGAAATCAAGAGGGCCGCTGCACTGGACAATGAGAAGTCCAACGGCACCATCATCCACGTGAAGGGCAAGCACCTGTGCCCTAGTCCTCTGTTCCCAGGCCCATCCAAACCTTTTTGGGTTCTTGTTGTGGTCGGGGGGGTGCTGGCCTGCTATTCTCTGCTGGTCACGGTGGCCTTCATAATTTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.61)
克隆24C8 CD28T CD3 zeta CAR AA重链和轻链
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGFYWSWIRQHPGKGLEWIGYIHHSGSTHYNPSLKSRVTISIDTSKNLFSLRLSSVTAADTAVYYCASLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.62)
克隆24C8 CD28 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGCTGCAGGAAAGCGGTCCGGGACTTGTCAAGCCGTCCCAAACGCTGAGTCTGACGTGTACTGTCTCTGGTGGCTCTATTTCTTCCGGGGGCTTTTATTGGTCTTGGATCAGACAACACCCTGGCAAAGGGCTGGAGTGGATAGGGTATATTCACCACTCTGGGTCCACTCACTACAACCCATCATTGAAATCCAGAGTGACTATCTCAATCGACACATCCAAGAACCTTTTCAGCCTGAGGTTGTCATCAGTTACCGCCGCTGACACCGCGGTGTATTATTGCGCCTCTCTCGTGTACTGCGGTGGCGATTGTTATAGTGGCTTTGACTACTGGGGGCAGGGGACATTGGTTACCGTTTCAAGTGGAGGCGGTGGGTCTGGCGGGGGCGGTAGCGGAGGTGGGGGGAGCGACATACAGCTTACGCAGAGCCCCTCCAGCCTTTCAGCCTCCGTGGGGGATAGGGTGTCCTTTACCTGCCAGGCTTCCCAGGACATAAACAACTTCCTCAATTGGTATCAGCAAAAGCCCGGGAAAGCACCAAAGCTGCTCATCTACGATGCCAGCAACCTGGAAACCGGAGTGCCGTCTCGCTTCTCTGGAAGTGGCAGTGGGACCGATTTCACTTTTACAATCTCAAGTTTGCAGCCAGAAGACATTGCAACATACTACTGTCAACAGTACGGCAATCTCCCCTTTACATTTGGGGGGGGAACTAAAGTGGAGATTAAGCGCGCTGCAGCCATTGAAGTTATGTATCCGCCCCCGTATCTGGATAACGAGAAATCTAATGGTACCATAATACATGTGAAGGGGAAGCACCTCTGTCCATCACCGCTGTTCCCCGGCCCTTCAAAACCTTTCTGGGTACTCGTTGTCGTGGGTGGAGTTCTGGCCTGCTATAGTCTGCTGGTGACCGTGGCGTTTATCATCTTCTGGGTAAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.63)
克隆24C8 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C8 CD28 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGCTGCAGGAAAGCGGTCCGGGACTTGTCAAGCCGTCCCAAACGCTGAGTCTGACGTGTACTGTCTCTGGTGGCTCTATTTCTTCCGGGGGCTTTTATTGGTCTTGGATCAGACAACACCCTGGCAAAGGGCTGGAGTGGATAGGGTATATTCACCACTCTGGGTCCACTCACTACAACCCATCATTGAAATCCAGAGTGACTATCTCAATCGACACATCCAAGAACCTTTTCAGCCTGAGGTTGTCATCAGTTACCGCCGCTGACACCGCGGTGTATTATTGCGCCTCTCTCGTGTACTGCGGTGGCGATTGTTATAGTGGCTTTGACTACTGGGGGCAGGGGACATTGGTTACCGTTTCAAGTGGAGGCGGTGGGTCTGGCGGGGGCGGTAGCGGAGGTGGGGGGAGCGACATACAGCTTACGCAGAGCCCCTCCAGCCTTTCAGCCTCCGTGGGGGATAGGGTGTCCTTTACCTGCCAGGCTTCCCAGGACATAAACAACTTCCTCAATTGGTATCAGCAAAAGCCCGGGAAAGCACCAAAGCTGCTCATCTACGATGCCAGCAACCTGGAAACCGGAGTGCCGTCTCGCTTCTCTGGAAGTGGCAGTGGGACCGATTTCACTTTTACAATCTCAAGTTTGCAGCCAGAAGACATTGCAACATACTACTGTCAACAGTACGGCAATCTCCCCTTTACATTTGGGGGGGGAACTAAAGTGGAGATTAAGCGCGCTGCAGCCATTGAAGTTATGTATCCGCCCCCGTATCTGGATAACGAGAAATCTAATGGTACCATAATACATGTGAAGGGGAAGCACCTCTGTCCATCACCGCTGTTCCCCGGCCCTTCAAAACCTTTCTGGGTACTCGTTGTCGTGGGTGGAGTTCTGGCCTGCTATAGTCTGCTGGTGACCGTGGCGTTTATCATCTTCTGGGTAAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.65)
克隆24C8 CD28 CD3 zeta CAR AA重链和轻链
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGFYWSWIRQHPGKGLEWIGYIHHSGSTHYNPSLKSRVTISIDTSKNLFSLRLSSVTAADTAVYYCASLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.66)
克隆24C8 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGTTGCAGGAAAGCGGGCCTGGCCTTGTGAAACCAAGCCAGACACTGAGCCTGACATGCACTGTGTCCGGCGGGTCCATATCTTCCGGGGGTTTTTATTGGTCCTGGATACGCCAGCATCCCGGGAAAGGACTTGAATGGATTGGATATATCCACCATTCCGGAAGCACCCACTACAATCCAAGCCTTAAATCCCGGGTGACAATCTCCATCGACACCTCAAAGAATCTTTTTTCCCTGCGGTTGTCTTCAGTAACTGCCGCCGATACCGCTGTGTACTACTGTGCCAGCCTCGTCTATTGCGGCGGAGATTGTTATTCTGGGTTCGATTATTGGGGTCAAGGCACACTGGTAACTGTCAGCAGCGGAGGCGGCGGTTCCGGGGGCGGGGGCAGTGGAGGGGGCGGATCTGACATTCAGCTTACGCAGTCCCCATCTTCACTTAGCGCCAGCGTTGGCGATCGGGTCAGCTTCACGTGTCAAGCAAGTCAGGATATCAACAACTTTCTTAACTGGTACCAGCAGAAGCCAGGCAAGGCACCCAAGTTGCTGATTTACGATGCTTCTAACCTCGAGACGGGAGTGCCTAGCCGCTTCTCCGGGAGCGGCAGCGGCACAGACTTTACCTTTACGATTTCCAGTCTGCAGCCAGAGGATATAGCAACTTATTACTGTCAGCAGTATGGCAACCTCCCTTTTACCTTCGGTGGTGGCACAAAGGTCGAGATTAAAAGAGCCGCAGCGTTGTCCAACTCCATAATGTATTTTTCTCATTTTGTGCCCGTCTTTCTGCCTGCCAAACCTACCACCACCCCCGCCCCACGACCACCTACTCCAGCCCCCACCATCGCCTCCCAGCCCCTCAGCCTGAGGCCAGAGGCTTGTCGCCCTGCTGCGGGGGGCGCTGTCCATACCAGAGGACTCGACTTCGCCTGCGATATTTATATATGGGCCCCCCTCGCCGGCACCTGCGGAGTCTTGCTCCTGAGCCTTGTGATCACGCTTTATTGTAACCATCGGAATAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.67)
克隆24C8 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆24C8 CD8 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGTTGCAGGAAAGCGGGCCTGGCCTTGTGAAACCAAGCCAGACACTGAGCCTGACATGCACTGTGTCCGGCGGGTCCATATCTTCCGGGGGTTTTTATTGGTCCTGGATACGCCAGCATCCCGGGAAAGGACTTGAATGGATTGGATATATCCACCATTCCGGAAGCACCCACTACAATCCAAGCCTTAAATCCCGGGTGACAATCTCCATCGACACCTCAAAGAATCTTTTTTCCCTGCGGTTGTCTTCAGTAACTGCCGCCGATACCGCTGTGTACTACTGTGCCAGCCTCGTCTATTGCGGCGGAGATTGTTATTCTGGGTTCGATTATTGGGGTCAAGGCACACTGGTAACTGTCAGCAGCGGAGGCGGCGGTTCCGGGGGCGGGGGCAGTGGAGGGGGCGGATCTGACATTCAGCTTACGCAGTCCCCATCTTCACTTAGCGCCAGCGTTGGCGATCGGGTCAGCTTCACGTGTCAAGCAAGTCAGGATATCAACAACTTTCTTAACTGGTACCAGCAGAAGCCAGGCAAGGCACCCAAGTTGCTGATTTACGATGCTTCTAACCTCGAGACGGGAGTGCCTAGCCGCTTCTCCGGGAGCGGCAGCGGCACAGACTTTACCTTTACGATTTCCAGTCTGCAGCCAGAGGATATAGCAACTTATTACTGTCAGCAGTATGGCAACCTCCCTTTTACCTTCGGTGGTGGCACAAAGGTCGAGATTAAAAGAGCCGCAGCGTTGTCCAACTCCATAATGTATTTTTCTCATTTTGTGCCCGTCTTTCTGCCTGCCAAACCTACCACCACCCCCGCCCCACGACCACCTACTCCAGCCCCCACCATCGCCTCCCAGCCCCTCAGCCTGAGGCCAGAGGCTTGTCGCCCTGCTGCGGGGGGCGCTGTCCATACCAGAGGACTCGACTTCGCCTGCGATATTTATATATGGGCCCCCCTCGCCGGCACCTGCGGAGTCTTGCTCCTGAGCCTTGTGATCACGCTTTATTGTAACCATCGGAATAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.69)
克隆24C8 CD8 CD3 zeta CAR AA重链和轻链
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGFYWSWIRQHPGKGLEWIGYIHHSGSTHYNPSLKSRVTISIDTSKNLFSLRLSSVTAADTAVYYCASLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA TKDTYDALHM QALPPR(SEQ ID NO.70)
克隆20C5.1 HC DNA
CAGGTCCAACTGGTGCAGTCCGGAGCCGAAGTCAAGAAACCAGGTGCCTCCGTTAAAGTGAGTTGCAAAGTCTCTGGATACACTCTGACCGAGCTCTCTATGCACTGGGTCCGGCAGGCCCCCGGCAAGGGATTGGAATGGATGGGCGGGTTCGATCCTGAGGACGGAGAGACTATCTACGCTCAAAAATTCCAGGGACGAGTGACTGTGACCGAAGACACTAGTACCGACACTGCCTACATGGAACTTTCCTCTCTGCGATCAGAAGATACCGCAGTGTACTACTGTGCTACTGAATCTAGGGGCATTGGATGGCCCTACTTCGATTACTGGGGTCAGGGAACTCTGGTGACTGTCTCCAGC(SEQ IDNO.71)
克隆20C5.1 AA HC(CDR加下划线)
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTVTEDTSTDTAYMELSSLRSEDTAVYYCATESRGIGWPYFDYWGQGTLVTVSS(SEQ ID NO.72)
克隆20C5.1 HC AA CDR1:GYTLTEL(SEQ ID NO.73)
克隆20C5.1 HC AA CDR2:DPEDGE(SEQ ID NO.74)
克隆20C5.1 HC AA CDR3:ESRGIGWPYFDY(SEQ ID NO.75)
克隆20C5.1 LC DNA
GATATTCAGATGACTCAATCTCCTTCTTCTCTGTCCGCTTCCGTGGGCGATAGAGTGACCATTACTTGTAGGGCGTCCCAGTCAATCTCCAGTTATTTGAATTGGTATCAGCAGAAGCCCGGGAAAGCACCTAAGCTGTTGATCAGCGGGGCTTCTAGCCTGAAGAGTGGGGTACCTTCACGGTTCAGCGGAAGCGGAAGCGGAACCGATTTCACCCTGACTATCAGCAGCCTGCCACCTGAGGACTTTGCAACTTACTACTGCCAACAGTCATACAGCACTCCGATCACTTTCGGCCAGGGCACCCGGCTCGAAATCAAGCGC(SEQ ID NO.76)
克隆20C5.1 AA LC(CDR加下划线)
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLISGASSLKSGVPSRFSGSGSGTDFTLTISSLPPEDFATYYCQQSYSTPITFGQGTRLEIKR(SEQ ID NO.77)
克隆20C5.1 AA LC CDR1:RASQSISSYLN(SEQ ID NO.78)
克隆20C5.1 AA LC CDR2:GASSLKS(SEQ ID NO.79)
克隆20C5.1 AA LC CDR3:QQSYSTPIT(SEQ ID NO.80)
克隆20C5.1 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTCCAACTGGTGCAGTCCGGAGCCGAAGTCAAGAAACCAGGTGCCTCCGTTAAAGTGAGTTGCAAAGTCTCTGGATACACTCTGACCGAGCTCTCTATGCACTGGGTCCGGCAGGCCCCCGGCAAGGGATTGGAATGGATGGGCGGGTTCGATCCTGAGGACGGAGAGACTATCTACGCTCAAAAATTCCAGGGACGAGTGACTGTGACCGAAGACACTAGTACCGACACTGCCTACATGGAACTTTCCTCTCTGCGATCAGAAGATACCGCAGTGTACTACTGTGCTACTGAATCTAGGGGCATTGGATGGCCCTACTTCGATTACTGGGGTCAGGGAACTCTGGTGACTGTCTCCAGCGGTGGAGGTGGCAGCGGTGGTGGCGGAAGCGGGGGGGGCGGCTCTGATATTCAGATGACTCAATCTCCTTCTTCTCTGTCCGCTTCCGTGGGCGATAGAGTGACCATTACTTGTAGGGCGTCCCAGTCAATCTCCAGTTATTTGAATTGGTATCAGCAGAAGCCCGGGAAAGCACCTAAGCTGTTGATCAGCGGGGCTTCTAGCCTGAAGAGTGGGGTACCTTCACGGTTCAGCGGAAGCGGAAGCGGAACCGATTTCACCCTGACTATCAGCAGCCTGCCACCTGAGGACTTTGCAACTTACTACTGCCAACAGTCATACAGCACTCCGATCACTTTCGGCCAGGGCACCCGGCTCGAAATCAAGCGCGCTGCTGCTTTGGACAATGAGAAGTCAAACGGCACCATCATACATGTTAAAGGTAAACATCTGTGTCCCTCCCCGCTGTTCCCCGGCCCTTCCAAACCGTTCTGGGTTCTGGTGGTGGTCGGAGGCGTACTCGCTTGCTATAGTCTGCTGGTAACTGTCGCCTTCATCATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.81)
克隆20C5.1 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.1 CD28T CD3 zeta CAR DNA重链和轻链
CAGGTCCAACTGGTGCAGTCCGGAGCCGAAGTCAAGAAACCAGGTGCCTCCGTTAAAGTGAGTTGCAAAGTCTCTGGATACACTCTGACCGAGCTCTCTATGCACTGGGTCCGGCAGGCCCCCGGCAAGGGATTGGAATGGATGGGCGGGTTCGATCCTGAGGACGGAGAGACTATCTACGCTCAAAAATTCCAGGGACGAGTGACTGTGACCGAAGACACTAGTACCGACACTGCCTACATGGAACTTTCCTCTCTGCGATCAGAAGATACCGCAGTGTACTACTGTGCTACTGAATCTAGGGGCATTGGATGGCCCTACTTCGATTACTGGGGTCAGGGAACTCTGGTGACTGTCTCCAGCGGTGGAGGTGGCAGCGGTGGTGGCGGAAGCGGGGGGGGCGGCTCTGATATTCAGATGACTCAATCTCCTTCTTCTCTGTCCGCTTCCGTGGGCGATAGAGTGACCATTACTTGTAGGGCGTCCCAGTCAATCTCCAGTTATTTGAATTGGTATCAGCAGAAGCCCGGGAAAGCACCTAAGCTGTTGATCAGCGGGGCTTCTAGCCTGAAGAGTGGGGTACCTTCACGGTTCAGCGGAAGCGGAAGCGGAACCGATTTCACCCTGACTATCAGCAGCCTGCCACCTGAGGACTTTGCAACTTACTACTGCCAACAGTCATACAGCACTCCGATCACTTTCGGCCAGGGCACCCGGCTCGAAATCAAGCGCGCTGCTGCTTTGGACAATGAGAAGTCAAACGGCACCATCATACATGTTAAAGGTAAACATCTGTGTCCCTCCCCGCTGTTCCCCGGCCCTTCCAAACCGTTCTGGGTTCTGGTGGTGGTCGGAGGCGTACTCGCTTGCTATAGTCTGCTGGTAACTGTCGCCTTCATCATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.83)
克隆20C5.1 CD28T CD3 zeta CAR AA重链和轻链
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTVTEDTSTDTAYMELSSLRSEDTAVYYCATESRGIGWPYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLISGASSLKSGVPSRFSGSGSGTDFTLTISSLPPEDFATYYCQQSYSTPITFGQGTRLEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.84)
克隆20C5.1 CD28 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGCTTGTGCAGAGCGGGGCCGAGGTGAAGAAGCCCGGGGCCAGCGTCAAAGTGTCCTGTAAGGTCAGCGGTTACACCCTCACCGAGCTGAGCATGCACTGGGTACGGCAGGCTCCCGGCAAAGGTCTTGAGTGGATGGGTGGATTTGATCCAGAAGATGGAGAGACTATCTACGCCCAGAAGTTCCAGGGCCGGGTCACCGTAACAGAAGACACCTCAACTGACACCGCTTACATGGAGCTGAGTTCACTGCGGTCCGAGGACACGGCCGTGTATTATTGTGCCACCGAGAGCCGCGGAATCGGATGGCCTTACTTCGACTACTGGGGACAGGGTACACTTGTTACAGTATCATCCGGGGGTGGCGGCTCTGGTGGGGGCGGCTCCGGAGGGGGTGGATCAGATATCCAAATGACTCAAAGTCCAAGTTCCCTGTCTGCCTCAGTCGGAGATAGAGTCACCATAACCTGCAGGGCAAGTCAGTCCATCTCCTCCTATCTGAACTGGTACCAACAGAAACCTGGAAAGGCGCCTAAGCTCCTGATCTCCGGAGCCTCATCTTTGAAATCCGGTGTCCCATCTCGCTTCAGTGGCTCTGGAAGCGGTACAGATTTTACTTTGACCATTAGCAGCCTCCCACCGGAAGACTTTGCTACATATTACTGCCAGCAGTCTTACTCAACCCCAATCACCTTCGGGCAAGGCACCAGACTCGAAATAAAAAGAGCAGCTGCTATCGAGGTTATGTACCCACCGCCGTACTTGGATAACGAAAAAAGCAATGGGACCATCATTCATGTGAAGGGTAAGCACCTTTGCCCTAGCCCACTGTTTCCTGGCCCGAGTAAACCCTTTTGGGTACTTGTGGTCGTCGGCGGCGTGCTGGCCTGCTACTCACTCCTGGTTACCGTCGCATTCATCATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.85)
克隆20C5.1 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.1 CD28 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGCTTGTGCAGAGCGGGGCCGAGGTGAAGAAGCCCGGGGCCAGCGTCAAAGTGTCCTGTAAGGTCAGCGGTTACACCCTCACCGAGCTGAGCATGCACTGGGTACGGCAGGCTCCCGGCAAAGGTCTTGAGTGGATGGGTGGATTTGATCCAGAAGATGGAGAGACTATCTACGCCCAGAAGTTCCAGGGCCGGGTCACCGTAACAGAAGACACCTCAACTGACACCGCTTACATGGAGCTGAGTTCACTGCGGTCCGAGGACACGGCCGTGTATTATTGTGCCACCGAGAGCCGCGGAATCGGATGGCCTTACTTCGACTACTGGGGACAGGGTACACTTGTTACAGTATCATCCGGGGGTGGCGGCTCTGGTGGGGGCGGCTCCGGAGGGGGTGGATCAGATATCCAAATGACTCAAAGTCCAAGTTCCCTGTCTGCCTCAGTCGGAGATAGAGTCACCATAACCTGCAGGGCAAGTCAGTCCATCTCCTCCTATCTGAACTGGTACCAACAGAAACCTGGAAAGGCGCCTAAGCTCCTGATCTCCGGAGCCTCATCTTTGAAATCCGGTGTCCCATCTCGCTTCAGTGGCTCTGGAAGCGGTACAGATTTTACTTTGACCATTAGCAGCCTCCCACCGGAAGACTTTGCTACATATTACTGCCAGCAGTCTTACTCAACCCCAATCACCTTCGGGCAAGGCACCAGACTCGAAATAAAAAGAGCAGCTGCTATCGAGGTTATGTACCCACCGCCGTACTTGGATAACGAAAAAAGCAATGGGACCATCATTCATGTGAAGGGTAAGCACCTTTGCCCTAGCCCACTGTTTCCTGGCCCGAGTAAACCCTTTTGGGTACTTGTGGTCGTCGGCGGCGTGCTGGCCTGCTACTCACTCCTGGTTACCGTCGCATTCATCATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.87)
克隆20C5.1 CD28 CD3 zeta CAR AA重链和轻链
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTVTEDTSTDTAYMELSSLRSEDTAVYYCATESRGIGWPYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLISGASSLKSGVPSRFSGSGSGTDFTLTISSLPPEDFATYYCQQSYSTPITFGQGTRLEIKRAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR(SEQ ID NO.88)
克隆20C5.1 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGTTGGTGCAAAGCGGCGCAGAAGTTAAGAAACCTGGGGCGTCAGTTAAGGTGTCTTGCAAAGTATCTGGCTATACCCTCACTGAGCTGTCCATGCATTGGGTAAGGCAGGCTCCTGGAAAGGGGCTCGAATGGATGGGAGGATTTGACCCTGAAGACGGAGAGACCATCTACGCCCAGAAATTCCAGGGTAGAGTAACAGTGACTGAGGACACTAGCACTGACACAGCGTACATGGAGCTGAGTTCTCTGAGAAGTGAGGACACAGCCGTTTACTACTGCGCTACCGAGTCCAGAGGTATTGGCTGGCCATACTTCGACTATTGGGGTCAGGGCACCCTGGTTACAGTGAGTTCAGGAGGCGGGGGCTCTGGGGGGGGCGGTTCCGGAGGGGGGGGCTCAGATATACAGATGACGCAGAGTCCATCAAGTCTCTCAGCCAGCGTGGGAGATCGCGTGACTATTACTTGCCGCGCCAGCCAGAGTATTAGCTCCTATCTGAATTGGTACCAGCAAAAGCCCGGGAAGGCCCCTAAGCTTCTGATTTCTGGCGCCTCCTCTTTGAAGTCAGGTGTGCCAAGCAGATTTAGCGGGTCTGGAAGTGGCACTGACTTTACACTTACTATCTCCAGCCTGCCCCCAGAGGATTTTGCCACATATTACTGTCAGCAAAGCTACTCTACTCCAATCACTTTCGGCCAGGGCACAAGATTGGAGATTAAGAGGGCTGCCGCACTTTCAAATTCCATCATGTATTTCAGCCATTTTGTGCCTGTTTTTCTTCCGGCCAAACCTACAACCACTCCCGCCCCACGCCCACCTACTCCCGCCCCTACCATTGCCTCCCAGCCTCTGTCTCTTAGACCTGAGGCTTGTAGACCTGCTGCCGGCGGAGCCGTGCACACTCGCGGTCTGGACTTCGCCTGCGACATCTATATCTGGGCCCCTCTGGCCGGCACCTGCGGCGTTCTCCTTCTCTCACTCGTAATCACACTCTATTGCAATCACAGGAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.89)
克隆20C5.1 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.1 CD8 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGTTGGTGCAAAGCGGCGCAGAAGTTAAGAAACCTGGGGCGTCAGTTAAGGTGTCTTGCAAAGTATCTGGCTATACCCTCACTGAGCTGTCCATGCATTGGGTAAGGCAGGCTCCTGGAAAGGGGCTCGAATGGATGGGAGGATTTGACCCTGAAGACGGAGAGACCATCTACGCCCAGAAATTCCAGGGTAGAGTAACAGTGACTGAGGACACTAGCACTGACACAGCGTACATGGAGCTGAGTTCTCTGAGAAGTGAGGACACAGCCGTTTACTACTGCGCTACCGAGTCCAGAGGTATTGGCTGGCCATACTTCGACTATTGGGGTCAGGGCACCCTGGTTACAGTGAGTTCAGGAGGCGGGGGCTCTGGGGGGGGCGGTTCCGGAGGGGGGGGCTCAGATATACAGATGACGCAGAGTCCATCAAGTCTCTCAGCCAGCGTGGGAGATCGCGTGACTATTACTTGCCGCGCCAGCCAGAGTATTAGCTCCTATCTGAATTGGTACCAGCAAAAGCCCGGGAAGGCCCCTAAGCTTCTGATTTCTGGCGCCTCCTCTTTGAAGTCAGGTGTGCCAAGCAGATTTAGCGGGTCTGGAAGTGGCACTGACTTTACACTTACTATCTCCAGCCTGCCCCCAGAGGATTTTGCCACATATTACTGTCAGCAAAGCTACTCTACTCCAATCACTTTCGGCCAGGGCACAAGATTGGAGATTAAGAGGGCTGCCGCACTTTCAAATTCCATCATGTATTTCAGCCATTTTGTGCCTGTTTTTCTTCCGGCCAAACCTACAACCACTCCCGCCCCACGCCCACCTACTCCCGCCCCTACCATTGCCTCCCAGCCTCTGTCTCTTAGACCTGAGGCTTGTAGACCTGCTGCCGGCGGAGCCGTGCACACTCGCGGTCTGGACTTCGCCTGCGACATCTATATCTGGGCCCCTCTGGCCGGCACCTGCGGCGTTCTCCTTCTCTCACTCGTAATCACACTCTATTGCAATCACAGGAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.91)
克隆20C5.1 CD8 CD3 zeta CAR AA重链和轻链
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTVTEDTSTDTAYMELSSLRSEDTAVYYCATESRGIGWPYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLISGASSLKSGVPSRFSGSGSGTDFTLTISSLPPEDFATYYCQQSYSTPITFGQGTRLEIKRAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.92)
克隆20C5.2 HC DNA
CAGGTCCAGTTGGTCGAAAGTGGCGGTGGTGTAGTGCAGCCGGGCCGCAGTTTGAGGCTTTCCTGTGCGGCTTCAGGCTTTACTTTTTCCAGCTATGGAATGCACTGGGTGCGGCAGGCCCCCGGCAAAGGACTTGAGTGGGTGGCCGTCATTTCTTATGACGGATCAGATAAGTACTACGTGGACAGCGTCAAGGGCAGATTCACCATCTCTAGGGACAACAGTAAAAATAGACTCTACCTCCAGATGAATAGCCTCAGAGCTGAAGACACGGCCGTCTACTATTGTGCTCGGGAGCGGTATAGTGGCAGAGACTACTGGGGGCAGGGCACACTCGTTACAGTGAGTAGC(SEQ ID NO.93)
克隆20C5.2 AA HC(CDR加下划线)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSS(SEQ ID NO.94)
克隆20C5.2 HC AA CDR1:GFTFSSY(SEQ ID NO.95)
克隆20C5.2 HC AA CDR2:SYDGSD(SEQ ID NO.96)
克隆20C5.2 HC AA CDR3:ERYSGRDY(SEQ ID NO.97)
克隆20C5.2 LC DNA
GAGATTGTTATGACCCAGAGTCCTGCGACCCTCTCAGTCAGCCCCGGGGAGCGCGCAACTTTGTCTTGCAGAGCTAGTCAGTCCGTGTCCTCTCTTCTGACATGGTACCAGCAAAAGCCCGGGCAGGCTCCGCGCCTTTTGATCTTTGGGGCTTCAACAAGAGCCACTGGGATTCCCGCACGATTCTCTGGCTCCGGGAGCGGTACTGGTTTCACCCTGACGATTAGCAGTCTCCAGAGCGAGGACTTCGCCGTATACTACTGCCAGCAGTACGATACGTGGCCATTCACTTTTGGACCAGGGACTAAAGTGGATTTTAAGCGC(SEQ ID NO.98)
克隆20C5.2 AA LC(CDR加下划线)
EIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKR(SEQ ID NO.99)
克隆20C5.2 AA LC CDR1:RASQSVSSLLT(SEQ ID NO.100)
克隆20C5.2 AA LC CDR2:GASTRAT(SEQ ID NO.101)
克隆20C5.2 AA LC CDR3:QQYDTWPFT(SEQ ID NO.102)
克隆20C5.2 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTCCAGTTGGTCGAAAGTGGCGGTGGTGTAGTGCAGCCGGGCCGCAGTTTGAGGCTTTCCTGTGCGGCTTCAGGCTTTACTTTTTCCAGCTATGGAATGCACTGGGTGCGGCAGGCCCCCGGCAAAGGACTTGAGTGGGTGGCCGTCATTTCTTATGACGGATCAGATAAGTACTACGTGGACAGCGTCAAGGGCAGATTCACCATCTCTAGGGACAACAGTAAAAATAGACTCTACCTCCAGATGAATAGCCTCAGAGCTGAAGACACGGCCGTCTACTATTGTGCTCGGGAGCGGTATAGTGGCAGAGACTACTGGGGGCAGGGCACACTCGTTACAGTGAGTAGCGGCGGAGGAGGGAGTGGGGGCGGTGGCTCCGGTGGAGGAGGTTCTGAGATTGTTATGACCCAGAGTCCTGCGACCCTCTCAGTCAGCCCCGGGGAGCGCGCAACTTTGTCTTGCAGAGCTAGTCAGTCCGTGTCCTCTCTTCTGACATGGTACCAGCAAAAGCCCGGGCAGGCTCCGCGCCTTTTGATCTTTGGGGCTTCAACAAGAGCCACTGGGATTCCCGCACGATTCTCTGGCTCCGGGAGCGGTACTGGTTTCACCCTGACGATTAGCAGTCTCCAGAGCGAGGACTTCGCCGTATACTACTGCCAGCAGTACGATACGTGGCCATTCACTTTTGGACCAGGGACTAAAGTGGATTTTAAGCGCGCCGCCGCTCTCGATAACGAAAAGTCAAATGGCACCATAATCCACGTCAAAGGCAAGCACCTGTGCCCTTCCCCGCTCTTCCCCGGACCCAGTAAACCATTTTGGGTGCTGGTTGTTGTGGGGGGCGTGCTGGCCTGCTATAGCCTTTTGGTCACTGTAGCCTTCATTATTTTTTGGGTCAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ IDNO.103)
克隆20C5.2 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD28T CD3 zeta CAR DNA重链和轻链
CAGGTCCAGTTGGTCGAAAGTGGCGGTGGTGTAGTGCAGCCGGGCCGCAGTTTGAGGCTTTCCTGTGCGGCTTCAGGCTTTACTTTTTCCAGCTATGGAATGCACTGGGTGCGGCAGGCCCCCGGCAAAGGACTTGAGTGGGTGGCCGTCATTTCTTATGACGGATCAGATAAGTACTACGTGGACAGCGTCAAGGGCAGATTCACCATCTCTAGGGACAACAGTAAAAATAGACTCTACCTCCAGATGAATAGCCTCAGAGCTGAAGACACGGCCGTCTACTATTGTGCTCGGGAGCGGTATAGTGGCAGAGACTACTGGGGGCAGGGCACACTCGTTACAGTGAGTAGCGGCGGAGGAGGGAGTGGGGGCGGTGGCTCCGGTGGAGGAGGTTCTGAGATTGTTATGACCCAGAGTCCTGCGACCCTCTCAGTCAGCCCCGGGGAGCGCGCAACTTTGTCTTGCAGAGCTAGTCAGTCCGTGTCCTCTCTTCTGACATGGTACCAGCAAAAGCCCGGGCAGGCTCCGCGCCTTTTGATCTTTGGGGCTTCAACAAGAGCCACTGGGATTCCCGCACGATTCTCTGGCTCCGGGAGCGGTACTGGTTTCACCCTGACGATTAGCAGTCTCCAGAGCGAGGACTTCGCCGTATACTACTGCCAGCAGTACGATACGTGGCCATTCACTTTTGGACCAGGGACTAAAGTGGATTTTAAGCGCGCCGCCGCTCTCGATAACGAAAAGTCAAATGGCACCATAATCCACGTCAAAGGCAAGCACCTGTGCCCTTCCCCGCTCTTCCCCGGACCCAGTAAACCATTTTGGGTGCTGGTTGTTGTGGGGGGCGTGCTGGCCTGCTATAGCCTTTTGGTCACTGTAGCCTTCATTATTTTTTGGGTCAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.105)
克隆20C5.2 CD28T CD3 zeta CAR AA重链和轻链
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.106)
克隆20C5.2 CD28 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGCTCGTGGAGTCTGGCGGCGGCGTGGTCCAGCCCGGCCGGTCCCTGCGCCTGTCCTGCGCCGCCAGCGGGTTTACTTTTTCCTCCTACGGCATGCACTGGGTGCGCCAGGCTCCCGGCAAGGGCCTCGAGTGGGTCGCCGTGATCTCATACGATGGGTCAGACAAATACTATGTCGATTCTGTTAAAGGGCGGTTTACCATTTCAAGAGATAACTCTAAGAATAGGCTGTATTTGCAGATGAACAGCCTGAGGGCTGAAGATACCGCAGTGTACTATTGCGCTAGGGAGCGGTATAGTGGCCGCGATTACTGGGGACAGGGTACACTGGTGACCGTGAGCTCTGGGGGTGGCGGAAGCGGGGGTGGCGGAAGCGGCGGAGGGGGTAGTGAAATTGTGATGACCCAGTCTCCGGCTACACTTTCAGTCTCCCCTGGGGAGAGAGCTACACTGTCATGCAGAGCGTCCCAGTCCGTCTCTTCTCTCCTTACCTGGTATCAGCAGAAGCCCGGCCAGGCTCCTCGACTGCTGATCTTCGGTGCCTCCACAAGGGCGACCGGGATTCCAGCCCGCTTCTCAGGTTCTGGGAGCGGAACTGGTTTCACTTTGACAATCAGTTCACTGCAGTCAGAGGATTTCGCCGTGTACTACTGCCAGCAATACGACACATGGCCATTCACTTTCGGACCCGGTACCAAAGTCGATTTCAAGAGAGCCGCGGCCATCGAGGTTATGTACCCACCACCATATCTGGACAATGAAAAAAGCAATGGAACCATTATCCATGTGAAGGGTAAACACCTCTGCCCTAGCCCACTTTTCCCTGGCCCATCAAAGCCCTTCTGGGTCTTGGTGGTCGTGGGGGGTGTGCTGGCCTGTTACAGCCTTCTGGTGACGGTTGCTTTCATTATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.107)
克隆20C5.2 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD28 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGCTCGTGGAGTCTGGCGGCGGCGTGGTCCAGCCCGGCCGGTCCCTGCGCCTGTCCTGCGCCGCCAGCGGGTTTACTTTTTCCTCCTACGGCATGCACTGGGTGCGCCAGGCTCCCGGCAAGGGCCTCGAGTGGGTCGCCGTGATCTCATACGATGGGTCAGACAAATACTATGTCGATTCTGTTAAAGGGCGGTTTACCATTTCAAGAGATAACTCTAAGAATAGGCTGTATTTGCAGATGAACAGCCTGAGGGCTGAAGATACCGCAGTGTACTATTGCGCTAGGGAGCGGTATAGTGGCCGCGATTACTGGGGACAGGGTACACTGGTGACCGTGAGCTCTGGGGGTGGCGGAAGCGGGGGTGGCGGAAGCGGCGGAGGGGGTAGTGAAATTGTGATGACCCAGTCTCCGGCTACACTTTCAGTCTCCCCTGGGGAGAGAGCTACACTGTCATGCAGAGCGTCCCAGTCCGTCTCTTCTCTCCTTACCTGGTATCAGCAGAAGCCCGGCCAGGCTCCTCGACTGCTGATCTTCGGTGCCTCCACAAGGGCGACCGGGATTCCAGCCCGCTTCTCAGGTTCTGGGAGCGGAACTGGTTTCACTTTGACAATCAGTTCACTGCAGTCAGAGGATTTCGCCGTGTACTACTGCCAGCAATACGACACATGGCCATTCACTTTCGGACCCGGTACCAAAGTCGATTTCAAGAGAGCCGCGGCCATCGAGGTTATGTACCCACCACCATATCTGGACAATGAAAAAAGCAATGGAACCATTATCCATGTGAAGGGTAAACACCTCTGCCCTAGCCCACTTTTCCCTGGCCCATCAAAGCCCTTCTGGGTCTTGGTGGTCGTGGGGGGTGTGCTGGCCTGTTACAGCCTTCTGGTGACGGTTGCTTTCATTATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.109)
克隆20C5.2 CD28 CD3 zeta CAR AA重链和轻链
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.110)
克隆20C5.2 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGTTGGTTGAATCAGGAGGGGGTGTGGTGCAACCCGGTCGGTCACTGCGCCTCAGTTGTGCTGCTTCCGGGTTTACTTTCAGCTCATATGGGATGCACTGGGTACGGCAGGCTCCAGGTAAAGGCTTGGAATGGGTGGCGGTGATCAGCTATGACGGCTCTGACAAATATTATGTGGACTCCGTGAAAGGCAGATTCACCATCAGTCGAGACAACTCAAAGAATAGACTCTACTTGCAGATGAATAGCCTCCGGGCCGAAGATACTGCAGTCTATTATTGCGCCCGGGAGCGCTACAGTGGAAGAGACTATTGGGGGCAAGGAACTCTTGTCACAGTCTCATCTGGCGGCGGCGGCAGCGGTGGGGGCGGATCTGGCGGGGGCGGCAGCGAAATCGTTATGACTCAGAGTCCTGCCACACTGAGCGTTAGCCCTGGTGAGAGAGCAACACTTAGCTGCAGAGCTAGTCAGAGTGTTTCCAGTCTTTTGACATGGTACCAACAGAAGCCCGGTCAAGCTCCACGACTGCTCATCTTCGGTGCATCCACCCGCGCAACCGGGATACCCGCCCGGTTTTCCGGTTCTGGAAGTGGCACAGGATTCACGCTCACCATTTCTTCTCTGCAGTCTGAAGACTTTGCCGTGTATTACTGCCAGCAGTACGATACCTGGCCCTTTACCTTTGGCCCAGGTACTAAAGTGGATTTTAAACGAGCTGCTGCACTTTCCAATAGTATTATGTACTTTTCACATTTTGTGCCCGTGTTCCTGCCTGCGAAGCCTACGACAACCCCAGCCCCTAGGCCGCCCACACCGGCCCCAACTATTGCCTCCCAGCCATTGTCTCTGAGACCCGAAGCTTGCAGACCTGCTGCTGGAGGCGCCGTTCACACCCGAGGATTGGATTTCGCATGTGACATTTACATCTGGGCCCCTTTGGCCGGAACCTGCGGTGTGCTGCTGCTGTCACTCGTGATTACACTTTACTGCAACCACCGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.111)
克隆20C5.2 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD8 CD3 zeta CAR DNA重链和轻链
CAGGTGCAGTTGGTTGAATCAGGAGGGGGTGTGGTGCAACCCGGTCGGTCACTGCGCCTCAGTTGTGCTGCTTCCGGGTTTACTTTCAGCTCATATGGGATGCACTGGGTACGGCAGGCTCCAGGTAAAGGCTTGGAATGGGTGGCGGTGATCAGCTATGACGGCTCTGACAAATATTATGTGGACTCCGTGAAAGGCAGATTCACCATCAGTCGAGACAACTCAAAGAATAGACTCTACTTGCAGATGAATAGCCTCCGGGCCGAAGATACTGCAGTCTATTATTGCGCCCGGGAGCGCTACAGTGGAAGAGACTATTGGGGGCAAGGAACTCTTGTCACAGTCTCATCTGGCGGCGGCGGCAGCGGTGGGGGCGGATCTGGCGGGGGCGGCAGCGAAATCGTTATGACTCAGAGTCCTGCCACACTGAGCGTTAGCCCTGGTGAGAGAGCAACACTTAGCTGCAGAGCTAGTCAGAGTGTTTCCAGTCTTTTGACATGGTACCAACAGAAGCCCGGTCAAGCTCCACGACTGCTCATCTTCGGTGCATCCACCCGCGCAACCGGGATACCCGCCCGGTTTTCCGGTTCTGGAAGTGGCACAGGATTCACGCTCACCATTTCTTCTCTGCAGTCTGAAGACTTTGCCGTGTATTACTGCCAGCAGTACGATACCTGGCCCTTTACCTTTGGCCCAGGTACTAAAGTGGATTTTAAACGAGCTGCTGCACTTTCCAATAGTATTATGTACTTTTCACATTTTGTGCCCGTGTTCCTGCCTGCGAAGCCTACGACAACCCCAGCCCCTAGGCCGCCCACACCGGCCCCAACTATTGCCTCCCAGCCATTGTCTCTGAGACCCGAAGCTTGCAGACCTGCTGCTGGAGGCGCCGTTCACACCCGAGGATTGGATTTCGCATGTGACATTTACATCTGGGCCCCTTTGGCCGGAACCTGCGGTGTGCTGCTGCTGTCACTCGTGATTACACTTTACTGCAACCACCGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.113)
克隆20C5.2 CD8 CD3 zeta CAR AA重链和轻链
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.114)
克隆20C5.2 CD28T CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGAGATTGTGATGACCCAGTCCCCTGCTACCCTGTCCGTCAGTCCGGGCGAGAGAGCCACCTTGTCATGCCGGGCCAGCCAGTCCGTCAGCAGTCTCCTGACTTGGTATCAGCAAAAACCAGGGCAGGCACCGCGGCTTTTGATTTTTGGTGCAAGCACACGCGCCACTGGCATTCCAGCTAGGTTTTCTGGAAGTGGATCTGGGACAGGCTTCACTCTGACAATCAGTAGCCTGCAGAGTGAGGACTTTGCTGTTTACTACTGTCAACAGTACGACACCTGGCCATTCACATTCGGGCCCGGCACCAAGGTCGACTTCAAGAGGGGCGGTGGAGGTTCAGGTGGTGGCGGGTCAGGCGGCGGTGGGTCTCAGGTTCAACTGGTGGAATCAGGTGGCGGCGTTGTCCAACCGGGGCGATCACTTCGACTTTCCTGTGCTGCCTCAGGCTTTACTTTTTCATCCTATGGGATGCACTGGGTTCGGCAGGCTCCCGGAAAAGGACTCGAGTGGGTTGCAGTGATCTCTTACGATGGCTCAGACAAGTATTATGTGGACTCAGTCAAGGGGAGATTCACAATAAGCCGAGACAACTCCAAAAACCGGCTTTATCTCCAGATGAACAGCCTTAGAGCGGAAGATACCGCGGTATACTACTGTGCCCGCGAGAGGTATTCCGGCAGAGACTACTGGGGACAGGGCACACTGGTCACCGTGAGTTCTGCCGCAGCGCTCGATAACGAAAAGAGCAACGGAACCATTATCCACGTTAAGGGCAAGCACCTGTGCCCCAGTCCCCTCTTCCCAGGACCATCTAAACCCTTCTGGGTTCTGGTAGTAGTTGGAGGGGTCCTTGCATGTTACTCCCTTTTGGTCACCGTCGCCTTCATTATTTTCTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ IDNO.115)
克隆20C5.2 CD28T CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD28T CD3 zeta CAR DNA重链和轻链
GAGATTGTGATGACCCAGTCCCCTGCTACCCTGTCCGTCAGTCCGGGCGAGAGAGCCACCTTGTCATGCCGGGCCAGCCAGTCCGTCAGCAGTCTCCTGACTTGGTATCAGCAAAAACCAGGGCAGGCACCGCGGCTTTTGATTTTTGGTGCAAGCACACGCGCCACTGGCATTCCAGCTAGGTTTTCTGGAAGTGGATCTGGGACAGGCTTCACTCTGACAATCAGTAGCCTGCAGAGTGAGGACTTTGCTGTTTACTACTGTCAACAGTACGACACCTGGCCATTCACATTCGGGCCCGGCACCAAGGTCGACTTCAAGAGGGGCGGTGGAGGTTCAGGTGGTGGCGGGTCAGGCGGCGGTGGGTCTCAGGTTCAACTGGTGGAATCAGGTGGCGGCGTTGTCCAACCGGGGCGATCACTTCGACTTTCCTGTGCTGCCTCAGGCTTTACTTTTTCATCCTATGGGATGCACTGGGTTCGGCAGGCTCCCGGAAAAGGACTCGAGTGGGTTGCAGTGATCTCTTACGATGGCTCAGACAAGTATTATGTGGACTCAGTCAAGGGGAGATTCACAATAAGCCGAGACAACTCCAAAAACCGGCTTTATCTCCAGATGAACAGCCTTAGAGCGGAAGATACCGCGGTATACTACTGTGCCCGCGAGAGGTATTCCGGCAGAGACTACTGGGGACAGGGCACACTGGTCACCGTGAGTTCTGCCGCAGCGCTCGATAACGAAAAGAGCAACGGAACCATTATCCACGTTAAGGGCAAGCACCTGTGCCCCAGTCCCCTCTTCCCAGGACCATCTAAACCCTTCTGGGTTCTGGTAGTAGTTGGAGGGGTCCTTGCATGTTACTCCCTTTTGGTCACCGTCGCCTTCATTATTTTCTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.117)
克隆20C5.2 CD28T CD3 zeta CAR AA重链和轻链
EIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.118)
克隆20C5.2 CD28 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGAGATCGTCATGACACAGAGTCCAGCTACCCTGAGCGTGTCCCCTGGAGAGAGAGCCACCCTGTCCTGTAGGGCTAGTCAGAGTGTGTCCAGCCTCCTCACCTGGTATCAACAGAAGCCTGGTCAAGCTCCCCGGCTGCTTATCTTCGGGGCCAGCACGCGAGCCACAGGCATCCCGGCCAGATTCTCTGGCTCTGGCAGTGGCACCGGGTTCACTCTCACGATCTCATCCCTGCAGTCAGAGGATTTCGCTGTGTATTACTGTCAGCAGTACGATACATGGCCCTTCACCTTCGGCCCGGGCACAAAAGTAGATTTCAAGCGCGGCGGCGGGGGTAGTGGGGGCGGGGGATCAGGAGGAGGGGGCTCCCAAGTACAGCTGGTTGAGAGCGGCGGCGGGGTGGTTCAGCCCGGGCGCAGCCTCAGGCTGAGTTGCGCAGCATCAGGATTCACATTCAGTTCTTATGGAATGCATTGGGTCAGACAGGCTCCCGGGAAGGGCCTTGAATGGGTGGCAGTCATTAGCTACGACGGAAGCGATAAGTACTATGTGGACTCAGTTAAAGGGAGATTTACTATCAGCCGCGACAATTCCAAAAACAGATTGTATTTGCAGATGAACTCCCTCAGGGCGGAGGACACTGCTGTATATTACTGCGCACGAGAGAGATACTCCGGCCGAGACTATTGGGGCCAAGGAACATTGGTAACTGTGAGCTCCGCCGCAGCTATTGAGGTCATGTACCCCCCACCTTATCTCGATAATGAGAAGAGTAATGGGACTATAATTCACGTAAAGGGCAAACACCTGTGCCCTTCCCCGCTGTTTCCAGGTCCAAGTAAGCCGTTCTGGGTCCTGGTTGTGGTGGGAGGGGTGCTGGCCTGCTATTCTCTGTTGGTTACCGTGGCCTTTATCATTTTCTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.119)
克隆20C5.2 CD28 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD28 CD3 zeta CAR DNA重链和轻链
GAGATCGTCATGACACAGAGTCCAGCTACCCTGAGCGTGTCCCCTGGAGAGAGAGCCACCCTGTCCTGTAGGGCTAGTCAGAGTGTGTCCAGCCTCCTCACCTGGTATCAACAGAAGCCTGGTCAAGCTCCCCGGCTGCTTATCTTCGGGGCCAGCACGCGAGCCACAGGCATCCCGGCCAGATTCTCTGGCTCTGGCAGTGGCACCGGGTTCACTCTCACGATCTCATCCCTGCAGTCAGAGGATTTCGCTGTGTATTACTGTCAGCAGTACGATACATGGCCCTTCACCTTCGGCCCGGGCACAAAAGTAGATTTCAAGCGCGGCGGCGGGGGTAGTGGGGGCGGGGGATCAGGAGGAGGGGGCTCCCAAGTACAGCTGGTTGAGAGCGGCGGCGGGGTGGTTCAGCCCGGGCGCAGCCTCAGGCTGAGTTGCGCAGCATCAGGATTCACATTCAGTTCTTATGGAATGCATTGGGTCAGACAGGCTCCCGGGAAGGGCCTTGAATGGGTGGCAGTCATTAGCTACGACGGAAGCGATAAGTACTATGTGGACTCAGTTAAAGGGAGATTTACTATCAGCCGCGACAATTCCAAAAACAGATTGTATTTGCAGATGAACTCCCTCAGGGCGGAGGACACTGCTGTATATTACTGCGCACGAGAGAGATACTCCGGCCGAGACTATTGGGGCCAAGGAACATTGGTAACTGTGAGCTCCGCCGCAGCTATTGAGGTCATGTACCCCCCACCTTATCTCGATAATGAGAAGAGTAATGGGACTATAATTCACGTAAAGGGCAAACACCTGTGCCCTTCCCCGCTGTTTCCAGGTCCAAGTAAGCCGTTCTGGGTCCTGGTTGTGGTGGGAGGGGTGCTGGCCTGCTATTCTCTGTTGGTTACCGTGGCCTTTATCATTTTCTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.121)
克隆20C5.2 CD28 CD3 zeta CAR AA重链和轻链
EIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.122)
克隆20C5.2 CD8 CD3 zeta CAR DNA重链和轻链
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGAAATAGTGATGACTCAGTCCCCGGCCACCCTCAGCGTGTCCCCCGGGGAGCGAGCGACCCTGTCATGCAGGGCTTCCCAGAGTGTCAGCTCCCTGCTCACTTGGTATCAGCAAAAGCCGGGGCAGGCTCCCCGCCTCCTCATCTTCGGGGCATCAACTAGGGCCACCGGCATTCCTGCAAGATTTTCCGGGTCTGGCAGCGGCACCGGCTTCACCCTTACCATTAGCTCTCTGCAGTCTGAGGACTTCGCCGTTTACTATTGTCAGCAGTATGATACTTGGCCCTTTACCTTCGGTCCCGGAACTAAGGTGGACTTCAAGCGCGGGGGGGGTGGATCTGGAGGTGGTGGCTCCGGGGGCGGTGGAAGCCAGGTCCAGTTGGTTGAGAGCGGCGGCGGAGTGGTGCAGCCCGGGAGGTCCTTGCGGCTGAGCTGTGCAGCCTCCGGTTTTACTTTTTCTAGCTATGGAATGCATTGGGTAAGACAGGCTCCCGGAAAAGGCCTCGAGTGGGTGGCGGTCATTAGCTATGATGGATCTGATAAATACTATGTGGACTCAGTTAAGGGGCGCTTCACAATCTCAAGAGACAATAGCAAAAATAGACTGTACCTGCAGATGAATAGTCTGCGCGCCGAGGACACTGCCGTGTACTACTGCGCCCGCGAGAGATACAGCGGACGGGATTACTGGGGCCAGGGTACCCTCGTAACGGTGTCCTCCGCTGCCGCCCTTAGCAACAGCATTATGTACTTTTCTCATTTCGTGCCAGTCTTTCTCCCAGCAAAGCCCACCACTACCCCGGCCCCCAGGCCGCCTACTCCTGCCCCCACTATCGCGTCTCAGCCTCTCTCCTTGCGGCCCGAGGCCTGCCGGCCAGCCGCAGGGGGCGCCGTACATACTCGGGGTTTGGATTTCGCTTGCGACATATATATTTGGGCCCCCCTCGCCGGCACATGTGGAGTGCTGCTCCTGAGTCTCGTTATAACCCTCTATTGCAACCATAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGTAA(SEQ ID NO.123)
克隆20C5.2 CD8 CD3 zeta CAR AA重链和轻链
(信号肽为粗体)
克隆20C5.2 CD8 CD3 zeta CAR DNA重链和轻链
GAAATAGTGATGACTCAGTCCCCGGCCACCCTCAGCGTGTCCCCCGGGGAGCGAGCGACCCTGTCATGCAGGGCTTCCCAGAGTGTCAGCTCCCTGCTCACTTGGTATCAGCAAAAGCCGGGGCAGGCTCCCCGCCTCCTCATCTTCGGGGCATCAACTAGGGCCACCGGCATTCCTGCAAGATTTTCCGGGTCTGGCAGCGGCACCGGCTTCACCCTTACCATTAGCTCTCTGCAGTCTGAGGACTTCGCCGTTTACTATTGTCAGCAGTATGATACTTGGCCCTTTACCTTCGGTCCCGGAACTAAGGTGGACTTCAAGCGCGGGGGGGGTGGATCTGGAGGTGGTGGCTCCGGGGGCGGTGGAAGCCAGGTCCAGTTGGTTGAGAGCGGCGGCGGAGTGGTGCAGCCCGGGAGGTCCTTGCGGCTGAGCTGTGCAGCCTCCGGTTTTACTTTTTCTAGCTATGGAATGCATTGGGTAAGACAGGCTCCCGGAAAAGGCCTCGAGTGGGTGGCGGTCATTAGCTATGATGGATCTGATAAATACTATGTGGACTCAGTTAAGGGGCGCTTCACAATCTCAAGAGACAATAGCAAAAATAGACTGTACCTGCAGATGAATAGTCTGCGCGCCGAGGACACTGCCGTGTACTACTGCGCCCGCGAGAGATACAGCGGACGGGATTACTGGGGCCAGGGTACCCTCGTAACGGTGTCCTCCGCTGCCGCCCTTAGCAACAGCATTATGTACTTTTCTCATTTCGTGCCAGTCTTTCTCCCAGCAAAGCCCACCACTACCCCGGCCCCCAGGCCGCCTACTCCTGCCCCCACTATCGCGTCTCAGCCTCTCTCCTTGCGGCCCGAGGCCTGCCGGCCAGCCGCAGGGGGCGCCGTACATACTCGGGGTTTGGATTTCGCTTGCGACATATATATTTGGGCCCCCCTCGCCGGCACATGTGGAGTGCTGCTCCTGAGTCTCGTTATAACCCTCTATTGCAACCATAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG(SEQ ID NO.125)
克隆20C5.2 CD8 CD3 zeta CAR AA重链和轻链
EIVMTQSPATLSVSPGERATLSCRASQSVSSLLTWYQQKPGQAPRLLIFGASTRATGIPARFSGSGSGTGFTLTISSLQSEDFAVYYCQQYDTWPFTFGPGTKVDFKRGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKYYVDSVKGRFTISRDNSKNRLYLQMNSLRAEDTAVYYCARERYSGRDYWGQGTLVTVSSAAALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.126)
CAR信号肽DNA
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCG(SEQID NO.127)
CAR信号肽:MALPVTALLLPLALLLHAARP(SEQ ID NO.128)
scFv G4S接头DNA
GGCGGTGGAGGCTCCGGAGGGGGGGGCTCTGGCGGAGGGGGCTCC(SEQ ID NO.129)
scFv G4s接头:GGGGSGGGGSGGGGS(SEQ ID NO.130)
scFv Whitlow接头DNA
GGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG(SEQ ID NO.131)
scFv Whitlow接头:GSTSGSGKPGSGEGSTKG(SEQ ID NO.132)
CD28 AA胞外域
MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP(SEQ ID NO.133)
GX2X3X4X5X6X7X8X9(SEQ ID NO:134)
X1X2X3X4X5X6(SEQ ID NO:135)
X1X2X3X4X5X6X7X8X9X10X11X12DY(SEQ ID NO:136)
X1ASQX5X6X7X8X9LX11(SEQ ID NO:137)
X1ASX4X5X6X7(SEQ ID NO:138)
QQX3X4X5X6PX8T(SEQ ID NO:139)
4-1BB核酸序列(胞内域)
AAGCGCGGCAGGAAGAAGCTCCTCTACATTTTTAAGCAGCCTTTTATGAGGCCCGTACAGACAACACAGGAGGAAGATGGCTGTAGCTGCAGATTTCCCGAGGAGGAGGAAGGTGGGTGCGAGCTG(SEQ ID NO.140)
4-1 BB AA(胞内域)
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQ ID NO.141)
OX40 AA
RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI(SEQ ID NO.142)
前导序列AA
MALPVTALLLPLALLLHAARP(SEQ ID NO:143)
另外的G4S接头:GGGGSGGGGSGGGGSGGGGS(SEQ ID NO.144)
CD3 zeta变体AA
RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.145)
Axi Cel(KTE-C19)DNA(SEQ ID NO.146)
Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccagacatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcagaaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagattattctctcaccattagcaacctggagcaagaagatattgccacttacttttgccaacagggtaatacgcttccgtacacgttcggaggggggactaagttggaaataacaggctccacctctggatccggcaagcccggatctggcgagggatccaccaagggcgaggtgaaactgcaggagtcaggacctggcctggtggcgccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattacccgactatggtgtaagctggattcgccagcctccacgaaagggtctggagtggctgggagtaatatggggtagtgaaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgatgacacagccatttactactgtgccaaacattattactacggtggtagctatgctatggactactggggtcaaggaacctcagtcaccgtctcctcagcggccgcaattgaagttatgtatcctcctccttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtcccctatttcccggaccttctaagcccttttgggtgctggtggtggttgggggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacgcccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgc
Axi Cel(KTE-C19)AA(SEQ ID NO.147)
MLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
人源化抗-CD19 CAR DNA(SEQ ID NO.148)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGATATTCAAATGACCCAGTCCCCGTCCTCCCTGAGTGCCTCCGTCGGTGACCGTGTTACGATTACCTGCCGTGCGAGCCAAGACATCTCTAAATACCTGAACTGGTATCAGCAAAAACCGGATCAGGCACCGAAACTGCTGATCAAACATACCTCACGTCTGCACTCGGGTGTGCCGAGCCGCTTTAGTGGTTCCGGCTCAGGTACCGATTACACCCTGACGATCAGCTCTCTGCAGCCGGAAGACTTTGCCACGTATTACTGCCAGCAAGGTAATACCCTGCCGTATACGTTCGGCCAAGGTACCAAACTGGAAATCAAAGGCTCGACGAGCGGCTCTGGTAAACCGGGCTCTGGTGAAGGCAGTACCAAAGGTGAAGTGCAGCTGGTTGAAAGCGGTGGTGGTCTGGTTCAACCGGGTCGTTCCCTGCGTCTGTCATGTACGGCGAGTGGTGTCTCCCTGCCGGACTATGGCGTGTCCTGGATTCGTCAGCCGCCGGGTAAAGGCCTGGAATGGATTGGTGTCATCTGGGGCAGTGAAACCACGTATTACAACTCGGCCCTGAAAAGCCGTTTCACCATCTCTCGCGATAACAGTAAAAATACGCTGTACCTGCAGATGAATAGCCTGCGCGCGGAAGACACCGCCGTTTACTACTGCGCAAAACATTACTACTACGGTGGCAGCTATGCTATGGATTACTGGGGTCAAGGCACGCTGGTCACCGTTTCGTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCAcctagg
人源化抗-CD19 CAR AA(SEQ ID NO.149)
MALPVTALLLPLALLLHAARPDIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPDQAPKLLIKHTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPYTFGQGTKLEIKGSTSGSGKPGSGEGSTKGEVQLVESGGGLVQPGRSLRLSCTASGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
完全人抗-CD19 CAR DNA(SEQ ID NO.150)
Atggccctgcctgtgacagctctgctgctgcccctggccctgctgctgcatgccgccagacctgagatcgtgctgacccagtctcccggcaccctgtctctcagcccaggagagagagccaccctgagctgcagagccagccagagcgtgtccagcagctacctggcctggtatcagcagaagcccggacaggcccccagactgctgatctacggcgccagctctagagccaccggcatccccgacagattcagcggcagcggcagtggcaccgacttcaccctgaccatcagcagactggaacccgaggacttcgccgtgtactactgccagcagtacggcagcagccggttcaccttcggccctggcaccaaggtggacatcaagggcagcacctccggcagcggcaagcctggctctggcgagggctctaccaagggccaggtgcagctggtgcagtctggcgccgaagtgaagaaacccggctctagcgtgaaggtgtcctgcaaggacagcggcggcaccttcagcagctacgccatcagctgggtgcgccaggccccaggacaggggctggaatggatgggcggcatcatccccatcttcggcaccaccaactacgcccagcagttccagggcagagtgaccatcaccgccgacgagagcaccagcaccgcctacatggaactgagcagcctgcggagcgaggacacagccgtgtattactgtgcccgcgaggccgtggccgccgactggctggatccttggggacagggcaccctggtgacagtgtccagcttcgtgcccgtgttcctgcccgccaagcctaccaccacccctgcccctagacctcccaccccagccccaacaatcgccagccagcctctgtccctgcggcccgaagcctgtagacctgctgccggcggagccgtgcacaccagaggcctggacttcgcctgcgatatctacatctgggcccctctggccggcacctgtggcgtgctgctgctgagcctggtgatcaccctgtactgcaaccaccggaacagaagcaagcggagccggctgctgcacagcgactacatgaacatgaccccaagacggcctggccccacccggaagcactaccagccttacgcccctcccagagacttcgccgcctaccggtccagagtgaagttcagcagatccgccgacgcccctgcctaccagcagggacagaaccagctgtacaacgagctgaacctgggcagacgggaagagtacgacgtgctggacaagcggagaggccgggaccccgagatgggcggaaagcccagacggaagaacccccaggaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcgcggcaagggccacgatggcctgtaccagggcctgagcaccgccaccaaggacacctacgacgccctgcacatgcaggccctgccccccaga
完全人抗-CD19 CAR AA(SEQ ID NO.151)
MALPVTALLLPLALLLHAARPEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRFTFGPGTKVDIKGSTSGSGKPGSGEGSTKGQVQLVQSGAEVKKPGSSVKVSCKDSGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQQFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAVAADWLDPWGQGTLVTVSSFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MAGE A3/A6 TCR DNA(SEQ ID NO.152)
atggcatgccctggcttcctgtgggcacttgtgatctccacctgtcttgaatttagcatggctcagacagtcactcagtctcaaccagagatgtctgtgcaggaggcagagaccgtgaccctgagctgcacatatgacaccagtgagagtgattattatttattctggtacaagcagcctcccagcaggcagatgattctcgttattcgccaagaagcttataagcaacagaatgcaacagagaatcgtttctctgtgaacttccagaaagcagccaaatccttcagtctcaagatctcagactcacagctgggggatgccgcgatgtatttctgtgctctccggagctcaggaacctacaaatacatctttggaacaggcaccaggctgaaggttttagcaaatatccagaaccctgaacctgctgtgtaccagttaaaagatcctcggtctcaggacagcaccctctgcctgttcaccgactttgactcccaaatcaatgtgccgaaaaccatggaatctggaacgttcatcactgacaaaactgtgctggacatgaaagctatggattccaagagcaatggggccattgcctggagcaaccagacaagcttcacctgccaagatatcttcaaagagaccaacgccacctaccccagttcagacgttccctgtgatgccacgttgactgagaaaagctttgaaacagatatgaacctaaactttcaaaacctgtcagttatgggactccgaatcctcctgctgaaagtagccggatttaacctgctcatgacgctgaggctgtggtccagtcgggccaagcggtccggatccggagccaccaacttcagcctgctgaagcaggccggcgacgtggaggagaaccccggccccatgggcaccaggctcctcttctgggtggccttctgtctcctgggggcagatcacacaggagctggagtctcccagtcccccagtaacaaggtcacagagaagggaaaggatgtagagctcaggtgtgatccaatttcaggtcatactgccctttactggtaccgacagagcctggggcagggcctggagtttttaatttacttccaaggcaacagtgcaccagacaaatcagggctgcccagtgatcgcttctctgcagagaggactgggggatccgtctccactctgacgatccagcgcacacagcaggaggactcggccgtgtatctctgtgccagcatccggacagggccttttttctctggaaacaccatatattttggagagggaagttggctcactgttgtagaggacctgagaaacgtgaccccacccaaggtctccttgtttgagccatcaaaagcagagattgcaaacaaacaaaaggctaccctcgtgtgcttggccaggggcttcttccctgaccacgtggagctgagctggtgggtgaatggcaaggaggtccacagtggggtcagcacggaccctcaggcctacaaggagagcaattatagctactgcctgagcagccgcctgagggtctctgctaccttctggcacaatcctcgaaaccacttccgctgccaagtgcagttccatgggctttcagaggaggacaagtggccagagggctcacccaaacctgtcacacagaacatcagtgcagaggcctggggccgagcagactgtggaatcacttcagcatcctatcatcagggggttctgtctgcaaccatcctctatgagatcctactggggaaggccaccctatatgctgtgctggtcagtggcctggtgctgatggctatggtcaaaagaaagaactcatga
MAGE A3/A6 TCR AA(SEQ ID NO.153)
M A C P G F L W A L V I S T C L E F S M A Q T V T Q S Q P E M S V Q EA E T V T L S C T Y D T S E S D Y Y L F W Y K Q P P S R Q M I L V I R Q E A YK Q Q N A T E N R F S V N F Q K A A K S F S L K I S D S Q L G D A A M Y F C AL R S S G T Y K Y I F G T G T R L K V L A N I Q N P E P A V Y Q L K D P R S QD S T L C L F T D F D S Q I N V P K T M E S G T F I T D K T V L D M K A M D SK S N G A I A W S N Q T S F T C Q D I F K E T N A T Y P S S D V P C D A T L TE K S F E T D M N L N F Q N L S V M G L R I L L L K V A G F N L L M T L R L WS S R A K R S G S G A T N F S L L K Q A G D V E E N P G PM G T R L L F W V AF C L L G A D H T G A G V S Q S P S N K V T E K G K D V E L R C D P I S G H TA L Y W Y R Q S L G Q G L E F L I Y F Q G N S A P D K S G L P S D R F S A E RT G G S V S T L T I Q R T Q Q E D S A V Y L C A SI R T G P F F S G N T I Y FG E G S W L T V V E D L R N V T P P K V S L F E P S K A E I A N K Q K A T L VC L A R G F F P D H V E L S W W V N G K E V H S G V S T D P Q A Y K E S N Y SY C L S S R L R V S A T F W H N P R N H F R C Q V Q F H G L S E E D K W P E GS P K P V T Q N I S A E A W G R A D C G I T S A S Y H Q G V L S A T I L Y E IL L G K A T L Y A V L V S G L V L M A M V K R K N S终止
抗-CLL-1 CAR DNA(SEQ ID NO.154)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTCCAACTGCAAGAAAGCGGACCCGGACTGGTGAAGCCTTCTGAGACACTTAGTCTGACGTGCACGGTCAGTGGCGGCTCCATCTCCTCCTATTATTGGTCATGGATACGACAACCCCCAGGTAAGGGCCTGGAATGGATTGGCTATATCTACTATTCAGGAAGCACGAACTACAATCCCAGCCTGAAGTCCCGAGTGACAATTTCAGTAGATACCAGTAAAAACCAGTTCAGTCTTAAACTGTCAAGCGTGACAGCTGCCGACACCGCTGTGTATTACTGCGTCTCACTGGTGTATTGTGGAGGGGATTGTTATAGCGGGTTCGATTATTGGGGACAGGGAACCCTGGTGACTGTATCTTCCGGCGGCGGCGGCTCAGGGGGTGGCGGTAGTGGCGGTGGGGGTTCCGATATTCAACTGACACAATCCCCCAGCTCACTCAGCGCCAGCGTGGGGGACAGGGTTAGCTTTACCTGTCAAGCCTCTCAGGATATAAATAACTTTCTGAACTGGTATCAACAGAAGCCTGGGAAGGCGCCCAAACTCCTGATCTATGATGCGTCCAACCTGGAAACTGGCGTGCCTTCACGCTTTAGCGGCTCTGGCAGTGGTACAGACTTCACTTTTACCATCTCTTCACTTCAGCCGGAGGACATCGCCACATATTACTGTCAACAGTACGGAAACTTGCCCTTTACTTTTGGAGGCGGCACCAAAGTTGAAATCAAAAGGGCCGCTGCCCTGGATAACGAAAAGAGCAATGGGACTATAATACATGTTAAAGGAAAACACCTGTGTCCATCTCCCCTGTTCCCTGGACCGTCAAAGCCATTTTGGGTGCTCGTGGTTGTCGGTGGCGTTCTCGCCTGTTATAGCTTGCTGGTGACAGTAGCCTTCATTATCTTTTGGGTGAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCCGAGTGAAATTTTCTAGATCAGCTGATGCTCCCGCCTATCAGCAGGGACAGAATCAACTTTACAATGAGCTGAACCTGGGTCGCAGAGAAGAGTACGACGTTTTGGACAAACGCCGGGGCCGAGATCCTGAGATGGGGGGGAAGCCGAGAAGGAAGAATCCTCAAGAAGGCCTGTACAACGAGCTTCAAAAAGACAAAATGGCTGAGGCGTACTCTGAGATCGGCATGAAGGGCGAGCGGAGACGAGGCAAGGGTCACGATGGCTTGTATCAGGGCCTGAGTACAGCCACAAAGGACACCTATGACGCCCTCCACATGCAGGCACTGCCCCCACGC
抗-CLL-1CAR AA(SEQ ID NO.155)
MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
抗-BCMA CAR DNA(SEQ ID NO.156)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG
抗-BCMA CAR AA(SEQ ID NO.157)
MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKGPLQEPPYDYGMDVWGQGTTVTVSSGSTSGSGKPGSGEGSTKGEIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHHVWPLTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
C185 E711-19/HLA-A*02:01特异性TCR DNA(SEQ ID NO.158)
atgggcaccagactgttcttttatgtggccctgtgtctgctgtggaccggccacatggatgccggaattacacagagccccagacacaaagtgaccgagacaggcacccctgtgacactgagatgccaccagaccgagaaccaccgctacatgtactggtacagacaggatccaggccacggcctgagactgatccactacagctacggcgtgaaggacaccgacaagggcgaagtgtctgacggctacagcgtgtccagaagcaagaccgaggatttcctgctgaccctggaaagcgccacaagcagccagaccagcgtgtacttttgtgccatcagcggctacaagaacaccgaggcctttttcggccaaggcaccaggctgacagtggtggaagatctgaagaacgtgttcccacctgaggtggccgtgtttgagccttctgaggccgagatcagccacacacagaaagccacactcgtgtgcctggccaccggcttttatcccgatcacgtggaactgtcttggtgggtcaacggcaaagaggtgcacagcggcgttagcacagaccctcagcctctgaaagagcagcccgctctgaacgacagcagatactgtctgagcagcagactgagagtgtccgccaccttctggcagaaccccagaaaccacttcagatgccaggtgcagttctacggcctgtccgagaatgacgagtggacccaggatagagccaagccagtgacacagattgtgtctgccgaagcctggggcagagccgattgtggctttacaagcgagagctaccagcagggcgtgctgtctgccacaatcctgtatgagatcctgctgggcaaagccactctgtacgctgtgctggtgtctgccctggtgctgatggccatggtcaagagaaaggacagcagaggcagagccaagagatctggcagcggcgccacaaactttagcctgctgaaacaggccggcgacgtggaagagaaccctggacctatgaagtccctgcgggtgctgctggttattctgtggctgcagctgagctgggtttggagccagggacagcaagtgatgcagatccctcagtaccagcacgtgcaagaaggcgaggacttcaccacctactgcaacagcagcacaaccctgagcaacatccagtggtacaagcagaggcctggcgggcaccctgtgtttctgatccagctggttaagagcggcgaagtgaagaagcagaagcggctgacctttcagttcggcgaggccaagaagaacagcagcctgcacattaccgccacacagaccaccgacgtgggcacatatttttgcgctggcagagaaggcggcagcgagaagctggtttttggcaagggcaccaaactgaccgtgaatcccgacattcagaaccccgatccagccgtgtaccagctgagagacagcaagagcagcgacaagagcgtgtgtctgttcaccgacttcgactcccagaccaatgtgtcccagagcaaggactccgacgtgtacatcaccgataagaccgtgctggacatgcggagcatggacttcaagagcaatagcgccgtggcttggagcaacaagagcgactttgcctgcgccaacgccttcaacaacagcatcatccccgaggacacattcttcccaagtcctgagagcagctgcgacgtgaagctggtggaaaagagcttcgagacagacaccaacctgaacttccagaacctgagcgtgatcggcttcagaatcctgctgctgaaggtggccggcttcaacctgctgatgactctgagactgtggtccagctgaattcggatccaagcttaggcctgctcgctttcttgctgtcccatttctattaaaggttcctttgttc
C185 E711-19/HLA-A*02:01特异性TCR AA(SEQ ID NO.159)
MGTRLFFYVALCLLWTGHMDAGITQSPRHKVTETGTPVTLRCHQTENHRYMYWYRQDPGHGLRLIHYSYGVKDTDKGEVSDGYSVSRSKTEDFLLTLESATSSQTSVYFCAISGYKNTEAFFGQGTRLTVVEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRGRAKRSGSGATNFSLLKQAGDVEENPGPMKSLRVLLVILWLQLSWVWSQGQQVMQIPQYQHVQEGEDFTTYCNSSTTLSNIQWYKQRPGGHPVFLIQLVKSGEVKKQKRLTFQFGEAKKNSSLHITATQTTDVGTYFCAGREGGSEKLVFGKGTKLTVNPDIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
E711-19/HLA-A*02:01特异性TCR DNA(SEQ ID NO.160)
atgggacctggattgctttgttgggccctgctgtgtctgcttggagctggacttgtggatgccggcgtgacacagtctcccacacacctgatcaagaccagaggccagcaagtgaccctgagatgtagccctaagagcggccacgacaccgtgtcttggtatcagcaggctcttggccagggacctcagttcatcttccagtactacgaggaagaggaacggcagcggggcaacttccctgatagattctctggccatcagttccccaactacagcagcgagctgaacgtgaacgctctgctgctgggcgatagcgccctgtatctgtgtgccagttctcttggttggagaggcggcagatacaacgagcagttctttggccctggcaccagactgaccgtgctggaagatctgaagaacgtgttcccacctgaggtggccgtgtttgagccttctgaggccgagatcagccacacacagaaagccacactcgtgtgcctggccaccggcttttatcccgatcacgtggaactgtcttggtgggtcaacggcaaagaggtgcacagcggcgttagcacagaccctcagcctctgaaagagcagcccgctctgaacgacagcagatactgtctgagcagcagactgagagtgtccgccaccttctggcagaaccccagaaaccacttcagatgccaggtgcagttctacggcctgtccgagaatgacgagtggacccaggatagagccaagccagtgacacagattgtgtctgccgaagcctggggcagagccgattgtggctttacaagcgagagctaccagcagggcgtgctgtctgccacaatcctgtatgagatcctgctgggcaaagccactctgtacgctgtgctggtgtctgccctggtgctgatggccatggtcaagagaaaggacagcagaggcagagccaagagatctggcagcggcgccacaaactttagcctgctgaaacaggccggcgacgtggaagagaaccctggacctatgaagtccctgcgggtgctgctggttattctgtggctgcagctgagctgggtttggagccagggacagaacatcgaccagcctaccgagatgacagccaccgaaggcgccatcgtgcagatcaattgcacctaccagaccagcggcttcaacggcctgttctggtatcaacagcatgccggcgaggcccctaccttcctgagctataatgtgctggacggcctggaagaaaagggcagattcagcagcttcctgtccagaagcaagggctacagctacctgctgctgaaagaactccagatgaaggacagcgcctcctacctgtgtgcctccgtggatggaaacaacagactggccttcggcaagggcaaccaggtggtggtcatccccgacattcagaaccccgatccagccgtgtaccagctgagagacagcaagagcagcgacaagagcgtgtgtctgttcaccgacttcgactcccagaccaatgtgtcccagagcaaggactccgacgtgtacatcaccgataagaccgtgctggacatgcggagcatggacttcaagagcaatagcgccgtggcttggagcaacaagagcgactttgcctgcgccaacgccttcaacaacagcatcatccccgaggacacattcttcccaagtcctgagagcagctgcgacgtgaagctggtggaaaagagcttcgagacagacaccaacctgaacttccagaacctgagcgtgatcggcttcagaatcctgctgctgaaggtggccggcttcaacctgctgatgactctgagactgtggtccagctgaattcggatccaagcttaggcctgctcgctttcttgctgtcccatttctattaaaggttcctttgttc
E711-19/HLA-A*02:01特异性TCR AA(SEQ ID NO.161)
MGPGLLCWALLCLLGAGLVDAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWYQQALGQGPQFIFQYYEEEERQRGNFPDRFSGHQFPNYSSELNVNALLLGDSALYLCASSLGWRGGRYNEQFFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRGRAKRSGSGATNFSLLKQAGDVEENPGPMKSLRVLLVILWLQLSWVWSQGQNIDQPTEMTATEGAIVQINCTYQTSGFNGLFWYQQHAGEAPTFLSYNVLDGLEEKGRFSSFLSRSKGYSYLLLKELQMKDSASYLCASVDGNNRLAFGKGNQVVVIPDIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
Axi Cel(KTE-C19)前导序列(CSF2RA)DNA(SEQ ID NO.162)
Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatccca
Axi Cel(KTE-C19)前导序列(CSF2RA)AA(SEQ ID NO.163)
MLLLVTSLLLCELPHPAFLLIP
Axi Cel(KTE-C19)scFv重链DNA(SEQ ID NO.164)
gacatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcagaaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagattattctctcaccattagcaacctggagcaagaagatattgccacttacttttgccaacagggtaatacgcttccgtacacgttcggaggggggactaagttggaaataaca
Axi Cel(KTE-C19)scFv重链AA(SEQ ID NO.165)
DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT
Axi Cel(KTE-C19)接头(Whitlow)DNA(SEQ ID NO.166)
ggctccacctctggatccggcaagcccggatctggcgagggatccaccaagggc
Axi Cel(KTE-C19)接头(Whitlow)AA(SEQ ID NO.167)
GSTSGSGKPGSGEGSTKG
Axi Cel(KTE-C19)scFv轻链DNA(SEQ ID NO.168)
gaggtgaaactgcaggagtcaggacctggcctggtggcgccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattacccgactatggtgtaagctggattcgccagcctccacgaaagggtctggagtggctgggagtaatatggggtagtgaaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgatgacacagccatttactactgtgccaaacattattactacggtggtagctatgctatggactactggggtcaaggaacctcagtcaccgtctcctca
Axi Cel(KTE-C19)scFv轻链AA(SEQ ID NO.169)
EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS
Axi Cel(KTE-C19)微型间隔物DNA(SEQ ID NO.170)
gcggccgca
Axi Cel(KTE-C19)微型间隔物AA(SEQ ID NO.171)
AAA
Axi Cel(KTE-C19)CD28间隔物(胞外/CD28的TM区)DNA(SEQ ID NO.172)
attgaagttatgtatcctcctccttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtcccctatttcccggaccttctaagcccttttgggtgctggtggtggttgggggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtg
Axi Cel(KTE-C19)CD28间隔物(胞外/CD28的TM区)AA(SEQ ID NO.173)
IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWV
Axi Cel(KTE-C19)CD28共刺激(CD28的胞内区)DNA(SEQ ID NO.174)
aggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctcc
Axi Cel(KTE-C19)CD28共刺激(CD28的胞内区)AA(SEQ ID NO.175)
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
Axi Cel(KTE-C19)CD3 zeta DNA(SEQ ID NO.176)
agagtgaagttcagcaggagcgcagacgcccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgc
Axi Cel(KTE-C19)CD3 zeta AA(SEQ ID NO.177)
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
Axi Cel(KTE-C19)VL CDR1(Chothia)(SEQ ID NO.178)
RASQDISKYLN
Axi Cel(KTE-C19)VL CDR2(Chothia)(SEQ ID NO.179)
HTSRLHS
Axi Cel(KTE-C19)VL CDR3(Chothia)(SEQ ID NO.180)
QQGNTLPYT
Axi Cel(KTE-C19)VH CDR1(Chothia)(SEQ ID NO.181)
GVSLPDY
Axi Cel(KTE-C19)VH CDR2(Chothia)(SEQ ID NO.182)
WGSET
Axi Cel(KTE-C19)VH CDR3(Chothia)(SEQ ID NO.183)
HYYYGGSYAMDY
Axi Cel(KTE-C19)VL CDR1(Kabat)(SEQ ID NO.184)
RASQDISKYLN
Axi Cel(KTE-C19)VL CDR2(Kabat)(SEQ ID NO.185)
HTSRLHS
Axi Cel(KTE-C19)VL CDR3(Kabat)(SEQ ID NO.186)
QQGNTLPYT
Axi Cel(KTE-C19)VH CDR1(Kabat)(SEQ ID NO.187)
DYGVS
Axi Cel(KTE-C19)VH CDR2(Kabat)(SEQ ID NO.188)
VIWGSETTYYNSALKS
Axi Cel(KTE-C19)VH CDR3(Kabat)(SEQ ID NO.189)
HYYYGGSYAMDY
人源化抗-CD19 CAR CD8前导序列DNA(SEQ ID NO.190)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCG
人源化抗-CD19 CAR CD8前导序列AA(SEQ ID NO.191)
MALPVTALLLPLALLLHAARP
人源化抗-CD19 CAR scFv重链DNA(SEQ ID NO.192)
GATATTCAAATGACCCAGTCCCCGTCCTCCCTGAGTGCCTCCGTCGGTGACCGTGTTACGATTACCTGCCGTGCGAGCCAAGACATCTCTAAATACCTGAACTGGTATCAGCAAAAACCGGATCAGGCACCGAAACTGCTGATCAAACATACCTCACGTCTGCACTCGGGTGTGCCGAGCCGCTTTAGTGGTTCCGGCTCAGGTACCGATTACACCCTGACGATCAGCTCTCTGCAGCCGGAAGACTTTGCCACGTATTACTGCCAGCAAGGTAATACCCTGCCGTATACGTTCGGCCAAGGTACCAAACTGGAAATCAAA
人源化抗-CD19 CAR scFv重链AA(SEQ ID NO.193)
DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPDQAPKLLIKHTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPYTFGQGTKLEIK
人源化抗-CD19 CAR接头(Whitlow)DNA(SEQ ID NO.194)
GGCTCGACGAGCGGCTCTGGTAAACCGGGCTCTGGTGAAGGCAGTACCAAAGGT
人源化抗-CD19 CAR接头(Whitlow)AA(SEQ ID NO.195)
GSTSGSGKPGSGEGSTKG
人源化抗-CD19 CAR scFv轻链DNA(SEQ ID NO.196)
GAAGTGCAGCTGGTTGAAAGCGGTGGTGGTCTGGTTCAACCGGGTCGTTCCCTGCGTCTGTCATGTACGGCGAGTGGTGTCTCCCTGCCGGACTATGGCGTGTCCTGGATTCGTCAGCCGCCGGGTAAAGGCCTGGAATGGATTGGTGTCATCTGGGGCAGTGAAACCACGTATTACAACTCGGCCCTGAAAAGCCGTTTCACCATCTCTCGCGATAACAGTAAAAATACGCTGTACCTGCAGATGAATAGCCTGCGCGCGGAAGACACCGCCGTTTACTACTGCGCAAAACATTACTACTACGGTGGCAGCTATGCTATGGATTACTGGGGTCAAGGCACGCTGGTCACCGTTTCGTCA
人源化抗-CD19 CAR scFv轻链AA(SEQ ID NO.197)
EVQLVESGGGLVQPGRSLRLSCTASGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYNSALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS
人源化抗-CD19 CAR微型间隔物DNA(SEQ ID NO.198)
GCCGCTGCC
人源化抗-CD19 CAR微型间隔物AA(SEQ ID NO.199)
AAA
人源化抗-CD19 CAR CD28T间隔物(胞外/CD28的TM区)DNA(SEQ ID NO.200)
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTT
人源化抗-CD19 CAR CD28T间隔物(extra/CD28的TM区)AA(SEQ ID NO.201)
LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWV
人源化抗-CD19 CAR CD28共刺激(CD28的胞内区)DNA(SEQ ID NO.202)
AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC
人源化抗-CD19 CAR共刺激(CD28的胞内区)AA(SEQ ID NO.203)
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
人源化抗-CD19 CAR CD3 zeta DNA(SEQ ID NO.204)
AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCAcctagg
人源化抗-CD19 CAR CD3 zeta AA(SEQ ID NO.205)
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
人源化抗-CD19 CAR VL完全人抗-CD19 CDR1(Chothia)(SEQ ID NO.206)
RASQSVSSSYLA
人源化抗-CD19 CAR VL完全人抗-CD19 CDR2(Chothia)(SEQ ID NO.207)
GASSRAT
人源化抗-CD19 CAR VL完全人抗-CD19 CDR3(Chothia)(SEQ ID NO.208)
QQYGSSRFT
人源化抗-CD19 CAR VH完全人抗-CD19 CDR1(Chothia)(SEQ ID NO.209)
GGTFSSY
人源化抗-CD19 CAR VH完全人抗-CD19 CDR2(Chothia)(SEQ ID NO.210)
IPIFGT
人源化抗-CD19 CAR VH完全人抗-CD19 CDR3(Chothia)(SEQ ID NO.211)
EAVAADWLDP
人源化抗-CD19 CAR VL完全人抗-CD19 CDR1(Kabat)(SEQ ID NO.212)
RASQSVSSSYLA
人源化抗-CD19 CAR VL完全人抗-CD19 CDR2(Kabat)(SEQ ID NO.213)
GASSRAT
人源化抗-CD19 CAR VL完全人抗-CD19 CDR3(Kabat)(SEQ ID NO.214)
QQYGSSRFT
人源化抗-CD19 CAR VH完全人抗-CD19 CDR1(Kabat)(SEQ ID NO.215)
SYAIS
人源化抗-CD19 CAR VH完全人抗-CD19 CDR2(Kabat)(SEQ ID NO.216)
GIIPIFGTTNYAQQFQG
人源化抗-CD19 CAR VH完全人抗-CD19 CDR3(Kabat)(SEQ ID NO.217)
EAVAADWLDP
完全人抗-CD19 CAR前导序列(CD8a)DNA(SEQ ID NO.218)
Atggccctgcctgtgacagctctgctgctgcccctggccctgctgctgcatgccgccagacct
完全人抗-CD19 CAR前导序列(CD8a)AA(SEQ ID NO.219)
MALPVTALLLPLALLLHAARP
完全人抗-CD19 CAR scFv轻链DNA(SEQ ID NO.220)
gagatcgtgctgacccagtctcccggcaccctgtctctcagcccaggagagagagccaccctgagctgcagagccagccagagcgtgtccagcagctacctggcctggtatcagcagaagcccggacaggcccccagactgctgatctacggcgccagctctagagccaccggcatccccgacagattcagcggcagcggcagtggcaccgacttcaccctgaccatcagcagactggaacccgaggacttcgccgtgtactactgccagcagtacggcagcagccggttcaccttcggccctggcaccaaggtggacatcaag
完全人抗-CD19 CAR scFv轻链AA(SEQ ID NO.221)
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRFTFGPGTKVDIK
完全人抗-CD19 CAR接头(Whitlow)DNA(SEQ ID NO.222)
ggcagcacctccggcagcggcaagcctggctctggcgagggctctaccaagggc
完全人抗-CD19 CAR接头(Whitlow)AA(SEQ ID NO.223)
GSTSGSGKPGSGEGSTKG
完全人抗-CD19 CAR scFv重链DNA(SEQ ID NO.224)
caggtgcagctggtgcagtctggcgccgaagtgaagaaacccggctctagcgtgaaggtgtcctgcaaggacagcggcggcaccttcagcagctacgccatcagctgggtgcgccaggccccaggacaggggctggaatggatgggcggcatcatccccatcttcggcaccaccaactacgcccagcagttccagggcagagtgaccatcaccgccgacgagagcaccagcaccgcctacatggaactgagcagcctgcggagcgaggacacagccgtgtattactgtgcccgcgaggccgtggccgccgactggctggatccttggggacagggcaccctggtgacagtgtccagc
完全人抗-CD19 CAR scFv重链AA(SEQ ID NO.225)
QVQLVQSGAEVKKPGSSVKVSCKDSGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQQFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAVAADWLDPWGQGTLVTVSS
完全人抗-CD19 CAR CD8a间隔物和TM区DNA(SEQ ID NO.226)
ttcgtgcccgtgttcctgcccgccaagcctaccaccacccctgcccctagacctcccaccccagccccaacaatcgccagccagcctctgtccctgcggcccgaagcctgtagacctgctgccggcggagccgtgcacaccagaggcctggacttcgcctgcgatatctacatctgggcccctctggccggcacctgtggcgtgctgctgctgagcctggtgatcaccctgtactgcaaccaccggaac
完全人抗-CD19 CAR CD8a间隔物和TM区AA(SEQ ID NO.227)
FVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN
完全人抗-CD19 CAR CD28共刺激DNA(SEQ ID NO.228)
agaagcaagcggagccggctgctgcacagcgactacatgaacatgaccccaagacggcctggccccacccggaagcactaccagccttacgcccctcccagagacttcgccgcctaccggtcc
完全人抗-CD19 CAR CD28共刺激AA(SEQ ID NO.229)
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
完全人抗-CD19 CAR CD3 zeta DNA(SEQ ID NO.230)
agagtgaagttcagcagatccgccgacgcccctgcctaccagcagggacagaaccagctgtacaacgagctgaacctgggcagacgggaagagtacgacgtgctggacaagcggagaggccgggaccccgagatgggcggaaagcccagacggaagaacccccaggaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcgcggcaagggccacgatggcctgtaccagggcctgagcaccgccaccaaggacacctacgacgccctgcacatgcaggccctgccccccaga完全人抗-CD19 CAR CD3 zeta AA(SEQ IDNO.231)
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MAGE A3/A6 TCR构建体–可变alpha链–AV38-2 DNA(SEQ ID NO.232)
atggcatgccctggcttcctgtgggcacttgtgatctccacctgtcttgaatttagcatggctcagacagtcactcagtctcaaccagagatgtctgtgcaggaggcagagaccgtgaccctgagctgcacatatgacaccagtgagagtgattattatttattctggtacaagcagcctcccagcaggcagatgattctcgttattcgccaagaagcttataagcaacagaatgcaacagagaatcgtttctctgtgaacttccagaaagcagccaaatccttcagtctcaagatctcagactcacagctgggggatgccgcgatgtatttctgtgct
MAGE A3/A6 TCR构建体–可变alpha链–AV38-2 AA(SEQ ID NO.233)
M A C P G F L W A L V I S T C L E F S M A Q T V T Q S Q P E M S V Q EA E T V T L S C T Y D T S E S D Y Y L F W Y K Q P P S R Q M I L V I R Q E A YK Q Q N A T E N R F S V N F Q K A A K S F S L K I S D S Q L G D A A M Y F C AL R S S G T Y K Y I F G T G T R L K V L A N
MAGE A3/A6 TCR构建体–TRAJ40 DNA(SEQ ID NO.234)
ctccggagctcaggaacctacaaatacatctttggaacaggcaccaggctgaaggttttagcaaat
MAGE A3/A6 TCR构建体–鼠恒定alpha–鼠CA DNA(SEQ ID NO.235)
atccagaaccctgaacctgctgtgtaccagttaaaagatcctcggtctcaggacagcaccctctgcctgttcaccgactttgactcccaaatcaatgtgccgaaaaccatggaatctggaacgttcatcactgacaaaactgtgctggacatgaaagctatggattccaagagcaatggggccattgcctggagcaaccagacaagcttcacctgccaagatatcttcaaagagaccaacgccacctaccccagttcagacgttccctgtgatgccacgttgactgagaaaagctttgaaacagatatgaacctaaactttcaaaacctgtcagttatgggactccgaatcctcctgctgaaagtagccggatttaacctgctcatgacgctgaggctgtggtccagt
MAGE A3/A6 TCR构建体–鼠恒定alpha–鼠CA AA(SEQ ID NO.236)
I Q N P E P A V Y Q L K D P R S Q D S T L C L F T D F D S Q I N V P KT M E S G T F I T D K T V L D M K A M D S K S N G A I A W S N Q T S F T C Q DI F K E T N A T Y P S S D V P C D A T L T E K S F E T D M N L N F Q N L S V MG L R I L L L K V A G F N L L M T L R L W S S
MAGE A3/A6 TCR构建体–弗林蛋白酶-SG SG-P2A DNA(SEQ ID NO.237)
cgggccaagcggtccggatccggagccaccaacttcagcctgctgaagcaggccggcgacgtggaggagaaccccggcccc
MAGE A3/A6 TCR构建体–弗林蛋白酶-SG SG-P2A AA(SEQ ID NO.238)
R A K R S G S G A T N F S L L K Q A G D V E E N P G P
MAGE A3/A6 TCR构建体–可变beta链–BV7-2 DNA(SEQ ID NO.239)
atgggcaccaggctcctcttctgggtggccttctgtctcctgggggcagatcacacaggagctggagtctcccagtcccccagtaacaaggtcacagagaagggaaaggatgtagagctcaggtgtgatccaatttcaggtcatactgccctttactggtaccgacagagcctggggcagggcctggagtttttaatttacttccaaggcaacagtgcaccagacaaatcagggctgcccagtgatcgcttctctgcagagaggactgggggatccgtctccactctgacgatccagcgcacacagcaggaggactcggccgtgtatctctgtgccagca
MAGE A3/A6 TCR构建体–可变beta链–BV7-2 AA(SEQ ID NO.240)
M G T R L L F W V A F C L L G A D H T G A G V S Q S P S N K V T E K GK D V E L R C D P I S G H T A L Y W Y R Q S L G Q G L E F L I Y F Q G N S A PD K S G L P S D R F S A E R T G G S V S T L T I Q R T Q Q E D S A V Y L C ASI R T G P F F S G N T I Y F G E G S W L T V V E
MAGE A3/A6 TCR构建体–TRBJ1-3 DNA(SEQ ID NO.241)
tccggacagggccttttttctctggaaacaccatatattttggagagggaagttggctcactgttgtagag
MAGE A3/A6 TCR构建体–鼠恒定beta–鼠CB1 DNA(SEQ ID NO.242)
gacctgagaaacgtgaccccacccaaggtctccttgtttgagccatcaaaagcagagattgcaaacaaacaaaaggctaccctcgtgtgcttggccaggggcttcttccctgaccacgtggagctgagctggtgggtgaatggcaaggaggtccacagtggggtcagcacggaccctcaggcctacaaggagagcaattatagctactgcctgagcagccgcctgagggtctctgctaccttctggcacaatcctcgaaaccacttccgctgccaagtgcagttccatgggctttcagaggaggacaagtggccagagggctcacccaaacctgtcacacagaacatcagtgcagaggcctggggccgagcagactgtggaatcacttcagcatcctatcatcagggggttctgtctgcaaccatcctctatgagatcctactggggaaggccaccctatatgctgtgctggtcagtggcctggtgctgatggctatggtcaaaagaaagaactcatga
MAGE A3/A6 TCR构建体–鼠恒定beta–鼠CB1 AA(SEQ ID NO.243)
D L R N V T P P K V S L F E P S K A E I A N K Q K A T L V C L A R G FF P D H V E L S W W V N G K E V H S G V S T D P Q A Y K E S N Y S Y C L S S RL R V S A T F W H N P R N H F R C Q V Q F H G L S E E D K W P E G S P K P V TQ N I S A E A W G R A D C G I T S A S Y H Q G V L S A T I L Y E I L L G K A TL Y A V L V S G L V L M A M V K R K N S终止
MAGE A3/A6 TCR Va CDR1(SEQ ID NO.244)
TYDTSESDYYLF
MAGE A3/A6 TCR Va CDR2(SEQ ID NO.245)
QEAYKQQ
MAGE A3/A6 TCR Va CDR3(SEQ ID NO.246)
ALRSSGTYKYI
MAGE A3/A6 TCR Vb CDR1(SEQ ID NO.247)
DPISGHTALY
MAGE A3/A6 TCR Vb CDR2(SEQ ID NO.248)
FQGNSAPDKSG
MAGE A3/A6 TCR Vb CDR3(SEQ ID NO.249)
ASIRTGPFFSGNTIY
抗-CLL-1 CAR CD8前导序列DNA(SEQ ID NO.250)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCG
抗-CLL-1 CAR CD8前导序列AA(SEQ ID NO.251)
MALPVTALLLPLALLLHAARP
抗-CLL-1 CAR scFv重链DNA(SEQ ID NO.252)
CAGGTCCAACTGCAAGAAAGCGGACCCGGACTGGTGAAGCCTTCTGAGACACTTAGTCTGACGTGCACGGTCAGTGGCGGCTCCATCTCCTCCTATTATTGGTCATGGATACGACAACCCCCAGGTAAGGGCCTGGAATGGATTGGCTATATCTACTATTCAGGAAGCACGAACTACAATCCCAGCCTGAAGTCCCGAGTGACAATTTCAGTAGATACCAGTAAAAACCAGTTCAGTCTTAAACTGTCAAGCGTGACAGCTGCCGACACCGCTGTGTATTACTGCGTCTCACTGGTGTATTGTGGAGGGGATTGTTATAGCGGGTTCGATTATTGGGGACAGGGAACCCTGGTGACTGTATCTTCC
抗-CLL-1 CAR scFv重链AA(SEQ ID NO.253)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVSLVYCGGDCYSGFDYWGQGTLVTVSS
抗-CLL-1 CAR G4S接头DNA(SEQ ID NO.254)
GGCGGCGGCGGCTCAGGGGGTGGCGGTAGTGGCGGTGGGGGTTCC
抗-CLL-1 CAR G4S接头AA(SEQ ID NO.255)
GGGGSGGGGSGGGGS
抗-CLL-1 CAR scFv轻链DNA(SEQ ID NO.256)
GATATTCAACTGACACAATCCCCCAGCTCACTCAGCGCCAGCGTGGGGGACAGGGTTAGCTTTACCTGTCAAGCCTCTCAGGATATAAATAACTTTCTGAACTGGTATCAACAGAAGCCTGGGAAGGCGCCCAAACTCCTGATCTATGATGCGTCCAACCTGGAAACTGGCGTGCCTTCACGCTTTAGCGGCTCTGGCAGTGGTACAGACTTCACTTTTACCATCTCTTCACTTCAGCCGGAGGACATCGCCACATATTACTGTCAACAGTACGGAAACTTGCCCTTTACTTTTGGAGGCGGCACCAAAGTTGAAATCAAAAGG
抗-CLL-1 CAR scFv轻链AA(SEQ ID NO.257)
DIQLTQSPSSLSASVGDRVSFTCQASQDINNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYGNLPFTFGGGTKVEIKR
抗-CLL-1 CAR微型间隔物DNA(SEQ ID NO.258)
GCCGCTGCC
抗-CLL-1 CAR微型间隔物AA(SEQ ID NO.259)
AAA
抗-CLL-1 CAR CD28T(胞外/CD28的TM区)DNA(SEQ ID NO.260)
CTGGATAACGAAAAGAGCAATGGGACTATAATACATGTTAAAGGAAAACACCTGTGTCCATCTCCCCTGTTCCCTGGACCGTCAAAGCCATTTTGGGTGCTCGTGGTTGTCGGTGGCGTTCTCGCCTGTTATAGCTTGCTGGTGACAGTAGCCTTCATTATCTTTTGGGTG
抗-CLL-1 CAR CD28T(胞外/CD28的TM区)AA(SEQ ID NO.261)
LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWV
抗-CLL-1 CAR CD28(CD28的胞内共刺激区)DNA(SEQ ID NO.262)
AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC
抗-CLL-1 CAR CD28(CD28的胞内共刺激区)AA(SEQ ID NO.263)
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
抗-CLL-1CAR CD3 zeta DNA(SEQ ID NO.264)
CGAGTGAAATTTTCTAGATCAGCTGATGCTCCCGCCTATCAGCAGGGACAGAATCAACTTTACAATGAGCTGAACCTGGGTCGCAGAGAAGAGTACGACGTTTTGGACAAACGCCGGGGCCGAGATCCTGAGATGGGGGGGAAGCCGAGAAGGAAGAATCCTCAAGAAGGCCTGTACAACGAGCTTCAAAAAGACAAAATGGCTGAGGCGTACTCTGAGATCGGCATGAAGGGCGAGCGGAGACGAGGCAAGGGTCACGATGGCTTGTATCAGGGCCTGAGTACAGCCACAAAGGACACCTATGACGCCCTCCACATGCAGGCACTGCCCCCACGC
抗-CLL-1CAR CD3 zeta AA(SEQ ID NO.265)
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
CLL scFv(24C1)VL CDR1(SEQ ID NO.266)
QASQDINNFLN
CLL scFv(24C1)VL CDR2(SEQ ID NO.267)
DASNLET
CLL scFv(24C1)VL CDR3(SEQ ID NO.268)
QQYGNLPFT
CLL scFv(24C1)VH CDR1(SEQ ID NO.269)
GGSISSY
CLL scFv(24C1)VH CDR2(SEQ ID NO.270)
YYSGS
CLL scFv(24C1)VH CDR3(SEQ ID NO.271)
LVYCGGDCYSGFDY
抗-BCMA CAR前导序列(CD8a)DNA(SEQ ID NO.272)
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCG
抗-BCMA CAR前导序列(CD8a)AA(SEQ ID NO.273)
MALPVTALLLPLALLLHAARP
抗-BCMA CAR scFv重链DNA(SEQ ID NO.274)
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA
抗-BCMA CAR scFv重链AA(SEQ ID NO.275)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKGPLQEPPYDYGMDVWGQGTTVTVSS
抗-BCMA CAR接头(Whitlow)DNA(SEQ ID NO.276)
GGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG
抗-BCMA CAR接头(Whitlow)AA(SEQ ID NO.277)
GSTSGSGKPGSGEGSTKG
抗-BCMA CAR scFv轻链DNA(SEQ ID NO.278)
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGG
抗-BCMA CAR scFv轻链AA(SEQ ID NO.279)
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHHVWPLTFGGGTKVEIKR
抗-BCMA CAR微型间隔物DNA(SEQ ID NO.280)
GCCGCTGCC
抗-BCMA CAR微型间隔物AA(SEQ ID NO.281)
AAA
抗-BCMA CAR CD28T间隔物DNA(SEQ ID NO.282)
CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTT
抗-BCMA CAR CD28T间隔物AA(SEQ ID NO.283)
LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWV
抗-BCMA CAR CD28共刺激区DNA(SEQ ID NO.284)
AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC
抗-BCMA CAR CD28共刺激区AA(SEQ ID NO.285)
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
抗-BCMA CAR CD3 zeta DNA(SEQ ID NO.286)
AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG
抗-BCMA CAR CD3 zeta AA(SEQ ID NO.287)
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
抗-BCMA CAR VL CDR1(SEQ ID NO.288)
RASQSVSSNLA
抗-BCMA CAR VL CDR2(SEQ ID NO.289)
SASTRAT
抗-BCMA CAR VL CDR3(SEQ ID NO.290)
QQHHVWPLTF
抗-BCMA CAR VH CDR1(SEQ ID NO.291)
GFTFSSY
抗-BCMA CAR VH CDR2(SEQ ID NO.292)
VISYDGSNKYYADSVKG
抗-BCMA CAR VH CDR3(SEQ ID NO.293)
VKGPLQEPPYDYGMDV
C185 E711-19/HLA-A*02:01特异性TCR–TCR beta链可变区DNA(SEQ ID NO.294)
atgggcaccagactgttcttttatgtggccctgtgtctgctgtggaccggccacatggatgccggaattacacagagccccagacacaaagtgaccgagacaggcacccctgtgacactgagatgccaccagaccgagaaccaccgctacatgtactggtacagacaggatccaggccacggcctgagactgatccactacagctacggcgtgaaggacaccgacaagggcgaagtgtctgacggctacagcgtgtccagaagcaagaccgaggatttcctgctgaccctggaaagcgccacaagcagccagaccagcgtgtacttttgtgccatcagcggctacaagaacaccgaggcctttttcggccaaggcaccaggctgacagtggtg
C185 E711-19/HLA-A*02:01特异性TCR–TCR beta链可变区AA(SEQ ID NO.295)
MGTRLFFYVALCLLWTGHMDAGITQSPRHKVTETGTPVTLRCHQTENHRYMYWYRQDPGHGLRLIHYSYGVKDTDKGEVSDGYSVSRSKTEDFLLTLESATSSQTSVYFCAISGYKNTEAFFGQGTRLTVV
C185 E711-19/HLA-A*02:01特异性TCR–TCR beta链恒定区DNA(SEQ ID NO.296)
gaagatctgaagaacgtgttcccacctgaggtggccgtgtttgagccttctgaggccgagatcagccacacacagaaagccacactcgtgtgcctggccaccggcttttatcccgatcacgtggaactgtcttggtgggtcaacggcaaagaggtgcacagcggcgttagcacagaccctcagcctctgaaagagcagcccgctctgaacgacagcagatactgtctgagcagcagactgagagtgtccgccaccttctggcagaaccccagaaaccacttcagatgccaggtgcagttctacggcctgtccgagaatgacgagtggacccaggatagagccaagccagtgacacagattgtgtctgccgaagcctggggcagagccgattgtggctttacaagcgagagctaccagcagggcgtgctgtctgccacaatcctgtatgagatcctgctgggcaaagccactctgtacgctgtgctggtgtctgccctggtgctgatggccatggtcaagagaaaggacagcagaggc
C185 E711-19/HLA-A*02:01特异性TCR–TCR beta链恒定区AA(SEQ ID NO.297)
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
C185 E711-19/HLA-A*02:01特异性TCR–P2A肽(具有弗林蛋白酶切割位点和接头)DNA(SEQ ID NO.298)
agagccaagagatctggcagcggcgccacaaactttagcctgctgaaacaggccggcgacgtggaagagaaccctggacctC185 E711-19/HLA-A*02:01特异性TCR–P2A肽(具有弗林蛋白酶切割位点和接头)AA(SEQ ID NO.299)
RAKRSGSGATNFSLLKQAGDVEENPGP
C185 E711-19/HLA-A*02:01特异性TCR–TCR alpha链可变区DNA(SEQ ID NO.300)
atgaagtccctgcgggtgctgctggttattctgtggctgcagctgagctgggtttggagccagggacagcaagtgatgcagatccctcagtaccagcacgtgcaagaaggcgaggacttcaccacctactgcaacagcagcacaaccctgagcaacatccagtggtacaagcagaggcctggcgggcaccctgtgtttctgatccagctggttaagagcggcgaagtgaagaagcagaagcggctgacctttcagttcggcgaggccaagaagaacagcagcctgcacattaccgccacacagaccaccgacgtgggcacatatttttgcgctggcagagaaggcggcagcgagaagctggtttttggcaagggcaccaaactgaccgtgaatccc
C185 E711-19/HLA-A*02:01特异性TCR–TCR alpha链可变区AA(SEQ ID NO.301)
MKSLRVLLVILWLQLSWVWSQGQQVMQIPQYQHVQEGEDFTTYCNSSTTLSNIQWYKQRPGGHPVFLIQLVKSGEVKKQKRLTFQFGEAKKNSSLHITATQTTDVGTYFCAGREGGSEKLVFGKGTKLTVNP
C185 E711-19/HLA-A*02:01特异性TCR–TCR alpha链恒定区DNA(SEQ ID NO.302)
gacattcagaaccccgatccagccgtgtaccagctgagagacagcaagagcagcgacaagagcgtgtgtctgttcaccgacttcgactcccagaccaatgtgtcccagagcaaggactccgacgtgtacatcaccgataagaccgtgctggacatgcggagcatggacttcaagagcaatagcgccgtggcttggagcaacaagagcgactttgcctgcgccaacgccttcaacaacagcatcatccccgaggacacattcttcccaagtcctgagagcagctgcgacgtgaagctggtggaaaagagcttcgagacagacaccaacctgaacttccagaacctgagcgtgatcggcttcagaatcctgctgctgaaggtggccggcttcaacctgctgatgactctgagactgtggtccagctgaattcggatccaagcttaggcctgctcgctttcttgctgtcccatttctattaaaggttcctttgttc
C185 E711-19/HLA-A*02:01特异性TCR–TCR alpha链恒定区AA(SEQ ID NO.303)
DIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
C185 E711-19/HLA-A*02:01特异性TCR–alpha CDR1(SEQ ID NO.304)
TTLSN
C185 E711-19/HLA-A*02:01特异性TCR–alpha CDR2(SEQ ID NO.305)
LVKSGEV
C185 E711-19/HLA-A*02:01特异性TCR–alpha CDR3(SEQ ID NO.306)
AGREGGSEKLV
C185 E711-19/HLA-A*02:01特异性TCR–beta CDR1(SEQ ID NO.307)
ENHRY
C185 E711-19/HLA-A*02:01特异性TCR–beta CDR2(SEQ ID NO.308)
SYGVKD
C185 E711-19/HLA-A*02:01特异性TCR–beta CDR3(SEQ ID NO.309)
AISGYKNTEAF
E711-19/HLA-A*02:01特异性TCR–TCR beta链可变区DNA(SEQ ID NO.310)
atgggacctggattgctttgttgggccctgctgtgtctgcttggagctggacttgtggatgccggcgtgacacagtctcccacacacctgatcaagaccagaggccagcaagtgaccctgagatgtagccctaagagcggccacgacaccgtgtcttggtatcagcaggctcttggccagggacctcagttcatcttccagtactacgaggaagaggaacggcagcggggcaacttccctgatagattctctggccatcagttccccaactacagcagcgagctgaacgtgaacgctctgctgctgggcgatagcgccctgtatctgtgtgccagttctcttggttggagaggcggcagatacaacgagcagttctttggccctggcaccagactgaccgtgctg
E711-19/HLA-A*02:01特异性TCR–TCR beta链可变区AA(SEQ ID NO.311)
MGPGLLCWALLCLLGAGLVDAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWYQQALGQGPQFIFQYYEEEERQRGNFPDRFSGHQFPNYSSELNVNALLLGDSALYLCASSLGWRGGRYNEQFFGPGTRLTVL
E711-19/HLA-A*02:01特异性TCR–TCR beta链恒定区DNA(SEQ ID NO.312)
gaagatctgaagaacgtgttcccacctgaggtggccgtgtttgagccttctgaggccgagatcagccacacacagaaagccacactcgtgtgcctggccaccggcttttatcccgatcacgtggaactgtcttggtgggtcaacggcaaagaggtgcacagcggcgttagcacagaccctcagcctctgaaagagcagcccgctctgaacgacagcagatactgtctgagcagcagactgagagtgtccgccaccttctggcagaaccccagaaaccacttcagatgccaggtgcagttctacggcctgtccgagaatgacgagtggacccaggatagagccaagccagtgacacagattgtgtctgccgaagcctggggcagagccgattgtggctttacaagcgagagctaccagcagggcgtgctgtctgccacaatcctgtatgagatcctgctgggcaaagccactctgtacgctgtgctggtgtctgccctggtgctgatggccatggtcaagagaaaggacagcagaggc
E711-19/HLA-A*02:01特异性TCR–TCR beta链恒定区AA(SEQ ID NO.313)
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
E711-19/HLA-A*02:01特异性TCR–P2A(具有弗林蛋白酶切割位点和接头)DNA(SEQID NO.314)
agagccaagagatctggcagcggcgccacaaactttagcctgctgaaacaggccggcgacgtggaagagaaccctggacctE711-19/HLA-A*02:01特异性TCR–P2A(具有弗林蛋白酶切割位点和接头)AA(SEQ ID NO.315)
RAKRSGSGATNFSLLKQAGDVEENPGP
E711-19/HLA-A*02:01特异性TCR–TCR alpha链可变区DNA(SEQ ID NO.316)
atgaagtccctgcgggtgctgctggttattctgtggctgcagctgagctgggtttggagccagggacagaacatcgaccagcctaccgagatgacagccaccgaaggcgccatcgtgcagatcaattgcacctaccagaccagcggcttcaacggcctgttctggtatcaacagcatgccggcgaggcccctaccttcctgagctataatgtgctggacggcctggaagaaaagggcagattcagcagcttcctgtccagaagcaagggctacagctacctgctgctgaaagaactccagatgaaggacagcgcctcctacctgtgtgcctccgtggatggaaacaacagactggccttcggcaagggcaaccaggtggtggtcatcccc
E711-19/HLA-A*02:01特异性TCR–TCR alpha链可变区AA(SEQ ID NO.317)
MKSLRVLLVILWLQLSWVWSQGQNIDQPTEMTATEGAIVQINCTYQTSGFNGLFWYQQHAGEAPTFLSYNVLDGLEEKGRFSSFLSRSKGYSYLLLKELQMKDSASYLCASVDGNNRLAFGKGNQVVVIP
E711-19/HLA-A*02:01特异性TCR–TCR alpha链恒定区DNA(SEQ ID NO.318)
gacattcagaaccccgatccagccgtgtaccagctgagagacagcaagagcagcgacaagagcgtgtgtctgttcaccgacttcgactcccagaccaatgtgtcccagagcaaggactccgacgtgtacatcaccgataagaccgtgctggacatgcggagcatggacttcaagagcaatagcgccgtggcttggagcaacaagagcgactttgcctgcgccaacgccttcaacaacagcatcatccccgaggacacattcttcccaagtcctgagagcagctgcgacgtgaagctggtggaaaagagcttcgagacagacaccaacctgaacttccagaacctgagcgtgatcggcttcagaatcctgctgctgaaggtggccggcttcaacctgctgatgactctgagactgtggtccagctgaattcggatccaagcttaggcctgctcgctttcttgctgtcccatttctattaaaggttcctttgttc
E711-19/HLA-A*02:01特异性TCR–TCR alpha链恒定区AA(SEQ ID NO.319)
DIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
E711-19/HLA-A*02:01特异性TCR–alpha CDR1(SEQ ID NO.320)
TSGFNG
E711-19/HLA-A*02:01特异性TCR–alpha CDR2(SEQ ID NO.321)
NVLDGL
E711-19/HLA-A*02:01特异性TCR–alpha CDR3(SEQ ID NO.322)
ASVDGNNRLA
E711-19/HLA-A*02:01特异性TCR–beta CDR1(SEQ ID NO.323)
SGHDT
E711-19/HLA-A*02:01特异性TCR–beta CDR2(SEQ ID NO.324)
YYEEEE
E711-19/HLA-A*02:01特异性TCR–beta CDR3(SEQ ID NO.325)
ASSLGWRGGRYNEQF
本发明提供了
1.一种进行患者特异性免疫疗法规程的方法,所述方法包括:
通过计算装置接收创建用于患者的经转染的T细胞的细胞订购请求;
通过所述计算装置生成与所述细胞订购请求相关的患者特异性标识符,所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号;
通过所述计算装置启动创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:
对所述患者的血液样品进行白细胞单采术规程以从所述样品中收集T细胞,
将收集的T细胞转移到容器;
用所述患者特异性标识符标记所述容器,
将所述收集的T细胞传输到制造设施,
使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞,
从所述制造设施接收所述经转染的T细胞,以及
将所述经转染的T细胞输注到所述患者的血流中,
其中所述计算装置为所述过程中的每个步骤记录跟踪事件,每个跟踪事件包括所述患者特异性标识符,以及
其中所述跟踪事件包括在所述过程期间所述患者的T细胞的监管链。
2.项1的方法,其中通过用编码嵌合抗原受体(CAR)的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞,所述CAR包含特异性结合靶分子的抗原结合分子。
3.项2的方法,其中所述抗原结合分子是单链可变片段。
4.项2的方法,其中所述靶分子是血源性癌症相关抗原。
5.项2的方法,其中所述靶分子是病毒感染相关抗原。
6.项2的方法,其中所述嵌合抗原受体(CAR)进一步包含至少一个共刺激域。
7.项2的方法,其中所述嵌合抗原受体(CAR)进一步包含至少一个活化域。
8.项2的方法,其中所述多核苷酸是载体的组分。
9.项1的方法,其中通过用编码T细胞受体(TCR)的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞。
10.项9的方法,其中所述TCR结合肿瘤相关抗原。
11.项9的方法,其中所述TCR结合病毒感染相关抗原。
12.项9的方法,其中所述多核苷酸是载体的组分。
13.项1的方法,其中启动创建经转染的T细胞的过程进一步包括:
通过所述计算装置接收在创建后已经从第一地点运输所述经转染的T细胞的记号;以及
接收在输注前已经在第二地点接收所述经转染的T细胞的记号,
其中所述计算装置在接收已经运输所述经转染的T细胞的记号时记录跟踪事件,以及
其中所述计算装置在接收已经在第二地点接收所述经转染的T细胞的记号时记录跟踪事件。
14.项1的方法,其中所述患者身份要素包括与所述免疫疗法规程相关的第一患者ID和与实施以下一项或多项的设施相关的第二患者ID:白细胞单采术规程或所述经转染的T细胞的输注。
15.项1的方法,其中所述计算装置以有序顺序存储所述跟踪事件。
16.一种在免疫疗法规程期间跟踪细胞订购的方法,所述方法包括:
通过计算装置接收创建用于患者的经转染的T细胞的细胞订购请求;
通过所述计算装置生成与所述细胞订购请求相关的患者特异性标识符,所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号;
通过所述计算装置监视创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:
接收已经对所述患者的血液样品进行白细胞单采术规程以从所述样品收集T细胞的记号,
接收已经将收集的T细胞转移到容器的记号,
接收所述容器已经用所述患者特异性标识符标记的记号,
接收已经将所述收集的T细胞传输到制造设施的记号,
接收已经使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞的记号,
接收已经从所述制造设施接收所述经转染的T细胞的记号,以及
接收已经将所述经转染的T细胞输注到所述患者的血流中的记号,
当记号被接收时通过所述计算装置记录跟踪事件,每个跟踪事件包括所述患者特异性标识符,以及
通过存储所述过程期间的所述跟踪事件,通过所述计算装置维护所述患者的T细胞的监管链。
17.项16的方法,其中通过用编码嵌合抗原受体(CAR)的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞,所述CAR包含特异性结合靶分子的抗原结合分子。
18.项17的方法,其中所述抗原结合分子是单链可变片段。
19.项17的方法,其中所述靶分子是血源性癌症相关抗原。
20.项17的方法,其中所述靶分子是病毒感染相关抗原。
21.项17的方法,其中所述嵌合抗原受体(CAR)进一步包含至少一个共刺激域。
22.项17的方法,其中所述嵌合抗原受体(CAR)进一步包含至少一个活化域。
23.项17的方法,其中所述多核苷酸是载体的组分。
24.项16的方法,其中通过用编码T细胞受体(TCR)的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞。
25.项24的方法,其中所述TCR结合肿瘤相关抗原。
26.项24的方法,其中所述TCR结合病毒感染相关抗原。
27.项24的方法,其中所述多核苷酸是载体的组分。
28.项16的方法,其中启动创建经转染的T细胞的过程进一步包括:
通过所述计算装置接收在创建后已经从第一地点运输所述经转染的T细胞的记号;以及
接收在输注前已经在第二地点接收所述经转染的T细胞的记号,
其中所述计算装置在接收已经运输所述经转染的T细胞的记号时记录跟踪事件,以及
其中所述计算装置在接收已经在第二地点接收所述经转染的T细胞的记号时记录跟踪事件。
29.项16的方法,其中所述患者身份要素包括与所述免疫疗法规程相关的第一患者ID和与实施以下一项或多项的设施相关的第二患者ID:白细胞单采术规程或所述经转染的T细胞的输注。
30.项16的方法,其中所述计算装置以有序顺序存储所述跟踪事件。
31.一种进行患者特异性免疫疗法规程的方法,该方法包括:
接收创建用于患者的经转染的T细胞的细胞订购请求;
通过在处理器上执行的事件跟踪模块生成与所述细胞订购请求相关的患者特异性标识符;
启动创建用于输注到所述患者的血流中的经转染的T细胞的过程,该过程包括:
对所述患者的血液样品进行白细胞单采术规程以从所述样品中收集T细胞,
将收集的T细胞转移到容器;
用所述患者特异性标识符标记所述容器,
将所述收集的T细胞传输到制造设施,
使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞,
从所述制造设施接收所述经转染的T细胞,以及
将所述经转染的T细胞输注到所述患者的血流中,
在所述事件跟踪模块处,从位于所述白细胞单采术规程点处的第一客户端装置接收第一跟踪事件,其确认所述白细胞单采术规程并含有所述患者特异性标识符;
通过所述事件跟踪模块,将所述第一跟踪事件集成在与所述患者特异性标识符有关的数据结构中,其中在数据库中存储所述数据结构,并且集成步骤记录具有所述第一跟踪事件的第一时间戳;
在所述事件跟踪模块处,从位于所述制造设施处的第二客户端装置接收第二跟踪事件,其确认在所述制造设施处收到所述收集的T细胞并含有所述患者特异性标识符;以及
通过所述事件跟踪模块,将所述第二跟踪事件集成在与所述患者特异性标识符有关的所述数据结构中,其中集成步骤记录具有所述第二跟踪事件的第二时间戳。
32.一种进行患者特异性免疫疗法规程的方法,该方法包括:
通过在处理器上执行的跟踪模块,接收创建用于患者的经转染的T细胞的细胞订购请求;
通过所述跟踪模块生成与所述细胞订购请求相关的患者特异性标识符和细胞订购批次,所述患者特异性标识符识别患者。
在数据库中生成用于跟踪所述细胞订购的数据记录,所述数据记录根据所述患者特异性标识符在所述数据库中识别;
通过所述跟踪模块接收第一跟踪事件,所述第一跟踪事件指示收集的T细胞已准备好运输到制造设施;
根据所述第一跟踪事件,更新与所述患者特异性标识符对应的数据记录;
基于容器已经由所述制造设施接收,通过所述跟踪模块接收第二跟踪事件,所述第二跟踪事件指示所述收集的T细胞已经由制造设施接收;
根据所述第二跟踪事件,更新与所述患者特异性标识符对应的数据记录;
基于所述制造设施已经使用细胞修饰技术从所述收集的T细胞创建经转染的T细胞,通过所述跟踪模块接收第三跟踪事件,所述第三跟踪事件指示已经创建所述经转染的T细胞。
根据所述第三跟踪事件更新与所述患者特异性标识符对应的数据记录;
基于所述经转染的T细胞已经从所述制造设施接收,通过所述跟踪模块接收第四跟踪事件,所述第四跟踪事件指示已经接收所述经转染的T细胞;
根据所述第四跟踪事件,更新与所述患者特异性标识符对应的数据记录;
基于所述经转染的T细胞已经输注到所述患者的血流中,通过所述跟踪模块接收第五跟踪事件,所述第五跟踪事件指示已经将经转染的T细胞输注到所述患者的血流中;以及
根据所述第五跟踪事件,更新与所述患者特异性标识符对应的数据记录;
其中,所述第一、第二、第三、第四和第五跟踪事件中的每个含有所述患者特异性标识符、时间戳和事件标识符,以及
其中当根据相应事件更新所述数据记录时,与所述患者特异性标识符对应的数据记录以有序顺序存储所述第一、第二、第三、第四和第五跟踪事件。
序列表
<110> 凯德药业股份有限公司
<120> 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
<130> KPI-011WO
<140> PCT/US2018/051298
<141> 2018-09-17
<150> 62/566,912
<151> 2017-10-02
<150> 62/559,330
<151> 2017-09-15
<160> 326
<170> PatentIn version 3.5
<210> 1
<211> 294
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 1
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggtcgtagt gggtggagtc 120
ctcgcttgtt actctctgct cgtcaccgtg gcttttataa tcttctgggt tagatccaaa 180
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 240
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagc 294
<210> 2
<211> 98
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 2
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
20 25 30
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
35 40 45
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
50 55 60
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
65 70 75 80
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
85 90 95
Arg Ser
<210> 3
<211> 90
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 3
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca 90
<210> 4
<211> 30
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 4
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro
20 25 30
<210> 5
<211> 81
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 5
ttctgggtgt tggtcgtagt gggtggagtc ctcgcttgtt actctctgct cgtcaccgtg 60
gcttttataa tcttctgggt t 81
<210> 6
<211> 27
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 6
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25
<210> 7
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 7
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120
agc 123
<210> 8
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 8
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 9
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 9
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 60
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 120
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 180
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 240
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 300
tatgacgctc tccacatgca agccctgcca cctagg 336
<210> 10
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 10
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 11
<211> 117
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 11
attgaggtga tgtatccacc gccttacctg gataacgaaa agagtaacgg taccatcatt 60
cacgtgaaag gtaaacacct gtgtccttct cccctcttcc ccgggccatc aaagccc 117
<210> 12
<211> 39
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 12
Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn
1 5 10 15
Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
20 25 30
Phe Pro Gly Pro Ser Lys Pro
35
<210> 13
<211> 288
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 13
gctgcagcat tgagcaactc aataatgtat tttagtcact ttgtaccagt gttcttgccg 60
gctaagccta ctaccacacc cgctccacgg ccacctaccc cagctcctac catcgcttca 120
cagcctctgt ccctgcgccc agaggcttgc cgaccggccg cagggggcgc tgttcatacc 180
agaggactgg atttcgcctg cgatatctat atctgggcac ccctggccgg aacctgcggc 240
gtactcctgc tgtccctggt catcacgctc tattgtaatc acaggaac 288
<210> 14
<211> 96
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 14
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
1 5 10 15
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
20 25 30
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
35 40 45
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
50 55 60
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
65 70 75 80
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
85 90 95
<210> 15
<211> 366
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 15
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggtcatggat aaggcagccc 120
cccgggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac 180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg 240
aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctggtctat 300
tgcggtgggg attgttacag tggctttgac tattgggggc agggtactct ggttacagtt 360
tcttcc 366
<210> 16
<211> 122
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 16
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 17
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 17
Gly Gly Ser Ile Ser Ser Tyr
1 5
<210> 18
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 18
Tyr Tyr Ser Gly Ser
1 5
<210> 19
<211> 14
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 19
Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10
<210> 20
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 20
gacatccagt tgacacagag cccgagttcc ttgtccgcct ccgtcgggga tagagtgtca 60
tttacctgtc aggcctctca ggatattaat aactttctga attggtatca gcaaaagccc 120
ggaaaggcac ccaagctgtt gatttacgac gccagtaacc tggagacagg cgtgccctcc 180
cggtttagtg gtagcggaag cggtacggat tttaccttta ctatcagctc tctccaaccc 240
gaagacattg caacctacta ttgtcaacaa tatggaaacc tgccttttac atttggcggc 300
ggcaccaagg tggagattaa gcgg 324
<210> 21
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 21
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 22
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 22
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10
<210> 23
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 23
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 24
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 24
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5
<210> 25
<211> 1440
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 25
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc aactgcaaga aagcggaccc ggactggtga agccttctga gacacttagt 120
ctgacgtgca cggtcagtgg cggctccatc tcctcctatt attggtcatg gatacgacaa 180
cccccaggta agggcctgga atggattggc tatatctact attcaggaag cacgaactac 240
aatcccagcc tgaagtcccg agtgacaatt tcagtagata ccagtaaaaa ccagttcagt 300
cttaaactgt caagcgtgac agctgccgac accgctgtgt attactgcgt ctcactggtg 360
tattgtggag gggattgtta tagcgggttc gattattggg gacagggaac cctggtgact 420
gtatcttccg gcggcggcgg ctcagggggt ggcggtagtg gcggtggggg ttccgatatt 480
caactgacac aatcccccag ctcactcagc gccagcgtgg gggacagggt tagctttacc 540
tgtcaagcct ctcaggatat aaataacttt ctgaactggt atcaacagaa gcctgggaag 600
gcgcccaaac tcctgatcta tgatgcgtcc aacctggaaa ctggcgtgcc ttcacgcttt 660
agcggctctg gcagtggtac agacttcact tttaccatct cttcacttca gccggaggac 720
atcgccacat attactgtca acagtacgga aacttgccct ttacttttgg aggcggcacc 780
aaagttgaaa tcaaaagggc cgctgccctg gataacgaaa agagcaatgg gactataata 840
catgttaaag gaaaacacct gtgtccatct cccctgttcc ctggaccgtc aaagccattt 900
tgggtgctcg tggttgtcgg tggcgttctc gcctgttata gcttgctggt gacagtagcc 960
ttcattatct tttgggtgag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 26
<211> 479
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 26
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 27
<211> 1374
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 27
caggtccaac tgcaagaaag cggacccgga ctggtgaagc cttctgagac acttagtctg 60
acgtgcacgg tcagtggcgg ctccatctcc tcctattatt ggtcatggat acgacaaccc 120
ccaggtaagg gcctggaatg gattggctat atctactatt caggaagcac gaactacaat 180
cccagcctga agtcccgagt gacaatttca gtagatacca gtaaaaacca gttcagtctt 240
aaactgtcaa gcgtgacagc tgccgacacc gctgtgtatt actgcgtctc actggtgtat 300
tgtggagggg attgttatag cgggttcgat tattggggac agggaaccct ggtgactgta 360
tcttccggcg gcggcggctc agggggtggc ggtagtggcg gtgggggttc cgatattcaa 420
ctgacacaat cccccagctc actcagcgcc agcgtggggg acagggttag ctttacctgt 480
caagcctctc aggatataaa taactttctg aactggtatc aacagaagcc tgggaaggcg 540
cccaaactcc tgatctatga tgcgtccaac ctggaaactg gcgtgccttc acgctttagc 600
ggctctggca gtggtacaga cttcactttt accatctctt cacttcagcc ggaggacatc 660
gccacatatt actgtcaaca gtacggaaac ttgcccttta cttttggagg cggcaccaaa 720
gttgaaatca aaagggccgc tgccctggat aacgaaaaga gcaatgggac tataatacat 780
gttaaaggaa aacacctgtg tccatctccc ctgttccctg gaccgtcaaa gccattttgg 840
gtgctcgtgg ttgtcggtgg cgttctcgcc tgttatagct tgctggtgac agtagccttc 900
attatctttt gggtgagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1080
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg 1374
<210> 28
<211> 458
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 28
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445
Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 29
<211> 1467
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 29
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctgcagga atccggaccg gggctggtga agcccagcga gactctgagt 120
ctcacgtgta cagtttctgg aggtagcatt agctcctact attggtcatg gataaggcag 180
ccccccggga agggattgga atggatcggc tatatttact acagtgggag caccaattac 240
aacccctcac tgaagtctag agttacaatc agcgttgaca cctcaaagaa tcagttcagt 300
ttgaaattgt ctagcgtcac agcagctgat acagccgtct attattgtgt ttctctggtc 360
tattgcggtg gggattgtta cagtggcttt gactattggg ggcagggtac tctggttaca 420
gtttcttccg gggggggagg ctctgggggc ggaggctcag gtggtggagg cagcgacatc 480
cagttgacac agagcccgag ttccttgtcc gcctccgtcg gggatagagt gtcatttacc 540
tgtcaggcct ctcaggatat taataacttt ctgaattggt atcagcaaaa gcccggaaag 600
gcacccaagc tgttgattta cgacgccagt aacctggaga caggcgtgcc ctcccggttt 660
agtggtagcg gaagcggtac ggattttacc tttactatca gctctctcca acccgaagac 720
attgcaacct actattgtca acaatatgga aacctgcctt ttacatttgg cggcggcacc 780
aaggtggaga ttaagcgggc ggcagctatt gaggtgatgt atccaccgcc ttacctggat 840
aacgaaaaga gtaacggtac catcattcac gtgaaaggta aacacctgtg tccttctccc 900
ctcttccccg ggccatcaaa gcccttctgg gttcttgtgg tcgtgggagg cgtgcttgct 960
tgttattctc tgctcgttac cgtggcgttt atcatttttt gggttagatc caaaagaagc 1020
cgcctgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa 1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcggagcag ggtgaagttt 1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1200
aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag 1320
gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1380
gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1440
cacatgcaag ccctgccacc taggtaa 1467
<210> 30
<211> 488
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 30
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val
260 265 270
Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
275 280 285
Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
290 295 300
Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
305 310 315 320
Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
325 330 335
Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
340 345 350
Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365
Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380
Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400
Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415
Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445
Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460
Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480
His Met Gln Ala Leu Pro Pro Arg
485
<210> 31
<211> 1401
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 31
caggtgcagc tgcaggaatc cggaccgggg ctggtgaagc ccagcgagac tctgagtctc 60
acgtgtacag tttctggagg tagcattagc tcctactatt ggtcatggat aaggcagccc 120
cccgggaagg gattggaatg gatcggctat atttactaca gtgggagcac caattacaac 180
ccctcactga agtctagagt tacaatcagc gttgacacct caaagaatca gttcagtttg 240
aaattgtcta gcgtcacagc agctgataca gccgtctatt attgtgtttc tctggtctat 300
tgcggtgggg attgttacag tggctttgac tattgggggc agggtactct ggttacagtt 360
tcttccgggg ggggaggctc tgggggcgga ggctcaggtg gtggaggcag cgacatccag 420
ttgacacaga gcccgagttc cttgtccgcc tccgtcgggg atagagtgtc atttacctgt 480
caggcctctc aggatattaa taactttctg aattggtatc agcaaaagcc cggaaaggca 540
cccaagctgt tgatttacga cgccagtaac ctggagacag gcgtgccctc ccggtttagt 600
ggtagcggaa gcggtacgga ttttaccttt actatcagct ctctccaacc cgaagacatt 660
gcaacctact attgtcaaca atatggaaac ctgcctttta catttggcgg cggcaccaag 720
gtggagatta agcgggcggc agctattgag gtgatgtatc caccgcctta cctggataac 780
gaaaagagta acggtaccat cattcacgtg aaaggtaaac acctgtgtcc ttctcccctc 840
ttccccgggc catcaaagcc cttctgggtt cttgtggtcg tgggaggcgt gcttgcttgt 900
tattctctgc tcgttaccgt ggcgtttatc attttttggg ttagatccaa aagaagccgc 960
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1200
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1380
atgcaagccc tgccacctag g 1401
<210> 32
<211> 467
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 32
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460
Pro Pro Arg
465
<210> 33
<211> 1548
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 33
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc aattgcaaga gtccggcccc ggactcgtta aacccagtga gacgcttagc 120
ctgacctgta ccgtctcagg gggcagcatc tcctcttatt actggagctg gatcaggcag 180
cctccaggaa aaggccttga atggattggg tacatctact actctggctc aacaaattat 240
aatccatccc tgaagtcccg cgtgactatc tctgtggaca ccagcaagaa tcagttttca 300
ctgaagttgt ctagtgttac cgcggccgac accgccgtat actactgtgt gtctcttgtg 360
tactgtggcg gcgactgcta ttccgggttc gactactggg gccaagggac tctggtaacc 420
gtgtcctcag gcggcggcgg gtcaggagga ggcggcagtg gaggtggcgg ctccgacatc 480
cagctgacac aatcaccatc ttccctttca gcttcagtcg gggacagagt gtccttcaca 540
tgccaggcca gccaggatat caataacttc ctgaactggt accaacagaa acccggaaag 600
gctccaaagc tcctgatcta tgatgcttcc aacctggaga ccggcgtgcc ctccaggttc 660
agtggttcag gatcaggcac tgactttacg ttcaccatat ccagtcttca gcccgaagac 720
attgcaacct attactgcca acaatacggg aaccttccct ttacattcgg aggcggcacc 780
aaggtggaaa tcaaaagggc tgcagcattg agcaactcaa taatgtattt tagtcacttt 840
gtaccagtgt tcttgccggc taagcctact accacacccg ctccacggcc acctacccca 900
gctcctacca tcgcttcaca gcctctgtcc ctgcgcccag aggcttgccg accggccgca 960
gggggcgctg ttcataccag aggactggat ttcgcctgcg atatctatat ctgggcaccc 1020
ctggccggaa cctgcggcgt actcctgctg tccctggtca tcacgctcta ttgtaatcac 1080
aggaacagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1140
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1200
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1260
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1548
<210> 34
<211> 515
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 34
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn
260 265 270
Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285
Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350
Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510
Pro Pro Arg
515
<210> 35
<211> 1482
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 35
caggtgcaat tgcaagagtc cggccccgga ctcgttaaac ccagtgagac gcttagcctg 60
acctgtaccg tctcaggggg cagcatctcc tcttattact ggagctggat caggcagcct 120
ccaggaaaag gccttgaatg gattgggtac atctactact ctggctcaac aaattataat 180
ccatccctga agtcccgcgt gactatctct gtggacacca gcaagaatca gttttcactg 240
aagttgtcta gtgttaccgc ggccgacacc gccgtatact actgtgtgtc tcttgtgtac 300
tgtggcggcg actgctattc cgggttcgac tactggggcc aagggactct ggtaaccgtg 360
tcctcaggcg gcggcgggtc aggaggaggc ggcagtggag gtggcggctc cgacatccag 420
ctgacacaat caccatcttc cctttcagct tcagtcgggg acagagtgtc cttcacatgc 480
caggccagcc aggatatcaa taacttcctg aactggtacc aacagaaacc cggaaaggct 540
ccaaagctcc tgatctatga tgcttccaac ctggagaccg gcgtgccctc caggttcagt 600
ggttcaggat caggcactga ctttacgttc accatatcca gtcttcagcc cgaagacatt 660
gcaacctatt actgccaaca atacgggaac cttcccttta cattcggagg cggcaccaag 720
gtggaaatca aaagggctgc agcattgagc aactcaataa tgtattttag tcactttgta 780
ccagtgttct tgccggctaa gcctactacc acacccgctc cacggccacc taccccagct 840
cctaccatcg cttcacagcc tctgtccctg cgcccagagg cttgccgacc ggccgcaggg 900
ggcgctgttc ataccagagg actggatttc gcctgcgata tctatatctg ggcacccctg 960
gccggaacct gcggcgtact cctgctgtcc ctggtcatca cgctctattg taatcacagg 1020
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1080
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1140
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1200
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1260
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1320
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1380
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1440
gatacttatg acgctctcca catgcaagcc ctgccaccta gg 1482
<210> 36
<211> 494
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 36
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser
130 135 140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys
145 150 155 160
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys
165 170 175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu
180 185 190
Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
195 200 205
Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr
210 215 220
Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys
225 230 235 240
Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
245 250 255
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
260 265 270
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
275 280 285
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
290 295 300
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
305 310 315 320
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
325 330 335
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
340 345 350
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
355 360 365
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
370 375 380
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
385 390 395 400
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
405 410 415
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
420 425 430
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
435 440 445
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
450 455 460
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
465 470 475 480
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 37
<211> 1440
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 37
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatatcc agctcacgca atccccctca agcttgagtg cctccgtggg cgaccgggtg 120
tccttcacat gtcaggcaag ccaagacata aataatttcc tgaattggta ccaacaaaaa 180
cccggcaagg ctcccaaact cctgatttat gatgcctcca atctggagac cggggtccct 240
tctagattca gcggaagtgg cagcggcaca gactttacat ttactatctc ttctctgcaa 300
ccagaggaca tcgccacata ctattgccag caatacggca atctgccctt caccttcgga 360
ggcggaacca aggtagaaat taaaaggggc ggtggaggct ccggaggggg gggctctggc 420
ggagggggct cccaagtaca attgcaggag tcagggcctg gactcgtgaa gccttcagaa 480
actttgtcac tgacatgtac agtgtccggc ggaagcattt ccagttacta ttggtcctgg 540
attagacagc cacccggcaa aggactggaa tggattggat atatctacta ctctggatct 600
acaaactata atcccagcct caaatccagg gtcactatta gtgtggatac atcaaagaat 660
cagttctcct tgaagctgag ctcagtcact gctgccgaca ccgcagtgta ctattgtgtg 720
agcctggtct actgcggcgg agattgctac agcggtttcg attactgggg ccagggcacc 780
ctggttaccg ttagttccgc ggctgctctt gataacgaga agtccaacgg tacgattatc 840
cacgttaagg gtaagcacct ttgccctagc ccgctgttcc caggccccag taagcccttt 900
tgggtcctcg ttgtggtagg tggggtactc gcctgctact ccctgctcgt cactgtcgca 960
ttcatcatct tctgggtcag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctaggtaa 1440
<210> 38
<211> 470
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 38
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala
465 470
<210> 39
<211> 1374
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 39
gatatccagc tcacgcaatc cccctcaagc ttgagtgcct ccgtgggcga ccgggtgtcc 60
ttcacatgtc aggcaagcca agacataaat aatttcctga attggtacca acaaaaaccc 120
ggcaaggctc ccaaactcct gatttatgat gcctccaatc tggagaccgg ggtcccttct 180
agattcagcg gaagtggcag cggcacagac tttacattta ctatctcttc tctgcaacca 240
gaggacatcg ccacatacta ttgccagcaa tacggcaatc tgcccttcac cttcggaggc 300
ggaaccaagg tagaaattaa aaggggcggt ggaggctccg gagggggggg ctctggcgga 360
gggggctccc aagtacaatt gcaggagtca gggcctggac tcgtgaagcc ttcagaaact 420
ttgtcactga catgtacagt gtccggcgga agcatttcca gttactattg gtcctggatt 480
agacagccac ccggcaaagg actggaatgg attggatata tctactactc tggatctaca 540
aactataatc ccagcctcaa atccagggtc actattagtg tggatacatc aaagaatcag 600
ttctccttga agctgagctc agtcactgct gccgacaccg cagtgtacta ttgtgtgagc 660
ctggtctact gcggcggaga ttgctacagc ggtttcgatt actggggcca gggcaccctg 720
gttaccgtta gttccgcggc tgctcttgat aacgagaagt ccaacggtac gattatccac 780
gttaagggta agcacctttg ccctagcccg ctgttcccag gccccagtaa gcccttttgg 840
gtcctcgttg tggtaggtgg ggtactcgcc tgctactccc tgctcgtcac tgtcgcattc 900
atcatcttct gggtcagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 960
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1020
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1080
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1140
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1200
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1260
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1320
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc tagg 1374
<210> 40
<211> 458
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 40
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220
Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240
Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
245 250 255
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
260 265 270
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
275 280 285
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
290 295 300
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
305 310 315 320
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
325 330 335
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
340 345 350
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
355 360 365
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
370 375 380
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
385 390 395 400
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
405 410 415
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
420 425 430
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
435 440 445
Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 41
<211> 1467
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 41
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatatcc agctgaccca gtctccatcc tctttgagtg cctccgtggg tgaccgcgtc 120
tctttcactt gccaagccag ccaagacatc aacaactttc tgaattggta ccagcagaaa 180
ccaggcaaag caccaaagct cctcatctac gacgcctcca acctggaaac cggggtgccc 240
agcaggttta gcgggagcgg ttctggcacg gattttacgt tcaccatctc ctctctgcag 300
cccgaggata tagctactta ttactgtcag cagtacggga atctgccatt tacttttggg 360
ggtggaacta aggtggaaat caaaaggggc ggcgggggaa gcgggggcgg gggctcaggt 420
ggcggaggga gccaggtgca actccaggaa agtggcccag gattggtgaa gcccagcgag 480
accctttccc ttacttgtac tgttagcgga ggcagcataa gcagctacta ttggtcctgg 540
atcagacagc caccagggaa agggcttgaa tggattggct acatttacta ttccgggtcc 600
accaactaca acccatccct caagtcccgc gtgacaattt ccgtcgacac aagcaagaac 660
cagttctccc tgaaacttag tagcgtcact gctgcagata cagcagtgta ctattgtgtc 720
agccttgtct actgtggcgg cgactgctac agtggctttg attactgggg acagggcacg 780
ctcgtgacag tgtccagcgc tgcggctatc gaggtaatgt atccgccacc gtatctggac 840
aacgagaagt ctaatgggac aatcattcac gtgaagggga agcacctgtg tccatccccc 900
ctgtttccgg gtcccagtaa acccttctgg gtgcttgttg tcgttggcgg ggtgctggcc 960
tgctattccc tgctggtgac cgtcgcgttt attattttct gggttagatc caaaagaagc 1020
cgcctgctcc atagcgatta catgaatatg actccacgcc gccctggccc cacaaggaaa 1080
cactaccagc cttacgcacc acctagagat ttcgctgcct atcggagcag ggtgaagttt 1140
tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1200
aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1260
atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag 1320
gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1380
gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1440
cacatgcaag ccctgccacc taggtaa 1467
<210> 42
<211> 488
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 42
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val
260 265 270
Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
275 280 285
Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
290 295 300
Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala
305 310 315 320
Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg
325 330 335
Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro
340 345 350
Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro
355 360 365
Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala
370 375 380
Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
385 390 395 400
Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
405 410 415
Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
420 425 430
Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
435 440 445
Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
450 455 460
Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
465 470 475 480
His Met Gln Ala Leu Pro Pro Arg
485
<210> 43
<211> 1401
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 43
gatatccagc tgacccagtc tccatcctct ttgagtgcct ccgtgggtga ccgcgtctct 60
ttcacttgcc aagccagcca agacatcaac aactttctga attggtacca gcagaaacca 120
ggcaaagcac caaagctcct catctacgac gcctccaacc tggaaaccgg ggtgcccagc 180
aggtttagcg ggagcggttc tggcacggat tttacgttca ccatctcctc tctgcagccc 240
gaggatatag ctacttatta ctgtcagcag tacgggaatc tgccatttac ttttgggggt 300
ggaactaagg tggaaatcaa aaggggcggc gggggaagcg ggggcggggg ctcaggtggc 360
ggagggagcc aggtgcaact ccaggaaagt ggcccaggat tggtgaagcc cagcgagacc 420
ctttccctta cttgtactgt tagcggaggc agcataagca gctactattg gtcctggatc 480
agacagccac cagggaaagg gcttgaatgg attggctaca tttactattc cgggtccacc 540
aactacaacc catccctcaa gtcccgcgtg acaatttccg tcgacacaag caagaaccag 600
ttctccctga aacttagtag cgtcactgct gcagatacag cagtgtacta ttgtgtcagc 660
cttgtctact gtggcggcga ctgctacagt ggctttgatt actggggaca gggcacgctc 720
gtgacagtgt ccagcgctgc ggctatcgag gtaatgtatc cgccaccgta tctggacaac 780
gagaagtcta atgggacaat cattcacgtg aaggggaagc acctgtgtcc atcccccctg 840
tttccgggtc ccagtaaacc cttctgggtg cttgttgtcg ttggcggggt gctggcctgc 900
tattccctgc tggtgaccgt cgcgtttatt attttctggg ttagatccaa aagaagccgc 960
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1020
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1080
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1140
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1200
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1260
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1320
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1380
atgcaagccc tgccacctag g 1401
<210> 44
<211> 467
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 44
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys
210 215 220
Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu
225 230 235 240
Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
245 250 255
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
260 265 270
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
275 280 285
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
290 295 300
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
305 310 315 320
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
325 330 335
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
340 345 350
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460
Pro Pro Arg
465
<210> 45
<211> 1548
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 45
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggacattc aattgaccca gtcccctagc agtctctcag caagtgtggg agatagggtg 120
tcattcacct gtcaggcttc acaggacatc aacaacttcc tcaattggta tcagcagaag 180
ccagggaagg caccaaagct gctcatatat gacgcttcaa accttgaaac cggagtacct 240
agccgcttca gcggaagcgg atcagggact gacttcactt ttaccatctc ttcactgcag 300
cccgaagaca tcgccacata ctactgccag cagtacggaa acttgccttt tacatttggg 360
ggcggcacca aagtggagat taagcgaggg ggaggcggct caggaggcgg tggctccgga 420
ggcgggggtt cccaggtcca gctccaggaa tccggcccag gtctggttaa gcccagtgaa 480
actttgtccc tcacgtgtac tgtgagcggt ggttcaatct cctcatacta ttggtcttgg 540
atacggcaac ctcctggaaa gggcctcgag tggatcggct atatctacta tagtggctcc 600
actaattaca acccttccct caagtccaga gtcaccattt ccgtggacac atctaagaac 660
cagttcagtc tgaagttgtc cagcgttaca gccgcagaca cagccgttta ttactgtgtg 720
tctcttgttt actgcggggg agactgttat agcggcttcg attactgggg ccagggcacc 780
ttggtcacag tctcttccgc ggccgccctc tctaacagta ttatgtactt ttctcatttt 840
gtacccgtgt tccttcccgc taagccaact actaccccgg ccccacggcc gcctacccct 900
gcacccacaa tagccagtca gcctttgagc ctgagacctg aggcttgtcg gccggctgct 960
gggggtgcag tgcacacacg aggtcttgat tttgcttgcg acatatacat ctgggcccct 1020
ctggccggga cctgtggggt gctgcttctg agcttggtca tcacgctcta ttgcaaccat 1080
cgcaacagat ccaaaagaag ccgcctgctc catagcgatt acatgaatat gactccacgc 1140
cgccctggcc ccacaaggaa acactaccag ccttacgcac cacctagaga tttcgctgcc 1200
tatcggagca gggtgaagtt ttccagatct gcagatgcac cagcgtatca gcagggccag 1260
aaccaactgt ataacgagct caacctggga cgcagggaag agtatgacgt tttggacaag 1320
cgcagaggac gggaccctga gatgggtggc aaaccaagac gaaaaaaccc ccaggagggt 1380
ctctataatg agctgcagaa ggataagatg gctgaagcct attctgaaat aggcatgaaa 1440
ggagagcgga gaaggggaaa agggcacgac ggtttgtacc agggactcag cactgctacg 1500
aaggatactt atgacgctct ccacatgcaa gccctgccac ctaggtaa 1548
<210> 46
<211> 515
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 46
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln
35 40 45
Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
145 150 155 160
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
165 170 175
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
180 185 190
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
195 200 205
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 215 220
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
225 230 235 240
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn
260 265 270
Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285
Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350
Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510
Pro Pro Arg
515
<210> 47
<211> 1482
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 47
gacattcaat tgacccagtc ccctagcagt ctctcagcaa gtgtgggaga tagggtgtca 60
ttcacctgtc aggcttcaca ggacatcaac aacttcctca attggtatca gcagaagcca 120
gggaaggcac caaagctgct catatatgac gcttcaaacc ttgaaaccgg agtacctagc 180
cgcttcagcg gaagcggatc agggactgac ttcactttta ccatctcttc actgcagccc 240
gaagacatcg ccacatacta ctgccagcag tacggaaact tgccttttac atttgggggc 300
ggcaccaaag tggagattaa gcgaggggga ggcggctcag gaggcggtgg ctccggaggc 360
gggggttccc aggtccagct ccaggaatcc ggcccaggtc tggttaagcc cagtgaaact 420
ttgtccctca cgtgtactgt gagcggtggt tcaatctcct catactattg gtcttggata 480
cggcaacctc ctggaaaggg cctcgagtgg atcggctata tctactatag tggctccact 540
aattacaacc cttccctcaa gtccagagtc accatttccg tggacacatc taagaaccag 600
ttcagtctga agttgtccag cgttacagcc gcagacacag ccgtttatta ctgtgtgtct 660
cttgtttact gcgggggaga ctgttatagc ggcttcgatt actggggcca gggcaccttg 720
gtcacagtct cttccgcggc cgccctctct aacagtatta tgtacttttc tcattttgta 780
cccgtgttcc ttcccgctaa gccaactact accccggccc cacggccgcc tacccctgca 840
cccacaatag ccagtcagcc tttgagcctg agacctgagg cttgtcggcc ggctgctggg 900
ggtgcagtgc acacacgagg tcttgatttt gcttgcgaca tatacatctg ggcccctctg 960
gccgggacct gtggggtgct gcttctgagc ttggtcatca cgctctattg caaccatcgc 1020
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1080
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1140
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1200
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1260
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1320
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1380
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1440
gatacttatg acgctctcca catgcaagcc ctgccaccta gg 1482
<210> 48
<211> 492
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 48
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln
115 120 125
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr
130 135 140
Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile
145 150 155 160
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
165 170 175
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
180 185 190
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
195 200 205
Thr Ala Asp Thr Ala Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly
210 215 220
Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
225 230 235 240
Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser
245 250 255
His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
260 265 270
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
275 280 285
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
290 295 300
Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
305 310 315 320
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
325 330 335
Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350
Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445
Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 49
<211> 372
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 49
caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt 60
acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg 120
cagcacccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac 180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc 240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg 300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta 360
accgtgagct ct 372
<210> 50
<211> 124
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 50
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 51
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 51
Gly Gly Ser Ile Ser Ser Gly Gly Phe
1 5
<210> 52
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 52
His His Ser Gly Ser
1 5
<210> 53
<211> 14
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 53
Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10
<210> 54
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 54
gatatccagc tcactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt 60
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca 120
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt 180
cgattctctg ggtcagggtc cgggaccgac tttacgttta cgatctcctc tctgcagccc 240
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc 300
gggactaagg ttgaaatcaa gagg 324
<210> 55
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 55
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 56
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 56
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10
<210> 57
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 57
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 58
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 58
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5
<210> 59
<211> 1446
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 59
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtac agctgcagga atctgggccc ggacttgtca agccaagtca gacactttct 120
cttacatgta ccgtgagcgg cggaagtata agcagtggag gcttttactg gtcttggata 180
cggcagcacc caggcaaagg cttggagtgg attggataca ttcatcattc aggatctaca 240
cactataatc catcccttaa gtcccgggtc accattagca ttgatacgtc taagaatctg 300
ttcagtctca ggctgtcctc cgtcactgct gccgacacag ccgtgtacta ctgcgcctcc 360
ttggtttact gcggaggcga ctgttatagc ggctttgatt attgggggca ggggaccctc 420
gtaaccgtga gctctggagg gggtgggagc gggggaggag gttcaggggg gggcggctcc 480
gatatccagc tcactcaaag cccctctagt ctctctgcct cagtggggga tcgggtcagt 540
tttacttgtc aagcttcaca ggatatcaac aacttcctta attggtatca gcagaagcca 600
ggaaaagcac ccaagctgct catctatgat gcctcaaatt tggagacggg tgttcccagt 660
cgattctctg ggtcagggtc cgggaccgac tttacgttta cgatctcctc tctgcagccc 720
gaagacatcg ccacatacta ttgtcaacag tacggcaact tgcctttcac atttgggggc 780
gggactaagg ttgaaatcaa gagggccgct gcactggaca atgagaagtc caacggcacc 840
atcatccacg tgaagggcaa gcacctgtgc cctagtcctc tgttcccagg cccatccaaa 900
cctttttggg ttcttgttgt ggtcgggggg gtgctggcct gctattctct gctggtcacg 960
gtggccttca taattttctg ggttagatcc aaaagaagcc gcctgctcca tagcgattac 1020
atgaatatga ctccacgccg ccctggcccc acaaggaaac actaccagcc ttacgcacca 1080
cctagagatt tcgctgccta tcggagcagg gtgaagtttt ccagatctgc agatgcacca 1140
gcgtatcagc agggccagaa ccaactgtat aacgagctca acctgggacg cagggaagag 1200
tatgacgttt tggacaagcg cagaggacgg gaccctgaga tgggtggcaa accaagacga 1260
aaaaaccccc aggagggtct ctataatgag ctgcagaagg ataagatggc tgaagcctat 1320
tctgaaatag gcatgaaagg agagcggaga aggggaaaag ggcacgacgg tttgtaccag 1380
ggactcagca ctgctacgaa ggatacttat gacgctctcc acatgcaagc cctgccacct 1440
aggtaa 1446
<210> 60
<211> 481
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 60
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu
260 265 270
Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His
275 280 285
Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val
290 295 300
Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr
305 310 315 320
Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu
325 330 335
His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg
340 345 350
Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg
355 360 365
Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
370 375 380
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
385 390 395 400
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
405 410 415
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
420 425 430
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
435 440 445
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
450 455 460
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
465 470 475 480
Arg
<210> 61
<211> 1380
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 61
caggtacagc tgcaggaatc tgggcccgga cttgtcaagc caagtcagac actttctctt 60
acatgtaccg tgagcggcgg aagtataagc agtggaggct tttactggtc ttggatacgg 120
cagcacccag gcaaaggctt ggagtggatt ggatacattc atcattcagg atctacacac 180
tataatccat cccttaagtc ccgggtcacc attagcattg atacgtctaa gaatctgttc 240
agtctcaggc tgtcctccgt cactgctgcc gacacagccg tgtactactg cgcctccttg 300
gtttactgcg gaggcgactg ttatagcggc tttgattatt gggggcaggg gaccctcgta 360
accgtgagct ctggaggggg tgggagcggg ggaggaggtt cagggggggg cggctccgat 420
atccagctca ctcaaagccc ctctagtctc tctgcctcag tgggggatcg ggtcagtttt 480
acttgtcaag cttcacagga tatcaacaac ttccttaatt ggtatcagca gaagccagga 540
aaagcaccca agctgctcat ctatgatgcc tcaaatttgg agacgggtgt tcccagtcga 600
ttctctgggt cagggtccgg gaccgacttt acgtttacga tctcctctct gcagcccgaa 660
gacatcgcca catactattg tcaacagtac ggcaacttgc ctttcacatt tgggggcggg 720
actaaggttg aaatcaagag ggccgctgca ctggacaatg agaagtccaa cggcaccatc 780
atccacgtga agggcaagca cctgtgccct agtcctctgt tcccaggccc atccaaacct 840
ttttgggttc ttgttgtggt cgggggggtg ctggcctgct attctctgct ggtcacggtg 900
gccttcataa ttttctgggt tagatccaaa agaagccgcc tgctccatag cgattacatg 960
aatatgactc cacgccgccc tggccccaca aggaaacact accagcctta cgcaccacct 1020
agagatttcg ctgcctatcg gagcagggtg aagttttcca gatctgcaga tgcaccagcg 1080
tatcagcagg gccagaacca actgtataac gagctcaacc tgggacgcag ggaagagtat 1140
gacgttttgg acaagcgcag aggacgggac cctgagatgg gtggcaaacc aagacgaaaa 1200
aacccccagg agggtctcta taatgagctg cagaaggata agatggctga agcctattct 1260
gaaataggca tgaaaggaga gcggagaagg ggaaaagggc acgacggttt gtaccaggga 1320
ctcagcactg ctacgaagga tacttatgac gctctccaca tgcaagccct gccacctagg 1380
<210> 62
<211> 460
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 62
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser
245 250 255
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
260 265 270
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
275 280 285
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
290 295 300
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
305 310 315 320
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
325 330 335
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
340 345 350
Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
355 360 365
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
370 375 380
Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
385 390 395 400
Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
405 410 415
Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
420 425 430
Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
435 440 445
Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 63
<211> 1473
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 63
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctgcagga aagcggtccg ggacttgtca agccgtccca aacgctgagt 120
ctgacgtgta ctgtctctgg tggctctatt tcttccgggg gcttttattg gtcttggatc 180
agacaacacc ctggcaaagg gctggagtgg atagggtata ttcaccactc tgggtccact 240
cactacaacc catcattgaa atccagagtg actatctcaa tcgacacatc caagaacctt 300
ttcagcctga ggttgtcatc agttaccgcc gctgacaccg cggtgtatta ttgcgcctct 360
ctcgtgtact gcggtggcga ttgttatagt ggctttgact actgggggca ggggacattg 420
gttaccgttt caagtggagg cggtgggtct ggcgggggcg gtagcggagg tggggggagc 480
gacatacagc ttacgcagag cccctccagc ctttcagcct ccgtggggga tagggtgtcc 540
tttacctgcc aggcttccca ggacataaac aacttcctca attggtatca gcaaaagccc 600
gggaaagcac caaagctgct catctacgat gccagcaacc tggaaaccgg agtgccgtct 660
cgcttctctg gaagtggcag tgggaccgat ttcactttta caatctcaag tttgcagcca 720
gaagacattg caacatacta ctgtcaacag tacggcaatc tcccctttac atttgggggg 780
ggaactaaag tggagattaa gcgcgctgca gccattgaag ttatgtatcc gcccccgtat 840
ctggataacg agaaatctaa tggtaccata atacatgtga aggggaagca cctctgtcca 900
tcaccgctgt tccccggccc ttcaaaacct ttctgggtac tcgttgtcgt gggtggagtt 960
ctggcctgct atagtctgct ggtgaccgtg gcgtttatca tcttctgggt aagatccaaa 1020
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1080
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1140
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1200
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1260
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1320
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1380
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1440
gctctccaca tgcaagccct gccacctagg taa 1473
<210> 64
<211> 490
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 64
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
210 215 220
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
225 230 235 240
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
245 250 255
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile
260 265 270
Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly
275 280 285
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
290 295 300
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
305 310 315 320
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
325 330 335
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
340 345 350
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
355 360 365
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
370 375 380
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
385 390 395 400
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
405 410 415
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
420 425 430
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
435 440 445
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
450 455 460
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
465 470 475 480
Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 65
<211> 1407
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 65
caggtgcagc tgcaggaaag cggtccggga cttgtcaagc cgtcccaaac gctgagtctg 60
acgtgtactg tctctggtgg ctctatttct tccgggggct tttattggtc ttggatcaga 120
caacaccctg gcaaagggct ggagtggata gggtatattc accactctgg gtccactcac 180
tacaacccat cattgaaatc cagagtgact atctcaatcg acacatccaa gaaccttttc 240
agcctgaggt tgtcatcagt taccgccgct gacaccgcgg tgtattattg cgcctctctc 300
gtgtactgcg gtggcgattg ttatagtggc tttgactact gggggcaggg gacattggtt 360
accgtttcaa gtggaggcgg tgggtctggc gggggcggta gcggaggtgg ggggagcgac 420
atacagctta cgcagagccc ctccagcctt tcagcctccg tgggggatag ggtgtccttt 480
acctgccagg cttcccagga cataaacaac ttcctcaatt ggtatcagca aaagcccggg 540
aaagcaccaa agctgctcat ctacgatgcc agcaacctgg aaaccggagt gccgtctcgc 600
ttctctggaa gtggcagtgg gaccgatttc acttttacaa tctcaagttt gcagccagaa 660
gacattgcaa catactactg tcaacagtac ggcaatctcc cctttacatt tgggggggga 720
actaaagtgg agattaagcg cgctgcagcc attgaagtta tgtatccgcc cccgtatctg 780
gataacgaga aatctaatgg taccataata catgtgaagg ggaagcacct ctgtccatca 840
ccgctgttcc ccggcccttc aaaacctttc tgggtactcg ttgtcgtggg tggagttctg 900
gcctgctata gtctgctggt gaccgtggcg tttatcatct tctgggtaag atccaaaaga 960
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1020
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1080
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1140
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1200
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1260
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1320
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1380
ctccacatgc aagccctgcc acctagg 1407
<210> 66
<211> 469
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 66
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro
245 250 255
Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
260 265 270
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
275 280 285
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
290 295 300
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
305 310 315 320
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
325 330 335
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
340 345 350
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
355 360 365
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
370 375 380
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
385 390 395 400
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
405 410 415
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
420 425 430
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
435 440 445
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
450 455 460
Ala Leu Pro Pro Arg
465
<210> 67
<211> 1554
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 67
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttgcagga aagcgggcct ggccttgtga aaccaagcca gacactgagc 120
ctgacatgca ctgtgtccgg cgggtccata tcttccgggg gtttttattg gtcctggata 180
cgccagcatc ccgggaaagg acttgaatgg attggatata tccaccattc cggaagcacc 240
cactacaatc caagccttaa atcccgggtg acaatctcca tcgacacctc aaagaatctt 300
ttttccctgc ggttgtcttc agtaactgcc gccgataccg ctgtgtacta ctgtgccagc 360
ctcgtctatt gcggcggaga ttgttattct gggttcgatt attggggtca aggcacactg 420
gtaactgtca gcagcggagg cggcggttcc gggggcgggg gcagtggagg gggcggatct 480
gacattcagc ttacgcagtc cccatcttca cttagcgcca gcgttggcga tcgggtcagc 540
ttcacgtgtc aagcaagtca ggatatcaac aactttctta actggtacca gcagaagcca 600
ggcaaggcac ccaagttgct gatttacgat gcttctaacc tcgagacggg agtgcctagc 660
cgcttctccg ggagcggcag cggcacagac tttaccttta cgatttccag tctgcagcca 720
gaggatatag caacttatta ctgtcagcag tatggcaacc tcccttttac cttcggtggt 780
ggcacaaagg tcgagattaa aagagccgca gcgttgtcca actccataat gtatttttct 840
cattttgtgc ccgtctttct gcctgccaaa cctaccacca cccccgcccc acgaccacct 900
actccagccc ccaccatcgc ctcccagccc ctcagcctga ggccagaggc ttgtcgccct 960
gctgcggggg gcgctgtcca taccagagga ctcgacttcg cctgcgatat ttatatatgg 1020
gcccccctcg ccggcacctg cggagtcttg ctcctgagcc ttgtgatcac gctttattgt 1080
aaccatcgga atagatccaa aagaagccgc ctgctccata gcgattacat gaatatgact 1140
ccacgccgcc ctggccccac aaggaaacac taccagcctt acgcaccacc tagagatttc 1200
gctgcctatc ggagcagggt gaagttttcc agatctgcag atgcaccagc gtatcagcag 1260
ggccagaacc aactgtataa cgagctcaac ctgggacgca gggaagagta tgacgttttg 1320
gacaagcgca gaggacggga ccctgagatg ggtggcaaac caagacgaaa aaacccccag 1380
gagggtctct ataatgagct gcagaaggat aagatggctg aagcctattc tgaaataggc 1440
atgaaaggag agcggagaag gggaaaaggg cacgacggtt tgtaccaggg actcagcact 1500
gctacgaagg atacttatga cgctctccac atgcaagccc tgccacctag gtaa 1554
<210> 68
<211> 515
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 68
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Gly Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro
50 55 60
Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr
65 70 75 80
His Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr
85 90 95
Ser Lys Asn Leu Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys
115 120 125
Tyr Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
130 135 140
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
165 170 175
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
180 185 190
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
195 200 205
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Arg Phe Ser Gly Ser
210 215 220
Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu
225 230 235 240
Asp Ile Ala Thr Tyr Tyr Cys Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn
260 265 270
Ser Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys
275 280 285
Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
290 295 300
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
305 310 315 320
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
325 330 335
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
340 345 350
Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg
355 360 365
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
370 375 380
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
385 390 395 400
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510
Pro Pro Arg
515
<210> 69
<211> 1488
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 69
caggtgcagt tgcaggaaag cgggcctggc cttgtgaaac caagccagac actgagcctg 60
acatgcactg tgtccggcgg gtccatatct tccgggggtt tttattggtc ctggatacgc 120
cagcatcccg ggaaaggact tgaatggatt ggatatatcc accattccgg aagcacccac 180
tacaatccaa gccttaaatc ccgggtgaca atctccatcg acacctcaaa gaatcttttt 240
tccctgcggt tgtcttcagt aactgccgcc gataccgctg tgtactactg tgccagcctc 300
gtctattgcg gcggagattg ttattctggg ttcgattatt ggggtcaagg cacactggta 360
actgtcagca gcggaggcgg cggttccggg ggcgggggca gtggaggggg cggatctgac 420
attcagctta cgcagtcccc atcttcactt agcgccagcg ttggcgatcg ggtcagcttc 480
acgtgtcaag caagtcagga tatcaacaac tttcttaact ggtaccagca gaagccaggc 540
aaggcaccca agttgctgat ttacgatgct tctaacctcg agacgggagt gcctagccgc 600
ttctccggga gcggcagcgg cacagacttt acctttacga tttccagtct gcagccagag 660
gatatagcaa cttattactg tcagcagtat ggcaacctcc cttttacctt cggtggtggc 720
acaaaggtcg agattaaaag agccgcagcg ttgtccaact ccataatgta tttttctcat 780
tttgtgcccg tctttctgcc tgccaaacct accaccaccc ccgccccacg accacctact 840
ccagccccca ccatcgcctc ccagcccctc agcctgaggc cagaggcttg tcgccctgct 900
gcggggggcg ctgtccatac cagaggactc gacttcgcct gcgatattta tatatgggcc 960
cccctcgccg gcacctgcgg agtcttgctc ctgagccttg tgatcacgct ttattgtaac 1020
catcggaata gatccaaaag aagccgcctg ctccatagcg attacatgaa tatgactcca 1080
cgccgccctg gccccacaag gaaacactac cagccttacg caccacctag agatttcgct 1140
gcctatcgga gcagggtgaa gttttccaga tctgcagatg caccagcgta tcagcagggc 1200
cagaaccaac tgtataacga gctcaacctg ggacgcaggg aagagtatga cgttttggac 1260
aagcgcagag gacgggaccc tgagatgggt ggcaaaccaa gacgaaaaaa cccccaggag 1320
ggtctctata atgagctgca gaaggataag atggctgaag cctattctga aataggcatg 1380
aaaggagagc ggagaagggg aaaagggcac gacggtttgt accagggact cagcactgct 1440
acgaaggata cttatgacgc tctccacatg caagccctgc cacctagg 1488
<210> 70
<211> 496
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 70
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Phe Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile His His Ser Gly Ser Thr His Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Leu Thr
130 135 140
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Ser Phe
145 150 155 160
Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn Trp Tyr Gln
165 170 175
Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn
180 185 190
Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
195 200 205
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr
210 215 220
Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe Gly Gly Gly
225 230 235 240
Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met
245 250 255
Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr
260 265 270
Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
275 280 285
Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
290 295 300
Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
305 310 315 320
Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
325 330 335
Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His
340 345 350
Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys
355 360 365
His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
370 375 380
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
385 390 395 400
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
405 410 415
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
420 425 430
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
435 440 445
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
450 455 460
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
465 470 475 480
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 495
<210> 71
<211> 363
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 71
caggtccaac tggtgcagtc cggagccgaa gtcaagaaac caggtgcctc cgttaaagtg 60
agttgcaaag tctctggata cactctgacc gagctctcta tgcactgggt ccggcaggcc 120
cccggcaagg gattggaatg gatgggcggg ttcgatcctg aggacggaga gactatctac 180
gctcaaaaat tccagggacg agtgactgtg accgaagaca ctagtaccga cactgcctac 240
atggaacttt cctctctgcg atcagaagat accgcagtgt actactgtgc tactgaatct 300
aggggcattg gatggcccta cttcgattac tggggtcagg gaactctggt gactgtctcc 360
agc 363
<210> 72
<211> 121
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 72
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 73
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 73
Gly Tyr Thr Leu Thr Glu Leu
1 5
<210> 74
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 74
Asp Pro Glu Asp Gly Glu
1 5
<210> 75
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 75
Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr
1 5 10
<210> 76
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 76
gatattcaga tgactcaatc tccttcttct ctgtccgctt ccgtgggcga tagagtgacc 60
attacttgta gggcgtccca gtcaatctcc agttatttga attggtatca gcagaagccc 120
gggaaagcac ctaagctgtt gatcagcggg gcttctagcc tgaagagtgg ggtaccttca 180
cggttcagcg gaagcggaag cggaaccgat ttcaccctga ctatcagcag cctgccacct 240
gaggactttg caacttacta ctgccaacag tcatacagca ctccgatcac tttcggccag 300
ggcacccggc tcgaaatcaa gcgc 324
<210> 77
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 77
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Ser Gly Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
100 105
<210> 78
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 78
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 79
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 79
Gly Ala Ser Ser Leu Lys Ser
1 5
<210> 80
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 80
Gln Gln Ser Tyr Ser Thr Pro Ile Thr
1 5
<210> 81
<211> 1437
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 81
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc aactggtgca gtccggagcc gaagtcaaga aaccaggtgc ctccgttaaa 120
gtgagttgca aagtctctgg atacactctg accgagctct ctatgcactg ggtccggcag 180
gcccccggca agggattgga atggatgggc gggttcgatc ctgaggacgg agagactatc 240
tacgctcaaa aattccaggg acgagtgact gtgaccgaag acactagtac cgacactgcc 300
tacatggaac tttcctctct gcgatcagaa gataccgcag tgtactactg tgctactgaa 360
tctaggggca ttggatggcc ctacttcgat tactggggtc agggaactct ggtgactgtc 420
tccagcggtg gaggtggcag cggtggtggc ggaagcgggg ggggcggctc tgatattcag 480
atgactcaat ctccttcttc tctgtccgct tccgtgggcg atagagtgac cattacttgt 540
agggcgtccc agtcaatctc cagttatttg aattggtatc agcagaagcc cgggaaagca 600
cctaagctgt tgatcagcgg ggcttctagc ctgaagagtg gggtaccttc acggttcagc 660
ggaagcggaa gcggaaccga tttcaccctg actatcagca gcctgccacc tgaggacttt 720
gcaacttact actgccaaca gtcatacagc actccgatca ctttcggcca gggcacccgg 780
ctcgaaatca agcgcgctgc tgctttggac aatgagaagt caaacggcac catcatacat 840
gttaaaggta aacatctgtg tccctccccg ctgttccccg gcccttccaa accgttctgg 900
gttctggtgg tggtcggagg cgtactcgct tgctatagtc tgctggtaac tgtcgccttc 960
atcatctttt gggtgagatc caaaagaagc cgcctgctcc atagcgatta catgaatatg 1020
actccacgcc gccctggccc cacaaggaaa cactaccagc cttacgcacc acctagagat 1080
ttcgctgcct atcggagcag ggtgaagttt tccagatctg cagatgcacc agcgtatcag 1140
cagggccaga accaactgta taacgagctc aacctgggac gcagggaaga gtatgacgtt 1200
ttggacaagc gcagaggacg ggaccctgag atgggtggca aaccaagacg aaaaaacccc 1260
caggagggtc tctataatga gctgcagaag gataagatgg ctgaagccta ttctgaaata 1320
ggcatgaaag gagagcggag aaggggaaaa gggcacgacg gtttgtacca gggactcagc 1380
actgctacga aggatactta tgacgctctc cacatgcaag ccctgccacc taggtaa 1437
<210> 82
<211> 478
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 82
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu
260 265 270
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
275 280 285
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
290 295 300
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
305 310 315 320
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
325 330 335
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
340 345 350
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
355 360 365
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
370 375 380
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
385 390 395 400
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
405 410 415
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
420 425 430
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
435 440 445
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
450 455 460
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 83
<211> 1371
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 83
caggtccaac tggtgcagtc cggagccgaa gtcaagaaac caggtgcctc cgttaaagtg 60
agttgcaaag tctctggata cactctgacc gagctctcta tgcactgggt ccggcaggcc 120
cccggcaagg gattggaatg gatgggcggg ttcgatcctg aggacggaga gactatctac 180
gctcaaaaat tccagggacg agtgactgtg accgaagaca ctagtaccga cactgcctac 240
atggaacttt cctctctgcg atcagaagat accgcagtgt actactgtgc tactgaatct 300
aggggcattg gatggcccta cttcgattac tggggtcagg gaactctggt gactgtctcc 360
agcggtggag gtggcagcgg tggtggcgga agcggggggg gcggctctga tattcagatg 420
actcaatctc cttcttctct gtccgcttcc gtgggcgata gagtgaccat tacttgtagg 480
gcgtcccagt caatctccag ttatttgaat tggtatcagc agaagcccgg gaaagcacct 540
aagctgttga tcagcggggc ttctagcctg aagagtgggg taccttcacg gttcagcgga 600
agcggaagcg gaaccgattt caccctgact atcagcagcc tgccacctga ggactttgca 660
acttactact gccaacagtc atacagcact ccgatcactt tcggccaggg cacccggctc 720
gaaatcaagc gcgctgctgc tttggacaat gagaagtcaa acggcaccat catacatgtt 780
aaaggtaaac atctgtgtcc ctccccgctg ttccccggcc cttccaaacc gttctgggtt 840
ctggtggtgg tcggaggcgt actcgcttgc tatagtctgc tggtaactgt cgccttcatc 900
atcttttggg tgagatccaa aagaagccgc ctgctccata gcgattacat gaatatgact 960
ccacgccgcc ctggccccac aaggaaacac taccagcctt acgcaccacc tagagatttc 1020
gctgcctatc ggagcagggt gaagttttcc agatctgcag atgcaccagc gtatcagcag 1080
ggccagaacc aactgtataa cgagctcaac ctgggacgca gggaagagta tgacgttttg 1140
gacaagcgca gaggacggga ccctgagatg ggtggcaaac caagacgaaa aaacccccag 1200
gagggtctct ataatgagct gcagaaggat aagatggctg aagcctattc tgaaataggc 1260
atgaaaggag agcggagaag gggaaaaggg cacgacggtt tgtaccaggg actcagcact 1320
gctacgaagg atacttatga cgctctccac atgcaagccc tgccacctag g 1371
<210> 84
<211> 457
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 84
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr
245 250 255
Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro
260 265 270
Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu
275 280 285
Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
290 295 300
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
305 310 315 320
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
325 330 335
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
340 345 350
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
355 360 365
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
370 375 380
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
385 390 395 400
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
405 410 415
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
420 425 430
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
435 440 445
Leu His Met Gln Ala Leu Pro Pro Arg
450 455
<210> 85
<211> 1464
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 85
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agcttgtgca gagcggggcc gaggtgaaga agcccggggc cagcgtcaaa 120
gtgtcctgta aggtcagcgg ttacaccctc accgagctga gcatgcactg ggtacggcag 180
gctcccggca aaggtcttga gtggatgggt ggatttgatc cagaagatgg agagactatc 240
tacgcccaga agttccaggg ccgggtcacc gtaacagaag acacctcaac tgacaccgct 300
tacatggagc tgagttcact gcggtccgag gacacggccg tgtattattg tgccaccgag 360
agccgcggaa tcggatggcc ttacttcgac tactggggac agggtacact tgttacagta 420
tcatccgggg gtggcggctc tggtgggggc ggctccggag ggggtggatc agatatccaa 480
atgactcaaa gtccaagttc cctgtctgcc tcagtcggag atagagtcac cataacctgc 540
agggcaagtc agtccatctc ctcctatctg aactggtacc aacagaaacc tggaaaggcg 600
cctaagctcc tgatctccgg agcctcatct ttgaaatccg gtgtcccatc tcgcttcagt 660
ggctctggaa gcggtacaga ttttactttg accattagca gcctcccacc ggaagacttt 720
gctacatatt actgccagca gtcttactca accccaatca ccttcgggca aggcaccaga 780
ctcgaaataa aaagagcagc tgctatcgag gttatgtacc caccgccgta cttggataac 840
gaaaaaagca atgggaccat cattcatgtg aagggtaagc acctttgccc tagcccactg 900
tttcctggcc cgagtaaacc cttttgggta cttgtggtcg tcggcggcgt gctggcctgc 960
tactcactcc tggttaccgt cgcattcatc atcttttggg tgagatccaa aagaagccgc 1020
ctgctccata gcgattacat gaatatgact ccacgccgcc ctggccccac aaggaaacac 1080
taccagcctt acgcaccacc tagagatttc gctgcctatc ggagcagggt gaagttttcc 1140
agatctgcag atgcaccagc gtatcagcag ggccagaacc aactgtataa cgagctcaac 1200
ctgggacgca gggaagagta tgacgttttg gacaagcgca gaggacggga ccctgagatg 1260
ggtggcaaac caagacgaaa aaacccccag gagggtctct ataatgagct gcagaaggat 1320
aagatggctg aagcctattc tgaaataggc atgaaaggag agcggagaag gggaaaaggg 1380
cacgacggtt tgtaccaggg actcagcact gctacgaagg atacttatga cgctctccac 1440
atgcaagccc tgccacctag gtaa 1464
<210> 86
<211> 487
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 86
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met
260 265 270
Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile
275 280 285
His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro
290 295 300
Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
305 310 315 320
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
325 330 335
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
340 345 350
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
355 360 365
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
370 375 380
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480
Met Gln Ala Leu Pro Pro Arg
485
<210> 87
<211> 1398
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 87
caggtgcagc ttgtgcagag cggggccgag gtgaagaagc ccggggccag cgtcaaagtg 60
tcctgtaagg tcagcggtta caccctcacc gagctgagca tgcactgggt acggcaggct 120
cccggcaaag gtcttgagtg gatgggtgga tttgatccag aagatggaga gactatctac 180
gcccagaagt tccagggccg ggtcaccgta acagaagaca cctcaactga caccgcttac 240
atggagctga gttcactgcg gtccgaggac acggccgtgt attattgtgc caccgagagc 300
cgcggaatcg gatggcctta cttcgactac tggggacagg gtacacttgt tacagtatca 360
tccgggggtg gcggctctgg tgggggcggc tccggagggg gtggatcaga tatccaaatg 420
actcaaagtc caagttccct gtctgcctca gtcggagata gagtcaccat aacctgcagg 480
gcaagtcagt ccatctcctc ctatctgaac tggtaccaac agaaacctgg aaaggcgcct 540
aagctcctga tctccggagc ctcatctttg aaatccggtg tcccatctcg cttcagtggc 600
tctggaagcg gtacagattt tactttgacc attagcagcc tcccaccgga agactttgct 660
acatattact gccagcagtc ttactcaacc ccaatcacct tcgggcaagg caccagactc 720
gaaataaaaa gagcagctgc tatcgaggtt atgtacccac cgccgtactt ggataacgaa 780
aaaagcaatg ggaccatcat tcatgtgaag ggtaagcacc tttgccctag cccactgttt 840
cctggcccga gtaaaccctt ttgggtactt gtggtcgtcg gcggcgtgct ggcctgctac 900
tcactcctgg ttaccgtcgc attcatcatc ttttgggtga gatccaaaag aagccgcctg 960
ctccatagcg attacatgaa tatgactcca cgccgccctg gccccacaag gaaacactac 1020
cagccttacg caccacctag agatttcgct gcctatcgga gcagggtgaa gttttccaga 1080
tctgcagatg caccagcgta tcagcagggc cagaaccaac tgtataacga gctcaacctg 1140
ggacgcaggg aagagtatga cgttttggac aagcgcagag gacgggaccc tgagatgggt 1200
ggcaaaccaa gacgaaaaaa cccccaggag ggtctctata atgagctgca gaaggataag 1260
atggctgaag cctattctga aataggcatg aaaggagagc ggagaagggg aaaagggcac 1320
gacggtttgt accagggact cagcactgct acgaaggata cttatgacgc tctccacatg 1380
caagccctgc cacctagg 1398
<210> 88
<211> 466
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 88
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr
245 250 255
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
260 265 270
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
275 280 285
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
290 295 300
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
305 310 315 320
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
325 330 335
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
340 345 350
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
355 360 365
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
370 375 380
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
385 390 395 400
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
405 410 415
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
420 425 430
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
435 440 445
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
450 455 460
Pro Arg
465
<210> 89
<211> 1545
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 89
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggtgca aagcggcgca gaagttaaga aacctggggc gtcagttaag 120
gtgtcttgca aagtatctgg ctataccctc actgagctgt ccatgcattg ggtaaggcag 180
gctcctggaa aggggctcga atggatggga ggatttgacc ctgaagacgg agagaccatc 240
tacgcccaga aattccaggg tagagtaaca gtgactgagg acactagcac tgacacagcg 300
tacatggagc tgagttctct gagaagtgag gacacagccg tttactactg cgctaccgag 360
tccagaggta ttggctggcc atacttcgac tattggggtc agggcaccct ggttacagtg 420
agttcaggag gcgggggctc tggggggggc ggttccggag gggggggctc agatatacag 480
atgacgcaga gtccatcaag tctctcagcc agcgtgggag atcgcgtgac tattacttgc 540
cgcgccagcc agagtattag ctcctatctg aattggtacc agcaaaagcc cgggaaggcc 600
cctaagcttc tgatttctgg cgcctcctct ttgaagtcag gtgtgccaag cagatttagc 660
gggtctggaa gtggcactga ctttacactt actatctcca gcctgccccc agaggatttt 720
gccacatatt actgtcagca aagctactct actccaatca ctttcggcca gggcacaaga 780
ttggagatta agagggctgc cgcactttca aattccatca tgtatttcag ccattttgtg 840
cctgtttttc ttccggccaa acctacaacc actcccgccc cacgcccacc tactcccgcc 900
cctaccattg cctcccagcc tctgtctctt agacctgagg cttgtagacc tgctgccggc 960
ggagccgtgc acactcgcgg tctggacttc gcctgcgaca tctatatctg ggcccctctg 1020
gccggcacct gcggcgttct ccttctctca ctcgtaatca cactctattg caatcacagg 1080
aacagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1140
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1200
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1260
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1320
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1380
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1440
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1500
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1545
<210> 90
<211> 514
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 90
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
20 25 30
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr
35 40 45
Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile
65 70 75 80
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser
85 90 95
Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr
115 120 125
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln
145 150 155 160
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
165 170 175
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp
180 185 190
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala
195 200 205
Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
210 215 220
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe
225 230 235 240
Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly
245 250 255
Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser
260 265 270
Ile Met Tyr Phe Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro
275 280 285
Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
290 295 300
Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
305 310 315 320
Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile
325 330 335
Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val
340 345 350
Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu
355 360 365
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
370 375 380
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
385 390 395 400
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
405 410 415
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
420 425 430
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
435 440 445
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
450 455 460
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
465 470 475 480
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
485 490 495
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
500 505 510
Pro Arg
<210> 91
<211> 1479
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 91
caggtgcagt tggtgcaaag cggcgcagaa gttaagaaac ctggggcgtc agttaaggtg 60
tcttgcaaag tatctggcta taccctcact gagctgtcca tgcattgggt aaggcaggct 120
cctggaaagg ggctcgaatg gatgggagga tttgaccctg aagacggaga gaccatctac 180
gcccagaaat tccagggtag agtaacagtg actgaggaca ctagcactga cacagcgtac 240
atggagctga gttctctgag aagtgaggac acagccgttt actactgcgc taccgagtcc 300
agaggtattg gctggccata cttcgactat tggggtcagg gcaccctggt tacagtgagt 360
tcaggaggcg ggggctctgg ggggggcggt tccggagggg ggggctcaga tatacagatg 420
acgcagagtc catcaagtct ctcagccagc gtgggagatc gcgtgactat tacttgccgc 480
gccagccaga gtattagctc ctatctgaat tggtaccagc aaaagcccgg gaaggcccct 540
aagcttctga tttctggcgc ctcctctttg aagtcaggtg tgccaagcag atttagcggg 600
tctggaagtg gcactgactt tacacttact atctccagcc tgcccccaga ggattttgcc 660
acatattact gtcagcaaag ctactctact ccaatcactt tcggccaggg cacaagattg 720
gagattaaga gggctgccgc actttcaaat tccatcatgt atttcagcca ttttgtgcct 780
gtttttcttc cggccaaacc tacaaccact cccgccccac gcccacctac tcccgcccct 840
accattgcct cccagcctct gtctcttaga cctgaggctt gtagacctgc tgccggcgga 900
gccgtgcaca ctcgcggtct ggacttcgcc tgcgacatct atatctgggc ccctctggcc 960
ggcacctgcg gcgttctcct tctctcactc gtaatcacac tctattgcaa tcacaggaac 1020
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 1080
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1140
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1200
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1260
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1320
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1380
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1440
acttatgacg ctctccacat gcaagccctg ccacctagg 1479
<210> 92
<211> 493
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 92
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Glu Ser Arg Gly Ile Gly Trp Pro Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
130 135 140
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
145 150 155 160
Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
165 170 175
Gly Lys Ala Pro Lys Leu Leu Ile Ser Gly Ala Ser Ser Leu Lys Ser
180 185 190
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
195 200 205
Leu Thr Ile Ser Ser Leu Pro Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
210 215 220
Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu
225 230 235 240
Glu Ile Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser
245 250 255
His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
260 265 270
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
275 280 285
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
290 295 300
Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
305 310 315 320
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
325 330 335
Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
340 345 350
Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
355 360 365
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
370 375 380
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490
<210> 93
<211> 351
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 93
caggtccagt tggtcgaaag tggcggtggt gtagtgcagc cgggccgcag tttgaggctt 60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc 120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac 180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac 240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg 300
tatagtggca gagactactg ggggcagggc acactcgtta cagtgagtag c 351
<210> 94
<211> 117
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 94
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 95
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 95
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 96
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 96
Ser Tyr Asp Gly Ser Asp
1 5
<210> 97
<211> 8
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 97
Glu Arg Tyr Ser Gly Arg Asp Tyr
1 5
<210> 98
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 98
gagattgtta tgacccagag tcctgcgacc ctctcagtca gccccgggga gcgcgcaact 60
ttgtcttgca gagctagtca gtccgtgtcc tctcttctga catggtacca gcaaaagccc 120
gggcaggctc cgcgcctttt gatctttggg gcttcaacaa gagccactgg gattcccgca 180
cgattctctg gctccgggag cggtactggt ttcaccctga cgattagcag tctccagagc 240
gaggacttcg ccgtatacta ctgccagcag tacgatacgt ggccattcac ttttggacca 300
gggactaaag tggattttaa gcgc 324
<210> 99
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 99
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
100 105
<210> 100
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 100
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr
1 5 10
<210> 101
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 101
Gly Ala Ser Thr Arg Ala Thr
1 5
<210> 102
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 102
Gln Gln Tyr Asp Thr Trp Pro Phe Thr
1 5
<210> 103
<211> 1425
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 103
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc agttggtcga aagtggcggt ggtgtagtgc agccgggccg cagtttgagg 120
ctttcctgtg cggcttcagg ctttactttt tccagctatg gaatgcactg ggtgcggcag 180
gcccccggca aaggacttga gtgggtggcc gtcatttctt atgacggatc agataagtac 240
tacgtggaca gcgtcaaggg cagattcacc atctctaggg acaacagtaa aaatagactc 300
tacctccaga tgaatagcct cagagctgaa gacacggccg tctactattg tgctcgggag 360
cggtatagtg gcagagacta ctgggggcag ggcacactcg ttacagtgag tagcggcgga 420
ggagggagtg ggggcggtgg ctccggtgga ggaggttctg agattgttat gacccagagt 480
cctgcgaccc tctcagtcag ccccggggag cgcgcaactt tgtcttgcag agctagtcag 540
tccgtgtcct ctcttctgac atggtaccag caaaagcccg ggcaggctcc gcgccttttg 600
atctttgggg cttcaacaag agccactggg attcccgcac gattctctgg ctccgggagc 660
ggtactggtt tcaccctgac gattagcagt ctccagagcg aggacttcgc cgtatactac 720
tgccagcagt acgatacgtg gccattcact tttggaccag ggactaaagt ggattttaag 780
cgcgccgccg ctctcgataa cgaaaagtca aatggcacca taatccacgt caaaggcaag 840
cacctgtgcc cttccccgct cttccccgga cccagtaaac cattttgggt gctggttgtt 900
gtggggggcg tgctggcctg ctatagcctt ttggtcactg tagccttcat tattttttgg 960
gtcagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1140
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1200
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1320
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1425
<210> 104
<211> 474
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 104
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190
Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205
Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220
Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240
Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255
Val Asp Phe Lys Arg Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
290 295 300
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
305 310 315 320
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
325 330 335
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
340 345 350
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
355 360 365
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460
Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470
<210> 105
<211> 1359
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 105
caggtccagt tggtcgaaag tggcggtggt gtagtgcagc cgggccgcag tttgaggctt 60
tcctgtgcgg cttcaggctt tactttttcc agctatggaa tgcactgggt gcggcaggcc 120
cccggcaaag gacttgagtg ggtggccgtc atttcttatg acggatcaga taagtactac 180
gtggacagcg tcaagggcag attcaccatc tctagggaca acagtaaaaa tagactctac 240
ctccagatga atagcctcag agctgaagac acggccgtct actattgtgc tcgggagcgg 300
tatagtggca gagactactg ggggcagggc acactcgtta cagtgagtag cggcggagga 360
gggagtgggg gcggtggctc cggtggagga ggttctgaga ttgttatgac ccagagtcct 420
gcgaccctct cagtcagccc cggggagcgc gcaactttgt cttgcagagc tagtcagtcc 480
gtgtcctctc ttctgacatg gtaccagcaa aagcccgggc aggctccgcg ccttttgatc 540
tttggggctt caacaagagc cactgggatt cccgcacgat tctctggctc cgggagcggt 600
actggtttca ccctgacgat tagcagtctc cagagcgagg acttcgccgt atactactgc 660
cagcagtacg atacgtggcc attcactttt ggaccaggga ctaaagtgga ttttaagcgc 720
gccgccgctc tcgataacga aaagtcaaat ggcaccataa tccacgtcaa aggcaagcac 780
ctgtgccctt ccccgctctt ccccggaccc agtaaaccat tttgggtgct ggttgttgtg 840
gggggcgtgc tggcctgcta tagccttttg gtcactgtag ccttcattat tttttgggtc 900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1020
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1320
acttatgacg ctctccacat gcaagccctg ccacctagg 1359
<210> 106
<211> 453
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 106
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445
Ala Leu Pro Pro Arg
450
<210> 107
<211> 1452
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 107
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctcgtgga gtctggcggc ggcgtggtcc agcccggccg gtccctgcgc 120
ctgtcctgcg ccgccagcgg gtttactttt tcctcctacg gcatgcactg ggtgcgccag 180
gctcccggca agggcctcga gtgggtcgcc gtgatctcat acgatgggtc agacaaatac 240
tatgtcgatt ctgttaaagg gcggtttacc atttcaagag ataactctaa gaataggctg 300
tatttgcaga tgaacagcct gagggctgaa gataccgcag tgtactattg cgctagggag 360
cggtatagtg gccgcgatta ctggggacag ggtacactgg tgaccgtgag ctctgggggt 420
ggcggaagcg ggggtggcgg aagcggcgga gggggtagtg aaattgtgat gacccagtct 480
ccggctacac tttcagtctc ccctggggag agagctacac tgtcatgcag agcgtcccag 540
tccgtctctt ctctccttac ctggtatcag cagaagcccg gccaggctcc tcgactgctg 600
atcttcggtg cctccacaag ggcgaccggg attccagccc gcttctcagg ttctgggagc 660
ggaactggtt tcactttgac aatcagttca ctgcagtcag aggatttcgc cgtgtactac 720
tgccagcaat acgacacatg gccattcact ttcggacccg gtaccaaagt cgatttcaag 780
agagccgcgg ccatcgaggt tatgtaccca ccaccatatc tggacaatga aaaaagcaat 840
ggaaccatta tccatgtgaa gggtaaacac ctctgcccta gcccactttt ccctggccca 900
tcaaagccct tctgggtctt ggtggtcgtg gggggtgtgc tggcctgtta cagccttctg 960
gtgacggttg ctttcattat cttctgggtt agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 108
<211> 483
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 108
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser
145 150 155 160
Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys
165 170 175
Arg Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys
180 185 190
Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala
195 200 205
Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe
210 215 220
Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr
225 230 235 240
Cys Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys
245 250 255
Val Asp Phe Lys Arg Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
260 265 270
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 109
<211> 1386
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 109
caggtgcagc tcgtggagtc tggcggcggc gtggtccagc ccggccggtc cctgcgcctg 60
tcctgcgccg ccagcgggtt tactttttcc tcctacggca tgcactgggt gcgccaggct 120
cccggcaagg gcctcgagtg ggtcgccgtg atctcatacg atgggtcaga caaatactat 180
gtcgattctg ttaaagggcg gtttaccatt tcaagagata actctaagaa taggctgtat 240
ttgcagatga acagcctgag ggctgaagat accgcagtgt actattgcgc tagggagcgg 300
tatagtggcc gcgattactg gggacagggt acactggtga ccgtgagctc tgggggtggc 360
ggaagcgggg gtggcggaag cggcggaggg ggtagtgaaa ttgtgatgac ccagtctccg 420
gctacacttt cagtctcccc tggggagaga gctacactgt catgcagagc gtcccagtcc 480
gtctcttctc tccttacctg gtatcagcag aagcccggcc aggctcctcg actgctgatc 540
ttcggtgcct ccacaagggc gaccgggatt ccagcccgct tctcaggttc tgggagcgga 600
actggtttca ctttgacaat cagttcactg cagtcagagg atttcgccgt gtactactgc 660
cagcaatacg acacatggcc attcactttc ggacccggta ccaaagtcga tttcaagaga 720
gccgcggcca tcgaggttat gtacccacca ccatatctgg acaatgaaaa aagcaatgga 780
accattatcc atgtgaaggg taaacacctc tgccctagcc cacttttccc tggcccatca 840
aagcccttct gggtcttggt ggtcgtgggg ggtgtgctgg cctgttacag ccttctggtg 900
acggttgctt tcattatctt ctgggttaga tccaaaagaa gccgcctgct ccatagcgat 960
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1020
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1080
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1320
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1380
cctagg 1386
<210> 110
<211> 462
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 110
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 111
<211> 1533
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 111
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agttggttga atcaggaggg ggtgtggtgc aacccggtcg gtcactgcgc 120
ctcagttgtg ctgcttccgg gtttactttc agctcatatg ggatgcactg ggtacggcag 180
gctccaggta aaggcttgga atgggtggcg gtgatcagct atgacggctc tgacaaatat 240
tatgtggact ccgtgaaagg cagattcacc atcagtcgag acaactcaaa gaatagactc 300
tacttgcaga tgaatagcct ccgggccgaa gatactgcag tctattattg cgcccgggag 360
cgctacagtg gaagagacta ttgggggcaa ggaactcttg tcacagtctc atctggcggc 420
ggcggcagcg gtgggggcgg atctggcggg ggcggcagcg aaatcgttat gactcagagt 480
cctgccacac tgagcgttag ccctggtgag agagcaacac ttagctgcag agctagtcag 540
agtgtttcca gtcttttgac atggtaccaa cagaagcccg gtcaagctcc acgactgctc 600
atcttcggtg catccacccg cgcaaccggg atacccgccc ggttttccgg ttctggaagt 660
ggcacaggat tcacgctcac catttcttct ctgcagtctg aagactttgc cgtgtattac 720
tgccagcagt acgatacctg gccctttacc tttggcccag gtactaaagt ggattttaaa 780
cgagctgctg cactttccaa tagtattatg tacttttcac attttgtgcc cgtgttcctg 840
cctgcgaagc ctacgacaac cccagcccct aggccgccca caccggcccc aactattgcc 900
tcccagccat tgtctctgag acccgaagct tgcagacctg ctgctggagg cgccgttcac 960
acccgaggat tggatttcgc atgtgacatt tacatctggg cccctttggc cggaacctgc 1020
ggtgtgctgc tgctgtcact cgtgattaca ctttactgca accaccgaaa cagatccaaa 1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1500
gctctccaca tgcaagccct gccacctagg taa 1533
<210> 112
<211> 509
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 112
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr
65 70 75 80
Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp
115 120 125
Gly Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro
145 150 155 160
Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg
165 170 175
Ala Ser Gln Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro
180 185 190
Gly Gln Ala Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr
195 200 205
Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr
210 215 220
Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
225 230 235 240
Gln Gln Tyr Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val
245 250 255
Asp Phe Lys Arg Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser
260 265 270
His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
275 280 285
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
290 295 300
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
305 310 315 320
Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
325 330 335
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
340 345 350
Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
355 360 365
Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
370 375 380
Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
385 390 395 400
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
405 410 415
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
420 425 430
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
435 440 445
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
450 455 460
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
465 470 475 480
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
485 490 495
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505
<210> 113
<211> 1467
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 113
caggtgcagt tggttgaatc aggagggggt gtggtgcaac ccggtcggtc actgcgcctc 60
agttgtgctg cttccgggtt tactttcagc tcatatggga tgcactgggt acggcaggct 120
ccaggtaaag gcttggaatg ggtggcggtg atcagctatg acggctctga caaatattat 180
gtggactccg tgaaaggcag attcaccatc agtcgagaca actcaaagaa tagactctac 240
ttgcagatga atagcctccg ggccgaagat actgcagtct attattgcgc ccgggagcgc 300
tacagtggaa gagactattg ggggcaagga actcttgtca cagtctcatc tggcggcggc 360
ggcagcggtg ggggcggatc tggcgggggc ggcagcgaaa tcgttatgac tcagagtcct 420
gccacactga gcgttagccc tggtgagaga gcaacactta gctgcagagc tagtcagagt 480
gtttccagtc ttttgacatg gtaccaacag aagcccggtc aagctccacg actgctcatc 540
ttcggtgcat ccacccgcgc aaccgggata cccgcccggt tttccggttc tggaagtggc 600
acaggattca cgctcaccat ttcttctctg cagtctgaag actttgccgt gtattactgc 660
cagcagtacg atacctggcc ctttaccttt ggcccaggta ctaaagtgga ttttaaacga 720
gctgctgcac tttccaatag tattatgtac ttttcacatt ttgtgcccgt gttcctgcct 780
gcgaagccta cgacaacccc agcccctagg ccgcccacac cggccccaac tattgcctcc 840
cagccattgt ctctgagacc cgaagcttgc agacctgctg ctggaggcgc cgttcacacc 900
cgaggattgg atttcgcatg tgacatttac atctgggccc ctttggccgg aacctgcggt 960
gtgctgctgc tgtcactcgt gattacactt tactgcaacc accgaaacag atccaaaaga 1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1320
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1440
ctccacatgc aagccctgcc acctagg 1467
<210> 114
<211> 489
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 114
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
210 215 220
Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg
225 230 235 240
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 115
<211> 1425
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 115
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggagattg tgatgaccca gtcccctgct accctgtccg tcagtccggg cgagagagcc 120
accttgtcat gccgggccag ccagtccgtc agcagtctcc tgacttggta tcagcaaaaa 180
ccagggcagg caccgcggct tttgattttt ggtgcaagca cacgcgccac tggcattcca 240
gctaggtttt ctggaagtgg atctgggaca ggcttcactc tgacaatcag tagcctgcag 300
agtgaggact ttgctgttta ctactgtcaa cagtacgaca cctggccatt cacattcggg 360
cccggcacca aggtcgactt caagaggggc ggtggaggtt caggtggtgg cgggtcaggc 420
ggcggtgggt ctcaggttca actggtggaa tcaggtggcg gcgttgtcca accggggcga 480
tcacttcgac tttcctgtgc tgcctcaggc tttacttttt catcctatgg gatgcactgg 540
gttcggcagg ctcccggaaa aggactcgag tgggttgcag tgatctctta cgatggctca 600
gacaagtatt atgtggactc agtcaagggg agattcacaa taagccgaga caactccaaa 660
aaccggcttt atctccagat gaacagcctt agagcggaag ataccgcggt atactactgt 720
gcccgcgaga ggtattccgg cagagactac tggggacagg gcacactggt caccgtgagt 780
tctgccgcag cgctcgataa cgaaaagagc aacggaacca ttatccacgt taagggcaag 840
cacctgtgcc ccagtcccct cttcccagga ccatctaaac ccttctgggt tctggtagta 900
gttggagggg tccttgcatg ttactccctt ttggtcaccg tcgccttcat tattttctgg 960
gtgagatcca aaagaagccg cctgctccat agcgattaca tgaatatgac tccacgccgc 1020
cctggcccca caaggaaaca ctaccagcct tacgcaccac ctagagattt cgctgcctat 1080
cggagcaggg tgaagttttc cagatctgca gatgcaccag cgtatcagca gggccagaac 1140
caactgtata acgagctcaa cctgggacgc agggaagagt atgacgtttt ggacaagcgc 1200
agaggacggg accctgagat gggtggcaaa ccaagacgaa aaaaccccca ggagggtctc 1260
tataatgagc tgcagaagga taagatggct gaagcctatt ctgaaatagg catgaaagga 1320
gagcggagaa ggggaaaagg gcacgacggt ttgtaccagg gactcagcac tgctacgaag 1380
gatacttatg acgctctcca catgcaagcc ctgccaccta ggtaa 1425
<210> 116
<211> 474
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 116
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly
260 265 270
Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe
275 280 285
Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val
290 295 300
Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp
305 310 315 320
Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met
325 330 335
Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala
340 345 350
Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg
355 360 365
Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380
Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400
Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415
Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430
Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445
Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460
Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470
<210> 117
<211> 1359
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 117
gagattgtga tgacccagtc ccctgctacc ctgtccgtca gtccgggcga gagagccacc 60
ttgtcatgcc gggccagcca gtccgtcagc agtctcctga cttggtatca gcaaaaacca 120
gggcaggcac cgcggctttt gatttttggt gcaagcacac gcgccactgg cattccagct 180
aggttttctg gaagtggatc tgggacaggc ttcactctga caatcagtag cctgcagagt 240
gaggactttg ctgtttacta ctgtcaacag tacgacacct ggccattcac attcgggccc 300
ggcaccaagg tcgacttcaa gaggggcggt ggaggttcag gtggtggcgg gtcaggcggc 360
ggtgggtctc aggttcaact ggtggaatca ggtggcggcg ttgtccaacc ggggcgatca 420
cttcgacttt cctgtgctgc ctcaggcttt actttttcat cctatgggat gcactgggtt 480
cggcaggctc ccggaaaagg actcgagtgg gttgcagtga tctcttacga tggctcagac 540
aagtattatg tggactcagt caaggggaga ttcacaataa gccgagacaa ctccaaaaac 600
cggctttatc tccagatgaa cagccttaga gcggaagata ccgcggtata ctactgtgcc 660
cgcgagaggt attccggcag agactactgg ggacagggca cactggtcac cgtgagttct 720
gccgcagcgc tcgataacga aaagagcaac ggaaccatta tccacgttaa gggcaagcac 780
ctgtgcccca gtcccctctt cccaggacca tctaaaccct tctgggttct ggtagtagtt 840
ggaggggtcc ttgcatgtta ctcccttttg gtcaccgtcg ccttcattat tttctgggtg 900
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 960
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 1020
agcagggtga agttttccag atctgcagat gcaccagcgt atcagcaggg ccagaaccaa 1080
ctgtataacg agctcaacct gggacgcagg gaagagtatg acgttttgga caagcgcaga 1140
ggacgggacc ctgagatggg tggcaaacca agacgaaaaa acccccagga gggtctctat 1200
aatgagctgc agaaggataa gatggctgaa gcctattctg aaataggcat gaaaggagag 1260
cggagaaggg gaaaagggca cgacggtttg taccagggac tcagcactgc tacgaaggat 1320
acttatgacg ctctccacat gcaagccctg ccacctagg 1359
<210> 118
<211> 453
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 118
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val
245 250 255
Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys
260 265 270
Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
275 280 285
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg
290 295 300
Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro
305 310 315 320
Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe
325 330 335
Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
340 345 350
Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
355 360 365
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
370 375 380
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
385 390 395 400
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
405 410 415
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
420 425 430
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
435 440 445
Ala Leu Pro Pro Arg
450
<210> 119
<211> 1452
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 119
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggagatcg tcatgacaca gagtccagct accctgagcg tgtcccctgg agagagagcc 120
accctgtcct gtagggctag tcagagtgtg tccagcctcc tcacctggta tcaacagaag 180
cctggtcaag ctccccggct gcttatcttc ggggccagca cgcgagccac aggcatcccg 240
gccagattct ctggctctgg cagtggcacc gggttcactc tcacgatctc atccctgcag 300
tcagaggatt tcgctgtgta ttactgtcag cagtacgata catggccctt caccttcggc 360
ccgggcacaa aagtagattt caagcgcggc ggcgggggta gtgggggcgg gggatcagga 420
ggagggggct cccaagtaca gctggttgag agcggcggcg gggtggttca gcccgggcgc 480
agcctcaggc tgagttgcgc agcatcagga ttcacattca gttcttatgg aatgcattgg 540
gtcagacagg ctcccgggaa gggccttgaa tgggtggcag tcattagcta cgacggaagc 600
gataagtact atgtggactc agttaaaggg agatttacta tcagccgcga caattccaaa 660
aacagattgt atttgcagat gaactccctc agggcggagg acactgctgt atattactgc 720
gcacgagaga gatactccgg ccgagactat tggggccaag gaacattggt aactgtgagc 780
tccgccgcag ctattgaggt catgtacccc ccaccttatc tcgataatga gaagagtaat 840
gggactataa ttcacgtaaa gggcaaacac ctgtgccctt ccccgctgtt tccaggtcca 900
agtaagccgt tctgggtcct ggttgtggtg ggaggggtgc tggcctgcta ttctctgttg 960
gttaccgtgg cctttatcat tttctgggtg agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctaggt aa 1452
<210> 120
<211> 483
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 120
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro
260 265 270
Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 121
<211> 1386
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 121
gagatcgtca tgacacagag tccagctacc ctgagcgtgt cccctggaga gagagccacc 60
ctgtcctgta gggctagtca gagtgtgtcc agcctcctca cctggtatca acagaagcct 120
ggtcaagctc cccggctgct tatcttcggg gccagcacgc gagccacagg catcccggcc 180
agattctctg gctctggcag tggcaccggg ttcactctca cgatctcatc cctgcagtca 240
gaggatttcg ctgtgtatta ctgtcagcag tacgatacat ggcccttcac cttcggcccg 300
ggcacaaaag tagatttcaa gcgcggcggc gggggtagtg ggggcggggg atcaggagga 360
gggggctccc aagtacagct ggttgagagc ggcggcgggg tggttcagcc cgggcgcagc 420
ctcaggctga gttgcgcagc atcaggattc acattcagtt cttatggaat gcattgggtc 480
agacaggctc ccgggaaggg ccttgaatgg gtggcagtca ttagctacga cggaagcgat 540
aagtactatg tggactcagt taaagggaga tttactatca gccgcgacaa ttccaaaaac 600
agattgtatt tgcagatgaa ctccctcagg gcggaggaca ctgctgtata ttactgcgca 660
cgagagagat actccggccg agactattgg ggccaaggaa cattggtaac tgtgagctcc 720
gccgcagcta ttgaggtcat gtacccccca ccttatctcg ataatgagaa gagtaatggg 780
actataattc acgtaaaggg caaacacctg tgcccttccc cgctgtttcc aggtccaagt 840
aagccgttct gggtcctggt tgtggtggga ggggtgctgg cctgctattc tctgttggtt 900
accgtggcct ttatcatttt ctgggtgaga tccaaaagaa gccgcctgct ccatagcgat 960
tacatgaata tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca 1020
ccacctagag atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca 1080
ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcagggaa 1140
gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga 1200
cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc 1260
tattctgaaa taggcatgaa aggagagcgg agaaggggaa aagggcacga cggtttgtac 1320
cagggactca gcactgctac gaaggatact tatgacgctc tccacatgca agccctgcca 1380
cctagg 1386
<210> 122
<211> 462
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 122
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
245 250 255
Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
260 265 270
Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
275 280 285
Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
290 295 300
Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
305 310 315 320
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
325 330 335
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
340 345 350
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
355 360 365
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
370 375 380
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
385 390 395 400
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
405 410 415
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
420 425 430
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
435 440 445
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
450 455 460
<210> 123
<211> 1533
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 123
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggaaatag tgatgactca gtccccggcc accctcagcg tgtcccccgg ggagcgagcg 120
accctgtcat gcagggcttc ccagagtgtc agctccctgc tcacttggta tcagcaaaag 180
ccggggcagg ctccccgcct cctcatcttc ggggcatcaa ctagggccac cggcattcct 240
gcaagatttt ccgggtctgg cagcggcacc ggcttcaccc ttaccattag ctctctgcag 300
tctgaggact tcgccgttta ctattgtcag cagtatgata cttggccctt taccttcggt 360
cccggaacta aggtggactt caagcgcggg gggggtggat ctggaggtgg tggctccggg 420
ggcggtggaa gccaggtcca gttggttgag agcggcggcg gagtggtgca gcccgggagg 480
tccttgcggc tgagctgtgc agcctccggt tttacttttt ctagctatgg aatgcattgg 540
gtaagacagg ctcccggaaa aggcctcgag tgggtggcgg tcattagcta tgatggatct 600
gataaatact atgtggactc agttaagggg cgcttcacaa tctcaagaga caatagcaaa 660
aatagactgt acctgcagat gaatagtctg cgcgccgagg acactgccgt gtactactgc 720
gcccgcgaga gatacagcgg acgggattac tggggccagg gtaccctcgt aacggtgtcc 780
tccgctgccg cccttagcaa cagcattatg tacttttctc atttcgtgcc agtctttctc 840
ccagcaaagc ccaccactac cccggccccc aggccgccta ctcctgcccc cactatcgcg 900
tctcagcctc tctccttgcg gcccgaggcc tgccggccag ccgcaggggg cgccgtacat 960
actcggggtt tggatttcgc ttgcgacata tatatttggg cccccctcgc cggcacatgt 1020
ggagtgctgc tcctgagtct cgttataacc ctctattgca accatagaaa cagatccaaa 1080
agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgccc tggccccaca 1140
aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagcagggtg 1200
aagttttcca gatctgcaga tgcaccagcg tatcagcagg gccagaacca actgtataac 1260
gagctcaacc tgggacgcag ggaagagtat gacgttttgg acaagcgcag aggacgggac 1320
cctgagatgg gtggcaaacc aagacgaaaa aacccccagg agggtctcta taatgagctg 1380
cagaaggata agatggctga agcctattct gaaataggca tgaaaggaga gcggagaagg 1440
ggaaaagggc acgacggttt gtaccaggga ctcagcactg ctacgaagga tacttatgac 1500
gctctccaca tgcaagccct gccacctagg taa 1533
<210> 124
<211> 510
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 124
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu
20 25 30
Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Leu Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro
65 70 75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Asp Thr Trp Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
115 120 125
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
130 135 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
145 150 155 160
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
165 170 175
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
180 185 190
Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val
195 200 205
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
210 215 220
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
225 230 235 240
Ala Arg Glu Arg Tyr Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu
245 250 255
Val Thr Val Ser Ser Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe
260 265 270
Ser His Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro
275 280 285
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
290 295 300
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
305 310 315 320
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
325 330 335
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
340 345 350
Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp
355 360 365
Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr
370 375 380
Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val
385 390 395 400
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
405 410 415
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
420 425 430
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg
435 440 445
Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys
450 455 460
Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg
465 470 475 480
Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys
485 490 495
Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505 510
<210> 125
<211> 1467
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 125
gaaatagtga tgactcagtc cccggccacc ctcagcgtgt cccccgggga gcgagcgacc 60
ctgtcatgca gggcttccca gagtgtcagc tccctgctca cttggtatca gcaaaagccg 120
gggcaggctc cccgcctcct catcttcggg gcatcaacta gggccaccgg cattcctgca 180
agattttccg ggtctggcag cggcaccggc ttcaccctta ccattagctc tctgcagtct 240
gaggacttcg ccgtttacta ttgtcagcag tatgatactt ggccctttac cttcggtccc 300
ggaactaagg tggacttcaa gcgcgggggg ggtggatctg gaggtggtgg ctccgggggc 360
ggtggaagcc aggtccagtt ggttgagagc ggcggcggag tggtgcagcc cgggaggtcc 420
ttgcggctga gctgtgcagc ctccggtttt actttttcta gctatggaat gcattgggta 480
agacaggctc ccggaaaagg cctcgagtgg gtggcggtca ttagctatga tggatctgat 540
aaatactatg tggactcagt taaggggcgc ttcacaatct caagagacaa tagcaaaaat 600
agactgtacc tgcagatgaa tagtctgcgc gccgaggaca ctgccgtgta ctactgcgcc 660
cgcgagagat acagcggacg ggattactgg ggccagggta ccctcgtaac ggtgtcctcc 720
gctgccgccc ttagcaacag cattatgtac ttttctcatt tcgtgccagt ctttctccca 780
gcaaagccca ccactacccc ggcccccagg ccgcctactc ctgcccccac tatcgcgtct 840
cagcctctct ccttgcggcc cgaggcctgc cggccagccg cagggggcgc cgtacatact 900
cggggtttgg atttcgcttg cgacatatat atttgggccc ccctcgccgg cacatgtgga 960
gtgctgctcc tgagtctcgt tataaccctc tattgcaacc atagaaacag atccaaaaga 1020
agccgcctgc tccatagcga ttacatgaat atgactccac gccgccctgg ccccacaagg 1080
aaacactacc agccttacgc accacctaga gatttcgctg cctatcggag cagggtgaag 1140
ttttccagat ctgcagatgc accagcgtat cagcagggcc agaaccaact gtataacgag 1200
ctcaacctgg gacgcaggga agagtatgac gttttggaca agcgcagagg acgggaccct 1260
gagatgggtg gcaaaccaag acgaaaaaac ccccaggagg gtctctataa tgagctgcag 1320
aaggataaga tggctgaagc ctattctgaa ataggcatga aaggagagcg gagaagggga 1380
aaagggcacg acggtttgta ccagggactc agcactgcta cgaaggatac ttatgacgct 1440
ctccacatgc aagccctgcc acctagg 1467
<210> 126
<211> 489
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 126
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Leu
20 25 30
Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Phe Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Thr Trp Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys Arg Gly Gly Gly Gly
100 105 110
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val
115 120 125
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser
130 135 140
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val
145 150 155 160
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr
165 170 175
Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr
180 185 190
Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser
195 200 205
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Arg Tyr
210 215 220
Ser Gly Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240
Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro
245 250 255
Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
260 265 270
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
275 280 285
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
290 295 300
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
305 310 315 320
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 127
<211> 63
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 127
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63
<210> 128
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 128
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 129
<211> 45
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 129
ggcggtggag gctccggagg ggggggctct ggcggagggg gctcc 45
<210> 130
<211> 15
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 130
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 131
<211> 54
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 131
gggtctacat ccggctccgg gaagcccgga agtggcgaag gtagtacaaa gggg 54
<210> 132
<211> 18
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 132
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 133
<211> 152
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 133
Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val
1 5 10 15
Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr
20 25 30
Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser
35 40 45
Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu
50 55 60
Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser
65 70 75 80
Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr
85 90 95
Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys
100 105 110
Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser
115 120 125
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
130 135 140
Leu Phe Pro Gly Pro Ser Lys Pro
145 150
<210> 134
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (2)..(9)
<223> 任意氨基酸
<400> 134
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 135
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (1)..(6)
<223> 任意氨基酸
<400> 135
Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 136
<211> 14
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (1)..(12)
<223> 任意氨基酸
<400> 136
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Tyr
1 5 10
<210> 137
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> 任意氨基酸
<220>
<221> MOD_RES
<222> (5)..(9)
<223> 任意氨基酸
<220>
<221> MOD_RES
<222> (11)..(11)
<223> 任意氨基酸
<400> 137
Xaa Ala Ser Gln Xaa Xaa Xaa Xaa Xaa Leu Xaa
1 5 10
<210> 138
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> 任意氨基酸
<220>
<221> MOD_RES
<222> (4)..(7)
<223> 任意氨基酸
<400> 138
Xaa Ala Ser Xaa Xaa Xaa Xaa
1 5
<210> 139
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<220>
<221> MOD_RES
<222> (3)..(6)
<223> 任意氨基酸
<220>
<221> MOD_RES
<222> (8)..(8)
<223> 任意氨基酸
<400> 139
Gln Gln Xaa Xaa Xaa Xaa Pro Xaa Thr
1 5
<210> 140
<211> 126
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 140
aagcgcggca ggaagaagct cctctacatt tttaagcagc cttttatgag gcccgtacag 60
acaacacagg aggaagatgg ctgtagctgc agatttcccg aggaggagga aggtgggtgc 120
gagctg 126
<210> 141
<211> 42
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 141
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
1 5 10 15
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
20 25 30
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
35 40
<210> 142
<211> 37
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 142
Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly
1 5 10 15
Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser
20 25 30
Thr Leu Ala Lys Ile
35
<210> 143
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 143
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 144
<211> 20
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 144
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 145
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 145
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 146
<211> 1467
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 146
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccagaca tccagatgac acagactaca tcctccctgt ctgcctctct gggagacaga 120
gtcaccatca gttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcag 180
aaaccagatg gaactgttaa actcctgatc taccatacat caagattaca ctcaggagtc 240
ccatcaaggt tcagtggcag tgggtctgga acagattatt ctctcaccat tagcaacctg 300
gagcaagaag atattgccac ttacttttgc caacagggta atacgcttcc gtacacgttc 360
ggagggggga ctaagttgga aataacaggc tccacctctg gatccggcaa gcccggatct 420
ggcgagggat ccaccaaggg cgaggtgaaa ctgcaggagt caggacctgg cctggtggcg 480
ccctcacaga gcctgtccgt cacatgcact gtctcagggg tctcattacc cgactatggt 540
gtaagctgga ttcgccagcc tccacgaaag ggtctggagt ggctgggagt aatatggggt 600
agtgaaacca catactataa ttcagctctc aaatccagac tgaccatcat caaggacaac 660
tccaagagcc aagttttctt aaaaatgaac agtctgcaaa ctgatgacac agccatttac 720
tactgtgcca aacattatta ctacggtggt agctatgcta tggactactg gggtcaagga 780
acctcagtca ccgtctcctc agcggccgca attgaagtta tgtatcctcc tccttaccta 840
gacaatgaga agagcaatgg aaccattatc catgtgaaag ggaaacacct ttgtccaagt 900
cccctatttc ccggaccttc taagcccttt tgggtgctgg tggtggttgg gggagtcctg 960
gcttgctata gcttgctagt aacagtggcc tttattattt tctgggtgag gagtaagagg 1020
agcaggctcc tgcacagtga ctacatgaac atgactcccc gccgccccgg gcccacccgc 1080
aagcattacc agccctatgc cccaccacgc gacttcgcag cctatcgctc cagagtgaag 1140
ttcagcagga gcgcagacgc ccccgcgtac cagcagggcc agaaccagct ctataacgag 1200
ctcaatctag gacgaagaga ggagtacgat gttttggaca agagacgtgg ccgggaccct 1260
gagatggggg gaaagccgag aaggaagaac cctcaggaag gcctgtacaa tgaactgcag 1320
aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc 1380
aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc 1440
cttcacatgc aggccctgcc ccctcgc 1467
<210> 147
<211> 489
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 147
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
20 25 30
Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser
35 40 45
Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly
50 55 60
Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val
65 70 75 80
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr
85 90 95
Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
100 105 110
Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
115 120 125
Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala
145 150 155 160
Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu
165 170 175
Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu
180 185 190
Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser
195 200 205
Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln
210 215 220
Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr
225 230 235 240
Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
245 250 255
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ala Ala Ile Glu
260 265 270
Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr
275 280 285
Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro
290 295 300
Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu
305 310 315 320
Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 148
<211> 1437
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 148
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccggatattc aaatgaccca gtccccgtcc tccctgagtg cctccgtcgg tgaccgtgtt 120
acgattacct gccgtgcgag ccaagacatc tctaaatacc tgaactggta tcagcaaaaa 180
ccggatcagg caccgaaact gctgatcaaa catacctcac gtctgcactc gggtgtgccg 240
agccgcttta gtggttccgg ctcaggtacc gattacaccc tgacgatcag ctctctgcag 300
ccggaagact ttgccacgta ttactgccag caaggtaata ccctgccgta tacgttcggc 360
caaggtacca aactggaaat caaaggctcg acgagcggct ctggtaaacc gggctctggt 420
gaaggcagta ccaaaggtga agtgcagctg gttgaaagcg gtggtggtct ggttcaaccg 480
ggtcgttccc tgcgtctgtc atgtacggcg agtggtgtct ccctgccgga ctatggcgtg 540
tcctggattc gtcagccgcc gggtaaaggc ctggaatgga ttggtgtcat ctggggcagt 600
gaaaccacgt attacaactc ggccctgaaa agccgtttca ccatctctcg cgataacagt 660
aaaaatacgc tgtacctgca gatgaatagc ctgcgcgcgg aagacaccgc cgtttactac 720
tgcgcaaaac attactacta cggtggcagc tatgctatgg attactgggg tcaaggcacg 780
ctggtcaccg tttcgtcagc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt 840
cacgtgaagg gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc 900
tgggtgttgg tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct 960
tttataatct tctgggttag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag cagggtgaag ttttccagat ctgcagatgc accagcgtat 1140
cagcagggcc agaaccaact gtataacgag ctcaacctgg gacgcaggga agagtatgac 1200
gttttggaca agcgcagagg acgggaccct gagatgggtg gcaaaccaag acgaaaaaac 1260
ccccaggagg gtctctataa tgagctgcag aaggataaga tggctgaagc ctattctgaa 1320
ataggcatga aaggagagcg gagaagggga aaagggcacg acggtttgta ccagggactc 1380
agcactgcta cgaaggatac ttatgacgct ctccacatgc aagccctgcc acctagg 1437
<210> 149
<211> 479
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 149
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
35 40 45
Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gln Ala
50 55 60
Pro Lys Leu Leu Ile Lys His Thr Ser Arg Leu His Ser Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly
100 105 110
Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
115 120 125
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
130 135 140
Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
145 150 155 160
Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Val Ser Leu Pro
165 170 175
Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
180 185 190
Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala
195 200 205
Leu Lys Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
210 215 220
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
225 230 235 240
Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 150
<211> 1506
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 150
atggccctgc ctgtgacagc tctgctgctg cccctggccc tgctgctgca tgccgccaga 60
cctgagatcg tgctgaccca gtctcccggc accctgtctc tcagcccagg agagagagcc 120
accctgagct gcagagccag ccagagcgtg tccagcagct acctggcctg gtatcagcag 180
aagcccggac aggcccccag actgctgatc tacggcgcca gctctagagc caccggcatc 240
cccgacagat tcagcggcag cggcagtggc accgacttca ccctgaccat cagcagactg 300
gaacccgagg acttcgccgt gtactactgc cagcagtacg gcagcagccg gttcaccttc 360
ggccctggca ccaaggtgga catcaagggc agcacctccg gcagcggcaa gcctggctct 420
ggcgagggct ctaccaaggg ccaggtgcag ctggtgcagt ctggcgccga agtgaagaaa 480
cccggctcta gcgtgaaggt gtcctgcaag gacagcggcg gcaccttcag cagctacgcc 540
atcagctggg tgcgccaggc cccaggacag gggctggaat ggatgggcgg catcatcccc 600
atcttcggca ccaccaacta cgcccagcag ttccagggca gagtgaccat caccgccgac 660
gagagcacca gcaccgccta catggaactg agcagcctgc ggagcgagga cacagccgtg 720
tattactgtg cccgcgaggc cgtggccgcc gactggctgg atccttgggg acagggcacc 780
ctggtgacag tgtccagctt cgtgcccgtg ttcctgcccg ccaagcctac caccacccct 840
gcccctagac ctcccacccc agccccaaca atcgccagcc agcctctgtc cctgcggccc 900
gaagcctgta gacctgctgc cggcggagcc gtgcacacca gaggcctgga cttcgcctgc 960
gatatctaca tctgggcccc tctggccggc acctgtggcg tgctgctgct gagcctggtg 1020
atcaccctgt actgcaacca ccggaacaga agcaagcgga gccggctgct gcacagcgac 1080
tacatgaaca tgaccccaag acggcctggc cccacccgga agcactacca gccttacgcc 1140
cctcccagag acttcgccgc ctaccggtcc agagtgaagt tcagcagatc cgccgacgcc 1200
cctgcctacc agcagggaca gaaccagctg tacaacgagc tgaacctggg cagacgggaa 1260
gagtacgacg tgctggacaa gcggagaggc cgggaccccg agatgggcgg aaagcccaga 1320
cggaagaacc cccaggaagg cctgtataac gaactgcaga aagacaagat ggccgaggcc 1380
tacagcgaga tcggcatgaa gggcgagcgg aggcgcggca agggccacga tggcctgtac 1440
cagggcctga gcaccgccac caaggacacc tacgacgccc tgcacatgca ggccctgccc 1500
cccaga 1506
<210> 151
<211> 502
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 151
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu
20 25 30
Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
35 40 45
Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60
Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile
65 70 75 80
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
85 90 95
Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln
100 105 110
Tyr Gly Ser Ser Arg Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile
115 120 125
Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
145 150 155 160
Pro Gly Ser Ser Val Lys Val Ser Cys Lys Asp Ser Gly Gly Thr Phe
165 170 175
Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
180 185 190
Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala
195 200 205
Gln Gln Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser
210 215 220
Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
225 230 235 240
Tyr Tyr Cys Ala Arg Glu Ala Val Ala Ala Asp Trp Leu Asp Pro Trp
245 250 255
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Phe Val Pro Val Phe Leu
260 265 270
Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala
275 280 285
Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
290 295 300
Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys
305 310 315 320
Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu
325 330 335
Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys
340 345 350
Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg
355 360 365
Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp
370 375 380
Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala
385 390 395 400
Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu
405 410 415
Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
420 425 430
Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu
435 440 445
Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
450 455 460
Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
465 470 475 480
Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
485 490 495
Gln Ala Leu Pro Pro Arg
500
<210> 152
<211> 1824
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 152
atggcatgcc ctggcttcct gtgggcactt gtgatctcca cctgtcttga atttagcatg 60
gctcagacag tcactcagtc tcaaccagag atgtctgtgc aggaggcaga gaccgtgacc 120
ctgagctgca catatgacac cagtgagagt gattattatt tattctggta caagcagcct 180
cccagcaggc agatgattct cgttattcgc caagaagctt ataagcaaca gaatgcaaca 240
gagaatcgtt tctctgtgaa cttccagaaa gcagccaaat ccttcagtct caagatctca 300
gactcacagc tgggggatgc cgcgatgtat ttctgtgctc tccggagctc aggaacctac 360
aaatacatct ttggaacagg caccaggctg aaggttttag caaatatcca gaaccctgaa 420
cctgctgtgt accagttaaa agatcctcgg tctcaggaca gcaccctctg cctgttcacc 480
gactttgact cccaaatcaa tgtgccgaaa accatggaat ctggaacgtt catcactgac 540
aaaactgtgc tggacatgaa agctatggat tccaagagca atggggccat tgcctggagc 600
aaccagacaa gcttcacctg ccaagatatc ttcaaagaga ccaacgccac ctaccccagt 660
tcagacgttc cctgtgatgc cacgttgact gagaaaagct ttgaaacaga tatgaaccta 720
aactttcaaa acctgtcagt tatgggactc cgaatcctcc tgctgaaagt agccggattt 780
aacctgctca tgacgctgag gctgtggtcc agtcgggcca agcggtccgg atccggagcc 840
accaacttca gcctgctgaa gcaggccggc gacgtggagg agaaccccgg ccccatgggc 900
accaggctcc tcttctgggt ggccttctgt ctcctggggg cagatcacac aggagctgga 960
gtctcccagt cccccagtaa caaggtcaca gagaagggaa aggatgtaga gctcaggtgt 1020
gatccaattt caggtcatac tgccctttac tggtaccgac agagcctggg gcagggcctg 1080
gagtttttaa tttacttcca aggcaacagt gcaccagaca aatcagggct gcccagtgat 1140
cgcttctctg cagagaggac tgggggatcc gtctccactc tgacgatcca gcgcacacag 1200
caggaggact cggccgtgta tctctgtgcc agcatccgga cagggccttt tttctctgga 1260
aacaccatat attttggaga gggaagttgg ctcactgttg tagaggacct gagaaacgtg 1320
accccaccca aggtctcctt gtttgagcca tcaaaagcag agattgcaaa caaacaaaag 1380
gctaccctcg tgtgcttggc caggggcttc ttccctgacc acgtggagct gagctggtgg 1440
gtgaatggca aggaggtcca cagtggggtc agcacggacc ctcaggccta caaggagagc 1500
aattatagct actgcctgag cagccgcctg agggtctctg ctaccttctg gcacaatcct 1560
cgaaaccact tccgctgcca agtgcagttc catgggcttt cagaggagga caagtggcca 1620
gagggctcac ccaaacctgt cacacagaac atcagtgcag aggcctgggg ccgagcagac 1680
tgtggaatca cttcagcatc ctatcatcag ggggttctgt ctgcaaccat cctctatgag 1740
atcctactgg ggaaggccac cctatatgct gtgctggtca gtggcctggt gctgatggct 1800
atggtcaaaa gaaagaactc atga 1824
<210> 153
<211> 607
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 153
Met Ala Cys Pro Gly Phe Leu Trp Ala Leu Val Ile Ser Thr Cys Leu
1 5 10 15
Glu Phe Ser Met Ala Gln Thr Val Thr Gln Ser Gln Pro Glu Met Ser
20 25 30
Val Gln Glu Ala Glu Thr Val Thr Leu Ser Cys Thr Tyr Asp Thr Ser
35 40 45
Glu Ser Asp Tyr Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Arg Gln
50 55 60
Met Ile Leu Val Ile Arg Gln Glu Ala Tyr Lys Gln Gln Asn Ala Thr
65 70 75 80
Glu Asn Arg Phe Ser Val Asn Phe Gln Lys Ala Ala Lys Ser Phe Ser
85 90 95
Leu Lys Ile Ser Asp Ser Gln Leu Gly Asp Ala Ala Met Tyr Phe Cys
100 105 110
Ala Leu Arg Ser Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr
115 120 125
Arg Leu Lys Val Leu Ala Asn Ile Gln Asn Pro Glu Pro Ala Val Tyr
130 135 140
Gln Leu Lys Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu Phe Thr
145 150 155 160
Asp Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser Gly Thr
165 170 175
Phe Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp Ser Lys
180 185 190
Ser Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln
195 200 205
Asp Ile Phe Lys Glu Thr Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro
210 215 220
Cys Asp Ala Thr Leu Thr Glu Lys Ser Phe Glu Thr Asp Met Asn Leu
225 230 235 240
Asn Phe Gln Asn Leu Ser Val Met Gly Leu Arg Ile Leu Leu Leu Lys
245 250 255
Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser Arg
260 265 270
Ala Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln
275 280 285
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Gly Thr Arg Leu Leu
290 295 300
Phe Trp Val Ala Phe Cys Leu Leu Gly Ala Asp His Thr Gly Ala Gly
305 310 315 320
Val Ser Gln Ser Pro Ser Asn Lys Val Thr Glu Lys Gly Lys Asp Val
325 330 335
Glu Leu Arg Cys Asp Pro Ile Ser Gly His Thr Ala Leu Tyr Trp Tyr
340 345 350
Arg Gln Ser Leu Gly Gln Gly Leu Glu Phe Leu Ile Tyr Phe Gln Gly
355 360 365
Asn Ser Ala Pro Asp Lys Ser Gly Leu Pro Ser Asp Arg Phe Ser Ala
370 375 380
Glu Arg Thr Gly Gly Ser Val Ser Thr Leu Thr Ile Gln Arg Thr Gln
385 390 395 400
Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ile Arg Thr Gly Pro
405 410 415
Phe Phe Ser Gly Asn Thr Ile Tyr Phe Gly Glu Gly Ser Trp Leu Thr
420 425 430
Val Val Glu Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe
435 440 445
Glu Pro Ser Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala Thr Leu Val
450 455 460
Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp
465 470 475 480
Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala
485 490 495
Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg Leu Arg Val
500 505 510
Ser Ala Thr Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val
515 520 525
Gln Phe His Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro
530 535 540
Lys Pro Val Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp
545 550 555 560
Cys Gly Ile Thr Ser Ala Ser Tyr His Gln Gly Val Leu Ser Ala Thr
565 570 575
Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu
580 585 590
Val Ser Gly Leu Val Leu Met Ala Met Val Lys Arg Lys Asn Ser
595 600 605
<210> 154
<211> 1437
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 154
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtcc aactgcaaga aagcggaccc ggactggtga agccttctga gacacttagt 120
ctgacgtgca cggtcagtgg cggctccatc tcctcctatt attggtcatg gatacgacaa 180
cccccaggta agggcctgga atggattggc tatatctact attcaggaag cacgaactac 240
aatcccagcc tgaagtcccg agtgacaatt tcagtagata ccagtaaaaa ccagttcagt 300
cttaaactgt caagcgtgac agctgccgac accgctgtgt attactgcgt ctcactggtg 360
tattgtggag gggattgtta tagcgggttc gattattggg gacagggaac cctggtgact 420
gtatcttccg gcggcggcgg ctcagggggt ggcggtagtg gcggtggggg ttccgatatt 480
caactgacac aatcccccag ctcactcagc gccagcgtgg gggacagggt tagctttacc 540
tgtcaagcct ctcaggatat aaataacttt ctgaactggt atcaacagaa gcctgggaag 600
gcgcccaaac tcctgatcta tgatgcgtcc aacctggaaa ctggcgtgcc ttcacgcttt 660
agcggctctg gcagtggtac agacttcact tttaccatct cttcacttca gccggaggac 720
atcgccacat attactgtca acagtacgga aacttgccct ttacttttgg aggcggcacc 780
aaagttgaaa tcaaaagggc cgctgccctg gataacgaaa agagcaatgg gactataata 840
catgttaaag gaaaacacct gtgtccatct cccctgttcc ctggaccgtc aaagccattt 900
tgggtgctcg tggttgtcgg tggcgttctc gcctgttata gcttgctggt gacagtagcc 960
ttcattatct tttgggtgag atccaaaaga agccgcctgc tccatagcga ttacatgaat 1020
atgactccac gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga 1080
gatttcgctg cctatcggag ccgagtgaaa ttttctagat cagctgatgc tcccgcctat 1140
cagcagggac agaatcaact ttacaatgag ctgaacctgg gtcgcagaga agagtacgac 1200
gttttggaca aacgccgggg ccgagatcct gagatggggg ggaagccgag aaggaagaat 1260
cctcaagaag gcctgtacaa cgagcttcaa aaagacaaaa tggctgaggc gtactctgag 1320
atcggcatga agggcgagcg gagacgaggc aagggtcacg atggcttgta tcagggcctg 1380
agtacagcca caaaggacac ctatgacgcc ctccacatgc aggcactgcc cccacgc 1437
<210> 155
<211> 479
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 155
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
20 25 30
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly
35 40 45
Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys
50 55 60
Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr
65 70 75 80
Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys
85 90 95
Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
100 105 110
Val Tyr Tyr Cys Val Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser
115 120 125
Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
145 150 155 160
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
165 170 175
Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
225 230 235 240
Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe Thr Phe
245 250 255
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala Leu Asp Asn
260 265 270
Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys
275 280 285
Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val
290 295 300
Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala
305 310 315 320
Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser
325 330 335
Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His
340 345 350
Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg
355 360 365
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
370 375 380
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
385 390 395 400
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
405 410 415
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
420 425 430
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
435 440 445
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
450 455 460
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475
<210> 156
<211> 1449
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 156
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccgcaggtgc agctggtgga gtctggggga ggcgtggtcc agcctgggag gtccctgaga 120
ctctcctgtg cagcgtctgg attcaccttc agtagctatg gcatgcactg ggtccgccag 180
gctccaggca aggggctgga gtgggtggca gttatatcgt atgatggaag taataaatac 240
tatgcagact ccgtgaaggg ccgattcacc atctccagag acaattccaa gaacacgctg 300
tatctgcaaa tgaacagcct gagagccgag gacacggcgg tgtactactg cgtcaagggg 360
ccgttgcagg agccgccata cgattatgga atggacgtat ggggccaggg aacaactgtc 420
accgtctcct cagggtctac atccggctcc gggaagcccg gaagtggcga aggtagtaca 480
aagggggaaa tagtgatgac gcagtctcca gccaccctgt ctgtgtctcc aggggaaaga 540
gccaccctct cctgcagggc cagtcagagt gttagcagca acttagcctg gtaccagcag 600
aaacctggcc aggctcccag gctcctcatc tatagcgcat ccaccagggc cactggtatc 660
ccagccaggt tcagtggcag tgggtctggg acagagttca ctctcaccat cagcagcctg 720
cagtctgaag attttgcagt ttattactgt cagcagcacc acgtctggcc tctcactttt 780
ggcggaggga ccaaggttga gatcaaacgg gccgctgccc ttgataatga aaagtcaaac 840
ggaacaatca ttcacgtgaa gggcaagcac ctctgtccgt cacccttgtt ccctggtcca 900
tccaagccat tctgggtgtt ggtcgtagtg ggtggagtcc tcgcttgtta ctctctgctc 960
gtcaccgtgg cttttataat cttctgggtt agatccaaaa gaagccgcct gctccatagc 1020
gattacatga atatgactcc acgccgccct ggccccacaa ggaaacacta ccagccttac 1080
gcaccaccta gagatttcgc tgcctatcgg agcagggtga agttttccag atctgcagat 1140
gcaccagcgt atcagcaggg ccagaaccaa ctgtataacg agctcaacct gggacgcagg 1200
gaagagtatg acgttttgga caagcgcaga ggacgggacc ctgagatggg tggcaaacca 1260
agacgaaaaa acccccagga gggtctctat aatgagctgc agaaggataa gatggctgaa 1320
gcctattctg aaataggcat gaaaggagag cggagaaggg gaaaagggca cgacggtttg 1380
taccagggac tcagcactgc tacgaaggat acttatgacg ctctccacat gcaagccctg 1440
ccacctagg 1449
<210> 157
<211> 483
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 157
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
20 25 30
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
35 40 45
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys
50 55 60
Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
65 70 75 80
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
85 90 95
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
100 105 110
Ala Val Tyr Tyr Cys Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp
115 120 125
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
130 135 140
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
145 150 155 160
Lys Gly Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser
165 170 175
Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser
180 185 190
Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
195 200 205
Leu Ile Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe
210 215 220
Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu
225 230 235 240
Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp
245 250 255
Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala
260 265 270
Ala Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly
275 280 285
Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe
290 295 300
Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu
305 310 315 320
Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg
325 330 335
Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro
340 345 350
Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala
355 360 365
Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
370 375 380
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
385 390 395 400
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
405 410 415
Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
420 425 430
Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
435 440 445
Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
450 455 460
Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
465 470 475 480
Pro Pro Arg
<210> 158
<211> 1900
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 158
atgggcacca gactgttctt ttatgtggcc ctgtgtctgc tgtggaccgg ccacatggat 60
gccggaatta cacagagccc cagacacaaa gtgaccgaga caggcacccc tgtgacactg 120
agatgccacc agaccgagaa ccaccgctac atgtactggt acagacagga tccaggccac 180
ggcctgagac tgatccacta cagctacggc gtgaaggaca ccgacaaggg cgaagtgtct 240
gacggctaca gcgtgtccag aagcaagacc gaggatttcc tgctgaccct ggaaagcgcc 300
acaagcagcc agaccagcgt gtacttttgt gccatcagcg gctacaagaa caccgaggcc 360
tttttcggcc aaggcaccag gctgacagtg gtggaagatc tgaagaacgt gttcccacct 420
gaggtggccg tgtttgagcc ttctgaggcc gagatcagcc acacacagaa agccacactc 480
gtgtgcctgg ccaccggctt ttatcccgat cacgtggaac tgtcttggtg ggtcaacggc 540
aaagaggtgc acagcggcgt tagcacagac cctcagcctc tgaaagagca gcccgctctg 600
aacgacagca gatactgtct gagcagcaga ctgagagtgt ccgccacctt ctggcagaac 660
cccagaaacc acttcagatg ccaggtgcag ttctacggcc tgtccgagaa tgacgagtgg 720
acccaggata gagccaagcc agtgacacag attgtgtctg ccgaagcctg gggcagagcc 780
gattgtggct ttacaagcga gagctaccag cagggcgtgc tgtctgccac aatcctgtat 840
gagatcctgc tgggcaaagc cactctgtac gctgtgctgg tgtctgccct ggtgctgatg 900
gccatggtca agagaaagga cagcagaggc agagccaaga gatctggcag cggcgccaca 960
aactttagcc tgctgaaaca ggccggcgac gtggaagaga accctggacc tatgaagtcc 1020
ctgcgggtgc tgctggttat tctgtggctg cagctgagct gggtttggag ccagggacag 1080
caagtgatgc agatccctca gtaccagcac gtgcaagaag gcgaggactt caccacctac 1140
tgcaacagca gcacaaccct gagcaacatc cagtggtaca agcagaggcc tggcgggcac 1200
cctgtgtttc tgatccagct ggttaagagc ggcgaagtga agaagcagaa gcggctgacc 1260
tttcagttcg gcgaggccaa gaagaacagc agcctgcaca ttaccgccac acagaccacc 1320
gacgtgggca catatttttg cgctggcaga gaaggcggca gcgagaagct ggtttttggc 1380
aagggcacca aactgaccgt gaatcccgac attcagaacc ccgatccagc cgtgtaccag 1440
ctgagagaca gcaagagcag cgacaagagc gtgtgtctgt tcaccgactt cgactcccag 1500
accaatgtgt cccagagcaa ggactccgac gtgtacatca ccgataagac cgtgctggac 1560
atgcggagca tggacttcaa gagcaatagc gccgtggctt ggagcaacaa gagcgacttt 1620
gcctgcgcca acgccttcaa caacagcatc atccccgagg acacattctt cccaagtcct 1680
gagagcagct gcgacgtgaa gctggtggaa aagagcttcg agacagacac caacctgaac 1740
ttccagaacc tgagcgtgat cggcttcaga atcctgctgc tgaaggtggc cggcttcaac 1800
ctgctgatga ctctgagact gtggtccagc tgaattcgga tccaagctta ggcctgctcg 1860
ctttcttgct gtcccatttc tattaaaggt tcctttgttc 1900
<210> 159
<211> 610
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 159
Met Gly Thr Arg Leu Phe Phe Tyr Val Ala Leu Cys Leu Leu Trp Thr
1 5 10 15
Gly His Met Asp Ala Gly Ile Thr Gln Ser Pro Arg His Lys Val Thr
20 25 30
Glu Thr Gly Thr Pro Val Thr Leu Arg Cys His Gln Thr Glu Asn His
35 40 45
Arg Tyr Met Tyr Trp Tyr Arg Gln Asp Pro Gly His Gly Leu Arg Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Lys Asp Thr Asp Lys Gly Glu Val Ser
65 70 75 80
Asp Gly Tyr Ser Val Ser Arg Ser Lys Thr Glu Asp Phe Leu Leu Thr
85 90 95
Leu Glu Ser Ala Thr Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ile
100 105 110
Ser Gly Tyr Lys Asn Thr Glu Ala Phe Phe Gly Gln Gly Thr Arg Leu
115 120 125
Thr Val Val Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly Arg Ala Lys Arg Ser Gly Ser Gly Ala Thr
305 310 315 320
Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly
325 330 335
Pro Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
340 345 350
Ser Trp Val Trp Ser Gln Gly Gln Gln Val Met Gln Ile Pro Gln Tyr
355 360 365
Gln His Val Gln Glu Gly Glu Asp Phe Thr Thr Tyr Cys Asn Ser Ser
370 375 380
Thr Thr Leu Ser Asn Ile Gln Trp Tyr Lys Gln Arg Pro Gly Gly His
385 390 395 400
Pro Val Phe Leu Ile Gln Leu Val Lys Ser Gly Glu Val Lys Lys Gln
405 410 415
Lys Arg Leu Thr Phe Gln Phe Gly Glu Ala Lys Lys Asn Ser Ser Leu
420 425 430
His Ile Thr Ala Thr Gln Thr Thr Asp Val Gly Thr Tyr Phe Cys Ala
435 440 445
Gly Arg Glu Gly Gly Ser Glu Lys Leu Val Phe Gly Lys Gly Thr Lys
450 455 460
Leu Thr Val Asn Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
465 470 475 480
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
485 490 495
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
500 505 510
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
515 520 525
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
530 535 540
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
545 550 555 560
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
565 570 575
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
580 585 590
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
595 600 605
Ser Ser
610
<210> 160
<211> 1906
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 160
atgggacctg gattgctttg ttgggccctg ctgtgtctgc ttggagctgg acttgtggat 60
gccggcgtga cacagtctcc cacacacctg atcaagacca gaggccagca agtgaccctg 120
agatgtagcc ctaagagcgg ccacgacacc gtgtcttggt atcagcaggc tcttggccag 180
ggacctcagt tcatcttcca gtactacgag gaagaggaac ggcagcgggg caacttccct 240
gatagattct ctggccatca gttccccaac tacagcagcg agctgaacgt gaacgctctg 300
ctgctgggcg atagcgccct gtatctgtgt gccagttctc ttggttggag aggcggcaga 360
tacaacgagc agttctttgg ccctggcacc agactgaccg tgctggaaga tctgaagaac 420
gtgttcccac ctgaggtggc cgtgtttgag ccttctgagg ccgagatcag ccacacacag 480
aaagccacac tcgtgtgcct ggccaccggc ttttatcccg atcacgtgga actgtcttgg 540
tgggtcaacg gcaaagaggt gcacagcggc gttagcacag accctcagcc tctgaaagag 600
cagcccgctc tgaacgacag cagatactgt ctgagcagca gactgagagt gtccgccacc 660
ttctggcaga accccagaaa ccacttcaga tgccaggtgc agttctacgg cctgtccgag 720
aatgacgagt ggacccagga tagagccaag ccagtgacac agattgtgtc tgccgaagcc 780
tggggcagag ccgattgtgg ctttacaagc gagagctacc agcagggcgt gctgtctgcc 840
acaatcctgt atgagatcct gctgggcaaa gccactctgt acgctgtgct ggtgtctgcc 900
ctggtgctga tggccatggt caagagaaag gacagcagag gcagagccaa gagatctggc 960
agcggcgcca caaactttag cctgctgaaa caggccggcg acgtggaaga gaaccctgga 1020
cctatgaagt ccctgcgggt gctgctggtt attctgtggc tgcagctgag ctgggtttgg 1080
agccagggac agaacatcga ccagcctacc gagatgacag ccaccgaagg cgccatcgtg 1140
cagatcaatt gcacctacca gaccagcggc ttcaacggcc tgttctggta tcaacagcat 1200
gccggcgagg cccctacctt cctgagctat aatgtgctgg acggcctgga agaaaagggc 1260
agattcagca gcttcctgtc cagaagcaag ggctacagct acctgctgct gaaagaactc 1320
cagatgaagg acagcgcctc ctacctgtgt gcctccgtgg atggaaacaa cagactggcc 1380
ttcggcaagg gcaaccaggt ggtggtcatc cccgacattc agaaccccga tccagccgtg 1440
taccagctga gagacagcaa gagcagcgac aagagcgtgt gtctgttcac cgacttcgac 1500
tcccagacca atgtgtccca gagcaaggac tccgacgtgt acatcaccga taagaccgtg 1560
ctggacatgc ggagcatgga cttcaagagc aatagcgccg tggcttggag caacaagagc 1620
gactttgcct gcgccaacgc cttcaacaac agcatcatcc ccgaggacac attcttccca 1680
agtcctgaga gcagctgcga cgtgaagctg gtggaaaaga gcttcgagac agacaccaac 1740
ctgaacttcc agaacctgag cgtgatcggc ttcagaatcc tgctgctgaa ggtggccggc 1800
ttcaacctgc tgatgactct gagactgtgg tccagctgaa ttcggatcca agcttaggcc 1860
tgctcgcttt cttgctgtcc catttctatt aaaggttcct ttgttc 1906
<210> 161
<211> 612
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 161
Met Gly Pro Gly Leu Leu Cys Trp Ala Leu Leu Cys Leu Leu Gly Ala
1 5 10 15
Gly Leu Val Asp Ala Gly Val Thr Gln Ser Pro Thr His Leu Ile Lys
20 25 30
Thr Arg Gly Gln Gln Val Thr Leu Arg Cys Ser Pro Lys Ser Gly His
35 40 45
Asp Thr Val Ser Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Gln Phe
50 55 60
Ile Phe Gln Tyr Tyr Glu Glu Glu Glu Arg Gln Arg Gly Asn Phe Pro
65 70 75 80
Asp Arg Phe Ser Gly His Gln Phe Pro Asn Tyr Ser Ser Glu Leu Asn
85 90 95
Val Asn Ala Leu Leu Leu Gly Asp Ser Ala Leu Tyr Leu Cys Ala Ser
100 105 110
Ser Leu Gly Trp Arg Gly Gly Arg Tyr Asn Glu Gln Phe Phe Gly Pro
115 120 125
Gly Thr Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro
130 135 140
Glu Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln
145 150 155 160
Lys Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val
165 170 175
Glu Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser
180 185 190
Thr Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg
195 200 205
Tyr Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn
210 215 220
Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu
225 230 235 240
Asn Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val
245 250 255
Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser
260 265 270
Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu
275 280 285
Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met
290 295 300
Ala Met Val Lys Arg Lys Asp Ser Arg Gly Arg Ala Lys Arg Ser Gly
305 310 315 320
Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu
325 330 335
Glu Asn Pro Gly Pro Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu
340 345 350
Trp Leu Gln Leu Ser Trp Val Trp Ser Gln Gly Gln Asn Ile Asp Gln
355 360 365
Pro Thr Glu Met Thr Ala Thr Glu Gly Ala Ile Val Gln Ile Asn Cys
370 375 380
Thr Tyr Gln Thr Ser Gly Phe Asn Gly Leu Phe Trp Tyr Gln Gln His
385 390 395 400
Ala Gly Glu Ala Pro Thr Phe Leu Ser Tyr Asn Val Leu Asp Gly Leu
405 410 415
Glu Glu Lys Gly Arg Phe Ser Ser Phe Leu Ser Arg Ser Lys Gly Tyr
420 425 430
Ser Tyr Leu Leu Leu Lys Glu Leu Gln Met Lys Asp Ser Ala Ser Tyr
435 440 445
Leu Cys Ala Ser Val Asp Gly Asn Asn Arg Leu Ala Phe Gly Lys Gly
450 455 460
Asn Gln Val Val Val Ile Pro Asp Ile Gln Asn Pro Asp Pro Ala Val
465 470 475 480
Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe
485 490 495
Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp
500 505 510
Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe
515 520 525
Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys
530 535 540
Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro
545 550 555 560
Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu
565 570 575
Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg
580 585 590
Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg
595 600 605
Leu Trp Ser Ser
610
<210> 162
<211> 66
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 162
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atccca 66
<210> 163
<211> 22
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 163
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro
20
<210> 164
<211> 321
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 164
gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60
atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca 120
gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca 180
aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240
gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300
gggactaagt tggaaataac a 321
<210> 165
<211> 107
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 165
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
35 40 45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65 70 75 80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr
100 105
<210> 166
<211> 54
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 166
ggctccacct ctggatccgg caagcccgga tctggcgagg gatccaccaa gggc 54
<210> 167
<211> 18
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 167
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 168
<211> 360
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 168
gaggtgaaac tgcaggagtc aggacctggc ctggtggcgc cctcacagag cctgtccgtc 60
acatgcactg tctcaggggt ctcattaccc gactatggtg taagctggat tcgccagcct 120
ccacgaaagg gtctggagtg gctgggagta atatggggta gtgaaaccac atactataat 180
tcagctctca aatccagact gaccatcatc aaggacaact ccaagagcca agttttctta 240
aaaatgaaca gtctgcaaac tgatgacaca gccatttact actgtgccaa acattattac 300
tacggtggta gctatgctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360
<210> 169
<211> 120
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 169
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
1 5 10 15
Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr
20 25 30
Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
50 55 60
Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
65 70 75 80
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 170
<211> 9
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 170
gcggccgca 9
<210> 171
<211> 3
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 171
Ala Ala Ala
1
<210> 172
<211> 198
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 172
attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60
catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagcccttt 120
tgggtgctgg tggtggttgg gggagtcctg gcttgctata gcttgctagt aacagtggcc 180
tttattattt tctgggtg 198
<210> 173
<211> 66
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 173
Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn
1 5 10 15
Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
20 25 30
Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly
35 40 45
Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
50 55 60
Trp Val
65
<210> 174
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 174
aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60
gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120
tcc 123
<210> 175
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 175
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 176
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 176
agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60
tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120
cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180
gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240
cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300
tacgacgccc ttcacatgca ggccctgccc cctcgc 336
<210> 177
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 177
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 178
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 178
Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn
1 5 10
<210> 179
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 179
His Thr Ser Arg Leu His Ser
1 5
<210> 180
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 180
Gln Gln Gly Asn Thr Leu Pro Tyr Thr
1 5
<210> 181
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 181
Gly Val Ser Leu Pro Asp Tyr
1 5
<210> 182
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 182
Trp Gly Ser Glu Thr
1 5
<210> 183
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 183
His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
1 5 10
<210> 184
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 184
Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn
1 5 10
<210> 185
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 185
His Thr Ser Arg Leu His Ser
1 5
<210> 186
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 186
Gln Gln Gly Asn Thr Leu Pro Tyr Thr
1 5
<210> 187
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 187
Asp Tyr Gly Val Ser
1 5
<210> 188
<211> 16
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 188
Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
1 5 10 15
<210> 189
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 189
His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
1 5 10
<210> 190
<211> 63
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 190
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63
<210> 191
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 191
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 192
<211> 321
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 192
gatattcaaa tgacccagtc cccgtcctcc ctgagtgcct ccgtcggtga ccgtgttacg 60
attacctgcc gtgcgagcca agacatctct aaatacctga actggtatca gcaaaaaccg 120
gatcaggcac cgaaactgct gatcaaacat acctcacgtc tgcactcggg tgtgccgagc 180
cgctttagtg gttccggctc aggtaccgat tacaccctga cgatcagctc tctgcagccg 240
gaagactttg ccacgtatta ctgccagcaa ggtaataccc tgccgtatac gttcggccaa 300
ggtaccaaac tggaaatcaa a 321
<210> 193
<211> 107
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 193
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gln Ala Pro Lys Leu Leu Ile
35 40 45
Lys His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 194
<211> 54
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 194
ggctcgacga gcggctctgg taaaccgggc tctggtgaag gcagtaccaa aggt 54
<210> 195
<211> 18
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 195
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 196
<211> 360
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 196
gaagtgcagc tggttgaaag cggtggtggt ctggttcaac cgggtcgttc cctgcgtctg 60
tcatgtacgg cgagtggtgt ctccctgccg gactatggcg tgtcctggat tcgtcagccg 120
ccgggtaaag gcctggaatg gattggtgtc atctggggca gtgaaaccac gtattacaac 180
tcggccctga aaagccgttt caccatctct cgcgataaca gtaaaaatac gctgtacctg 240
cagatgaata gcctgcgcgc ggaagacacc gccgtttact actgcgcaaa acattactac 300
tacggtggca gctatgctat ggattactgg ggtcaaggca cgctggtcac cgtttcgtca 360
<210> 197
<211> 120
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 197
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Val Ser Leu Pro Asp Tyr
20 25 30
Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
50 55 60
Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 198
<211> 9
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 198
gccgctgcc 9
<210> 199
<211> 3
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 199
Ala Ala Ala
1
<210> 200
<211> 171
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 200
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggtcgtagt gggtggagtc 120
ctcgcttgtt actctctgct cgtcaccgtg gcttttataa tcttctgggt t 171
<210> 201
<211> 57
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 201
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
20 25 30
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
35 40 45
Thr Val Ala Phe Ile Ile Phe Trp Val
50 55
<210> 202
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 202
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120
agc 123
<210> 203
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 203
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 204
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 204
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 60
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 120
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 180
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 240
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 300
tatgacgctc tccacatgca agccctgcca cctagg 336
<210> 205
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 205
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 206
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 206
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 207
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 207
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 208
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 208
Gln Gln Tyr Gly Ser Ser Arg Phe Thr
1 5
<210> 209
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 209
Gly Gly Thr Phe Ser Ser Tyr
1 5
<210> 210
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 210
Ile Pro Ile Phe Gly Thr
1 5
<210> 211
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 211
Glu Ala Val Ala Ala Asp Trp Leu Asp Pro
1 5 10
<210> 212
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 212
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 213
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 213
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 214
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 214
Gln Gln Tyr Gly Ser Ser Arg Phe Thr
1 5
<210> 215
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 215
Ser Tyr Ala Ile Ser
1 5
<210> 216
<211> 17
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 216
Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Gln Phe Gln
1 5 10 15
Gly
<210> 217
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 217
Glu Ala Val Ala Ala Asp Trp Leu Asp Pro
1 5 10
<210> 218
<211> 63
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 218
atggccctgc ctgtgacagc tctgctgctg cccctggccc tgctgctgca tgccgccaga 60
cct 63
<210> 219
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 219
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 220
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 220
gagatcgtgc tgacccagtc tcccggcacc ctgtctctca gcccaggaga gagagccacc 60
ctgagctgca gagccagcca gagcgtgtcc agcagctacc tggcctggta tcagcagaag 120
cccggacagg cccccagact gctgatctac ggcgccagct ctagagccac cggcatcccc 180
gacagattca gcggcagcgg cagtggcacc gacttcaccc tgaccatcag cagactggaa 240
cccgaggact tcgccgtgta ctactgccag cagtacggca gcagccggtt caccttcggc 300
cctggcacca aggtggacat caag 324
<210> 221
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 221
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Arg
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 222
<211> 54
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 222
ggcagcacct ccggcagcgg caagcctggc tctggcgagg gctctaccaa gggc 54
<210> 223
<211> 18
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 223
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 224
<211> 357
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 224
caggtgcagc tggtgcagtc tggcgccgaa gtgaagaaac ccggctctag cgtgaaggtg 60
tcctgcaagg acagcggcgg caccttcagc agctacgcca tcagctgggt gcgccaggcc 120
ccaggacagg ggctggaatg gatgggcggc atcatcccca tcttcggcac caccaactac 180
gcccagcagt tccagggcag agtgaccatc accgccgacg agagcaccag caccgcctac 240
atggaactga gcagcctgcg gagcgaggac acagccgtgt attactgtgc ccgcgaggcc 300
gtggccgccg actggctgga tccttgggga cagggcaccc tggtgacagt gtccagc 357
<210> 225
<211> 119
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 225
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Asp Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Gln Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ala Val Ala Ala Asp Trp Leu Asp Pro Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 226
<211> 249
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 226
ttcgtgcccg tgttcctgcc cgccaagcct accaccaccc ctgcccctag acctcccacc 60
ccagccccaa caatcgccag ccagcctctg tccctgcggc ccgaagcctg tagacctgct 120
gccggcggag ccgtgcacac cagaggcctg gacttcgcct gcgatatcta catctgggcc 180
cctctggccg gcacctgtgg cgtgctgctg ctgagcctgg tgatcaccct gtactgcaac 240
caccggaac 249
<210> 227
<211> 83
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 227
Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro
1 5 10 15
Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu
20 25 30
Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
35 40 45
Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly
50 55 60
Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn
65 70 75 80
His Arg Asn
<210> 228
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 228
agaagcaagc ggagccggct gctgcacagc gactacatga acatgacccc aagacggcct 60
ggccccaccc ggaagcacta ccagccttac gcccctccca gagacttcgc cgcctaccgg 120
tcc 123
<210> 229
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 229
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 230
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 230
agagtgaagt tcagcagatc cgccgacgcc cctgcctacc agcagggaca gaaccagctg 60
tacaacgagc tgaacctggg cagacgggaa gagtacgacg tgctggacaa gcggagaggc 120
cgggaccccg agatgggcgg aaagcccaga cggaagaacc cccaggaagg cctgtataac 180
gaactgcaga aagacaagat ggccgaggcc tacagcgaga tcggcatgaa gggcgagcgg 240
aggcgcggca agggccacga tggcctgtac cagggcctga gcaccgccac caaggacacc 300
tacgacgccc tgcacatgca ggccctgccc cccaga 336
<210> 231
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 231
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 232
<211> 339
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 232
atggcatgcc ctggcttcct gtgggcactt gtgatctcca cctgtcttga atttagcatg 60
gctcagacag tcactcagtc tcaaccagag atgtctgtgc aggaggcaga gaccgtgacc 120
ctgagctgca catatgacac cagtgagagt gattattatt tattctggta caagcagcct 180
cccagcaggc agatgattct cgttattcgc caagaagctt ataagcaaca gaatgcaaca 240
gagaatcgtt tctctgtgaa cttccagaaa gcagccaaat ccttcagtct caagatctca 300
gactcacagc tgggggatgc cgcgatgtat ttctgtgct 339
<210> 233
<211> 135
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 233
Met Ala Cys Pro Gly Phe Leu Trp Ala Leu Val Ile Ser Thr Cys Leu
1 5 10 15
Glu Phe Ser Met Ala Gln Thr Val Thr Gln Ser Gln Pro Glu Met Ser
20 25 30
Val Gln Glu Ala Glu Thr Val Thr Leu Ser Cys Thr Tyr Asp Thr Ser
35 40 45
Glu Ser Asp Tyr Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Arg Gln
50 55 60
Met Ile Leu Val Ile Arg Gln Glu Ala Tyr Lys Gln Gln Asn Ala Thr
65 70 75 80
Glu Asn Arg Phe Ser Val Asn Phe Gln Lys Ala Ala Lys Ser Phe Ser
85 90 95
Leu Lys Ile Ser Asp Ser Gln Leu Gly Asp Ala Ala Met Tyr Phe Cys
100 105 110
Ala Leu Arg Ser Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr
115 120 125
Arg Leu Lys Val Leu Ala Asn
130 135
<210> 234
<211> 66
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 234
ctccggagct caggaaccta caaatacatc tttggaacag gcaccaggct gaaggtttta 60
gcaaat 66
<210> 235
<211> 408
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 235
atccagaacc ctgaacctgc tgtgtaccag ttaaaagatc ctcggtctca ggacagcacc 60
ctctgcctgt tcaccgactt tgactcccaa atcaatgtgc cgaaaaccat ggaatctgga 120
acgttcatca ctgacaaaac tgtgctggac atgaaagcta tggattccaa gagcaatggg 180
gccattgcct ggagcaacca gacaagcttc acctgccaag atatcttcaa agagaccaac 240
gccacctacc ccagttcaga cgttccctgt gatgccacgt tgactgagaa aagctttgaa 300
acagatatga acctaaactt tcaaaacctg tcagttatgg gactccgaat cctcctgctg 360
aaagtagccg gatttaacct gctcatgacg ctgaggctgt ggtccagt 408
<210> 236
<211> 136
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 236
Ile Gln Asn Pro Glu Pro Ala Val Tyr Gln Leu Lys Asp Pro Arg Ser
1 5 10 15
Gln Asp Ser Thr Leu Cys Leu Phe Thr Asp Phe Asp Ser Gln Ile Asn
20 25 30
Val Pro Lys Thr Met Glu Ser Gly Thr Phe Ile Thr Asp Lys Thr Val
35 40 45
Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn Gly Ala Ile Ala Trp
50 55 60
Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile Phe Lys Glu Thr Asn
65 70 75 80
Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp Ala Thr Leu Thr Glu
85 90 95
Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe Gln Asn Leu Ser Val
100 105 110
Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu
115 120 125
Met Thr Leu Arg Leu Trp Ser Ser
130 135
<210> 237
<211> 81
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 237
cgggccaagc ggtccggatc cggagccacc aacttcagcc tgctgaagca ggccggcgac 60
gtggaggaga accccggccc c 81
<210> 238
<211> 27
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 238
Arg Ala Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys
1 5 10 15
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro
20 25
<210> 239
<211> 340
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 239
atgggcacca ggctcctctt ctgggtggcc ttctgtctcc tgggggcaga tcacacagga 60
gctggagtct cccagtcccc cagtaacaag gtcacagaga agggaaagga tgtagagctc 120
aggtgtgatc caatttcagg tcatactgcc ctttactggt accgacagag cctggggcag 180
ggcctggagt ttttaattta cttccaaggc aacagtgcac cagacaaatc agggctgccc 240
agtgatcgct tctctgcaga gaggactggg ggatccgtct ccactctgac gatccagcgc 300
acacagcagg aggactcggc cgtgtatctc tgtgccagca 340
<210> 240
<211> 137
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 240
Met Gly Thr Arg Leu Leu Phe Trp Val Ala Phe Cys Leu Leu Gly Ala
1 5 10 15
Asp His Thr Gly Ala Gly Val Ser Gln Ser Pro Ser Asn Lys Val Thr
20 25 30
Glu Lys Gly Lys Asp Val Glu Leu Arg Cys Asp Pro Ile Ser Gly His
35 40 45
Thr Ala Leu Tyr Trp Tyr Arg Gln Ser Leu Gly Gln Gly Leu Glu Phe
50 55 60
Leu Ile Tyr Phe Gln Gly Asn Ser Ala Pro Asp Lys Ser Gly Leu Pro
65 70 75 80
Ser Asp Arg Phe Ser Ala Glu Arg Thr Gly Gly Ser Val Ser Thr Leu
85 90 95
Thr Ile Gln Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala
100 105 110
Ser Ile Arg Thr Gly Pro Phe Phe Ser Gly Asn Thr Ile Tyr Phe Gly
115 120 125
Glu Gly Ser Trp Leu Thr Val Val Glu
130 135
<210> 241
<211> 71
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 241
tccggacagg gccttttttc tctggaaaca ccatatattt tggagaggga agttggctca 60
ctgttgtaga g 71
<210> 242
<211> 519
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 242
gacctgagaa acgtgacccc acccaaggtc tccttgtttg agccatcaaa agcagagatt 60
gcaaacaaac aaaaggctac cctcgtgtgc ttggccaggg gcttcttccc tgaccacgtg 120
gagctgagct ggtgggtgaa tggcaaggag gtccacagtg gggtcagcac ggaccctcag 180
gcctacaagg agagcaatta tagctactgc ctgagcagcc gcctgagggt ctctgctacc 240
ttctggcaca atcctcgaaa ccacttccgc tgccaagtgc agttccatgg gctttcagag 300
gaggacaagt ggccagaggg ctcacccaaa cctgtcacac agaacatcag tgcagaggcc 360
tggggccgag cagactgtgg aatcacttca gcatcctatc atcagggggt tctgtctgca 420
accatcctct atgagatcct actggggaag gccaccctat atgctgtgct ggtcagtggc 480
ctggtgctga tggctatggt caaaagaaag aactcatga 519
<210> 243
<211> 172
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 243
Asp Leu Arg Asn Val Thr Pro Pro Lys Val Ser Leu Phe Glu Pro Ser
1 5 10 15
Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala Thr Leu Val Cys Leu Ala
20 25 30
Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
35 40 45
Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Ala Tyr Lys Glu
50 55 60
Ser Asn Tyr Ser Tyr Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr
65 70 75 80
Phe Trp His Asn Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His
85 90 95
Gly Leu Ser Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val
100 105 110
Thr Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Ile
115 120 125
Thr Ser Ala Ser Tyr His Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr
130 135 140
Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Gly
145 150 155 160
Leu Val Leu Met Ala Met Val Lys Arg Lys Asn Ser
165 170
<210> 244
<211> 12
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 244
Thr Tyr Asp Thr Ser Glu Ser Asp Tyr Tyr Leu Phe
1 5 10
<210> 245
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 245
Gln Glu Ala Tyr Lys Gln Gln
1 5
<210> 246
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 246
Ala Leu Arg Ser Ser Gly Thr Tyr Lys Tyr Ile
1 5 10
<210> 247
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 247
Asp Pro Ile Ser Gly His Thr Ala Leu Tyr
1 5 10
<210> 248
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 248
Phe Gln Gly Asn Ser Ala Pro Asp Lys Ser Gly
1 5 10
<210> 249
<211> 15
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 249
Ala Ser Ile Arg Thr Gly Pro Phe Phe Ser Gly Asn Thr Ile Tyr
1 5 10 15
<210> 250
<211> 63
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 250
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63
<210> 251
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 251
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 252
<211> 366
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 252
caggtccaac tgcaagaaag cggacccgga ctggtgaagc cttctgagac acttagtctg 60
acgtgcacgg tcagtggcgg ctccatctcc tcctattatt ggtcatggat acgacaaccc 120
ccaggtaagg gcctggaatg gattggctat atctactatt caggaagcac gaactacaat 180
cccagcctga agtcccgagt gacaatttca gtagatacca gtaaaaacca gttcagtctt 240
aaactgtcaa gcgtgacagc tgccgacacc gctgtgtatt actgcgtctc actggtgtat 300
tgtggagggg attgttatag cgggttcgat tattggggac agggaaccct ggtgactgta 360
tcttcc 366
<210> 253
<211> 122
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 253
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Ser Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 254
<211> 45
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 254
ggcggcggcg gctcaggggg tggcggtagt ggcggtgggg gttcc 45
<210> 255
<211> 15
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 255
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 256
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 256
gatattcaac tgacacaatc ccccagctca ctcagcgcca gcgtggggga cagggttagc 60
tttacctgtc aagcctctca ggatataaat aactttctga actggtatca acagaagcct 120
gggaaggcgc ccaaactcct gatctatgat gcgtccaacc tggaaactgg cgtgccttca 180
cgctttagcg gctctggcag tggtacagac ttcactttta ccatctcttc acttcagccg 240
gaggacatcg ccacatatta ctgtcaacag tacggaaact tgccctttac ttttggaggc 300
ggcaccaaag ttgaaatcaa aagg 324
<210> 257
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 257
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Ser Phe Thr Cys Gln Ala Ser Gln Asp Ile Asn Asn Phe
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Asn Leu Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 258
<211> 9
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 258
gccgctgcc 9
<210> 259
<211> 3
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 259
Ala Ala Ala
1
<210> 260
<211> 171
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 260
ctggataacg aaaagagcaa tgggactata atacatgtta aaggaaaaca cctgtgtcca 60
tctcccctgt tccctggacc gtcaaagcca ttttgggtgc tcgtggttgt cggtggcgtt 120
ctcgcctgtt atagcttgct ggtgacagta gccttcatta tcttttgggt g 171
<210> 261
<211> 57
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 261
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
20 25 30
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
35 40 45
Thr Val Ala Phe Ile Ile Phe Trp Val
50 55
<210> 262
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 262
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120
agc 123
<210> 263
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 263
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 264
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 264
cgagtgaaat tttctagatc agctgatgct cccgcctatc agcagggaca gaatcaactt 60
tacaatgagc tgaacctggg tcgcagagaa gagtacgacg ttttggacaa acgccggggc 120
cgagatcctg agatgggggg gaagccgaga aggaagaatc ctcaagaagg cctgtacaac 180
gagcttcaaa aagacaaaat ggctgaggcg tactctgaga tcggcatgaa gggcgagcgg 240
agacgaggca agggtcacga tggcttgtat cagggcctga gtacagccac aaaggacacc 300
tatgacgccc tccacatgca ggcactgccc ccacgc 336
<210> 265
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 265
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 266
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 266
Gln Ala Ser Gln Asp Ile Asn Asn Phe Leu Asn
1 5 10
<210> 267
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 267
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 268
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 268
Gln Gln Tyr Gly Asn Leu Pro Phe Thr
1 5
<210> 269
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 269
Gly Gly Ser Ile Ser Ser Tyr
1 5
<210> 270
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 270
Tyr Tyr Ser Gly Ser
1 5
<210> 271
<211> 14
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 271
Leu Val Tyr Cys Gly Gly Asp Cys Tyr Ser Gly Phe Asp Tyr
1 5 10
<210> 272
<211> 63
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 272
atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60
ccg 63
<210> 273
<211> 21
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 273
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20
<210> 274
<211> 369
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 274
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatcgtatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggcggtgt actactgcgt caaggggccg 300
ttgcaggagc cgccatacga ttatggaatg gacgtatggg gccagggaac aactgtcacc 360
gtctcctca 369
<210> 275
<211> 123
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 275
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 276
<211> 54
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 276
gggtctacat ccggctccgg gaagcccgga agtggcgaag gtagtacaaa gggg 54
<210> 277
<211> 18
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 277
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly
<210> 278
<211> 324
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 278
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatagc gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag caccacgtct ggcctctcac ttttggcgga 300
gggaccaagg ttgagatcaa acgg 324
<210> 279
<211> 108
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 279
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His His Val Trp Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 280
<211> 9
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 280
gccgctgcc 9
<210> 281
<211> 3
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 281
Ala Ala Ala
1
<210> 282
<211> 171
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 282
cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60
tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggtcgtagt gggtggagtc 120
ctcgcttgtt actctctgct cgtcaccgtg gcttttataa tcttctgggt t 171
<210> 283
<211> 57
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 283
Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
1 5 10 15
His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
20 25 30
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
35 40 45
Thr Val Ala Phe Ile Ile Phe Trp Val
50 55
<210> 284
<211> 123
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 284
agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60
ggccccacaa ggaaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120
agc 123
<210> 285
<211> 41
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 285
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 286
<211> 336
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 286
agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 60
tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 120
cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 180
gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 240
agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 300
tatgacgctc tccacatgca agccctgcca cctagg 336
<210> 287
<211> 112
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 287
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 288
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 288
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10
<210> 289
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 289
Ser Ala Ser Thr Arg Ala Thr
1 5
<210> 290
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 290
Gln Gln His His Val Trp Pro Leu Thr Phe
1 5 10
<210> 291
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 291
Gly Phe Thr Phe Ser Ser Tyr
1 5
<210> 292
<211> 17
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 292
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 293
<211> 16
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 293
Val Lys Gly Pro Leu Gln Glu Pro Pro Tyr Asp Tyr Gly Met Asp Val
1 5 10 15
<210> 294
<211> 393
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 294
atgggcacca gactgttctt ttatgtggcc ctgtgtctgc tgtggaccgg ccacatggat 60
gccggaatta cacagagccc cagacacaaa gtgaccgaga caggcacccc tgtgacactg 120
agatgccacc agaccgagaa ccaccgctac atgtactggt acagacagga tccaggccac 180
ggcctgagac tgatccacta cagctacggc gtgaaggaca ccgacaaggg cgaagtgtct 240
gacggctaca gcgtgtccag aagcaagacc gaggatttcc tgctgaccct ggaaagcgcc 300
acaagcagcc agaccagcgt gtacttttgt gccatcagcg gctacaagaa caccgaggcc 360
tttttcggcc aaggcaccag gctgacagtg gtg 393
<210> 295
<211> 131
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 295
Met Gly Thr Arg Leu Phe Phe Tyr Val Ala Leu Cys Leu Leu Trp Thr
1 5 10 15
Gly His Met Asp Ala Gly Ile Thr Gln Ser Pro Arg His Lys Val Thr
20 25 30
Glu Thr Gly Thr Pro Val Thr Leu Arg Cys His Gln Thr Glu Asn His
35 40 45
Arg Tyr Met Tyr Trp Tyr Arg Gln Asp Pro Gly His Gly Leu Arg Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Lys Asp Thr Asp Lys Gly Glu Val Ser
65 70 75 80
Asp Gly Tyr Ser Val Ser Arg Ser Lys Thr Glu Asp Phe Leu Leu Thr
85 90 95
Leu Glu Ser Ala Thr Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ile
100 105 110
Ser Gly Tyr Lys Asn Thr Glu Ala Phe Phe Gly Gln Gly Thr Arg Leu
115 120 125
Thr Val Val
130
<210> 296
<211> 537
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 296
gaagatctga agaacgtgtt cccacctgag gtggccgtgt ttgagccttc tgaggccgag 60
atcagccaca cacagaaagc cacactcgtg tgcctggcca ccggctttta tcccgatcac 120
gtggaactgt cttggtgggt caacggcaaa gaggtgcaca gcggcgttag cacagaccct 180
cagcctctga aagagcagcc cgctctgaac gacagcagat actgtctgag cagcagactg 240
agagtgtccg ccaccttctg gcagaacccc agaaaccact tcagatgcca ggtgcagttc 300
tacggcctgt ccgagaatga cgagtggacc caggatagag ccaagccagt gacacagatt 360
gtgtctgccg aagcctgggg cagagccgat tgtggcttta caagcgagag ctaccagcag 420
ggcgtgctgt ctgccacaat cctgtatgag atcctgctgg gcaaagccac tctgtacgct 480
gtgctggtgt ctgccctggt gctgatggcc atggtcaaga gaaaggacag cagaggc 537
<210> 297
<211> 179
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 297
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 298
<211> 81
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 298
agagccaaga gatctggcag cggcgccaca aactttagcc tgctgaaaca ggccggcgac 60
gtggaagaga accctggacc t 81
<210> 299
<211> 27
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 299
Arg Ala Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys
1 5 10 15
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro
20 25
<210> 300
<211> 396
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 300
atgaagtccc tgcgggtgct gctggttatt ctgtggctgc agctgagctg ggtttggagc 60
cagggacagc aagtgatgca gatccctcag taccagcacg tgcaagaagg cgaggacttc 120
accacctact gcaacagcag cacaaccctg agcaacatcc agtggtacaa gcagaggcct 180
ggcgggcacc ctgtgtttct gatccagctg gttaagagcg gcgaagtgaa gaagcagaag 240
cggctgacct ttcagttcgg cgaggccaag aagaacagca gcctgcacat taccgccaca 300
cagaccaccg acgtgggcac atatttttgc gctggcagag aaggcggcag cgagaagctg 360
gtttttggca agggcaccaa actgaccgtg aatccc 396
<210> 301
<211> 132
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 301
Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu Ser
1 5 10 15
Trp Val Trp Ser Gln Gly Gln Gln Val Met Gln Ile Pro Gln Tyr Gln
20 25 30
His Val Gln Glu Gly Glu Asp Phe Thr Thr Tyr Cys Asn Ser Ser Thr
35 40 45
Thr Leu Ser Asn Ile Gln Trp Tyr Lys Gln Arg Pro Gly Gly His Pro
50 55 60
Val Phe Leu Ile Gln Leu Val Lys Ser Gly Glu Val Lys Lys Gln Lys
65 70 75 80
Arg Leu Thr Phe Gln Phe Gly Glu Ala Lys Lys Asn Ser Ser Leu His
85 90 95
Ile Thr Ala Thr Gln Thr Thr Asp Val Gly Thr Tyr Phe Cys Ala Gly
100 105 110
Arg Glu Gly Gly Ser Glu Lys Leu Val Phe Gly Lys Gly Thr Lys Leu
115 120 125
Thr Val Asn Pro
130
<210> 302
<211> 493
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 302
gacattcaga accccgatcc agccgtgtac cagctgagag acagcaagag cagcgacaag 60
agcgtgtgtc tgttcaccga cttcgactcc cagaccaatg tgtcccagag caaggactcc 120
gacgtgtaca tcaccgataa gaccgtgctg gacatgcgga gcatggactt caagagcaat 180
agcgccgtgg cttggagcaa caagagcgac tttgcctgcg ccaacgcctt caacaacagc 240
atcatccccg aggacacatt cttcccaagt cctgagagca gctgcgacgt gaagctggtg 300
gaaaagagct tcgagacaga caccaacctg aacttccaga acctgagcgt gatcggcttc 360
agaatcctgc tgctgaaggt ggccggcttc aacctgctga tgactctgag actgtggtcc 420
agctgaattc ggatccaagc ttaggcctgc tcgctttctt gctgtcccat ttctattaaa 480
ggttcctttg ttc 493
<210> 303
<211> 141
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 303
Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
1 5 10 15
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
20 25 30
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr
35 40 45
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
50 55 60
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
65 70 75 80
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
85 90 95
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
100 105 110
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
115 120 125
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
130 135 140
<210> 304
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 304
Thr Thr Leu Ser Asn
1 5
<210> 305
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 305
Leu Val Lys Ser Gly Glu Val
1 5
<210> 306
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 306
Ala Gly Arg Glu Gly Gly Ser Glu Lys Leu Val
1 5 10
<210> 307
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 307
Glu Asn His Arg Tyr
1 5
<210> 308
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 308
Ser Tyr Gly Val Lys Asp
1 5
<210> 309
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 309
Ala Ile Ser Gly Tyr Lys Asn Thr Glu Ala Phe
1 5 10
<210> 310
<211> 405
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 310
atgggacctg gattgctttg ttgggccctg ctgtgtctgc ttggagctgg acttgtggat 60
gccggcgtga cacagtctcc cacacacctg atcaagacca gaggccagca agtgaccctg 120
agatgtagcc ctaagagcgg ccacgacacc gtgtcttggt atcagcaggc tcttggccag 180
ggacctcagt tcatcttcca gtactacgag gaagaggaac ggcagcgggg caacttccct 240
gatagattct ctggccatca gttccccaac tacagcagcg agctgaacgt gaacgctctg 300
ctgctgggcg atagcgccct gtatctgtgt gccagttctc ttggttggag aggcggcaga 360
tacaacgagc agttctttgg ccctggcacc agactgaccg tgctg 405
<210> 311
<211> 135
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 311
Met Gly Pro Gly Leu Leu Cys Trp Ala Leu Leu Cys Leu Leu Gly Ala
1 5 10 15
Gly Leu Val Asp Ala Gly Val Thr Gln Ser Pro Thr His Leu Ile Lys
20 25 30
Thr Arg Gly Gln Gln Val Thr Leu Arg Cys Ser Pro Lys Ser Gly His
35 40 45
Asp Thr Val Ser Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Gln Phe
50 55 60
Ile Phe Gln Tyr Tyr Glu Glu Glu Glu Arg Gln Arg Gly Asn Phe Pro
65 70 75 80
Asp Arg Phe Ser Gly His Gln Phe Pro Asn Tyr Ser Ser Glu Leu Asn
85 90 95
Val Asn Ala Leu Leu Leu Gly Asp Ser Ala Leu Tyr Leu Cys Ala Ser
100 105 110
Ser Leu Gly Trp Arg Gly Gly Arg Tyr Asn Glu Gln Phe Phe Gly Pro
115 120 125
Gly Thr Arg Leu Thr Val Leu
130 135
<210> 312
<211> 537
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 312
gaagatctga agaacgtgtt cccacctgag gtggccgtgt ttgagccttc tgaggccgag 60
atcagccaca cacagaaagc cacactcgtg tgcctggcca ccggctttta tcccgatcac 120
gtggaactgt cttggtgggt caacggcaaa gaggtgcaca gcggcgttag cacagaccct 180
cagcctctga aagagcagcc cgctctgaac gacagcagat actgtctgag cagcagactg 240
agagtgtccg ccaccttctg gcagaacccc agaaaccact tcagatgcca ggtgcagttc 300
tacggcctgt ccgagaatga cgagtggacc caggatagag ccaagccagt gacacagatt 360
gtgtctgccg aagcctgggg cagagccgat tgtggcttta caagcgagag ctaccagcag 420
ggcgtgctgt ctgccacaat cctgtatgag atcctgctgg gcaaagccac tctgtacgct 480
gtgctggtgt ctgccctggt gctgatggcc atggtcaaga gaaaggacag cagaggc 537
<210> 313
<211> 179
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 313
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 314
<211> 81
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
寡核苷酸"
<400> 314
agagccaaga gatctggcag cggcgccaca aactttagcc tgctgaaaca ggccggcgac 60
gtggaagaga accctggacc t 81
<210> 315
<211> 27
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 315
Arg Ala Lys Arg Ser Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys
1 5 10 15
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro
20 25
<210> 316
<211> 390
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 316
atgaagtccc tgcgggtgct gctggttatt ctgtggctgc agctgagctg ggtttggagc 60
cagggacaga acatcgacca gcctaccgag atgacagcca ccgaaggcgc catcgtgcag 120
atcaattgca cctaccagac cagcggcttc aacggcctgt tctggtatca acagcatgcc 180
ggcgaggccc ctaccttcct gagctataat gtgctggacg gcctggaaga aaagggcaga 240
ttcagcagct tcctgtccag aagcaagggc tacagctacc tgctgctgaa agaactccag 300
atgaaggaca gcgcctccta cctgtgtgcc tccgtggatg gaaacaacag actggccttc 360
ggcaagggca accaggtggt ggtcatcccc 390
<210> 317
<211> 130
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 317
Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu Ser
1 5 10 15
Trp Val Trp Ser Gln Gly Gln Asn Ile Asp Gln Pro Thr Glu Met Thr
20 25 30
Ala Thr Glu Gly Ala Ile Val Gln Ile Asn Cys Thr Tyr Gln Thr Ser
35 40 45
Gly Phe Asn Gly Leu Phe Trp Tyr Gln Gln His Ala Gly Glu Ala Pro
50 55 60
Thr Phe Leu Ser Tyr Asn Val Leu Asp Gly Leu Glu Glu Lys Gly Arg
65 70 75 80
Phe Ser Ser Phe Leu Ser Arg Ser Lys Gly Tyr Ser Tyr Leu Leu Leu
85 90 95
Lys Glu Leu Gln Met Lys Asp Ser Ala Ser Tyr Leu Cys Ala Ser Val
100 105 110
Asp Gly Asn Asn Arg Leu Ala Phe Gly Lys Gly Asn Gln Val Val Val
115 120 125
Ile Pro
130
<210> 318
<211> 493
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 318
gacattcaga accccgatcc agccgtgtac cagctgagag acagcaagag cagcgacaag 60
agcgtgtgtc tgttcaccga cttcgactcc cagaccaatg tgtcccagag caaggactcc 120
gacgtgtaca tcaccgataa gaccgtgctg gacatgcgga gcatggactt caagagcaat 180
agcgccgtgg cttggagcaa caagagcgac tttgcctgcg ccaacgcctt caacaacagc 240
atcatccccg aggacacatt cttcccaagt cctgagagca gctgcgacgt gaagctggtg 300
gaaaagagct tcgagacaga caccaacctg aacttccaga acctgagcgt gatcggcttc 360
agaatcctgc tgctgaaggt ggccggcttc aacctgctga tgactctgag actgtggtcc 420
agctgaattc ggatccaagc ttaggcctgc tcgctttctt gctgtcccat ttctattaaa 480
ggttcctttg ttc 493
<210> 319
<211> 141
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多肽"
<400> 319
Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
1 5 10 15
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
20 25 30
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr
35 40 45
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
50 55 60
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
65 70 75 80
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
85 90 95
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
100 105 110
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
115 120 125
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
130 135 140
<210> 320
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 320
Thr Ser Gly Phe Asn Gly
1 5
<210> 321
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 321
Asn Val Leu Asp Gly Leu
1 5
<210> 322
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 322
Ala Ser Val Asp Gly Asn Asn Arg Leu Ala
1 5 10
<210> 323
<211> 5
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 323
Ser Gly His Asp Thr
1 5
<210> 324
<211> 6
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 324
Tyr Tyr Glu Glu Glu Glu
1 5
<210> 325
<211> 15
<212> PRT
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
肽"
<400> 325
Ala Ser Ser Leu Gly Trp Arg Gly Gly Arg Tyr Asn Glu Gln Phe
1 5 10 15
<210> 326
<211> 6762
<212> DNA
<213> 人工序列
<220>
<221> 来源
<223> /注释="人工序列的说明: 合成
多核苷酸"
<400> 326
ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 60
ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg 120
ccacgttcgc cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat 180
ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg 240
ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 300
gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt 360
tataagggat tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat 420
ttaacgcgaa ttttaacaaa atattaacgc ttacaatttg ccattcgcca ttcaggctgc 480
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 540
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt 600
gtaaaacgac ggccagtgaa ttgtaatacg actcactata gggcgacccg gggatggcgc 660
gccagtaatc aattacgggg tcattagttc atagcccata tatggagttc cgcgttacat 720
aacttacggt aaatggcccg cctggctgac cgcccaacga cccccgccca ttgacgtcaa 780
taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt caatgggtgg 840
agtatttacg gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc 900
cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag tacatgacct 960
tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt accatgctga 1020
tgcggttttg gcagtacatc aatgggcgtg gatagcggtt tgactcacgg ggatttccaa 1080
gtctccaccc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa cgggactttc 1140
caaaatgtcg taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacggtggg 1200
aggtctatat aagcagagct ggtttagtga accggggtct ctctggttag accagatctg 1260
agcctgggag ctctctggct aactagggaa cccactgctt aagcctcaat aaagcttgcc 1320
ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac tctggtaact agagatccct 1380
cagacccttt tagtcagtgt ggaaaatctc tagcagtggc gcccgaacag ggacttgaaa 1440
gcgaaaggga aaccagagga gctctctcga cgcaggactc ggcttgctga agcgcgcacg 1500
gcaagaggcg aggggcggcg actggtgagt acgccaaaaa ttttgactag cggaggctag 1560
aaggagagag atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgcgatgg 1620
gaaaaaattc ggttaaggcc agggggaaag aaaaaatata aattaaaaca tatagtatgg 1680
gcaagcaggg agctagaacg attcgcagtt aatcctggcc tgttagaaac atcagaaggc 1740
tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga agaacttaga 1800
tcattatata atacagtagc aaccctctat tgtgtgcatc aaaggataga gataaaagac 1860
accaaggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac caccgcacag 1920
caagccgccg ctgatcttca gacctggagg aggagatatg agggacaatt ggagaagtga 1980
attatataaa tataaagtag taaaaattga accattagga gtagcaccca ccaaggcaaa 2040
gagaagagtg gtgcagagag aaaaaagagc agtgggaata ggagctttgt tccttgggtt 2100
cttgggagca gcaggaagca ctatgggcgc agcgtcaatg acgctgacgg tacaggccag 2160
acaattattg tctggtatag tgcagcagca gaacaatttg ctgagggcta ttgaggcgca 2220
acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa gaatcctggc 2280
tgtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgct ctggaaaact 2340
catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc tggaacagat 2400
ttggaatcac acgacctgga tggagtggga cagagaaatt aacaattaca caagcttaat 2460
acactcctta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag aattattgga 2520
attagataaa tgggcaagtt tgtggaattg gtttaacata acaaattggc tgtggtatat 2580
aaaattattc ataatgatag taggaggctt ggtaggttta agaatagttt ttgctgtact 2640
ttctatagtg aatagagtta ggcagggata ttcaccatta tcgtttcaga cccacctccc 2700
aaccccgagg ggacccgaca ggcccgaagg aatagaagaa gaaggtggag agagagacag 2760
agacagatcc attcgattag tgaacggatc tcgacggtat cggttaactt ttaaaagaaa 2820
aggggggatt ggggggtaca gtgcagggga aagaatagta gacataatag caacagacat 2880
acaaactaaa gaattacaaa aacaaattac aaaattcaaa attttatcgc gatcgcggaa 2940
tgaaagaccc cacctgtagg tttggcaagc tagcttaagt aacgccattt tgcaaggcat 3000
ggaaaataca taactgagaa tagagaagtt cagatcaagg ttaggaacag agagacagca 3060
gaatatgggc caaacaggat atctgtggta agcagttcct gccccggctc agggccaaga 3120
acagatggtc cccagatgcg gtcccgccct cagcagtttc tagagaacca tcagatgttt 3180
ccagggtgcc ccaaggacct gaaaatgacc ctgtgcctta tttgaactaa ccaatcagtt 3240
cgcttctcgc ttctgttcgc gcgcttctgc tccccgagct caataaaaga gcccacaacc 3300
cctcactcgg cgcgccagtc cttcgaagta gatctttgtc gatcctacca tccactcgac 3360
acacccgcca gcggccgctg ccaagcttcc gagctctcga attaattcac ggtacccacc 3420
atggcctagg gagactagtc gaatcgatat caacctctgg attacaaaat ttgtgaaaga 3480
ttgactggta ttcttaacta tgttgctcct tttacgctat gtggatacgc tgctttaatg 3540
cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt gtataaatcc 3600
tggttgctgt ctctttatga ggagttgtgg cccgttgtca ggcaacgtgg cgtggtgtgc 3660
actgtgtttg ctgacgcaac ccccactggt tggggcattg ccaccacctg tcagctcctt 3720
tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc cgcctgcctt 3780
gcccgctgct ggacaggggc tcggctgttg ggcactgaca attccgtggt gttgtcgggg 3840
aagctgacgt ccttttcatg gctgctcgcc tgtgttgcca cctggattct gcgcgggacg 3900
tccttctgct acgtcccttc ggccctcaat ccagcggacc ttccttcccg cggcctgctg 3960
ccggctctgc ggcctcttcc gcgtcttcgc cttcgccctc agacgagtcg gatctccctt 4020
tgggccgcct ccccgcctgg ttaattaaag tacctttaag accaatgact tacaaggcag 4080
ctgtagatct tagccacttt ttaaaagaaa aggggggact ggaagggcga attcactccc 4140
aacgaagaca agatctgctt tttgcttgta ctgggtctct ctggttagac cagatctgag 4200
cctgggagct ctctggctaa ctagggaacc cactgcttaa gcctcaataa agcttgcctt 4260
gagtgcttca agtagtgtgt gcccgtctgt tgtgtgactc tggtaactag agatccctca 4320
gaccctttta gtcagtgtgg aaaatctcta gcaggcatgc cagacatgat aagatacatt 4380
gatgagtttg gacaaaccac aactagaatg cagtgaaaaa aatgctttat ttgtgaaatt 4440
tgtgatgcta ttgctttatt tgtaaccatt ataagctgca ataaacaagt taacaacaac 4500
aattgcattc attttatgtt tcaggttcag ggggaggtgt gggaggtttt ttggcgcgcc 4560
atcgtcgagg ttccctttag tgagggttaa ttgcgagctt ggcgtaatca tggtcatagc 4620
tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca 4680
taaagtgtaa agcctggggt gcctaatgag tgagctaact cacattaatt gcgttgcgct 4740
cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac 4800
gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc 4860
tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt 4920
tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 4980
ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg 5040
agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 5100
accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 5160
ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct 5220
gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc 5280
ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa 5340
gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 5400
taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag 5460
tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt 5520
gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 5580
cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 5640
agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca 5700
cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 5760
cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat 5820
ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 5880
taccatctgg ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt 5940
tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 6000
ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 6060
atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 6120
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 6180
tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 6240
cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 6300
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 6360
ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 6420
ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 6480
cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 6540
ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 6600
gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa 6660
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 6720
aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc ac 6762
Claims (51)
1.组合物,其包含免疫-肿瘤学药剂,其中所述免疫-肿瘤学药剂通过方法获得,所述方法包括:
通过白细胞单采术从患者的血液获得T细胞;
将收集的T细胞转移到用患者特异性标识符标记的容器;
将标记的收集的T细胞传输到制造设施,
通过用编码嵌合抗原受体(CAR)或T细胞受体(TCR)的多核苷酸转染所述标记的收集的T细胞创建经转染的T细胞以获得所述免疫-肿瘤学药剂;
从所述制造设施接收所述免疫-肿瘤学药剂;并且
将所述免疫-肿瘤学药剂输注到所述患者中,
其中对所述方法中的每个步骤记录跟踪事件,每个跟踪事件包括所述患者特异性标识符,且
其中所述跟踪事件包括在所述方法期间所述患者的T细胞的监管链。
2.权利要求1的组合物,其中所述CAR包含特异性结合靶分子的抗原结合分子。
3.权利要求2的组合物,其中所述抗原结合分子是单链可变片段。
4.权利要求2的组合物,其中所述靶分子是血源性癌症相关抗原。
5.权利要求2的组合物,其中所述靶分子是病毒感染相关抗原。
6.权利要求1的组合物,其中所述CAR进一步包含至少一个共刺激域。
7.权利要求1的组合物,其中所述CAR进一步包含至少一个活化域。
8.权利要求1的组合物,其中所述多核苷酸是载体的组分。
9.权利要求1的组合物,其中所述方法进一步包括接收细胞订购请求以为所述患者创建所述经转染的T细胞。
10.权利要求1的组合物,其中所述TCR结合肿瘤相关抗原。
11.权利要求1的组合物,其中所述TCR结合病毒感染相关抗原。
12.权利要求1的组合物,其中所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号。
13.权利要求1的组合物,其中通过计算装置对所述方法的每个步骤记录所述追踪事件。
14.权利要求13的组合物,其中所述方法进一步包括:
通过所述计算装置接收在创建后已经从第一地点运输所述经转染的T细胞的记号;以及
接收在输注前已经在第二地点接收所述经转染的T细胞的记号。
15.权利要求12的组合物,其中所述患者身份要素包括与免疫疗法规程相关的第一患者ID和与实施以下一项或多项的设施相关的第二患者ID:白细胞单采术或所述经转染的T细胞的输注。
16.权利要求13的组合物,其中所述计算装置以有序顺序存储所述跟踪事件。
17.一种在免疫疗法规程期间跟踪细胞订购的方法,所述方法包括:
通过白细胞单采术从患者的血液获得T细胞;
将收集的T细胞转移到用患者特异性标识符标记的容器;
将标记的收集的T细胞传输到制造设施,
通过用编码嵌合抗原受体(CAR)或T细胞受体(TCR)的多核苷酸转染所述标记的收集的T细胞创建经转染的T细胞以获得免疫-肿瘤学药剂;
从所述制造设施接收所述免疫-肿瘤学药剂;并且
将所述免疫-肿瘤学药剂输注到所述患者中,
其中对所述方法中的每个步骤记录跟踪事件,每个跟踪事件包括所述患者特异性标识符,且
其中所述跟踪事件包括在所述方法期间所述患者的T细胞的监管链。
18.权利要求1或17的方法,其中通过用编码所述CAR的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞,所述CAR包含特异性结合靶分子的抗原结合分子。
19.权利要求18的方法,其中所述抗原结合分子是单链可变片段。
20.权利要求18的方法,其中所述靶分子是血源性癌症相关抗原。
21.权利要求18的方法,其中所述靶分子是病毒感染相关抗原。
22.权利要求18的方法,其中所述CAR进一步包含至少一个共刺激域。
23.权利要求18的方法,其中所述CAR进一步包含至少一个活化域。
24.权利要求1或17的方法,其中所述多核苷酸是载体的组分。
25.权利要求1或17的方法,其中通过用编码所述TCR的多核苷酸转染所述收集的T细胞来创建所述经转染的T细胞。
26.权利要求25的方法,其中所述TCR结合肿瘤相关抗原。
27.权利要求25的方法,其中所述TCR结合病毒感染相关抗原。
28.权利要求17的方法,其进一步包括:接收细胞订购请求以为所述患者创建所述经转染的T细胞。
29.权利要求17的组合物,其中通过计算装置对每个步骤记录所述追踪事件。
30.权利要求29的方法,其中所述方法进一步包括:
通过所述计算装置接收在创建后已经从第一地点运输所述经转染的T细胞的记号;以及
接收在输注前已经在第二地点接收所述经转染的T细胞的记号。
31.权利要求17的方法,其中所述患者特异性标识符包括患者身份要素、销售订购标识符和细胞订购批号,并且其中所述患者身份要素包括与所述免疫疗法规程相关的第一患者ID和与实施以下一项或多项的设施相关的第二患者ID:白细胞单采术或所述经转染的T细胞的输注。
32.权利要求29的方法,其中所述计算装置以有序顺序存储所述跟踪事件。
33.权利要求22的方法,其中所述至少一个共刺激域包含CD28或CD8。
34.权利要求33的方法,其中所述至少一个共刺激域包含SEQ ID NO.2,SEQ ID NO.4,SEQ ID NO.6,SEQ ID NO.8或SEQ ID NO.14的序列。
35.权利要求23的方法,其中所述至少一个活化域包含CD3。
36.权利要求35的方法,其中所述至少一个活化域包含SEQ ID NO.10的序列。
37.根据权利要求1或17的方法,其中所述CAR包含:抗CD19 scFv,CD8和4-1BB;抗BCMAscFv和CD8;抗CD19 scFv,CD28和4-1BB;抗CD22 scFv和CD8;抗CD19 scFv,CD28和EGFRt/19-28z/4-lBBL;抗MUC16scFv和CD28;抗CD 171;抗CD123和CD28;抗BCMA,CD8和4-IBB;抗CD19和CD28;抗CD19和CD8;或CD28。
38.根据权利要求1或17的方法,其中所述CAR包含前导序列(CSF2RA)、抗CD 19scFv、Whitlow接头、CD28间隔物、CD28共刺激域和CD3 zeta。
39.权利要求38的方法,其中所述CAR包含SEQ ID NO.147的序列。
40.根据权利要求1或17的方法,其中所述CAR包含前导序列(CD8)、抗CD19 scFv、Whitlow接头、CD28T间隔物、CD28共刺激域和CD3 zeta。
41.权利要求40的方法,其中所述CAR包含SEQ ID NO.149的序列。
42.根据权利要求1或17的方法,其中所述CAR包含前导序列(CD8a)、抗CD19 scFv、Whitlow接头、CD8a间隔物和跨膜域、CD28共刺激域和CD3zeta。
43.权利要求42的方法,其中所述CAR包含SEQ ID NO.151的序列。
44.根据权利要求1或17的方法,其中所述CAR包含前导序列(CD8)、抗CLL-1scFv、G4S接头、微型间隔物、CD28T、CD28的胞内共刺激区和CD3 zeta。
45.权利要求44的方法,其中所述CAR包含SEQ ID NO.155的序列。
46.根据权利要求1或17的方法,其中所述CAR包含前导序列(CD8a)、抗BCMA scFv、Whitlow接头、CD28T间隔物、CD28共刺激域和CD3 zeta。
47.权利要求46的方法,其中所述CAR包含SEQ ID NO.157的序列。
48.根据权利要求1或17的方法,其中所述TCR包含AV38-2可变alpha链、BV7-2可变beta链、鼠恒定alpha域、鼠恒定beta域、TRAJ40、弗林蛋白酶-SG SG-P2A和TRBJ1-3。
49.权利要求48的方法,其中所述TCR包含SEQ ID NO.153的序列。
50.根据权利要求1或17的方法,其中所述TCR包含TCR beta链可变区、TCR beta链恒定区、具有弗林蛋白酶切割位点的P2A肽和接头、TCR alpha链可变区和TCR alpha链恒定区。
51.权利要求50的方法,其中所述TCR包含SEQ ID NO.159或SEQ ID NO.161的序列。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762559330P | 2017-09-15 | 2017-09-15 | |
US62/559,330 | 2017-09-15 | ||
US201762566912P | 2017-10-02 | 2017-10-02 | |
US62/566,912 | 2017-10-02 | ||
CN201880060078.9A CN111315403A (zh) | 2017-09-15 | 2018-09-17 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
PCT/US2018/051298 WO2019055896A1 (en) | 2017-09-15 | 2018-09-17 | METHODS AND SYSTEMS FOR PERFORMING A PATIENT-CLEAN IMMUNOTHERAPY PROCEDURE WITH FOLLOW-UP OF BIOLOGICAL SAMPLE CHAIN OF CONTROL AND IDENTITY CHAIN |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880060078.9A Division CN111315403A (zh) | 2017-09-15 | 2018-09-17 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114533863A true CN114533863A (zh) | 2022-05-27 |
Family
ID=63878791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880060078.9A Pending CN111315403A (zh) | 2017-09-15 | 2018-09-17 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
CN202210008931.0A Pending CN114533863A (zh) | 2017-09-15 | 2018-09-17 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880060078.9A Pending CN111315403A (zh) | 2017-09-15 | 2018-09-17 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20200268860A1 (zh) |
EP (2) | EP3681531A1 (zh) |
JP (3) | JP2020537635A (zh) |
KR (2) | KR102521245B1 (zh) |
CN (2) | CN111315403A (zh) |
AU (2) | AU2018334279A1 (zh) |
CA (1) | CA3075619A1 (zh) |
IL (1) | IL273234A (zh) |
SG (1) | SG11202002327PA (zh) |
WO (1) | WO2019055896A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
EP3681531A1 (en) * | 2017-09-15 | 2020-07-22 | Kite Pharma, Inc. | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
EP3887978A4 (en) | 2018-11-29 | 2022-08-17 | Vineti Inc. | CENTRALIZED AND DECENTRALIZED CUSTOMIZED MEDICATION PLATFORM |
US11321652B1 (en) | 2019-02-20 | 2022-05-03 | Vineti Inc. | Smart label devices, systems, and methods |
JP2023524639A (ja) * | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
JPWO2022210581A1 (zh) * | 2021-03-31 | 2022-10-06 | ||
EP4323943A1 (en) * | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
US11615874B1 (en) | 2021-09-30 | 2023-03-28 | Vineti Inc. | Personalized medicine and therapies platform |
WO2023077015A2 (en) * | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2024107646A1 (en) * | 2022-11-14 | 2024-05-23 | Caribou Biosciences, Inc. | Anti-cll-1 chimeric antigen receptors, engineered cells and related methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106670A (zh) * | 2014-10-31 | 2017-08-29 | 宾夕法尼亚大学董事会 | 用于修饰的t细胞的方法和组合物 |
CN107110876A (zh) * | 2014-07-21 | 2017-08-29 | 通用电气医疗集团生物科学公司 | 平行细胞处理方法和设施 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6969519B2 (en) * | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
DK3214091T3 (en) | 2010-12-09 | 2019-01-07 | Univ Pennsylvania | USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER |
US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
BR112015009003B1 (pt) * | 2012-10-24 | 2023-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígeno quiméricos que se ligam especificamente a cd22, ácido nucleico, vetor de expressão recombinante, microrganismo transgênico, composição farmacêutica, e uso dos mesmos |
US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
CN106467906B (zh) * | 2015-08-20 | 2019-09-27 | 北京马力喏生物科技有限公司 | 构建体、转基因淋巴细胞及其制备方法和用途 |
US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
EP4212166A1 (en) * | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
CN117025539A (zh) * | 2015-12-28 | 2023-11-10 | 诺华股份有限公司 | 制备嵌合抗原受体表达细胞的方法 |
JP2020512983A (ja) * | 2017-04-03 | 2020-04-30 | カイト ファーマ インコーポレイテッドKite Pharma, Inc | 最適化された多機能性t細胞を含むキメラ受容体t細胞を使用する治療 |
EP3681531A1 (en) * | 2017-09-15 | 2020-07-22 | Kite Pharma, Inc. | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
-
2018
- 2018-09-17 EP EP18788926.6A patent/EP3681531A1/en not_active Withdrawn
- 2018-09-17 CN CN201880060078.9A patent/CN111315403A/zh active Pending
- 2018-09-17 WO PCT/US2018/051298 patent/WO2019055896A1/en unknown
- 2018-09-17 CA CA3075619A patent/CA3075619A1/en active Pending
- 2018-09-17 CN CN202210008931.0A patent/CN114533863A/zh active Pending
- 2018-09-17 JP JP2020514925A patent/JP2020537635A/ja active Pending
- 2018-09-17 SG SG11202002327PA patent/SG11202002327PA/en unknown
- 2018-09-17 KR KR1020207010509A patent/KR102521245B1/ko active IP Right Grant
- 2018-09-17 KR KR1020237011792A patent/KR20230052312A/ko not_active Application Discontinuation
- 2018-09-17 US US16/646,239 patent/US20200268860A1/en not_active Abandoned
- 2018-09-17 EP EP22150767.6A patent/EP4035674A1/en active Pending
- 2018-09-17 AU AU2018334279A patent/AU2018334279A1/en not_active Abandoned
-
2020
- 2020-03-11 IL IL273234A patent/IL273234A/en unknown
-
2021
- 2021-11-24 JP JP2021189818A patent/JP2022031770A/ja active Pending
-
2022
- 2022-02-24 US US17/679,521 patent/US20220249631A1/en active Pending
-
2023
- 2023-03-07 AU AU2023201386A patent/AU2023201386A1/en active Pending
- 2023-12-07 JP JP2023207292A patent/JP2024028918A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107110876A (zh) * | 2014-07-21 | 2017-08-29 | 通用电气医疗集团生物科学公司 | 平行细胞处理方法和设施 |
CN107106670A (zh) * | 2014-10-31 | 2017-08-29 | 宾夕法尼亚大学董事会 | 用于修饰的t细胞的方法和组合物 |
Non-Patent Citations (1)
Title |
---|
BRUCE L. LEVINE等: "Global Manufacturing of CAR T Cell Therapy", MOLECULAR THERAPY:METHODS & CLINICAL DEVELOPMENT, vol. 4, 31 March 2017 (2017-03-31), pages 1 - 4 * |
Also Published As
Publication number | Publication date |
---|---|
US20220249631A1 (en) | 2022-08-11 |
US20200268860A1 (en) | 2020-08-27 |
AU2023201386A1 (en) | 2023-04-13 |
SG11202002327PA (en) | 2020-04-29 |
CA3075619A1 (en) | 2019-03-21 |
KR20200053558A (ko) | 2020-05-18 |
JP2024028918A (ja) | 2024-03-05 |
AU2018334279A1 (en) | 2020-04-02 |
JP2022031770A (ja) | 2022-02-22 |
IL273234A (en) | 2020-04-30 |
EP3681531A1 (en) | 2020-07-22 |
JP2020537635A (ja) | 2020-12-24 |
WO2019055896A1 (en) | 2019-03-21 |
EP4035674A1 (en) | 2022-08-03 |
CN111315403A (zh) | 2020-06-19 |
KR20230052312A (ko) | 2023-04-19 |
KR102521245B1 (ko) | 2023-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102521245B1 (ko) | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 | |
KR102427334B1 (ko) | 키메라 항원 및 t 세포 수용체 및 사용 방법 | |
CN109641008B (zh) | 嵌合受体及其方法和用途 | |
KR102397674B1 (ko) | Bcma 결합 분자 및 그의 사용 방법 | |
AU2022200108B2 (en) | Chimeric receptors to FLT3 and methods of use thereof | |
AU2019202514B2 (en) | Chimeric antigen receptors and methods of making | |
KR20210018797A (ko) | Dll3에 대한 키메라 수용체 및 이의 사용 방법 | |
KR20200104284A (ko) | Hpv-특이적 결합 분자 | |
KR20220016083A (ko) | 키메라 수용체 및 이의 사용 방법 | |
CN114585645A (zh) | 对杂合性丧失作出响应的细胞表面受体 | |
KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
CN112390891B (zh) | 嵌合抗原受体及其构建方法和应用 | |
CN112390892B (zh) | 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞 | |
BR112021002245A2 (pt) | métodos para avaliar ácidos nucleicos integrados | |
Boga | Generation of a cellular library of CAR T cells for rapid screening and identification of antigen specific, functional CAR constructs | |
Boğa | Inaugural dissertation for obtaining the doctoral degree of the Combined Faculty of Mathematics, Engineering and Natural Sciences of the Ruprecht-Karls-University Heidelberg |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40073067 Country of ref document: HK |